<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003094.pub3" GROUP_ID="PREG" ID="012599112314404256" MERGED_FROM="" MODIFIED="2011-12-05 14:56:59 +0100" MODIFIED_BY="Sonja Henderson" NOTES="&lt;p&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.4&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.4&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.6&lt;br&gt;Short title (no longer in use): Iron deficiency anaemia treatment in pregnancy&lt;/p&gt;&lt;p&gt;&lt;br&gt;Old title: Treatments for iron-deficiency anaemia in pregnancy&lt;/p&gt;" NOTES_MODIFIED="2011-12-05 10:58:49 +0000" NOTES_MODIFIED_BY="Sonja Henderson" REVIEW_NO="0238" REVMAN_SUB_VERSION="5.1.4" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.0">
<COVER_SHEET MODIFIED="2011-12-05 14:56:59 +0100" MODIFIED_BY="Sonja Henderson">
<TITLE>Treatments for iron-deficiency anaemia in pregnancy</TITLE>
<CONTACT MODIFIED="2011-12-05 14:56:59 +0100" MODIFIED_BY="Sonja Henderson"><PERSON ID="14522" ROLE="AUTHOR"><FIRST_NAME>Ludovic</FIRST_NAME><LAST_NAME>Reveiz</LAST_NAME><SUFFIX>MD, MSc, PhD (Cand)</SUFFIX><POSITION>Advisor</POSITION><EMAIL_1>mmreveiz@hotmail.com</EMAIL_1><EMAIL_2>lreveiz@yahoo.com</EMAIL_2><ADDRESS><DEPARTMENT>Research Promotion and Development Team</DEPARTMENT><ORGANISATION>Health Systems Based on Primary Health Care (HSS), Pan American Health Organization</ORGANISATION><ADDRESS_1>525, 23rd St, NW</ADDRESS_1><CITY>Washington DC</CITY><ZIP>20037-2895</ZIP><COUNTRY CODE="US">USA</COUNTRY><PHONE_2>+1 202 974 3135</PHONE_2></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2011-12-05 14:56:59 +0100" MODIFIED_BY="Sonja Henderson"><PERSON ID="14522" ROLE="AUTHOR"><FIRST_NAME>Ludovic</FIRST_NAME><LAST_NAME>Reveiz</LAST_NAME><SUFFIX>MD, MSc, PhD (Cand)</SUFFIX><POSITION>Advisor</POSITION><EMAIL_1>mmreveiz@hotmail.com</EMAIL_1><EMAIL_2>lreveiz@yahoo.com</EMAIL_2><ADDRESS><DEPARTMENT>Research Promotion and Development Team</DEPARTMENT><ORGANISATION>Health Systems Based on Primary Health Care (HSS), Pan American Health Organization</ORGANISATION><ADDRESS_1>525, 23rd St, NW</ADDRESS_1><CITY>Washington DC</CITY><ZIP>20037-2895</ZIP><COUNTRY CODE="US">USA</COUNTRY><PHONE_2>+1 202 974 3135</PHONE_2></ADDRESS></PERSON><PERSON ID="7570" ROLE="AUTHOR"><PREFIX>Mrs</PREFIX><FIRST_NAME>Gillian</FIRST_NAME><MIDDLE_INITIALS>ML</MIDDLE_INITIALS><LAST_NAME>Gyte</LAST_NAME><POSITION>Research Associate</POSITION><EMAIL_1>ggyte@cochrane.co.uk</EMAIL_1><ADDRESS><DEPARTMENT>Cochrane Pregnancy and Childbirth Group, Department of Women's and Children's Health</DEPARTMENT><ORGANISATION>The University of Liverpool</ORGANISATION><ADDRESS_1>First Floor, Liverpool Women's NHS Foundation Trust</ADDRESS_1><ADDRESS_2>Crown Street</ADDRESS_2><CITY>Liverpool</CITY><ZIP>L8 7SS</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 151 7024066</PHONE_1><FAX_1>+44 151 7024335</FAX_1></ADDRESS></PERSON><PERSON ID="D34EDBC282E26AA20080535F3A0DAD03" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Luis Gabriel</FIRST_NAME><LAST_NAME>Cuervo</LAST_NAME><EMAIL_1>cuervolu@paho.org</EMAIL_1><EMAIL_2>lgcuervo@gmail.com</EMAIL_2><URL>http://www.linkedin.com/in/lgcuervo</URL><MOBILE_PHONE>+1 (202) 213-7402</MOBILE_PHONE><ADDRESS><DEPARTMENT>Research Promotion Team and Development</DEPARTMENT><ORGANISATION>Pan American Health Organization (PAHO/WHO)</ORGANISATION><ADDRESS_1>525 23rd St NW</ADDRESS_1><CITY>Washington DC</CITY><ZIP>20037-2895</ZIP><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 202 9743135</PHONE_1><PHONE_2>+1 202 9743000</PHONE_2></ADDRESS></PERSON><PERSON ID="84267695327009499088100429154406" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Alexandra</FIRST_NAME><LAST_NAME>Casasbuenas</LAST_NAME><POSITION>Physician</POSITION><EMAIL_1>alexacasasbuenas@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Maternal and Fetal Medicine - Obstetrics and Gynecology</DEPARTMENT><ORGANISATION>Fundación Santa Fe de Bogotá</ORGANISATION><ADDRESS_1>Clle 119 N 7 - 75</ADDRESS_1><CITY>Bogotá</CITY><ZIP>571</ZIP><REGION>Cundinamarca</REGION><COUNTRY CODE=" CO">Colombia</COUNTRY><PHONE_1>+57 1 6030303</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2011-12-05 10:54:56 +0000" MODIFIED_BY="Sonja Henderson">
<UP_TO_DATE>
<DATE DAY="24" MONTH="8" YEAR="2011"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="7" MONTH="6" YEAR="2011"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="8" YEAR="2012"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="1999"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2001"/>
<LAST_CITATION_ISSUE ISSUE="10" YEAR="2011"/>
</DATES>
<WHATS_NEW MODIFIED="2011-12-05 10:58:49 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-12-05 10:58:49 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="5" MONTH="12" YEAR="2011"/>
<DESCRIPTION>
<P>Corrected typographical error.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2011-12-05 10:58:33 +0000" MODIFIED_BY="Jill V Hampson">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-12-05 10:58:33 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="7" MONTH="6" YEAR="2011"/>
<DESCRIPTION>
<P>This update is based on a search run in June 2011, which identified six new randomised controlled trials (RCTs). There are now a total of 23 RCTs included in the review. The inclusion of the 6 new included studies did not change the overall conclusions (<LINK REF="STD-Digumarthi-2008" TYPE="STUDY">Digumarthi 2008</LINK>; <LINK REF="STD-Khalafallah-2010" TYPE="STUDY">Khalafallah 2010</LINK>; <LINK REF="STD-Nappi-2009" TYPE="STUDY">Nappi 2009</LINK>; <LINK REF="STD-Saha-2007" TYPE="STUDY">Saha 2007</LINK>; <LINK REF="STD-Sun-2010" TYPE="STUDY">Sun 2010</LINK>; <LINK REF="STD-Zhou-2007" TYPE="STUDY">Zhou 2007</LINK>). In addition, a 'risk of bias' assessment was performed for all RCTs.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2011-12-05 10:58:30 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="7" MONTH="6" YEAR="2011"/>
<DESCRIPTION>
<P>New author joined the review team.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-02-16 15:57:58 +0000" MODIFIED_BY="Jill V Hampson">
<DATE DAY="9" MONTH="2" YEAR="2010"/>
<DESCRIPTION>
<P>Search updated. Fifteen reports added to <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK>.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-02-09 21:31:38 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="12" MONTH="5" YEAR="2009"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-05-12 11:57:22 +0100" MODIFIED_BY="Denise Atherton">
<DATE DAY="20" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-10-27 09:34:37 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="13" MONTH="2" YEAR="2007"/>
<DESCRIPTION>
<P>An updated search of the Pregnancy and Childbirth Group's Trials Register on 31 January 2007 identified seven new trial reports which have been added to the awaiting assessment section for assessment in the next update.</P>
<P>This update is based on a search run in December 2005, which identified twelve new trials (<LINK REF="STD-Al-2005" TYPE="STUDY">Al 2005</LINK>; <LINK REF="STD-Bayoumeu-2002" TYPE="STUDY">Bayoumeu 2002</LINK>; <LINK REF="STD-Breymann-2001" TYPE="STUDY">Breymann 2001</LINK>; <LINK REF="STD-De-Souza-2004" TYPE="STUDY">De Souza 2004</LINK>; <LINK REF="STD-Komolafe-2003" TYPE="STUDY">Komolafe 2003</LINK>; <LINK REF="STD-Kumar-2005" TYPE="STUDY">Kumar 2005</LINK>; <LINK REF="STD-Mumtaz-2000" TYPE="STUDY">Mumtaz 2000</LINK>; <LINK REF="STD-Ogunbode-1980" TYPE="STUDY">Ogunbode 1980</LINK>; <LINK REF="STD-Oluboyede-1980" TYPE="STUDY">Oluboyede 1980</LINK>; <LINK REF="STD-Sood-1979" TYPE="STUDY">Sood 1979</LINK>; <LINK REF="STD-Wali-2002" TYPE="STUDY">Wali 2002</LINK>; <LINK REF="STD-Zutschi-2004" TYPE="STUDY">Zutschi 2004</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2008-10-27 09:34:42 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="1" MONTH="2" YEAR="2007"/>
<DESCRIPTION>
<P>There are now a total of 17 trials included in the review. The inclusion of these trials have generally not changed the conclusions although there are now concerns about possible important adverse effects.<BR/>
<BR/>Ludovic Reveiz is now the guarantor of the review.<BR/>
<BR/>
<BR/>
</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2010-11-10 19:45:15 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2010-11-10 19:45:01 +0000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2010-11-10 19:45:01 +0000" MODIFIED_BY="[Empty name]">
<NAME>None</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2010-11-10 19:45:15 +0000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2010-11-10 19:45:15 +0000" MODIFIED_BY="[Empty name]">
<NAME>None</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2011-12-05 10:56:06 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2011-08-12 13:39:48 +0100" MODIFIED_BY="Heather Maxwell">
<TITLE MODIFIED="2011-06-09 14:27:18 +0100" MODIFIED_BY="[Empty name]">Treatments for anaemia in pregnancy thought to be due to iron deficiency</TITLE>
<SUMMARY_BODY MODIFIED="2011-08-12 13:39:48 +0100" MODIFIED_BY="Heather Maxwell">
<P>When the blood has insufficient red cells, or the red cells carry insufficient haemoglobin to deliver adequate oxygen to the tissues, this is called anaemia. There is normally a reduction in the haemoglobin concentrations in the mother's blood during pregnancy, and this allows a better blood flow around the womb (uterus) and to the baby. This is sometime called physiological anaemia and needs no treatment. True anaemia, however, can be mild, moderate or severe and can cause weakness, tiredness and dizziness. Severe anaemia makes women at risk of cardiac failure and is very common in low-income countries Anaemia has many causes including a shortage or iron, folic acid or vitamin B<SUB>12</SUB>. These are all required for making red cells and are available in a good diet. Iron shortage, however, is the most common cause of anaemia during pregnancy. Iron treatment can be given by mouth (oral), by injection into the muscle (intramuscular) or injection into the vein (intravenous). Blood transfusion or giving something which stimulates the body to produce more red cells (erythropoietin) are also possible treatments.</P>
<P>In this review, we identified 23 trials involving 3198 pregnant women. Many of the trials were in low-income countries and many treatment variations were studied. Oral iron reduced the incidence of anaemia but is known to sometimes cause constipation and nausea. Although the intramuscular and intravenous routes produced better levels of red cells and iron stores than the oral route, no clinical outcomes (such as pre-eclampsia, preterm births, postpartum haemorrhage) were assessed and there were insufficient data on adverse effects. Intravenous treatment can cause venous thrombosis (blockages in the veins) and intramuscular treatment causes important pain and discolouration at the injection site. It was unclear if women and babies were healthier when women were given iron for mild or moderate anaemia during pregnancy. There were no studies on using blood transfusions.</P>
<P>Overall, there was insufficient evidence to say when or how anaemia in pregnancy needs to or should be treated.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2011-08-23 21:37:20 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>Iron deficiency, the most common cause of anaemia in pregnancy worldwide, can be mild, moderate or severe. Severe anaemia can have very serious consequences for mothers and babies, but there is controversy about whether treating mild or moderate anaemia provides more benefit than harm. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2011-08-12 13:39:48 +0100" MODIFIED_BY="Heather Maxwell">
<P>To assess the effects of different treatments for anaemia in pregnancy attributed to iron deficiency (defined as haemoglobin less than 11 g/dL or other equivalent parameters) on maternal and neonatal morbidity and mortality.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2011-08-23 21:37:20 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (7 June 2011), CENTRAL (2011, Issue 5), PubMed (1966 to June 2011), the International Clinical Trials Registry Platform (ICTRP) (2 May 2011), Health Technology Assessment Program (HTA) (2 May 2011) and LATINREC (Colombia) (2 May 2011).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2011-08-23 21:30:12 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials comparing treatments for anaemia in pregnancy attributed to iron deficiency. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2011-06-09 15:05:28 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;To be updated when new trials assessed.&lt;/p&gt;" NOTES_MODIFIED="2011-06-09 15:05:28 +0100" NOTES_MODIFIED_BY="[Empty name]">
<P>We identified 23 trials, involving 3.198 women. We assessed their risk of bias. Three further studies identified are awaiting classification.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2011-08-11 16:58:17 +0100" MODIFIED_BY="Heather Maxwell">
<P>Many of the trials were from low-income countries; they were generally small and frequently methodologically poor. They covered a very wide range of differing drugs, doses and routes of administration, making it difficult to pool data. Oral iron in pregnancy showed a reduction in the incidence of anaemia (risk ratio 0.38, 95% confidence interval 0.26 to 0.55, one trial, 125 women) and better haematological indices than placebo (two trials). It was not possible to assess the effects of treatment by severity of anaemia. A trend was found between dose and reported adverse effects. Most trials reported no clinically relevant outcomes nor adverse effects. Although the intramuscular and intravenous routes produced better haematological indices in women than the oral route, no clinical outcomes were assessed and there were insufficient data on adverse effects, for example, on venous thrombosis and severe allergic reactions. Daily low-dose iron supplements may be effective at treating anaemia in pregnancy with less gastrointestinal side effects compared with higher doses.<BR/>
</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2011-08-12 13:39:48 +0100" MODIFIED_BY="Heather Maxwell">
<P>Despite the high incidence and burden of disease associated with this condition, there is a paucity of good quality trials assessing clinical maternal and neonatal effects of iron administration in women with anaemia. Daily oral iron treatment improves haematological indices but causes frequent gastrointestinal adverse effects. Parenteral (intramuscular and intravenous) iron enhances haematological response, compared with oral iron, but there are concerns about possible important adverse effects (for intravenous treatment venous thrombosis and allergic reactions and for intramuscular treatment important pain, discolouration and allergic reactions). Large, good quality trials, assessing clinical outcomes (including adverse effects) as well as the effects of treatment by severity of anaemia are required.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2011-12-05 10:56:06 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2011-09-04 15:13:36 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2011-09-04 15:13:36 +0100" MODIFIED_BY="[Empty name]">
<P>Iron deficiency, and particularly iron deficiency anaemia, is one of the most severe and important nutritional deficiencies worldwide. Iron deficiency is defined as "a condition in which there are no mobilizable iron stores and in which signs of a compromised supply of iron to tissues, including the erythron, are noted. The more severe stages of iron deficiency are associated with anaemia" (<LINK REF="REF-WHO-2001" TYPE="REFERENCE">WHO 2001</LINK>). Anaemia is a reduction in the normal number of circulating red blood cells and in the quantity of haemoglobin (Hb) in the blood. More than half of the pregnant women in low-income countries suffer from anaemia and iron deficiency is the most common cause of anaemia in pregnancy (<LINK REF="REF-WHO-2001" TYPE="REFERENCE">WHO 2001</LINK>). Using data from the World Health Organization (WHO) Vitamin and Mineral Nutrition Information System for 1993 to 2005, global anaemia prevalence was estimated to be 41.8% (95% confidence interval (CI) 39.9 to 43.8 %) in pregnant women (<LINK REF="REF-McLean-2009" TYPE="REFERENCE">McLean 2009</LINK>). The high prevalence of anaemia has been associated with low socio-economic status (odds ratio (OR) 1.419, 95% CI 1.05 to 1.90) (<LINK REF="REF-Noronha-2010" TYPE="REFERENCE">Noronha 2010</LINK>).</P>
<P>More than half a million maternal deaths occur each year, approximately 90% of which are in low-income countries, making evident a large discrepancy between high- and low-income countries. The common causes of anaemia include iron deficiency, folate deficiency, vitamin B12 deficiency, bone marrow suppression, haemolytic diseases (sickle cell disease and malaria), chronic blood loss (for example, hook worm infestation) and underlying malignancies (<LINK REF="REF-WHO-1992" TYPE="REFERENCE">WHO 1992</LINK>), with iron-deficiency being the most common cause of anaemia in pregnant women worldwide (<LINK REF="REF-Goroll-1997" TYPE="REFERENCE">Goroll 1997</LINK>; <LINK REF="REF-Lops-1995" TYPE="REFERENCE">Lops 1995</LINK>; <LINK REF="REF-Williams-1992" TYPE="REFERENCE">Williams 1992</LINK>). The diverse main preventable factors relating to maternal mortality have been described, and include chronic anaemia, infections, bleeding, hypertensive disorders, obstructed labour and unsafe abortions (<LINK REF="REF-WHO-2000" TYPE="REFERENCE">WHO 2000</LINK>).</P>
<P>Haemoglobin is the protein in the red blood cell which carries oxygen to the tissues and iron is part of the Hb molecule. There are a variety of indicators of iron status such as bone marrow iron, serum ferritin, transferrin saturation, erythrocyte protoporphyrin, transferrin receptors and also red cell mean corpuscular volume (MCV), red cell mean corpuscular haemoglobin (MCH) and red cell mean corpuscular haemoglobin concentration (MCHC). However, neither blood Hb concentration nor serum iron are thought to be good indicators of anaemia because there can be depletion of body iron stores in the presence of normal Hb levels and serum iron fluctuates depending on recent iron intake. Serum ferritin may be a better indicator of iron status as the examination of iron stores in the bone marrow is impractical. Historically, blood Hb levels have been used as indicators of anaemia, the test being simple and inexpensive to undertake. Anaemia is associated with general weakness, tiredness and dizziness but the level of Hb associated with these symptoms in pregnancy is unknown. These symptoms are nonspecific and frequently appear in cases of severe anaemia too and in association with other medical problems. Anaemia in pregnancy is defined by the WHO as a Hb value below 11 g/dL (<LINK REF="REF-WHO-1992" TYPE="REFERENCE">WHO 1992</LINK>; <LINK REF="REF-WHO-2001" TYPE="REFERENCE">WHO 2001</LINK>). Although anaemia is frequently graded as "mild", "moderate", or "severe", the Hb values at which the division into these three categories is made vary and are arbitrary. Standardised cut-off values are difficult to define because populations, geographic settings and needs are different according to specific areas. Some authors suggest that Hb values at sea level should be categorised as follows (<LINK REF="REF-WHO-1989" TYPE="REFERENCE">WHO 1989</LINK>): (1) mild anaemia (Hb 10 to 10.9 g/dL); (2) moderate anaemia (Hb 7 to 9.9 g/dL); (3) severe anaemia (Hb less than 7 g/dL). However, other criteria have been widely used in the literature to define anaemia cut-off values: (1) mild (Hb 9 to 10.9 g/dL), (2) moderate (Hb 7 to 8.9 g/dL) and (3) severe (Hb below 7 g/dL) (<LINK REF="REF-Adam-2005" TYPE="REFERENCE">Adam 2005</LINK>); and (1) mild anaemia (Hb 7 to 11 g/dL), moderate anaemia (5 to 7 g/dL) and severe anaemia (below 5 g/dL) (<LINK REF="REF-Brabin-2001" TYPE="REFERENCE">Brabin 2001</LINK>). The interpretation of Hb concentrations in pregnancy is sometimes difficult because of the normal physiological decrease in blood Hb concentration in pregnancy and in certain conditions where water balance is affected (i.e. pre-eclampsia) Hb concentrations may be overestimated as a result of dehydration (<LINK REF="REF-Letsky-1991" TYPE="REFERENCE">Letsky 1991</LINK>).</P>
<P>It is suggested that the iron stores of the woman's body become reduced during pregnancy (as a result of the increased red cell mass and the demands of the fetus exceeding iron intake), and that this can take place in the presence of normal blood Hb levels. Some will argue that this is a well-designed physiological mechanism to continue to deliver oxygen to the tissues in the presence of lowered blood Hb levels in pregnancy. An observational study undertaken in London, UK, found that low levels of Hb, commonly considered as mild anaemia, were associated with a better prognosis for the fetus, although figures did not appear to be corrected for women with pre-eclampsia (<LINK REF="REF-Steer-1995" TYPE="REFERENCE">Steer 1995</LINK>). However, others argue that reduced iron stores are a health problem for pregnant women and their babies (<LINK REF="REF-Letsky-2001" TYPE="REFERENCE">Letsky 2001</LINK>). Several studies considered anaemia (Hb levels between 7 g/dL and 10 g/dL) as a risk factor for fetal death, premature delivery, low birthweight and other adverse outcomes (<LINK REF="REF-Williams-1992" TYPE="REFERENCE">Williams 1992</LINK>). Some suggest a link between maternal anaemia in pregnancy on the later developmental problems of the children (<LINK REF="REF-Letsky-2001" TYPE="REFERENCE">Letsky 2001</LINK>; <LINK REF="REF-Williams-1992" TYPE="REFERENCE">Williams 1992</LINK>). There is evidence indicating that maternal Hb levels under 7 g/dL are associated with a higher risk in the mother of developing cardiac heart failure, which has adverse consequences on the mother and fetus (<LINK REF="REF-Lops-1995" TYPE="REFERENCE">Lops 1995</LINK>; <LINK REF="REF-WHO-1992" TYPE="REFERENCE">WHO 1992</LINK>; <LINK REF="REF-Williams-1992" TYPE="REFERENCE">Williams 1992</LINK>). A cohort study done in Pakistan found that the risk of low birthweight and preterm delivery among anaemic women (Hb under 11 g/dL) was 1.9 and four times higher, respectively, than non-anaemic women. In addition, the neonates of anaemic women had a 3.7 greater risk of intrauterine fetal death and 1.8 times increased risk having low Apgar scores at one minute when compared to non-anaemic women (<LINK REF="REF-Lone-2004" TYPE="REFERENCE">Lone 2004</LINK>). There is a strong case for studying separately physiological anaemia, mild anaemia and severe anaemia in pregnancy.</P>
<P>In low-income countries, anaemia in pregnancy is frequent and has been attributed to poor nutrition and a high incidence of concurrent diseases, and can potentially complicate conditions such as postpartum haemorrhage which is a major contributor to maternal mortality in many developing countries (<LINK REF="REF-WHO-1992" TYPE="REFERENCE">WHO 1992</LINK>). A case control study, conducted in India, evaluated maternal mortality risk factors from 25,926 households in 411 villages. The authors reported that the major related causes of maternal deaths were haemorrhage, severe anaemia, puerperal sepsis, and abortion (<LINK REF="REF-Gupta-2010" TYPE="REFERENCE">Gupta 2010</LINK>). However, anaemia may only be a marker of various social and nutritional conditions, and raising Hb levels could have little, if any, effect on morbidity or mortality if those conditions are not improved (<LINK REF="REF-Goroll-1997" TYPE="REFERENCE">Goroll 1997</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2011-08-11 11:14:49 +0100" MODIFIED_BY="Heather Maxwell">
<P>There are various considerations that need to be taken into account when treating iron-deficiency anaemia:</P>
<P>Iron can be given by mouth, by intramuscular (IM) injection or intravenous (IV) injection. It is also possible to deliver iron by giving a blood transfusion, and recombinant erythropoietin in conjunction with iron is a further possibility. Some evidence suggests that oral iron given to anaemic pregnant and non-pregnant women is associated with gastrointestinal side effects such as nausea and constipation (<LINK REF="REF-WHO-2000" TYPE="REFERENCE">WHO 2000</LINK> ). IM or IV iron are thought to be associated with allergic reactions and anaphylactic shock, as well as venous thrombosis and occasionally cardiac arrest and death. Blood transfusion carries the risk of transmitting parasitic or viral infections including HIV, hepatitis, and Chagas disease (trypanosomiasis), despite preventive blood screening. There is also the possibility of bovine spongiform encephalitis, and as yet unknown viral infections. Oral iron is often the preferred route of administration for mild anaemia, while IM and IV routes are more frequently used in people with severe anaemia when the risks of cardiac failure due to severe anaemia are perceived to outweigh the risks of potential adverse effects.</P>
<P>There are also variations in the doses used (e.g. low or high doses), differing regimens (e.g. single, daily, monthly or intermittent doses), differing forms of iron (e.g. dextran, fumarate) and sometimes adjuncts given (e.g. vitamin A, erythropoietin).</P>
</INTERVENTION>
<THEORY MODIFIED="2011-08-12 13:39:48 +0100" MODIFIED_BY="Heather Maxwell">
<P>Physiological changes during pregnancy may affect laboratory parameters such as the haematocrit and the Hb (<LINK REF="REF-Klajnbard-2010" TYPE="REFERENCE">Klajnbard 2010</LINK>). Transfer of iron from the mother to the fetus is regulated by the placenta (<LINK REF="REF-Allen-2000" TYPE="REFERENCE">Allen 2000</LINK>). During pregnancy, there is an increase in maternal iron absorption and also an increase in both red cell mass and plasma volume to accommodate the needs of the growing uterus and fetus. However, plasma volume increases more than the red cell mass leading to a fall in the concentration of Hb in the blood, despite the increase in the total number of red cells (<LINK REF="REF-Letsky-1991" TYPE="REFERENCE">Letsky 1991</LINK>). This drop in Hb concentration decreases the blood viscosity and it is thought this enhances the placental perfusion providing a better maternal-fetal gas and nutrient exchange (<LINK REF="REF-Mani-1995" TYPE="REFERENCE">Mani 1995</LINK>). There is controversy around the significance for women and their babies of this physiological haemodilution of pregnancy and at what level of Hb women and babies would benefit from iron treatment. As discussed below, some studies suggest that the physiological decrease in Hb is associated with improved outcomes for the baby (<LINK REF="REF-Mahomed-1989" TYPE="REFERENCE">Mahomed 1989</LINK>; <LINK REF="REF-Steer-1995" TYPE="REFERENCE">Steer 1995</LINK>), whilst others have identified adverse long-term outcomes for the baby (<LINK REF="REF-Walter-1994" TYPE="REFERENCE">Walter 1994</LINK>).</P>
<P>For pathological changes, treatment for iron deficiency focuses on increasing the iron stores and blood Hb levels, so they reach normal levels and can provide a normal oxygen supply to the tissues. In anaemia in pregnancy, the treatment should not only normalise iron stores and blood Hb levels, but should also be shown to improves clinical outcomes for both mother and baby.</P>
</THEORY>
<IMPORTANCE MODIFIED="2011-08-12 13:39:48 +0100" MODIFIED_BY="Heather Maxwell">
<P>Iron is the most common strategy currently used to control iron deficiency and anaemia in low-income countries (<LINK REF="REF-WHO-2001" TYPE="REFERENCE">WHO 2001</LINK>). Recommendations for the treatment of anaemia are frequently based on the expectation that they may be benevolent but are seldom supported by reproducible robust studies, especially randomised controlled trials. Furthermore, they may not take into account important adverse effects such as allergic reactions, viral or parasitic transmission from blood transfusions, gastrointestinal complications, and discomfort generated by common side effects of iron (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). Therefore, it is difficult to balance the benefits and harms of treatments, let alone determine if there is a case to recommend a particular anaemia treatment for all women with anaemia in pregnancy.</P>
<P>The aim of this review was to use a systematic approach to identify and synthesise the evidence of randomised controlled trials evaluating the effects of treatments for anaemia in pregnancy, and provide robust valid and useful evidence to inform clinical practice.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2011-08-11 09:38:05 +0100" MODIFIED_BY="Heather Maxwell">
<P>The principal objective was to determine the overall effects of different forms of iron therapy given to pregnant women diagnosed with anaemia attributed to iron-deficiency, measuring neonatal and maternal morbidity and mortality, haematological parameters and side effects, especially adverse effects of treatment. The review aimed to assess the effects of iron treatments when delivered to women categorised in three groups (mild, moderate or severe anaemia, as defined by trialists) at inception into the randomised controlled trial.</P>
<P>The review did not address the need for iron supplementation of non-anaemic women; this question has been addressed in several other reviews and evidence summaries. Similarly, it did not focus vitamin B12, micronutrients, folate deficiency, infectious or genetic anaemia, which will be or are covered by other reviews (<LINK REF="REF-Pena_x002d_Rosas-2009" TYPE="REFERENCE">Pena-Rosas 2009</LINK>; <LINK REF="REF-Van-den-Broek-2010" TYPE="REFERENCE">Van den Broek 2010</LINK>).</P>
</OBJECTIVES>
<METHODS MODIFIED="2011-12-05 10:56:06 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2011-08-12 13:39:48 +0100" MODIFIED_BY="Heather Maxwell">
<CRIT_STUDIES MODIFIED="2011-08-12 13:39:48 +0100" MODIFIED_BY="Heather Maxwell">
<P>This review considered randomised controlled trials assessing the effects of treatments for anaemia in pregnancy attributed to iron deficiency. When information in the abstract was unclear or incomplete, we reviewed the 'materials and methods' of the reports. Quasi-random studies were not eligible for this review.</P>
<P>As previously mentioned, the use of Hb &lt;11g/dL (at sea level) only helps to diagnose anaemia but not iron deficiency anaemia. Iron-deficiency anaemia definitions may be problematic due to the controversy about which diagnostic tests are sufficient and reliable enough to rule out other causes of anaemia, and that anaemia causes are frequently combined. Therefore, for this review we accepted the diagnosis of anaemia defined by the authors of the studies.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2011-08-12 13:39:48 +0100" MODIFIED_BY="Heather Maxwell">
<P>Pregnant women with a diagnosis of anaemia (Hb levels under 11 g/dL, or other tests for anaemia as described by trialists) attributed to iron deficiency.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2011-08-11 11:22:20 +0100" MODIFIED_BY="Heather Maxwell">
<P>We included the following interventions.</P>
<OL>
<LI>Oral iron.</LI>
<LI>Oral iron plus adjuncts.</LI>
<LI>Intramuscular (IM) iron.</LI>
<LI>Intravenous (IV) iron.</LI>
<LI>Blood transfusion.</LI>
<LI>Recombinent erythropoietin.</LI>
</OL>
<P>We looked for studies that compared these intervention against placebo and against each other. We also looked at different doses, routes of administration and regimens.</P>
<P>* For the purpose of this review, regular oral iron will include preparations different from controlled-release oral iron.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2011-08-12 13:39:48 +0100" MODIFIED_BY="Heather Maxwell">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2011-06-02 16:15:06 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Women</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Clinical outcomes</HEADING>
<P>Mortality<BR/>Morbidity<BR/>Puerperal sepsis<BR/>Systemic bacterial infection after delivery<BR/>Days in intensive care unit<BR/>Days hospitalised during pregnancy</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Newborn</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Clinical outcomes</HEADING>
<P>Mortality<BR/>Morbidity<BR/>Days hospitalised<BR/>Admission to neonatal intensive care unit</P>
</SUBSECTION>
</SUBSECTION>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2011-08-12 13:39:48 +0100" MODIFIED_BY="Heather Maxwell">
<SUBSECTION>
<HEADING LEVEL="5">Women</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Clinical outcomes</HEADING>
<P>Preterm labour<BR/>Premature delivery<BR/>Pneumonia<BR/>Postpartum haemorrhage (equal to or more than 500 ml)<BR/>Heart failure<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Haematological outcomes</HEADING>
<P>Maternal serum ferritin<BR/>Maternal serum iron<BR/>Hb levels<BR/>Long-term haematological outcomes (not pre-specified in original protocol)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Maternal side effects</HEADING>
<P>General symptoms (e.g. weakness, tiredness, dizziness)Gastrointestinal effects (e.g. nausea, vomiting, diarrhoea, epigastric pain, constipation)<BR/>Local symptoms (e.g. pain or tenderness, erythema)<BR/>Systemic symptoms (e.g. myalgia, arthralgia, abscess formation at injection site, allergic reactions etc)<BR/>
</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Newborn</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Clinical outcomes</HEADING>
<P>Low birthweight (less than 2500 g)<BR/>Respiratory disease requiring ventilation<BR/>Small-for-gestational age<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Haematological outcomes</HEADING>
<P>Cord serum ferritin<BR/>Cord Hb<BR/>Other long-term outcomes<BR/>
</P>
</SUBSECTION>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2011-08-24 10:13:53 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2011-08-24 10:13:53 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Pregnancy and Childbirth Group's Trials Register by contacting the Trials Search Co-ordinator (7 June 2011).</P>
<P>The Cochrane Pregnancy and Childbirth Group&#8217;s Trials Register is maintained by the Trials Search Co-ordinator and contains trials identified from: </P>
<OL>
<LI>quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);</LI>
<LI>weekly searches of MEDLINE;</LI>
<LI>weekly searches of EMBASE;</LI>
<LI>handsearches of 30 journals and the proceedings of major conferences;</LI>
<LI>weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts.</LI>
</OL>
<P>Details of the search strategies for CENTRAL and MEDLINE, the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service can be found in the &#8216;Specialized Register&#8217; section within the editorial information about the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PREG/frame.html">Cochrane Pregnancy and Childbirth Group</A>. </P>
<P>Trials identified through the searching activities described above are each assigned to a review topic (or topics). The Trials Search Co-ordinator searches the register for each review using the topic list rather than keywords. </P>
<P>In addition, we searched CENTRAL (<I>The Cochrane Library</I> 2011, Issue 2 of 4) and PubMed (1966 to June 2011) using the search strategies given in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
<P>In order to further identify ongoing RCTs and unpublished studies we searched the following trials registers (2 May 2011) using the terms and phrases detailed in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.<BR/>
</P>
<UL>
<LI>Search Portal of the International Clinical Trials Registry Platform (ICTRP; <A HREF="http://www.who.int/ictrp/">www.who.int/ictrp/</A>) for appropriate ongoing and recently completed studies</LI>
<LI>Health Technology Assessment Program (HTA) (<A HREF="http://www.hta.ac.uk/">www.hta.ac.uk/</A>) (United Kingdom)</LI>
<LI>LATINREC [<A HREF="http://www.latinrec.net">www.latinrec.net</A>], Colombia</LI>
</UL>
<P>For details of searching carried out in the previous version of the review, <I>see: </I>
<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2011-08-11 11:32:22 +0100" MODIFIED_BY="Heather Maxwell">
<P>We searched the bibliographies of all papers identified by these strategies.</P>
<P>We did not apply any language restrictions.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-12-05 10:56:06 +0000" MODIFIED_BY="[Empty name]">
<P>For the methods used when assessing the trials identified in the previous version of this review, <I>see </I>
<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>.</P>
<P>For this update, we used the following methods when assessing the reports identified by the updated search.</P>
<STUDY_SELECTION MODIFIED="2011-12-05 10:56:06 +0000" MODIFIED_BY="[Empty name]">
<P>Two<I> </I>review authors (Ludovic Reveiz (LR), Alexandra Casasbuenas (AC)) independently assessed for inclusion all the potential studies we identified as a result of the search strategy. We resolved any disagreement through discussion or, if required, we consulted a third person (Luis Gabriel Cuervo (LGC)).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2011-08-12 13:39:48 +0100" MODIFIED_BY="Heather Maxwell">
<P>We designed a form to extract data. For eligible studies, two review authors (LR, AC) extracted the data using the agreed form. We resolved discrepancies through discussion or, if required, we consulted another review author (LGC<I>)</I>. We entered data into Review Manager software (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>) and checked for accuracy.</P>
<P>When information regarding any of the above was unclear, we attempted to contact authors of the original reports to provide further details.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2011-09-04 15:06:15 +0100" MODIFIED_BY="[Empty name]">
<P>Two<I> </I>review authors (LR, AC) independently assessed risk of bias for each study using the criteria outlined in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We resolved any disagreement by discussion.</P>
<SUBSECTION>
<HEADING LEVEL="4">(1) Sequence generation (checking for possible selection bias)</HEADING>
<P>We described for each included study the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups.</P>
<P>We assessed the method as:</P>
<UL>
<LI>low risk (any truly random process, e.g. random number table; computer random number generator);</LI>
<LI>high risk (any non-random process, e.g. odd or even date of birth; hospital or clinic record number);</LI>
<LI>unclear risk.   </LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4"> (2) Allocation concealment (checking for possible selection bias)</HEADING>
<P>We described for each included study the method used to conceal the allocation sequence and determine whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>low risk (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes);</LI>
<LI>high risk (open random allocation; unsealed or non-opaque envelopes, alternation; date of birth);</LI>
<LI>unclear risk.   </LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(3) Blinding (checking for possible performance bias)</HEADING>
<P>We described for each included study the methods used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. We considered that studies were at low risk of bias if they were blinded, or if we judged that the lack of blinding could not have affected the results. We assessed blinding separately for different outcomes or classes of outcomes.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>low risk, high risk or unclear risk for participants;</LI>
<LI>low risk, high risk or unclear risk for personnel;</LI>
<LI>low risk, high risk or unclear risk for outcome assessors.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(4) Incomplete outcome data (checking for possible attrition bias through withdrawals, dropouts, protocol deviations)</HEADING>
<P>We described for each included study, and for each outcome or class of outcomes, the completeness of data including attrition and exclusions from the analysis. We stated whether attrition and exclusions were reported, the numbers included in the analysis at each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes.  Where sufficient information was reported, or could be supplied by the trial authors, we re-included missing data in the analyses which we undertook. We assessed methods as:</P>
<UL>
<LI>low risk;</LI>
<LI>high risk;</LI>
<LI>unclear risk.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(5) Selective reporting bias</HEADING>
<P>We described for each included study how we investigated the possibility of selective outcome reporting bias and what we found.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>low risk (where it is clear that all of the study&#8217;s pre-specified outcomes and all expected outcomes of interest to the review have been reported);</LI>
<LI>high risk (where not all the study&#8217;s pre-specified outcomes have been reported; one or more reported primary outcomes were not pre-specified; outcomes of interest were reported incompletely and so could not be used; study failed to include results of a key outcome that would have been expected to have been reported);</LI>
<LI>unclear risk.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(6) Other sources of bias</HEADING>
<P>We described for each included study any important concerns we have about other possible sources of bias.</P>
<P>We assessed whether each study was free of other problems that could put it at risk of bias:</P>
<UL>
<LI>low risk;</LI>
<LI>high risk;</LI>
<LI>unclear risk.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(7) Overall risk of bias</HEADING>
<P>We made explicit judgements about whether studies were at high risk of bias, according to the criteria given in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). With reference to (1) to (6) above, we assessed the likely magnitude and direction of the bias and whether we considered it was likely to impact on the findings.  We explored the impact of the level of bias through undertaking sensitivity analyses - <I>see </I>
<LINK TAG="SENSITIVITY_ANALYSIS" TYPE="SECTION">Sensitivity analysis</LINK>.</P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2011-08-12 13:39:48 +0100" MODIFIED_BY="Heather Maxwell">
<SUBSECTION>
<HEADING LEVEL="4">Dichotomous data</HEADING>
<P>For dichotomous data, we presented results as summary risk ratio (RR) with 95% confidence intervals (CIs).<I> </I>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Continuous data</HEADING>
<P>For continuous data, we used the mean difference (MD) if outcomes were measured in the same way between trials. We used the standardised mean difference (SMD) to combine trials that measured the same outcome, but used different methods. <B> </B>
</P>
</SUBSECTION>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2010-04-19 16:42:54 +0100" MODIFIED_BY="[Empty name]">
<P>For included studies, we noted levels of attrition. We explored the impact of including studies with high levels of missing data in the overall assessment of treatment effect by using sensitivity analysis.</P>
<P>For all outcomes, we carried out analyses, as far as possible, on information about<SUP> </SUP>retaining participants in their original assigned groups, i.e. we attempted to include all participants randomised to each group in the analyses, and all participants were analysed in the group to which they were allocated, regardless of whether or not they received the allocated intervention. The denominator for each outcome in each trial was the number randomised minus any participants whose outcomes are known to be missing.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2011-08-12 13:39:48 +0100" MODIFIED_BY="Heather Maxwell">
<P>We assessed statistical heterogeneity in each meta-analysis using the T², I² and Chi² statistics. We regarded heterogeneity as substantial if T² was greater than zero and either I² was greater than 30% or there is a low P value (less than 0.10) in the Chi² test for heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2011-08-12 13:39:48 +0100" MODIFIED_BY="Heather Maxwell">
<P>If there had been 10 or more studies in the meta-analysis we planned to investigate reporting biases (such as publication bias) using funnel plots. We would have assessed funnel plot asymmetry visually, and used formal tests for funnel plot asymmetry. For continuous outcomes we would have used the test proposed by <LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>, and for dichotomous outcomes, the test proposed by <LINK REF="REF-Harbord-2006" TYPE="REFERENCE">Harbord 2006</LINK>. If asymmetry had been detected in any of these tests, or was suggested by a visual assessment, we would have performed exploratory analyses to investigate it.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2011-08-12 13:39:48 +0100" MODIFIED_BY="Heather Maxwell">
<P>We carried out statistical analysis using the Review Manager software (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>). We used fixed-effect meta-analysis for combining data where it was reasonable to assume that studies were estimating the same underlying treatment effect: i.e. where trials were examining the same intervention, and the trials&#8217; populations and methods were judged sufficiently similar. If there was clinical heterogeneity sufficient to expect that the underlying treatment effects differed between trials, or if substantial statistical heterogeneity was detected, we used random-effects meta-analysis to produce an overall summary if an average treatment effect across trials was considered clinically meaningful. The random-effects summary was treated as the average range of possible treatment effects and we discussed the clinical implications of treatment effects differing between trials. If the average treatment effect was not clinically meaningful, we did not combine trials.</P>
<P>Where we used random-effects analyses, the results were presented as the average treatment effect with its 95% CI, and the estimates of  T² and I².</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2011-08-12 13:39:48 +0100" MODIFIED_BY="Heather Maxwell">
<P>Had we identify substantial heterogeneity, we would have investigated it using subgroup analyses and sensitivity analyses. We would have considered whether an overall summary was meaningful, and if it was, used random-effects analysis to produce it.</P>
<P>We had planned to carry out the following subgroup analyses:</P>
<OL>
<LI>level of anaemia (mild, moderate, severe).     </LI>
</OL>
<P>The following outcomes would have been used in subgroup analysis:</P>
<OL>
<LI>maternal and newborn mortality;</LI>
<LI>maternal and newborn morbidity (puerperal sepsis, days hospitalised during pregnancy, low birthweight, newborn hospitalisations days);</LI>
<LI>Hb levels.</LI>
</OL>
<P>For fixed-effect inverse variance meta-analyses, we would have assessed differences between subgroups by interaction tests. For random-effects and fixed-effect meta-analyses using methods other than inverse variance, we would have assessed differences between subgroups by inspection of the subgroups&#8217; CIs; non-overlapping CIs indicate a statistically significant difference in treatment effect between the subgroups.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2011-01-05 16:32:46 +0000" MODIFIED_BY="Denise Atherton">
<P>We had planned to carry out the following sensitivity analyses but there were insufficient data:</P>
<OL>
<LI>according to risk of bias assessment.</LI>
</OL>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2011-08-24 10:02:09 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2011-08-24 10:02:09 +0100" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2011-08-12 13:39:48 +0100" MODIFIED_BY="Heather Maxwell">
<P>The search identified 117 references: two unpublished trials, six congress abstracts, and 109 published trials. An initial trawl through this list (LR excluded 17 references of non-randomised controlled trials (RCTs). This left 100 trials for a more detailed evaluation. Seventy three studies were further excluded after first review because they were not RCTs; included mostly non-anaemic women; evaluated postpartum iron treatments; focused on non iron-deficiency anaemia; or had methodological flaws that seriously compromised their validity or resulted in insufficient useful reliable information (<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>). Two review authors (LR and AC) independently checked the trials against the inclusion criteria, and a third author (LGC) acted as the arbiter. We actively tried to contact the authors using contact information provided in their articles and on the Internet. We contacted and received responses from the authors listed in the following articles: <LINK REF="STD-Breymann-2001" TYPE="STUDY">Breymann 2001</LINK>; <LINK REF="STD-De-Souza-2004" TYPE="STUDY">De Souza 2004</LINK>; <LINK REF="STD-Mumtaz-2000" TYPE="STUDY">Mumtaz 2000</LINK>; <LINK REF="STD-Singh-1998" TYPE="STUDY">Singh 1998</LINK>; <LINK REF="STD-Suharno-1993" TYPE="STUDY">Suharno 1993</LINK>; <LINK REF="STD-Visca-1996" TYPE="STUDY">Visca 1996</LINK>. We did not receive a response to our communications from the authors of the articles listed as <LINK REF="STD-Al-Momen-1996" TYPE="STUDY">Al Momen 1996</LINK>; <LINK REF="STD-Khalafallah-2010" TYPE="STUDY">Khalafallah 2010</LINK>; <LINK REF="STD-Sarkate-2007" TYPE="STUDY">Sarkate 2007</LINK>; <LINK REF="STD-Ruangvutilet-2009" TYPE="STUDY">Ruangvutilet 2009</LINK>. We were unable to contact the authors for two articles (<LINK REF="STD-Stein-1991" TYPE="STUDY">Stein 1991</LINK>; <LINK REF="STD-Wu-1998" TYPE="STUDY">Wu 1998</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2011-08-24 10:02:09 +0100" MODIFIED_BY="[Empty name]">
<P>We included 23 RCTs in the review involving 3198 women (<LINK REF="STD-Al-2005" TYPE="STUDY">Al 2005</LINK>; <LINK REF="STD-Bayoumeu-2002" TYPE="STUDY">Bayoumeu 2002</LINK>; <LINK REF="STD-Breymann-2001" TYPE="STUDY">Breymann 2001</LINK>; <LINK REF="STD-Dawson-1965" TYPE="STUDY">Dawson 1965</LINK>; <LINK REF="STD-De-Souza-2004" TYPE="STUDY">De Souza 2004</LINK>; <LINK REF="STD-Digumarthi-2008" TYPE="STUDY">Digumarthi 2008</LINK>; <LINK REF="STD-Kaisi-1988" TYPE="STUDY">Kaisi 1988</LINK>; <LINK REF="STD-Khalafallah-2010" TYPE="STUDY">Khalafallah 2010</LINK>; <LINK REF="STD-Komolafe-2003" TYPE="STUDY">Komolafe 2003</LINK>; <LINK REF="STD-Kumar-2005" TYPE="STUDY">Kumar 2005</LINK>; <LINK REF="STD-Mumtaz-2000" TYPE="STUDY">Mumtaz 2000</LINK>; <LINK REF="STD-Nappi-2009" TYPE="STUDY">Nappi 2009</LINK>; <LINK REF="STD-Ogunbode-1980" TYPE="STUDY">Ogunbode 1980</LINK>; <LINK REF="STD-Oluboyede-1980" TYPE="STUDY">Oluboyede 1980</LINK>; <LINK REF="STD-Saha-2007" TYPE="STUDY">Saha 2007</LINK>; <LINK REF="STD-Singh-1998" TYPE="STUDY">Singh 1998</LINK>; <LINK REF="STD-Sood-1979" TYPE="STUDY">Sood 1979</LINK>; <LINK REF="STD-Suharno-1993" TYPE="STUDY">Suharno 1993</LINK>;<LINK REF="STD-Sun-2010" TYPE="STUDY">Sun 2010</LINK>; <LINK REF="STD-Symonds-1969" TYPE="STUDY">Symonds 1969</LINK>; <LINK REF="STD-Wali-2002" TYPE="STUDY">Wali 2002</LINK>; <LINK REF="STD-Zhou-2007" TYPE="STUDY">Zhou 2007</LINK>; <LINK REF="STD-Zutschi-2004" TYPE="STUDY">Zutschi 2004</LINK>). Most focused on laboratory results rather than clinical outcomes. Clinical outcomes were assessed in seven RCTs (<LINK REF="STD-Al-2005" TYPE="STUDY">Al 2005</LINK>; <LINK REF="STD-Bayoumeu-2002" TYPE="STUDY">Bayoumeu 2002</LINK>; <LINK REF="STD-Breymann-2001" TYPE="STUDY">Breymann 2001</LINK>; <LINK REF="STD-Oluboyede-1980" TYPE="STUDY">Oluboyede 1980</LINK>; <LINK REF="STD-Singh-1998" TYPE="STUDY">Singh 1998</LINK>; <LINK REF="STD-Zhou-2007" TYPE="STUDY">Zhou 2007</LINK>; <LINK REF="STD-Zutschi-2004" TYPE="STUDY">Zutschi 2004</LINK>).Although Breymann and Singh's data were unpublished, these data were provided by the main author of <LINK REF="STD-Singh-1998" TYPE="STUDY">Singh 1998</LINK> and have been incorporated into the review. LR and AC independently extracted data from the articles. LGC was expected to act as arbiter if differences arose in the data extraction, but this did not happen. LR performed data entry, and G Gyte (GG) and AC checked data entries for accuracy. Six RCTs were included in this update (<LINK REF="STD-Digumarthi-2008" TYPE="STUDY">Digumarthi 2008</LINK>; <LINK REF="STD-Khalafallah-2010" TYPE="STUDY">Khalafallah 2010</LINK>; <LINK REF="STD-Nappi-2009" TYPE="STUDY">Nappi 2009</LINK>; <LINK REF="STD-Saha-2007" TYPE="STUDY">Saha 2007</LINK>; <LINK REF="STD-Sun-2010" TYPE="STUDY">Sun 2010</LINK>; <LINK REF="STD-Zhou-2007" TYPE="STUDY">Zhou 2007</LINK>). In addition, we have added three reports to <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK> because authors did not provide useful data for analysis (<LINK REF="STD-Paleru-2011" TYPE="STUDY">Paleru 2011</LINK>; <LINK REF="STD-Pandit-2009" TYPE="STUDY">Pandit 2009</LINK>; <LINK REF="STD-Sarkate-2007" TYPE="STUDY">Sarkate 2007</LINK>) and one study was ongoing (<LINK REF="STD-Ruangvutilet-2009" TYPE="STUDY">Ruangvutilet 2009</LINK>). We contacted authors by email but only the authors of the ongoing RCT replied informing us that they were still at the stage of analysis (<LINK REF="STD-Ruangvutilet-2009" TYPE="STUDY">Ruangvutilet 2009</LINK>).<BR/>
<BR/>Seven groups of RCTs were described according to the type of intervention. However, groups were further divided according to co-interventions, dose, regimen, route, or type of chemical components of the intervention (i.e. iron sucrose, dextran), as follows.</P>
<P>(1) Oral iron<BR/>
</P>
<UL>
<LI>Oral iron versus placebo (<LINK REF="STD-Suharno-1993" TYPE="STUDY">Suharno 1993</LINK>;<LINK REF="STD-Sun-2010" TYPE="STUDY">Sun 2010</LINK>; <LINK REF="STD-Symonds-1969" TYPE="STUDY">Symonds 1969</LINK>)</LI>
<LI>Oral iron plus vitamin A versus placebo (<LINK REF="STD-Suharno-1993" TYPE="STUDY">Suharno 1993</LINK>)</LI>
<LI>Oral iron plus vitamin A versus oral iron (<LINK REF="STD-Suharno-1993" TYPE="STUDY">Suharno 1993</LINK>)</LI>
<LI>Oral iron versus bovine lactoferrin (<LINK REF="STD-Nappi-2009" TYPE="STUDY">Nappi 2009</LINK>)</LI>
</UL>
<P>
<BR/>(2) Different regimens of oral iron treatment<BR/>
</P>
<UL>
<LI>Daily oral iron versus twice-weekly (<LINK REF="STD-De-Souza-2004" TYPE="STUDY">De Souza 2004</LINK>; <LINK REF="STD-Mumtaz-2000" TYPE="STUDY">Mumtaz 2000</LINK>)</LI>
<LI>Daily oral iron versus once a week (<LINK REF="STD-De-Souza-2004" TYPE="STUDY">De Souza 2004</LINK>)</LI>
<LI>Twice-weekly iron versus once weekly iron (<LINK REF="STD-De-Souza-2004" TYPE="STUDY">De Souza 2004</LINK>)</LI>
<LI>600 mg oral iron versus 1200 mg oral iron (<LINK REF="STD-Ogunbode-1980" TYPE="STUDY">Ogunbode 1980</LINK>)</LI>
<LI>Controlled-release oral iron versus regular oral iron (<LINK REF="STD-Symonds-1969" TYPE="STUDY">Symonds 1969</LINK>)</LI>
<LI>Iron polymaltose versus ferrous sulphate (<LINK REF="STD-Saha-2007" TYPE="STUDY">Saha 2007</LINK>)</LI>
<LI>Elemental iron 20; 40 or 80 mg (<LINK REF="STD-Zhou-2007" TYPE="STUDY">Zhou 2007</LINK>)</LI>
</UL>
<P>
<BR/>(3) Intramuscular (IM) iron<BR/>
</P>
<UL>
<LI>IM iron sorbitol versus IM dextran (<LINK REF="STD-Dawson-1965" TYPE="STUDY">Dawson 1965</LINK>)</LI>
<LI>IM iron sorbitol versus intravenous (IV) iron dextran (<LINK REF="STD-Oluboyede-1980" TYPE="STUDY">Oluboyede 1980</LINK>)</LI>
</UL>
<P>
<BR/>(4) Intravenous (IV) iron<BR/>
</P>
<UL>
<LI>IV route versus placebo (<LINK REF="STD-Symonds-1969" TYPE="STUDY">Symonds 1969</LINK>)</LI>
</UL>
<P>
<BR/>(5) Parenteral route (IM or IV) versus oral route<BR/>
</P>
<UL>
<LI>IM versus oral iron treatment (<LINK REF="STD-Komolafe-2003" TYPE="STUDY">Komolafe 2003</LINK>; <LINK REF="STD-Kumar-2005" TYPE="STUDY">Kumar 2005</LINK>; <LINK REF="STD-Ogunbode-1980" TYPE="STUDY">Ogunbode 1980</LINK>; <LINK REF="STD-Zutschi-2004" TYPE="STUDY">Zutschi 2004</LINK>)</LI>
<LI>IV versus oral iron treatment (<LINK REF="STD-Al-2005" TYPE="STUDY">Al 2005</LINK>; <LINK REF="STD-Bayoumeu-2002" TYPE="STUDY">Bayoumeu 2002</LINK>; <LINK REF="STD-Digumarthi-2008" TYPE="STUDY">Digumarthi 2008</LINK>; <LINK REF="STD-Khalafallah-2010" TYPE="STUDY">Khalafallah 2010</LINK>; <LINK REF="STD-Singh-1998" TYPE="STUDY">Singh 1998</LINK>; <LINK REF="STD-Sood-1979" TYPE="STUDY">Sood 1979</LINK>; <LINK REF="STD-Symonds-1969" TYPE="STUDY">Symonds 1969</LINK>)</LI>
</UL>
<P>
<BR/>(6) IV iron versus IM iron with different regimens of parenteral iron treatment<BR/>
</P>
<UL>
<LI>IV iron versus IM iron (<LINK REF="STD-Oluboyede-1980" TYPE="STUDY">Oluboyede 1980</LINK>)</LI>
<LI>Different IM preparations (<LINK REF="STD-Dawson-1965" TYPE="STUDY">Dawson 1965</LINK>)</LI>
<LI>IV iron versus IM iron (<LINK REF="STD-Dawson-1965" TYPE="STUDY">Dawson 1965</LINK>)</LI>
<LI>IV iron with hydrocortisone versus IV iron (<LINK REF="STD-Dawson-1965" TYPE="STUDY">Dawson 1965</LINK>)</LI>
<LI>Two differing IV doses (<LINK REF="STD-Kaisi-1988" TYPE="STUDY">Kaisi 1988</LINK>)</LI>
<LI>IV iron versus IM iron (<LINK REF="STD-Wali-2002" TYPE="STUDY">Wali 2002</LINK>)</LI>
</UL>
<P>
<BR/>(7) IV administered iron sucrose with and without adjuvant recombinant human erythropoietin (<LINK REF="STD-Breymann-2001" TYPE="STUDY">Breymann 2001</LINK>)</P>
<P>For details of included studies <I>see: </I>
<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table. We have two studies awaiting classification, see <LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification</LINK>). There is one ongoing study (<LINK REF="STD-Ruangvutilet-2009" TYPE="STUDY">Ruangvutilet 2009</LINK>).</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2011-08-12 13:39:48 +0100" MODIFIED_BY="Heather Maxwell">
<P>The reasons for excluding studies are reported in <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies.</LINK> </P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2011-08-23 22:19:40 +0100" MODIFIED_BY="[Empty name]">
<P>We (LR, AC) assessed the risk of bias of the included studies independently as described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We resolved differences in interpretations by consensus among three review authors (LR, AC, LGC), after checking the criteria agreed in the original review protocol. When RCTs had potential validity or interpretation problems and just part of the data were deemed useful, we would only use such data. For example, when RCTs had high withdrawal rates, and therefore, incomplete data on outcomes at the end of follow-up, but still offered complete data at a given time that fulfilled our pre-defined inclusion criteria, we used the later data. A summary of the assessment can be viewed in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.</P>
<ALLOCATION MODIFIED="2011-08-12 13:39:48 +0100" MODIFIED_BY="Heather Maxwell">
<P>Twelve out of 23 RCTs reported on how the randomisation sequence was generated (<LINK REF="STD-Al-2005" TYPE="STUDY">Al 2005</LINK>; <LINK REF="STD-Bayoumeu-2002" TYPE="STUDY">Bayoumeu 2002</LINK>; <LINK REF="STD-Breymann-2001" TYPE="STUDY">Breymann 2001</LINK>; <LINK REF="STD-Dawson-1965" TYPE="STUDY">Dawson 1965</LINK>; <LINK REF="STD-Kaisi-1988" TYPE="STUDY">Kaisi 1988</LINK>; <LINK REF="STD-Khalafallah-2010" TYPE="STUDY">Khalafallah 2010</LINK>; <LINK REF="STD-Komolafe-2003" TYPE="STUDY">Komolafe 2003</LINK>; <LINK REF="STD-Mumtaz-2000" TYPE="STUDY">Mumtaz 2000</LINK>; <LINK REF="STD-Nappi-2009" TYPE="STUDY">Nappi 2009</LINK> ; <LINK REF="STD-Singh-1998" TYPE="STUDY">Singh 1998</LINK>; <LINK REF="STD-Suharno-1993" TYPE="STUDY">Suharno 1993</LINK>; <LINK REF="STD-Zhou-2007" TYPE="STUDY">Zhou 2007</LINK>); no information was available for the remaining RCTs.</P>
<P>Seven out of 23 studies reported adequate allocation concealment (<LINK REF="STD-Al-2005" TYPE="STUDY">Al 2005</LINK>; <LINK REF="STD-Breymann-2001" TYPE="STUDY">Breymann 2001</LINK>; <LINK REF="STD-Khalafallah-2010" TYPE="STUDY">Khalafallah 2010</LINK>; <LINK REF="STD-Mumtaz-2000" TYPE="STUDY">Mumtaz 2000</LINK>; <LINK REF="STD-Singh-1998" TYPE="STUDY">Singh 1998</LINK>; <LINK REF="STD-Suharno-1993" TYPE="STUDY">Suharno 1993</LINK>; <LINK REF="STD-Zhou-2007" TYPE="STUDY">Zhou 2007</LINK>). Published details of the randomisation were insufficient in the <LINK REF="STD-Singh-1998" TYPE="STUDY">Singh 1998</LINK> and <LINK REF="STD-Breymann-2001" TYPE="STUDY">Breymann 2001</LINK> articles, but additional details were provided by the authors upon request.</P>
<P>The allocation strategy and concealment were considered adequate in six of the 23 studies (<LINK REF="STD-Al-2005" TYPE="STUDY">Al 2005</LINK>; <LINK REF="STD-Breymann-2001" TYPE="STUDY">Breymann 2001</LINK>; <LINK REF="STD-Khalafallah-2010" TYPE="STUDY">Khalafallah 2010</LINK>; <LINK REF="STD-Mumtaz-2000" TYPE="STUDY">Mumtaz 2000</LINK>; <LINK REF="STD-Suharno-1993" TYPE="STUDY">Suharno 1993</LINK>; <LINK REF="STD-Zhou-2007" TYPE="STUDY">Zhou 2007</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2011-08-12 13:39:49 +0100" MODIFIED_BY="Heather Maxwell">
<P>In most RCTs, blinding was not used; these were open RCTs. Six RCTs described blinding (masking), three of which were adequately reported (<LINK REF="STD-Nappi-2009" TYPE="STUDY">Nappi 2009</LINK>; <LINK REF="STD-Saha-2007" TYPE="STUDY">Saha 2007</LINK>; <LINK REF="STD-Zhou-2007" TYPE="STUDY">Zhou 2007</LINK>). However, in two RCTs it was unclear whether the participants or healthcare providers were blinded to the interventions (<LINK REF="STD-Mumtaz-2000" TYPE="STUDY">Mumtaz 2000</LINK>; <LINK REF="STD-Sun-2010" TYPE="STUDY">Sun 2010</LINK>; <LINK REF="STD-Suharno-1993" TYPE="STUDY">Suharno 1993</LINK>); both RCTs assessed oral administration.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2011-08-12 13:39:49 +0100" MODIFIED_BY="Heather Maxwell">
<P>Withdrawal rates (drop outs and losses to follow up) were reported in eleven RCTs (<LINK REF="STD-Al-2005" TYPE="STUDY">Al 2005</LINK>; <LINK REF="STD-Breymann-2001" TYPE="STUDY">Breymann 2001</LINK>;<LINK REF="STD-Khalafallah-2010" TYPE="STUDY">Khalafallah 2010</LINK>; <LINK REF="STD-Komolafe-2003" TYPE="STUDY">Komolafe 2003</LINK>; <LINK REF="STD-Nappi-2009" TYPE="STUDY">Nappi 2009</LINK>; <LINK REF="STD-Ogunbode-1980" TYPE="STUDY">Ogunbode 1980</LINK>; <LINK REF="STD-Singh-1998" TYPE="STUDY">Singh 1998</LINK>;<LINK REF="STD-Sun-2010" TYPE="STUDY">Sun 2010</LINK>; <LINK REF="STD-Symonds-1969" TYPE="STUDY">Symonds 1969</LINK>; <LINK REF="STD-Zhou-2007" TYPE="STUDY">Zhou 2007</LINK>; <LINK REF="STD-Zutschi-2004" TYPE="STUDY">Zutschi 2004</LINK>).</P>
<UL>
<LI>Less than 5%: withdrawal rates were lower than 5% in five RCTs (<LINK REF="STD-Nappi-2009" TYPE="STUDY">Nappi 2009</LINK>; <LINK REF="STD-Oluboyede-1980" TYPE="STUDY">Oluboyede 1980</LINK>; <LINK REF="STD-Sood-1979" TYPE="STUDY">Sood 1979</LINK>; <LINK REF="STD-Sun-2010" TYPE="STUDY">Sun 2010</LINK>; <LINK REF="STD-Zhou-2007" TYPE="STUDY">Zhou 2007</LINK>).</LI>
</UL>
<UL>
<LI>5% to 9.9%: an RCT from Pakistan (<LINK REF="STD-Wali-2002" TYPE="STUDY">Wali 2002</LINK>) had five withdrawals (8.3%) due to intolerance in the IM iron group. An RCT from France had three withdrawals (6%) (<LINK REF="STD-Bayoumeu-2002" TYPE="STUDY">Bayoumeu 2002</LINK>) and the RCT from Australia had 17 withdrawals (8.5%) (<LINK REF="STD-Khalafallah-2010" TYPE="STUDY">Khalafallah 2010</LINK>).</LI>
</UL>
<UL>
<LI>10% to 19.9%: the West Java RCT (<LINK REF="STD-Suharno-1993" TYPE="STUDY">Suharno 1993</LINK>) had complete data available on 251 (83%) women: reasons for withdrawals are further described in the article.</LI>
</UL>
<UL>
<LI>More than 20%: an RCT from Pakistan (<LINK REF="STD-Mumtaz-2000" TYPE="STUDY">Mumtaz 2000</LINK>) recruited 191 women; of these, 160 were successfully followed for at least four weeks and supplemented for an average of 10.9 weeks. Fifty-five per cent completed the entire duration of follow-up; 15% of the women recruited did not return for a single visit and were excluded from the analysis. The remaining 30% did not complete the entire 12 weeks of planned follow-up. No significant differences were found for population characteristics (age, socio-economic status score, parity, time since last pregnancy, body mass index, initial Hb, dependants or family and the duration of follow-up) between women who withdrew and those who completed the study. The RCT from Brazil (<LINK REF="STD-De-Souza-2004" TYPE="STUDY">De Souza 2004</LINK>) had 41 (21.5%) women who withdrew or were lost to follow up; the reasons were described in the article. The analysis was done using data at 16 weeks of treatment. The UK RCT (<LINK REF="STD-Dawson-1965" TYPE="STUDY">Dawson 1965</LINK>) had high rates of losses to follow up. The RCT focused on assessing adverse effects. The RCT from Tasmania (<LINK REF="STD-Kaisi-1988" TYPE="STUDY">Kaisi 1988</LINK>) had high withdrawal rates for most outcomes (loss to follow up for Hb result was 47%) and only data on adverse effects were used for this review. The RCT from India (<LINK REF="STD-Kumar-2005" TYPE="STUDY">Kumar 2005</LINK>) recruited 220 women of whom 150 (68%) completed the study. No significant differences were found on data of initial haematological parameters, gestation, parity or literacy between women who completed the study and women who withdrew. However, withdrawals were different for women receiving oral treatment (13.5%) and those receiving IM treatment (38.5%).</LI>
</UL>
<P>A number of studies did not adequately report the outcomes (i.e. standard deviations were not reported) (<I>see</I> <LINK TAG="STUDY_QUALITY" TYPE="SECTION">Risk of bias in included studies</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2011-05-25 19:52:20 +0100" MODIFIED_BY="[Empty name]">
<P>Relevant neonatal and maternal outcomes were not frequently reported by most studies (<I>see</I> <LINK TAG="STUDY_QUALITY" TYPE="SECTION">Risk of bias in included studies</LINK>). The protocol was not available in any study (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). Only two studies (<LINK REF="STD-Khalafallah-2010" TYPE="STUDY">Khalafallah 2010</LINK>; <LINK REF="STD-Zhou-2007" TYPE="STUDY">Zhou 2007</LINK>) were registered in an international clinical trial registry.</P>
</SELECTIVE_REPORTING>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2011-08-12 13:41:03 +0100" MODIFIED_BY="Heather Maxwell">
<P>Twenty-three RCTs, involving 3198 women, met the inclusion criteria. Overall, we found insufficient assessment of the outcomes relevant to the focus of this review, especially of clinical outcomes. Most results were provided by one or two small RCTs with methodological limitations. The effect size for these are represented in this review using the risk ratio (RR) and mean difference (MD). Uncertainty levels are quantified using 95% confidence intervals (CI).</P>
<SUBSECTION>
<HEADING LEVEL="3">(1) Oral iron</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Oral iron versus placebo (comparison 01)</HEADING>
<P>We found three RCTs involving 266 women (<LINK REF="STD-Suharno-1993" TYPE="STUDY">Suharno 1993</LINK>; <LINK REF="STD-Sun-2010" TYPE="STUDY">Sun 2010</LINK>; <LINK REF="STD-Symonds-1969" TYPE="STUDY">Symonds 1969</LINK>). Data from the first RCT showed that women receiving iron (ferrous sulphate) had a lower risk of being anaemic during the second trimester (RR 0.38; 95% CI 0.26 to 0.55, one RCT, 125 women, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). In the group receiving iron, the mean Hb level was higher (MD 1.34; 95% CI 0.0.27 to 2.41; two RCT, 215 women;I<SUP>2 </SUP>98% <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>) (<LINK REF="STD-Suharno-1993" TYPE="STUDY">Suharno 1993</LINK>; <LINK REF="STD-Sun-2010" TYPE="STUDY">Sun 2010</LINK>); both trials had individual significant differences favouring oral iron treatments. Similarly, the mean serum ferritin was higher for women receiving iron (MD 0.70; 95% CI 0.52 to 0.88; one RCT, 125 women; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). A trend towards increased adverse effects (for example, nausea, vomiting, constipation and abdominal cramps) was also noticed in the second RCT (ferrous gluconate), but figures were small to allow worthy comparisons (11/51 women with adverse effects). No other assessments were found for clinical outcomes. Hence, it is difficult to establish the clinical effects of treatments in women and newborns. Conclusions need to be approached with care because they are drawn from a small sample of participants. Furthermore, one RCT assessed outcomes at the second trimester (<LINK REF="STD-Suharno-1993" TYPE="STUDY">Suharno 1993</LINK>) and it is unclear if those women sustained similar Hb levels during the rest of their pregnancy, and no assessment of haematological results was done at delivery.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Oral iron plus vitamin A versus placebo (comparison 02)</HEADING>
<P>We found one RCT involving 125 women (<LINK REF="STD-Suharno-1993" TYPE="STUDY">Suharno 1993</LINK>). It included anaemic women with a high risk of suffering vitamin A deficiency. Adding vitamin A to regular iron (ferrous sulphate), resulted in improved Hb levels. Anaemia during the second trimester was lower with oral iron plus vitamin A, compared with placebo (RR 0.04; 95% CI 0.01 to 0.15; one RCT, 125 women; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). The difference was not as large when the comparator was iron therapy only (<I>see</I> below). The applicability of these results may be limited to women in populations with vitamin A deficiency.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Oral iron versus bovine lactoferrin (comparison 25)</HEADING>
<P>One RCT involving 97 women (<LINK REF="STD-Nappi-2009" TYPE="STUDY">Nappi 2009</LINK>) found a significant reduction in the mean level of anaemia at one month with oral ferrous sulphate compared with bovine lactoferrin (MD -0.30 95% CI -0.52 to -0.08; one RCT, 97 women, <LINK REF="CMP-025.01" TYPE="ANALYSIS">Analysis 25.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">(2) Different regimens of oral iron treatment (comparisons 15, 16, 17 and 21)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Daily oral iron versus twice-weekly (comparison 15)</HEADING>
<P>An RCT from Pakistan had a loss to follow up greater than 20% for most of the outcomes and so validity of the findings is unclear (<LINK REF="STD-Mumtaz-2000" TYPE="STUDY">Mumtaz 2000</LINK>). The study found that daily oral iron (ferrous sulphate) significantly increased Hb levels at four weeks, eight weeks, and 12 weeks, compared with twice-weekly oral iron. At 12 weeks, the mean Hb level was 11.36 g/dL compared with 10.09 g/dL, respectively (MD 1.27; 95% CI 0.68 to 1.86; one RCT, 105 women; <LINK REF="CMP-015.03" TYPE="ANALYSIS">Analysis 15.3</LINK>). In women receiving daily versus twice-weekly oral iron therapy (ferrous sulphate), an RCT from Brazil (<LINK REF="STD-De-Souza-2004" TYPE="STUDY">De Souza 2004</LINK>) found no significant difference in Hb levels (MD 0.30; 95% CI -0.01 to 0.61; one RCT, 102 women; <LINK REF="CMP-015.04" TYPE="ANALYSIS">Analysis 15.4</LINK>) or anaemia (RR 1.38; 95% CI 0.86 to 2.23; one RCT, 102 women; <LINK REF="CMP-015.05" TYPE="ANALYSIS">Analysis 15.5</LINK>) at 16 weeks of treatment. A trend was found between higher doses of iron and reported adverse effects (19/48 (40%) for 1/week, 24/53 (45%) for twice/week and 35/49 (71%) for daily treatment). No further description of adverse effects was provided.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Daily oral iron versus once-weekly (comparison 16)</HEADING>
<P>One RCT from<B> </B>Brazil also had a loss to follow up greater than 20% and so the findings also have uncertain validity (<LINK REF="STD-De-Souza-2004" TYPE="STUDY">De Souza 2004</LINK>). The study found that daily oral treatment (ferrous sulphate) increased Hb levels after 16 weeks of treatment, compared with weekly oral iron (MD 0.70; 95% CI 0.36 to 1.04; one RCT, 97 women; <LINK REF="CMP-016.01" TYPE="ANALYSIS">Analysis 16.1</LINK>), the proportion of women non-anaemic at the end of the follow-up (RR 1.73; 95% CI 1.00 to 3.01; one RCT, 97 women; <LINK REF="CMP-016.02" TYPE="ANALYSIS">Analysis 16.2</LINK>) and reduced treatment failure<B> </B>(RR 0.05; 95% CI 0.01 to 0.35; one RCT, 97 women; <LINK REF="CMP-016.03" TYPE="ANALYSIS">Analysis 16.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Twice-weekly iron versus once-weekly iron (comparison 17)</HEADING>
<P>The same RCT from Brazil (<LINK REF="STD-De-Souza-2004" TYPE="STUDY">De Souza 2004</LINK>) found that a twice-weekly regimen of ferrous sulphate resulted in a modest increase in Hb levels, compared with a weekly iron regimen (MD 0.40; 95% CI 0.03 to 0.77; one RCT, 101 women; <LINK REF="CMP-017.01" TYPE="ANALYSIS">Analysis 17.1</LINK>) and reduced treatment failure (RR 0.32; 95% CI 0.15 to 0.68; one RCT, 101 women; <LINK REF="CMP-017.03" TYPE="ANALYSIS">Analysis 17.3</LINK>). However, no significant differences were found in the proportion of women non-anaemic at 16 weeks of treatment (RR 1.25; 95% CI 0.69 to 2.28; one RCT, 101 women; <LINK REF="CMP-017.02" TYPE="ANALYSIS">Analysis 17.2</LINK>). There is again a high risk of bias due to a loss to follow up of greater than 20%.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">600 mg oral iron versus 1200 mg oral iron (comparison 21)</HEADING>
<P>An RCT conducted in Nigeria (<LINK REF="STD-Ogunbode-1980" TYPE="STUDY">Ogunbode 1980</LINK>) found no significant differences in Hb levels at four weeks ( MD 0.37; 95% CI -0.77 to 1.51; one RCT, 56 women; <LINK REF="CMP-021.01" TYPE="ANALYSIS">Analysis 21.1</LINK>) and eight weeks (MD 0.02; 95% CI -1.03 to 1.07; one RCT, 56 women; <LINK REF="CMP-021.02" TYPE="ANALYSIS">Analysis 21.2</LINK>) of treatment between women receiving 600 mg versus 1200 mg of oral ferrous sulphate. All women received daily 5 mg of folic acid and 25 mg of pyrimethamine daily, in addition to ferrous sulphate.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Controlled-release oral iron versus regular oral iron (comparison 03)</HEADING>
<P>One RCT conducted in Australia (<LINK REF="STD-Symonds-1969" TYPE="STUDY">Symonds 1969</LINK>) compared controlled-release oral iron versus other iron preparations. It provided information on adverse effects, but data on effectiveness were not included because it had a very high withdrawal rate. It found no differences in nausea and vomiting, constipation and abdominal cramps<B> </B>at one month between controlled-release iron and regular oral iron. The small sample size and broad CIs illustrate that the sample size is clearly insufficient to rule out any difference (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK> to <LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Iron polymaltose versus ferrous sulphate (comparison 24)</HEADING>
<P>One RCT from India (<LINK REF="STD-Saha-2007" TYPE="STUDY">Saha 2007</LINK>) that included 100 women compared iron polymaltose (100 mg elemental iron + folic acid 500 mcg for eight weeks versus ferrous sulphate (60 mg elemental iron + folic acid 500 mcg for eight weeks). No significant differences were found in the mean level of Hb and in the proportion of women with Hb greater than 11 g/dL between groups. Concerning adverse events, a significant difference was found in constipation (RR 0.30; 95% CI 0.14 to 0.64; one RCT, 100 women, <LINK REF="CMP-024.02" TYPE="ANALYSIS">Analysis 24.2</LINK>), gastrointestinal intolerance (RR 0.41; 95% CI 0.25 to 0.69; one RCT, 100 women, <LINK REF="CMP-024.03" TYPE="ANALYSIS">Analysis 24.3</LINK>) that favoured the iron polymaltose groups. However, no significant differences were found for other adverse events (metallic taste, diarrhoea, rashes), compliance, the cost due to hospital visits and the cost due to loss of work.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Ferrous sulphate (elemental iron 20 versus 40 versus 80 mg) (comparisons 26, 27 and 28)</HEADING>
<P>One RCT conducted in Australia (<LINK REF="STD-Zhou-2007" TYPE="STUDY">Zhou 2007</LINK>) that included 180 women compared three different doses of ferrous sulphate elemental iron.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">(3) Intramuscular (IM) iron</HEADING>
<P>We found no RCTs comparing IM iron versus placebo.</P>
<SUBSECTION>
<HEADING LEVEL="4">IM iron sorbitol versus IM dextran (comparison 04)</HEADING>
<P>We found one RCT that recruited 74 women (<LINK REF="STD-Dawson-1965" TYPE="STUDY">Dawson 1965</LINK>). It did not provide effectiveness figures and had high withdrawal rates, so the findings are at high risk of bias. It found that iron sorbitol produced less skin discolouration (RR 0.21; 95% CI 0.07 to 0.65; one RCT, 48 women; <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>) and fewer headaches (RR 0.13; 95% CI 0.02 to 0.99; one RCT, 48 women; <LINK REF="CMP-004.05" TYPE="ANALYSIS">Analysis 4.5</LINK>) than IM dextran. These findings are inconclusive given the limitations of this single study and the high loss to follow up.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">IM iron sorbitol versus intravenous (IV) iron dextran (comparison 23)</HEADING>
<P>We found one RCT involving 63 women conducted in Nigeria (<LINK REF="STD-Oluboyede-1980" TYPE="STUDY">Oluboyede 1980</LINK>). It found that IM iron sorbitol increased haematocrit after four weeks of treatment (MD 2.18; 95% CI 0.77 to 3.59; one RCT, 59 women; <LINK REF="CMP-023.01" TYPE="ANALYSIS">Analysis 23.1</LINK>) and after eight weeks of treatment (MD 1.48; 95% CI 0.15 to 2.81; one RCT, 43 women; <LINK REF="CMP-023.02" TYPE="ANALYSIS">Analysis 23.2</LINK>), compared with IV iron dextran.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">(4) Intravenous (IV) iron</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">IV route versus placebo (comparison 07)</HEADING>
<P>We found one small RCT involving 54 women and conducted in Australia (<LINK REF="STD-Symonds-1969" TYPE="STUDY">Symonds 1969</LINK>). The RCT provided data on adverse effects. Data on effectiveness were not included. It found no significant differences between IV iron and placebo for: nausea and vomiting (RR 0.33; 95% CI 0.01 to 7.84; one RCT, 54 women; <LINK REF="CMP-007.02" TYPE="ANALYSIS">Analysis 7.2</LINK>), abdominal cramps (not estimable), and constipation (RR 0.25; 95% CI 0.03 to 2.09; one RCT, 54 women; <LINK REF="CMP-007.03" TYPE="ANALYSIS">Analysis 7.3</LINK>). However, the small sample size and broad CIs illustrate that the sample size is clearly insufficient to rule out any such adverse effects.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">(5) Parenteral route (IM or IV) versus oral route</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">IM versus oral iron treatment (comparisons 12, 13 and 14)</HEADING>
<P>We found four RCTs (571 women) comparing IM and oral administration of iron (<LINK REF="STD-Komolafe-2003" TYPE="STUDY">Komolafe 2003</LINK>; <LINK REF="STD-Kumar-2005" TYPE="STUDY">Kumar 2005</LINK>; <LINK REF="STD-Ogunbode-1980" TYPE="STUDY">Ogunbode 1980</LINK>; <LINK REF="STD-Zutschi-2004" TYPE="STUDY">Zutschi 2004</LINK>).</P>
<P>The first RCT, from India, (<LINK REF="STD-Zutschi-2004" TYPE="STUDY">Zutschi 2004</LINK>) evaluated 150 mg IM iron sorbitol (via three injections a day) at four-weekly intervals versus 100 mg of elemental oral iron for at least 100 days. IM iron significantly increased Hb (MD 0.54; 95% CI 0.30 to 0.78; one RCT, 200 women; <LINK REF="CMP-012.02" TYPE="ANALYSIS">Analysis 12.2</LINK>), and haematocrit levels (MD 1.40; 95% CI 0.67 to 2.13; one RCT, 200 women; <LINK REF="CMP-012.03" TYPE="ANALYSIS">Analysis 12.3</LINK>), compared with oral iron. A higher proportion of women were found to be non-anaemic at labour (RR 1.23; 95% CI 1.01 to 1.48; one RCT, 200 women; <LINK REF="CMP-012.01" TYPE="ANALYSIS">Analysis 12.1</LINK>). Adverse effects were not included in the reports of the article.</P>
<P>The second RCT, from India, compared IM sorbitol citric acid dose<B> </B>versus oral ferrous sulphate (100 mg of elemental iron) plus 5 mg of folic acid at 36 weeks of pregnancy (<LINK REF="STD-Kumar-2005" TYPE="STUDY">Kumar 2005</LINK>). Women receiving oral iron plus folic acid had a higher Hb level (MD 0.26; 95% CI 0.04 to 0.48; one RCT, 150 women; <LINK REF="CMP-014.01" TYPE="ANALYSIS">Analysis 14.1</LINK>). No significant differences were found for caesarean section rates or mean birthweight. Adverse effects were reported by 40 women receiving IM treatment versus 16 receiving oral treatment at 36 weeks of treatment (<LINK REF="CMP-014.03" TYPE="ANALYSIS">Analysis 14.3</LINK> to <LINK REF="CMP-014.15" TYPE="ANALYSIS">Analysis 14.15</LINK>). Gastrointestinal side effects (dyspepsia, constipation, diarrhoea, vomiting) were observed predominately in the oral group, while systemic reactions (local pain, staining, fever, systemic ache, arthralgia, itching and rash, immediate headache, malaise and vaso-vagal due to apprehension (it is unclear what the authors meant by this and what diagnostic criteria they used) were more frequently found in women receiving IM iron. No anaphylactic reaction or abscess formation were observed, but too few women participated in the RCT to assess these and other important adverse effects.<BR/>
<BR/>The third RCT, from Nigeria, (<LINK REF="STD-Ogunbode-1980" TYPE="STUDY">Ogunbode 1980</LINK>) was a three-arm RCT comparing iron sorbitol versus 600 mg oral ferrous sulphate versus 1200 mg oral ferrous sulphate. All women received a daily supplement of 5 mg of folic acid and 25 mg of pyrimethamine. After eight weeks, IM iron sorbitol had significantly improved haematocrit levels compared with 600 mg of oral iron (MD 2.62; 95% CI 1.26 to 3.98; one RCT, 59 women; <LINK REF="CMP-012.06" TYPE="ANALYSIS">Analysis 12.6</LINK>), and compared with 1200 mg of oral iron (MD 2.60; 95% CI 1.02 to 4.18; one RCT, 59 women; <LINK REF="CMP-012.08" TYPE="ANALYSIS">Analysis 12.8</LINK>). Adverse effects were not<B> </B>assessed.</P>
<P>The fourth RCT, conducted in Nigeria, compared IM iron dextran (250 mg iron dextran thrice-weekly until total calculated dose was given) versus 600 mg of oral ferrous sulphate plus vitamin C and folic acid (<LINK REF="STD-Komolafe-2003" TYPE="STUDY">Komolafe 2003</LINK>). It found that iron dextran significantly improved haematocrit levels after six weeks (MD 4.47; 95% CI 3.67 to 5.27; one RCT, 60 women; <LINK REF="CMP-013.01" TYPE="ANALYSIS">Analysis 13.1</LINK>) and the proportion of non-anaemic women after six weeks (RR 11.00; 95% CI 1.51 to 79.96; one RCT, 60 women; <LINK REF="CMP-013.02" TYPE="ANALYSIS">Analysis 13.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">IV versus oral iron treatment (comparisons 08 and 09)</HEADING>
<P>Pooled estimates (<LINK REF="STD-Al-2005" TYPE="STUDY">Al 2005</LINK>; <LINK REF="STD-Bayoumeu-2002" TYPE="STUDY">Bayoumeu 2002</LINK>; <LINK REF="STD-Digumarthi-2008" TYPE="STUDY">Digumarthi 2008</LINK>) for Hb levels at four weeks favoured IV iron (average MD 0.44; 95% CI 0.05 to 0.82; random-effects [X² = 3.43; T² = 0.05; P = 0.18; I²<SUP> </SUP>42%]; three RCTs, 167 women; <LINK REF="CMP-008.11" TYPE="ANALYSIS">Analysis 8.11</LINK>). Diarrhoea was less frequent in women receiving IV iron (RR 0.16; 95% CI 0.03 to 0.86; three RCTs, 237 women; <LINK REF="CMP-008.05" TYPE="ANALYSIS">Analysis 8.5</LINK>).<BR/>
<BR/>A French RCT compared IV iron sucrose given in six slow IV injections on days one, four, eight, 12, 15 and 21 according to a formula described in the article, with 240 mg of elemental iron sulphate tablets (<LINK REF="STD-Bayoumeu-2002" TYPE="STUDY">Bayoumeu 2002</LINK>); all women received 15 mg of folic acid in addition to iron. No significant differences were found in maternal Hb levels at four weeks of treatment, Hb levels in excess of 12 g/dL, neonatal Hb, ferritin levels, and birthweight. Similarly, no significant differences were found in the incidence of diarrhoea, postpartum haemorrhage, blood transfusion required, or neonatal mortality. The RCTs were underpowered to assess these outcomes properly.</P>
<P>An RCT conducted in Turkey (<LINK REF="STD-Al-2005" TYPE="STUDY">Al 2005</LINK>) compared IV iron sucrose calculated according to a formula described in the article (total dose was administered over five days and maximum daily dose administered was 400 mg elemental iron)<B> </B>versus 300 mg of elemental iron (polymaltose complex); all women were given 5 mg of folic acid daily. It found that IV iron significantly increased maternal Hb at four weeks (MD 0.68; 95% CI 0.39 to 0.97; one RCT, 90 women; <LINK REF="CMP-008.11" TYPE="ANALYSIS">Analysis 8.11</LINK>) and at birth (MD 0.75; 95% CI 0.34 to 1.16; one RCT, 90 women; <LINK REF="CMP-008.08" TYPE="ANALYSIS">Analysis 8.8</LINK>) and increased the proportion of non-anaemic women - those with Hb levels equal or greater than 11 g/dL (RR 1.54; 95% CI 1.21 to 1.94; one RCT, 90 women; <LINK REF="CMP-008.25" TYPE="ANALYSIS">Analysis 8.25</LINK>). No significant differences were found for caesarean section rates, neonatal birthweight, gestational hypertension, gestational diabetes and arthralgias (<LINK REF="CMP-008.02" TYPE="ANALYSIS">Analysis 8.2</LINK>; <LINK REF="CMP-008.14" TYPE="ANALYSIS">Analysis 8.14</LINK>; <LINK REF="CMP-008.18" TYPE="ANALYSIS">Analysis 8.18</LINK>; <LINK REF="CMP-008.23" TYPE="ANALYSIS">Analysis 8.23</LINK>; <LINK REF="CMP-008.24" TYPE="ANALYSIS">Analysis 8.24</LINK>; <LINK REF="CMP-008.27" TYPE="ANALYSIS">Analysis 8.27</LINK>).</P>
<P>A comparison of oral ferrous fumarate 200 mg three times a day versus IV iron dextrin (calculated according to described formula) found that oral treatments increased constipation, compared with IV treatments (<LINK REF="STD-Singh-1998" TYPE="STUDY">Singh 1998</LINK>) (RR 0.04; 95% CI 0.00 to 0.61; one RCT, 100 women; <LINK REF="CMP-008.03" TYPE="ANALYSIS">Analysis 8.3</LINK>). No significant differences were found for constipation when IV iron was compared with controlled-release iron. However, only one small RCT (<LINK REF="STD-Symonds-1969" TYPE="STUDY">Symonds 1969</LINK>) assessed this and it seemed to be underpowered to rule out clinically important effects (RR 0.22; 95% CI 0.03 to 1.85; one RCT, 51 women; <LINK REF="CMP-008.03" TYPE="ANALYSIS">Analysis 8.3</LINK>). One RCT, recruiting mostly Malayan and Chinese women, found that higher Hb levels were found at the end of gestation with IV versus oral treatments (<LINK REF="STD-Singh-1998" TYPE="STUDY">Singh 1998</LINK>). However, the standard deviations are 50 to 100 times narrower than those found in other studies, raising questions about their validity (<LINK REF="STD-Al-2005" TYPE="STUDY">Al 2005</LINK>; <LINK REF="STD-Suharno-1993" TYPE="STUDY">Suharno 1993</LINK>). We excluded data from the analysis pending a response from the trial's authors. No maternal or neonatal deaths were recorded in this RCT, which was the only one specifically assessing these outcomes in women receiving oral or IV treatments.</P>
<P>Three RCTs (<LINK REF="STD-Al-2005" TYPE="STUDY">Al 2005</LINK>; <LINK REF="STD-Singh-1998" TYPE="STUDY">Singh 1998</LINK>; <LINK REF="STD-Symonds-1969" TYPE="STUDY">Symonds 1969</LINK>), including one that assessed controlled-release iron (<LINK REF="STD-Symonds-1969" TYPE="STUDY">Symonds 1969</LINK>), found that oral iron was more frequently associated with complaints of nausea than IV preparations, and the magnitude of the effects was consistent across all three RCTs (RR 0.33; 95% CI 0.15 to 0.74; three trials, 244 women; <LINK REF="CMP-008.02" TYPE="ANALYSIS">Analysis 8.2</LINK>).</P>
<P>Two women were reported as suffering severe allergic reactions with IV dextran in an RCT comparing the latter with oral ferrous sulphate (<LINK REF="STD-Sood-1979" TYPE="STUDY">Sood 1979</LINK>). Data on other relevant outcomes were not available for comparison.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">IV + oral iron versus oral iron (comparisons 29)</HEADING>
<P>One RCT (<LINK REF="STD-Khalafallah-2010" TYPE="STUDY">Khalafallah 2010</LINK>) assessed daily oral ferrous sulphate 250mg (elemental iron 80 mg) with or without a single intravenous iron polymaltose infusion. The combined treatment significantly increased the mean Hb (MD 0.48 95% CI 0.21 to 0.75, one trial, 183 women; <LINK REF="CMP-029.01" TYPE="ANALYSIS">Analysis 29.1</LINK>) and in the proportion of women with mild or moderate anaemia predelivery (RR 0.55 95% CI 0.31 to 0.98) when compared with the oral treatment. Following delivery, the combined treatment also significantly increased the mean Hb (MD 0.39 95% CI 0.02 to 0.76, one trial, 183 women, <LINK REF="CMP-029.02" TYPE="ANALYSIS">Analysis 29.2</LINK>). No significant differences were found in the newborn weights, gestational age at delivery, placental cord Hb or iron status between the two treatment groups. Two patients developed urticarial reactions after commencement of IV iron infusion. Trialist reported that there was a significant benefit in the IV plus oral iron group in terms of amelioration of symptoms attributed to anaemia (energy level, well being and physical activity) within a shorter period of time</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">(6) IV iron versus IM iron with different regimens of parenteral iron treatment (comparisons 04, 05, 06, 18, 20 and 23)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">IV iron versus IM iron (comparison 23)</HEADING>
<P>An RCT from Nigeria (<LINK REF="STD-Oluboyede-1980" TYPE="STUDY">Oluboyede 1980</LINK>) found that IM sorbitol increased haematocrit levels compared with the IV dextran group at four weeks (MD 2.18; 95% CI 0.77 to 3.59, one RCT, 59 women, <LINK REF="CMP-023.01" TYPE="ANALYSIS">Analysis 23.1</LINK>) and eight weeks (MD 1.48; 95% CI 0.15 to 2.81; one RCT, 43 women; <LINK REF="CMP-023.02" TYPE="ANALYSIS">Analysis 23.2</LINK>). One women receiving IV iron suffered a severe allergic reaction whereas one participant of the IM group had viral hepatitis three months later. Authors reported that no significant differences in newborn weight and Apgar score at birth were found between the groups (no data were provided). Neonates were assessed for any complication at birth and within the first week of life; one neonate in each treatment group developed neonatal jaundice. Maternal outcomes were not reported for each group of treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Different IM preparations (comparison 04)</HEADING>
<P>One RCT compared two IM preparations (<LINK REF="STD-Dawson-1965" TYPE="STUDY">Dawson 1965</LINK>). It found that women receiving IM iron-sorbitol complex had a lower incidence of skin discolouration at injection sites at eight weeks<B> </B>(RR 0.21; 95% CI 0.07 to 0.65; one RCT, 48 women; <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>) and fewer headaches (RR 0.13; 95% CI 0.02 to 0.99; one RCT, 48 women; <LINK REF="CMP-004.05" TYPE="ANALYSIS">Analysis 4.5</LINK>) compared with IM iron dextran. Results should be interpreted with care as they come from a single, small RCT. However, this particular RCT had a robust randomisation and concealment strategy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">IV iron versus IM iron (comparison 05)</HEADING>
<P>One factorial RCT conducted in the UK compared IM treatments with IV treatment (<LINK REF="STD-Dawson-1965" TYPE="STUDY">Dawson 1965</LINK>). It found that IM iron was more frequently associated with pain in the injection site. This factorial design had some problems that were not addressed during the analysis: active treatments were compared with a single control group and no adjustments for multiple comparisons were done. This increases the possibilities of finding spurious associations. The RCT found a higher risk of skin discolouration in women receiving IM iron dextran compared with IV iron. Findings suggested a trend towards a higher risk of venous thrombosis with IV iron versus IM iron, but no statistical differences were found (RR 0.13; 95% CI 0.01 to 2.20; 4/26 with IV iron dextran (15%) versus 0/23 with IM iron; one RCT, 49 women; <LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>). However, this raises concern and an association can not be ruled out; the RCTs were underpowered to assess these outcomes properly, and these are very serious adverse effects.</P>
<P>The RCT found that IM iron dextran was not associated with higher complaints of headaches, compared with IV infusion of iron dextran (RR 3.96; 95% CI 0.91 to 17.17; one RCT, 49 women; <LINK REF="CMP-005.05" TYPE="ANALYSIS">Analysis 5.5</LINK>). The RCT was too small to rule out important clinical differences in measured adverse effects outcomes such as shivering, itching, metallic taste in mouth, severe delayed allergic reaction (<LINK REF="CMP-005.04" TYPE="ANALYSIS">Analysis 5.4</LINK> to <LINK REF="CMP-005.09" TYPE="ANALYSIS">Analysis 5.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Two differing IV doses of iron dextran (comparison 11)</HEADING>
<P>An RCT conducted in Tanzania<B> </B>compared two doses of IV iron dextran by total dose infusion (<LINK REF="STD-Kaisi-1988" TYPE="STUDY">Kaisi 1988</LINK>). All participants were given the full dose recommended by the manufacturer; group A received an additional 10 ml whereas group B was given two-thirds of that total dose. It found that allergic reactions after the infusion had finished were reduced with the lower dose (RR 0.62; 95% CI 0.45 to 0.86; one RCT, 623 women; <LINK REF="CMP-010.02" TYPE="ANALYSIS">Analysis 10.2</LINK>). No significant differences were found for life threatening allergic reactions. This RCT was not used to assess effectiveness as it failed to fulfil our quality criteria.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">IV iron versus IM iron (comparisons 19 and 20)</HEADING>
<P>An RCT conducted in Pakistan (<LINK REF="STD-Wali-2002" TYPE="STUDY">Wali 2002</LINK>) evaluated two doses of IV iron sucrose (500 mg versus 200 mg) and IM iron sorbitol. The participants were divided into three groups. In group A (n = 15), IV iron sucrose was administered intravenously according to the following formula: total iron deficit = body weight x (target Hb - actual Hb) x 0.24 + 500; in group B (n = 20) IV iron sucrose was administered using the same formula but 200 mg of iron being given for storage instead of 500 mg; in group C, iron was administered IM daily or alternate days; after parenteral administration, oral iron therapy (ferrous gluconate 250 mg) was continued until the time of giving birth. No significant differences were found regarding Hb levels and the proportion of non-anaemic women (with Hb levels greater than 11 g/dL at delivery) when the two different doses of IV iron were compared. Abdominal pain was reported by one woman in each group. Administration of IV iron sucrose (500 mg) significantly increased Hb levels (MD 1.60; 95% CI 0.87 to 2.33; one RCT, 40 women; <LINK REF="CMP-019.01" TYPE="ANALYSIS">Analysis 19.1</LINK>) and the proportion of women with Hb greater than 11 g/dL at delivery (RR 2.86; 95% CI 1.45 to 5.63; one RCT, 40 women; <LINK REF="CMP-020.02" TYPE="ANALYSIS">Analysis 20.2</LINK>) compared with IM iron sorbitol. Similarly, significant results favouring IV treatment were found when comparing IV iron sucrose (200 mg) and IM iron sorbitol for the same outcomes (MD 1.10; 95% CI 0.49 to 1.71; <LINK REF="CMP-020.01" TYPE="ANALYSIS">Analysis 20.1</LINK>), and (RR 2.50; 95% CI 1.25 to 4.99; one RCT, 45 women; <LINK REF="CMP-020.02" TYPE="ANALYSIS">Analysis 20.2</LINK>). In the IV groups 2/35 (5.7%) women had shivering and feeling of weakness within a few hours, and 3/35 (8.6%) had phlebitis at the site where IV canula was retained. In the IM group, 5/25 (20%) withdrew from the study due to intolerance (no further description was provided) and the majority complained of pain at the injection site.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">(7) IV administered iron sucrose with and without adjuvant recombinant human erythropoietin (comparison 11)</HEADING>
<P>One small size study evaluated adjuvant recombinant human erythropoietin when iron sucrose was administered intravenously (<LINK REF="STD-Breymann-2001" TYPE="STUDY">Breymann 2001</LINK>). No statistically significant differences were found in the number of women with a rise of Hb greater than 11 g/dL or caesarean delivery. The author provided unpublished data concerning birthweight and mean maternal blood pressure at the end of therapy; no significant differences were found (<LINK REF="CMP-011.06" TYPE="ANALYSIS">Analysis 11.6</LINK> and <LINK REF="CMP-011.08" TYPE="ANALYSIS">Analysis 11.8</LINK>) for these outcomes. None of the women required additional antepartum or postpartum blood transfusion.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2011-08-23 22:25:07 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2011-08-23 22:25:07 +0100" MODIFIED_BY="[Empty name]">
<P>Although iron treatments consistently increase maternal haematological indices in women diagnosed with anaemia in pregnancy attributed to iron deficiency, we found no evidence that these laboratory improvements reflected in clinical improvements such as reduced preterm delivery, reduced infant low birthweight, lower rates of pre-eclampsia, sepsis or postpartum haemorrhage and its complications (<LINK REF="REF-Scholl-1992" TYPE="REFERENCE">Scholl 1992</LINK>; <LINK REF="REF-Scholl-2000" TYPE="REFERENCE">Scholl 2000</LINK>). We found very few randomised controlled trials (RCTs) assessing clinical outcomes, and these RCTs were too small to estimate important clinical effects. Moreover, the studied populations turned out to be too small to deliver clear-cut answers to this review's questions.</P>
<P>The findings suggest that gastrointestinal adverse effects are more frequent with oral iron treatments, compared with other routes of iron administration, although these gastrointestinal effects may be considered less problematic than the adverse effects of intravenous and intramuscular iron (see below). The results of one RCT suggest that daily iron treatment is better than intermittent iron supplementation in increasing Hb at delivery in pregnant women based in developing countries. Higher doses of iron were not associated with improved haematological values. In one RCT (<LINK REF="STD-Zhou-2007" TYPE="STUDY">Zhou 2007</LINK>), daily low-dose iron supplements were effective at treating anaemia in pregnancy with less gastrointestinal side effects compared with higher doses. Although women with higher iron doses had a higher mean Hb concentration at the end of intervention, all groups of treatment (low, intermediate and high doses) were within the normal reference range for women. The neonatal and maternal outcomes were similar among groups of intervention. The assessment of the effects of controlled versus regular oral iron were mostly inconclusive; there seems to be a reduced incidence of constipation. Most oral iron studies were marred by high withdrawal rates, highlighting the importance of assessing adverse effects and compliance issues with these frequently-prescribed treatments.</P>
<P>The findings of this review suggest that adding vitamin A to regular iron (ferrous sulphate) resulted in improved Hb levels for women with vitamin A deficiency. Another Cochrane review that focused on vitamin A supplementation during pregnancy suggested beneficial effects for women in areas of poor nutritional intake (<LINK REF="REF-Van-den-Broek-2010" TYPE="REFERENCE">Van den Broek 2010</LINK>).</P>
<P>Compared with oral iron, intramuscular (IM) iron sorbitol and iron dextran improved haematological values, reduced the proportion of women without anaemia, and resulted in lower gastrointestinal side effects. But these preparations were associated with higher rates of systemic reactions.</P>
<P>The findings of this review also suggest that intravenous (IV) iron sucrose is effective, but there is uncertainty whether it may increase the incidence of serious adverse effects such as thrombosis, which was frequent (9/41; 22%). Similarly, there are worrying trends towards an increased risk of severe allergic reaction with IV dextran iron, but data were few. One study suggests that the risk of venous thrombosis may be lowered by adding hydrocortisone to the infusion, but it is unclear what the real impact of this might be and whether it has any other effects. Evidence of a relationship between doses of IV iron and risk of adverse allergic reactions is inconclusive. No effectiveness assessments were done for the compared doses of IV drugs. Compared with IM iron sucrose, IV iron sucrose significantly increased haematological indices but it is unclear what the effects are on maternal and neonatal morbidity. RCTs were insufficient to determine the clinical effects of treatments in women with iron-deficiency anaemia during pregnancy.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2011-08-12 13:39:49 +0100" MODIFIED_BY="Heather Maxwell">
<P>Although there were a reasonable number of RCTs and women in this review, the data are incomplete for a number of clinically important outcomes. In addition, there were multiple comparisons with few RCTs leading to limited opportunities to pool data. The applicability of the evidence outside the research setting is reasonable as all these studies were conducted in the clinical settings that are quite similar. The comparisons in the review are commonly undertaken and not difficult to apply. The 23 RCTs came from many different countries.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2011-06-09 15:51:51 +0100" MODIFIED_BY="[Empty name]">
<P>The objective of this review was to address the effects of iron anaemia treatments on maternal and neonatal morbidity and mortality. The review included 23 RCTs, most of which were small and with significant methodological flaws. These RCTs assessed many different questions and a broad range of treatments resulting in very limited opportunities to pool useful data. The paucity of robust studies assessing clinical effects of treatments makes it impossible to balance the benefits and harms of differing treatments for different levels of anaemia in pregnancy, in a meaningful and useful way. Many questions remain open. We cannot determine if women with mild anaemia, but otherwise healthy, will benefit from anaemia treatment; adverse effects can potentially outweigh benefits. It also remains unclear which treatments are safer and more effective in women with moderate or severe anaemia with and without associated illness.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2011-06-06 14:22:57 +0100" MODIFIED_BY="[Empty name]">
<P>We have produced updated coverage of randomised controlled trials of treatments for anaemia in pregnancy attributed to iron-deficiency by summarising the best available evidence using quantitative methods. We have endeavoured to provide information to help clinicians and stakeholders choose the most appropriate treatment. Several sources were searched to identify RCTs. However, we cannot ensure that all available RCTs were located. We had to impute data (i.e. standard deviation) from a number of RCTs. Using this technique may lead to introduce bias. In addition, a number of pooled outcomes may have been measured in different ways within RCTs (i.e. adverse events).</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2011-08-12 13:39:49 +0100" MODIFIED_BY="Heather Maxwell">
<P>Another Cochrane review that evaluated the effects and safety of preventive oral iron or iron + folic acid supplementation for women during pregnancy found that routine supplementation raised Hb levels although the authors found no evidence of the significant reduction in substantive maternal and neonatal adverse clinical outcomes (<LINK REF="REF-Pena_x002d_Rosas-2009" TYPE="REFERENCE">Pena-Rosas 2009</LINK>). Those findings are similar to those presented in this review.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2011-08-12 13:39:49 +0100" MODIFIED_BY="Heather Maxwell">
<IMPLICATIONS_PRACTICE MODIFIED="2011-08-12 13:39:49 +0100" MODIFIED_BY="Heather Maxwell">
<P>Avoidable limitations in the included randomised controlled trials (RCTs) resulted in these failing to provide sound evidence that currently available treatments for iron-deficiency anaemia in pregnant women are beneficial for women or their children. We found no scientific basis to suggest that in otherwise healthy women, the benefits of treatments for mild anaemia in pregnancy will outweigh the adverse effects associated with them. We found no evidence that in women with iron-deficiency anaemia in pregnancy, improvement in women's haematological indices translate into clinical improvements for them or their children. However, treatments are associated with frequent adverse effects such as gastrointestinal disturbances and poor compliance. Compared with oral iron, intramuscular (IM) iron improves haematological indices. But again, the support from clinical research seems to be missing and adverse effects remain poorly evaluated despite indications that treatments can result in important adverse outcomes. Intravenous (IV) iron sorbitol improves haematological values compared with IM or oral iron, but serious adverse effects are possible and remain poorly studied; knowledge of their magnitude and mitigation strategies is missing. Potential adverse effects may include venous thrombosis and severe allergic reactions. Treatment of mild anaemia in pregnancy remains controversial and unsupported by scientific proof. It is also unclear what treatments work better for severe anaemia in pregnancy. In one RCT (<LINK REF="STD-Zhou-2007" TYPE="STUDY">Zhou 2007</LINK>) daily low-dose iron supplements were effective at treating anaemia in pregnancy with less gastrointestinal side effects compared with higher doses.</P>
<P>Iron-deficiency anaemia in pregnancy is frequently diagnosed and treated, but the effects of these treatments remain largely unknown. Severe iron-deficiency anaemia affects many pregnant women in developing countries and may have considerable impact on maternal and neonatal health.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2011-08-12 13:39:49 +0100" MODIFIED_BY="Heather Maxwell">
<P>Considerable resources are being used globally to diagnose and treat anaemia in pregnant women, but it remains unclear if these efforts are worthy and beneficial to individuals or populations. Also, it is unclear if there is a positive return for this investment, and if it improves people's lives. This review is an invitation for researchers, especially those working towards the improvement of health of communities in under-resourced settings, to implement high-quality RCTs addressing knowledge gaps (such as those flagged up by this review), for this common condition. In particular, determining when treatments are worthwhile, and providing sufficient information to allow better balancing of the benefits and harms of treatments. The authors of this systematic review consider that a solution to this would be to conduct a large multicenter RCT assessing the clinical effects of a selection of commonly-used treatments in different regions of the world. The sample and duration of the follow-up in such an RCT should be estimated to allow the identification of important, frequent, and long-term effects in women and babies. Large RCTs such as the MAGPIE trial (<LINK REF="REF-Magpie-2002" TYPE="REFERENCE">Magpie 2002</LINK>) or the CRASH trial (<LINK REF="REF-Edwards-2005" TYPE="REFERENCE">Edwards 2005</LINK>) illustrate how gaps in knowledge can be effectively addressed through research, and how this can reduce harmful practices and inappropriate use of resources. We found a compelling case for a similar approach to be taken on iron-deficiency anaemia in pregnancy.</P>
<P>Some important considerations for future research are as follows.</P>
<OL>
<LI>There is an urgent need to determine what treatments improve maternal and neonatal prognosis in women with severe and moderate anaemia in poorly-resourced settings.</LI>
<LI>The effects of different doses, regimens and routes of administrations for commonly-used treatments remain to be determined. The suitability of the route of administration may be influenced by the setting or cultural background.</LI>
<LI>Stratification according to anaemia severity can help address questions of the effects in different populations, and balance differently the benefits and harms.</LI>
<LI>Women with additional factors contributing to their anaemia, such as vitamin A deficiency, need to be studied as a different population.</LI>
<LI>Clinical outcomes, including adverse effects and quality of life, need to be better addressed and considered for study sample size calculations.</LI>
<LI>Offspring outcomes are particularly important given the possibility that iron has been associated with adverse effects in some observational studies.</LI>
<LI>RCTs need to have sample sizes big enough to allow assessing adverse effects such as venous thrombosis, allergic reactions, infections, and rare but serious adverse effects, as well as long-term outcomes.</LI>
<LI>For women with mild iron-deficiency anaemia, it would be helpful to assess whether oral iron is overall beneficial compared with placebo or no treatment. Researchers need to remain aware about the clinical effects of high iron on Hb levels, and possible overdosing.</LI>
<LI>We found no studies on oral erythropoietin or transfusions; these need to be evaluated in populations where they remain likely to be used. But providing scientific support for commonly-used treatments seems to be the priority; we do not know if more harm then good is being done and yet these interventions remain widely prescribed and used.</LI>
<LI>Studies are needed to determine the effects in specific populations such as pregnant women who are anaemic and also infected with human immunodeficiency virus.</LI>
<LI>To use the CONSORT statement to improve the quality of reports of randomised trials (<LINK REF="REF-Schulz-2010" TYPE="REFERENCE">Schulz 2010</LINK>: http://www.consort-statement.org/).</LI>
</OL>
<P>[Note: The three citations in the awaiting classification section of the review may alter the conclusions of the review once assessed.]</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2011-08-19 10:22:43 +0100" MODIFIED_BY="Denise Atherton">
<P>We are grateful to Lynn Hampson, from the Cochrane Pregnancy and Childbirth Group, for her assistance with trials search. We thank Professor Jianping Liu, from the Evidence-Based Chinese Medicine Center for Clinical Research and Evaluation (Beijing University of Chinese Medicine), for translating a Chinese trial. We thank the Cochrane Pregnancy and Childbirth Group editorial staff for arranging commentaries to improve this manuscript.</P>
<P>As part of the pre-publication editorial process, this review has been commented on by three peers (an editor and two referees who are external to the editorial team), a member of the Pregnancy and Childbirth Group's international panel of consumers and the Group's Statistical Adviser.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2011-08-24 13:57:19 +0100" MODIFIED_BY="[Empty name]">
<P>Ludovic Reveiz and Luis Gabriel Cuervo have contributed to this systematic review in a personal capacity and during their spare time. Most of their contributions were made before joining the Pan American Health Organization. The Pan American Health Organization does not assume responsibility for the statements contained therein.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2011-08-24 10:04:29 +0100" MODIFIED_BY="[Empty name]">
<P>For the 2011 update, Ludovic Reveiz and Alexandra Casasbuenas appraised the papers independently. Ludovic Reveiz took the lead on writing the review, with Gill Gyte, Alexandra Casasbuenas and Luis Gabriel Cuervo providing comments on the various drafts, and revised the review in response to the editorial feedback.</P>
<P>The first published review was prepared by Luis Gabriel Cuervo and Kassam Mahomed (<LINK REF="REF-Cuervo-2001" TYPE="REFERENCE">Cuervo 2001</LINK>). The second published review was prepared by Ludovic Reveiz, Gill Gyte and Luis Gabriel Cuervo (<LINK REF="REF-Reveiz-2007" TYPE="REFERENCE">Reveiz 2007</LINK>).</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2011-06-07 07:21:39 +0100" MODIFIED_BY="[Empty name]">
<P>We have modified the 'Outcome measures' as a result of suggestions from a referee.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2011-08-24 10:04:29 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2011-08-23 22:09:44 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2011-08-11 09:34:42 +0100" MODIFIED_BY="Heather Maxwell">
<STUDY DATA_SOURCE="PUB" ID="STD-Al-2005" NAME="Al 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Al RA, Unlubilgin E, Kandemir O, Yalvac S, Cakir L, Haberal A</AU>
<TI>Intravenous versus oral iron for treatment of anemia in pregnancy: a randomized trial</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>2005</YR>
<VL>106</VL>
<NO>6</NO>
<PG>1335-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16319260"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bayoumeu-2002" MODIFIED="2010-11-15 23:09:47 +0000" MODIFIED_BY="[Empty name]" NAME="Bayoumeu 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-11-15 23:09:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bayoumeu F, Subiran-Buisset C, Baka NE, Legagneur H, Monnier-Barbarino P, Laxenaire MC</AU>
<TI>Iron therapy in iron deficiency anemia in pregnancy: intravenous route versus oral route</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2002</YR>
<VL>186</VL>
<NO>3</NO>
<PG>518-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-15 23:08:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bayoumeu F, Subiran-Buisset C, Baka NE, Legagneur H, Monnier-Barbarino P, Laxenaire MC</AU>
<TI>Iron therapy in iron deficiency anemia in pregnancy: intravenous route versus oral route</TI>
<SO>European Journal of Obstetrics &amp; Gynecology and Reproductive Biology</SO>
<YR>2005</YR>
<VL>123</VL>
<PG>S15-S19</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Breymann-2001" NAME="Breymann 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Breymann C, Visca E, Huch R, Huch A</AU>
<TI>Efficacy and safety of intravenously administered iron sucrose with and without adjuvant recombinant human erythropoietin for the treatment of resistant iron-deficiency anemia during pregnancy</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2001</YR>
<VL>184</VL>
<NO>4</NO>
<PG>662-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dawson-1965" NAME="Dawson 1965" YEAR="1965">
<REFERENCE NOTES="&lt;p&gt;Dawson D, Goldthorp W, Spencer D. Parenteral iron therapy in pregnancy. J Obstet Gynaecol Br Cmmwlth 1965; 72: 89-93.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dawson D, Goldthorp W, Spencer D</AU>
<TI>Parenteral iron therapy in pregnancy</TI>
<SO>Journal of Obstetrics and Gynaecology of the British Commonwealth</SO>
<YR>1965</YR>
<VL>72</VL>
<PG>89-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Souza-2004" MODIFIED="2010-03-11 15:26:50 +0000" MODIFIED_BY="[Empty name]" NAME="De Souza 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-03-11 15:26:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Souza AI, Batista Filho M, Ferreira LO, Figueiroa JN</AU>
<TI>The effectiveness of three regimens using ferrous sulfate to treat anemia in pregnant women</TI>
<SO>Pan American Journal of Public Health</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>5</NO>
<PG>313-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Digumarthi-2008" MODIFIED="2010-11-15 22:31:45 +0000" MODIFIED_BY="[Empty name]" NAME="Digumarthi 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-11-15 22:31:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Digumarthi L, Cheruku V</AU>
<TI>Comparison of intravenous versus oral iron in iron deficiency anaemia of pregnancy</TI>
<SO>BJOG: an international journal of obstetrics and gynaecology</SO>
<YR>2008</YR>
<VL>115</VL>
<NO>s1</NO>
<PG>53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaisi-1988" NAME="Kaisi 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Kaisi M, Ngwalle EWK, Runyoro DE, Rogers J. Evaluation of tolerance of and response to iron dextran (Imferon) adminisered by total dose infusion to pregnant women with iron deficiency anemia. Int J Gynecol Obstet 1988; 26(2): 235-243.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaisi M, Ngwalle EWK, Runyoro DE, Rogers J</AU>
<TI>Evaluation of tolerance of and response to iron dextran (Imferon) adminisered by total dose infusion to pregnant women with iron deficiency anemia</TI>
<SO>International Journal of Gynecology &amp; Obstetrics</SO>
<YR>1988</YR>
<VL>26</VL>
<NO>2</NO>
<PG>235-43</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1988255482"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Khalafallah-2010" MODIFIED="2011-08-11 09:32:17 +0100" MODIFIED_BY="Heather Maxwell" NAME="Khalafallah 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-08-11 09:32:17 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Khalafallah A, Dennis A, Bates J, Bates G, Robertson IK, Smith L, et al</AU>
<TI>A prospective randomized, controlled trial of intravenous versus oral iron for moderate iron deficiency anaemia of pregnancy</TI>
<SO>Journal of Internal Medicine</SO>
<YR>2010</YR>
<VL>268</VL>
<NO>3</NO>
<PG>286-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-06-01 20:51:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Khalafallah AA, Dennis A, Bates J, Bates G, Smith L, Shaw S, et al</AU>
<TI>A prospective randomised trial of intravenous iron therapy versus oral iron for iron deficiency anaemia in pregnant Australian women [abstract]</TI>
<SO>Blood</SO>
<YR>2007</YR>
<VL>110</VL>
<NO>11</NO>
<PG>Abstract no: 3750</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Komolafe-2003" NAME="Komolafe 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Komolafe JO, Kuti O, Ijadunola KT, Ogunniyi SO</AU>
<TI>A comparative study between intramuscular iron dextran and oral ferrous sulphate in the treatment of iron deficiency anaemia in pregnancy</TI>
<SO>Journal of Obstetrics and Gynaecology</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>6</NO>
<PG>628-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kumar-2005" NAME="Kumar 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kumar A, Jain S, Singh NP, Singh T</AU>
<TI>Oral versus high dose parenteral iron supplementation in pregnancy</TI>
<SO>International Journal of Gynecology &amp; Obstetrics</SO>
<YR>2005</YR>
<VL>89</VL>
<NO>1</NO>
<PG>7-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mumtaz-2000" NAME="Mumtaz 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mumtaz Z, Shahab S, Butt N, Rab MA, DeMuynck A</AU>
<TI>Daily iron supplementation is more effective than twice weekly iron supplementation in pregnant women in Pakistan in a randomized double-blind clinical trial</TI>
<SO>Journal of Nutrition</SO>
<YR>2000</YR>
<VL>130</VL>
<PG>2697-702</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nappi-2009" MODIFIED="2010-11-15 22:24:10 +0000" MODIFIED_BY="[Empty name]" NAME="Nappi 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-03-12 19:47:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nappi C, Tommaselli GA, Morra I, Massaro M, Formisano C, Di Carlo C</AU>
<TI>Efficacy and tolerability of oral bovine lactoferrin compared to ferrous sulfate in pregnant women with iron deficiency anemia: a prospective controlled randomized study</TI>
<SO>Acta Obstetricia et Gynecologica Scandinavica</SO>
<YR>2009</YR>
<VL>88</VL>
<NO>9</NO>
<PG>1031-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ogunbode-1980" NAME="Ogunbode 1980" YEAR="1980">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ogunbode O, Damole IO, Oluboyede OA</AU>
<TI>Iron supplement during pregnancy using three different iron regimens</TI>
<SO>Current Therapeutic Research, Clinical and Experimental</SO>
<YR>1980</YR>
<VL>27</VL>
<NO>1</NO>
<PG>75-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ogunbode O, Oluboyede O, Ayeni O</AU>
<TI>Iron deficiency anaemia during pregnancy: a comparative trial of treatment by iron poly (sorbitol-gluconic acid) complex, Ferastral and intravenous iron dextran (Imferon) infusion [abstract]</TI>
<SO>9th World Congress of Gynecology and Obstetrics; 1979 October 26-31; Tokyo, Japan</SO>
<YR>1979</YR>
<PG>266</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oluboyede-1980" NAME="Oluboyede 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oluboyede OA, Ogunbode O, Ayeni O</AU>
<TI>Iron deficiency anaemia during pregnancy. A comparative trial of treatment by iron-poly (sorbitol-gluconic acid) complex Ferastral(TM) given intramuscularly and iron dextran (Imferon)(TM) by total dose infusion</TI>
<SO>East African Medical Journal</SO>
<YR>1980</YR>
<VL>57</VL>
<PG>626-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saha-2007" MODIFIED="2010-11-15 22:24:41 +0000" MODIFIED_BY="[Empty name]" NAME="Saha 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-11-15 22:23:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saha L, Pandhi P, Gopalan S, Malhotra S, Saha P</AU>
<TI>Comparison of efficacy, tolerability, and cost of iron polymaltose complex with ferrous sulphate in the treatment of iron deficiency anemia in pregnant women</TI>
<SO>Medscape General Medicine</SO>
<YR>2007</YR>
<VL>9</VL>
<NO>1</NO>
<PG>1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Singh-1998" NAME="Singh 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Singh K, Fong YF, Kuperan P. A comparison between intravenous iron polymaltose complex (Ferrum Hausmann) and oral ferrous fumarate in the treatment of iron deficiency anaemia in pregnancy. Eur J Haematol 1998; 60: 119-124.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Singh K, Fong YF, Kuperan P</AU>
<TI>A comparison between intravenous iron polymaltose complex (Ferrum Hausmann) and oral ferrous fumarate in the treatment of iron deficiency anaemia in pregnancy</TI>
<SO>European Journal of Haematology</SO>
<YR>1998</YR>
<VL>60</VL>
<PG>119-24</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1998167778"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sood-1979" MODIFIED="2011-08-11 09:34:11 +0100" MODIFIED_BY="Heather Maxwell" NAME="Sood 1979" YEAR="1979">
<REFERENCE MODIFIED="2011-08-11 09:34:11 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sood SK, Ramachandran K, Rani K, Ramalingaswami V, Mathan VI, Ponniah J, et al</AU>
<TI>WHO sponsored collaborative studies on nutritional anaemia in India. The effect of parenteral iron administration in the control of anaemia of pregnancy</TI>
<SO>British Journal of Nutrition</SO>
<YR>1979</YR>
<VL>42</VL>
<PG>399-406</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Suharno-1993" NAME="Suharno 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Suharno D, West CE, Muhilal, Karyadi D, Hautvast JG. Supplementation with vitamin A and iron for nutritional anaemia in pregnant women in West Java, Indonesia. Lancet 1993; 342: 1325-1328.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Suharno D, West CE, Muhilal, Karyadi D, Hautvast JG</AU>
<TI>Supplementation with vitamin A and iron for nutritional anaemia in pregnant women in West Java, Indonesia</TI>
<SO>Lancet</SO>
<YR>1993</YR>
<VL>342</VL>
<PG>1325-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1994048760"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-2010" MODIFIED="2011-08-11 09:34:42 +0100" MODIFIED_BY="Heather Maxwell" NAME="Sun 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-08-11 09:34:42 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sun YY, Ma AG, Yang F, Zhang FZ, Luo YB, Jiang DC, et al</AU>
<TI>A combination of iron and retinol supplementation benefits iron status, IL-2 level and lymphocyte proliferation in anemic pregnant women</TI>
<SO>Asia Pacific Journal of Clinical Nutrition</SO>
<YR>2010</YR>
<VL>19</VL>
<NO>4</NO>
<PG>513-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Symonds-1969" NAME="Symonds 1969" YEAR="1969">
<REFERENCE NOTES="&lt;p&gt;Symonds E, Radden H, Cellier K. Controlled-release iron therapy in pregnancy. Aust NZ J Obstet Gynaecol 1969; 9(1): 21-25.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Symonds E, Radden H, Cellier K</AU>
<TI>Controlled-release iron therapy in pregnancy</TI>
<SO>Australian and New Zealand Journal of Obstetrics and Gynaecology</SO>
<YR>1969</YR>
<VL>9</VL>
<NO>1</NO>
<PG>21-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1969188811"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wali-2002" NAME="Wali 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wali A, Mushtaq A, Nilofer</AU>
<TI>Comparative study--efficacy, safety and compliance of intravenous iron sucrose and intramuscular iron sorbitol in iron deficiency anemia of pregnancy</TI>
<SO>Journal of the Pakistan Medical Association</SO>
<YR>2002</YR>
<VL>52</VL>
<NO>9</NO>
<PG>392-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhou-2007" MODIFIED="2010-11-15 23:07:30 +0000" MODIFIED_BY="[Empty name]" NAME="Zhou 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-11-15 23:07:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Makrides M</AU>
<TI>Efficacy and side effects of iron supplements for the correction of anaemia in pregnant women: a comparison of high dose vs low dose iron</TI>
<SO>Australian New Zealand Clinical Trials Registry (www.anzctr.org.au)</SO>
<YR>(accessed 19 February 2008)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-15 23:06:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhou SJ, Gibson RA, Crowther CA, Makrides M</AU>
<TI>Efficacy and side effects of iron supplements for the correction of anaemia in pregnancy: a comparison of high dose vs. low dose iron [abstract]</TI>
<SO>Journal of Paediatrics and Child Health</SO>
<YR>2007</YR>
<VL>43</VL>
<NO>Suppl 1</NO>
<PG>A30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-15 23:06:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zhou SJ, Gibson RA, Crowther CA, Makrides M</AU>
<TI>Should we lower the dose of iron when treating anaemia in pregnancy? A randomized dose-response trial</TI>
<SO>European Journal of Clinical Nutrition</SO>
<YR>2009</YR>
<VL>63</VL>
<NO>2</NO>
<PG>183-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-15 22:25:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhou SJ, Gibson RA, Makrides M</AU>
<TI>Routine iron supplementation in pregnancy has no effect on iron status of children at six months and four years of age</TI>
<SO>Journal of Pediatrics</SO>
<YR>2007</YR>
<VL>151</VL>
<NO>4</NO>
<PG>438-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zutschi-2004" NAME="Zutschi 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zutschi V, Batra S, Ahmad SS, Khera N, Chauhan G, Ghandi G, et al</AU>
<TI>Injectable iron supplementation instead of oral therapy for antenatal care</TI>
<SO>Journal of Obstetrics and Gynecology of India</SO>
<YR>2004</YR>
<VL>54</VL>
<NO>1</NO>
<PG>37-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2011-08-11 09:53:47 +0100" MODIFIED_BY="Heather Maxwell">
<STUDY DATA_SOURCE="PUB" ID="STD-Al-Momen-1996" MODIFIED="2011-08-11 09:38:39 +0100" MODIFIED_BY="Heather Maxwell" NAME="Al Momen 1996" YEAR="1996">
<REFERENCE MODIFIED="2011-08-11 09:38:39 +0100" MODIFIED_BY="Heather Maxwell" NOTES="&lt;p&gt;Al-Momen A, Al-Meshari A, Al-Nuaim L, et al. Intravenous iron sucrose complex in the treatmento of iron deficiency anemia during pregnancy. Eur J Obstet Gynecol Reprod Biol 1996; 69: 121-124.&lt;/p&gt;" NOTES_MODIFIED="2011-08-11 09:38:39 +0100" NOTES_MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Al-Momen A, Al-Meshari A, Al-Nuaim L, Saddique A, Abotalib Z, Khashogji T, et al</AU>
<TI>Intravenous iron sucrose complex in the treatment of iron deficiency anemia during pregnancy</TI>
<SO>European Journal of Obstetrics &amp; Gynecology and Reproductive Biology</SO>
<YR>1996</YR>
<VL>69</VL>
<PG>121-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1997058115"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Allaire-1961" NAME="Allaire 1961" YEAR="1961">
<REFERENCE NOTES="&lt;p&gt;Allaire B, Campagna F. Iron-deficiency anemia in pregnancy. Evaluation of diagnosis and therapy by bone marrow hemosiderin. Obstet Gynecol 1961; 17: 605-610.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Allaire B, Campagna F</AU>
<TI>Iron-deficiency anemia in pregnancy. Evaluation of diagnosis and therapy by bone marrow hemosiderin</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1961</YR>
<VL>17</VL>
<PG>605-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Amir-1983" NAME="Amir 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Amir M, Ahmad SH, Ansari Z, Dutta AK, Husain I</AU>
<TI>Total dose iron infusion during third trimester to iron deficient mothers and its influences on anemia of early infancy</TI>
<SO>Indian Pediatrics</SO>
<YR>1983</YR>
<VL>20</VL>
<NO>5</NO>
<PG>335-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ayub-2008" MODIFIED="2011-08-11 09:40:24 +0100" MODIFIED_BY="Heather Maxwell" NAME="Ayub 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-08-11 09:40:24 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ayub R, Tariq N, Adil MM, Iqbal M, Junaid A, Jaferry T</AU>
<TI>Efficacy and safety of total dose infusion of low molecular weight iron dextran in the treatment of iron deficiency anemia during pregnancy</TI>
<SO>Journal of the College of Physicians and Surgeons Pakistan</SO>
<YR>2008</YR>
<VL>18</VL>
<NO>7</NO>
<PG>424-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bare-1960" NAME="Bare 1960" YEAR="1960">
<REFERENCE NOTES="&lt;p&gt;Bare W, Sullivan A. Comparison of intravenous saccharated iron oxide and whole blood in treatment of hypochromic anemia of pregnancy. Am J Obstet Gynecol 1960; 79: 279-285.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bare W, Sullivan A</AU>
<TI>Comparison of intravenous saccharated iron oxide and whole blood in treatment of hypochromic anemia of pregnancy</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1960</YR>
<VL>79</VL>
<PG>279-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barrada-1991" MODIFIED="2011-08-11 09:41:34 +0100" MODIFIED_BY="Heather Maxwell" NAME="Barrada 1991" YEAR="1991">
<REFERENCE MODIFIED="2011-08-11 09:41:08 +0100" MODIFIED_BY="Heather Maxwell" NOTES="&lt;p&gt;Barrada M, Pateisky N, Schatten C, et al. Ferritin levels in newborn after prepartal iron medication. Geburtshilfe Frauenheilkd 1991; 51(5): 366-368.&lt;/p&gt;" NOTES_MODIFIED="2011-08-11 09:41:08 +0100" NOTES_MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Barrada M, Pateisky N, Schatten C, Salzer H, Vavra N, Spona J, et al</AU>
<TI>Ferritin levels in newborn after prepartal iron medication</TI>
<SO>Geburtshilfe und Frauenheilkunde</SO>
<YR>1991</YR>
<VL>51</VL>
<NO>5</NO>
<PG>366-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1991331243"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-08-11 09:41:34 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Barrada M, Salzer H, Schatten C, Pateisky N, Vavra N, Spona J, et al</AU>
<TI>Influence of prepartal iron-medication on newborns</TI>
<SO>Proceedings of the 13th World Congress of Gynaecology and Obstetrics (FIGO); 1991 September 15-20; Singapore</SO>
<YR>1991</YR>
<PG>38</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Basu-1973" NAME="Basu 1973" YEAR="1973">
<REFERENCE NOTES="&lt;p&gt;Basu RN, Sood SK, Ramachandan K, Mathur M, Ramalingaswami V. Ethiopathogenesis of nutritional anemia in pregnancy: a therapeutic approach. Am J Clin Nutr 1973; 26(6): 591-594.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Basu RN, Sood SK, Ramachandan K, Mathur M, Ramalingaswami V</AU>
<TI>Ethiopathogenesis of nutritional anemia in pregnancy: a therapeutic approach</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1973</YR>
<VL>26</VL>
<NO>6</NO>
<PG>591-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1973186956"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bencaiova-2009" MODIFIED="2010-11-15 23:09:31 +0000" MODIFIED_BY="[Empty name]" NAME="Bencaiova 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-11-15 23:09:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bencaiova G, von Mandach U, Zimmerman R</AU>
<TI>Optimal prophylaxis of iron deficiency and iron-deficiency anemia during pregnancy: a randomized study</TI>
<SO>Gynakologisch-Geburtshilfliche Rundschau</SO>
<YR>2007</YR>
<VL>47</VL>
<PG>140</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-15 23:09:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bencaiova G, von Mandach U, Zimmermann R</AU>
<TI>Iron prophylaxis in pregnancy: intravenous route versus oral route</TI>
<SO>European Journal Obstetrics &amp; Gynecology and Reproductive Biology</SO>
<YR>2009</YR>
<VL>144</VL>
<NO>2</NO>
<PG>135-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bhatla-2009" MODIFIED="2011-08-11 09:42:10 +0100" MODIFIED_BY="Heather Maxwell" NAME="Bhatla 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-08-11 09:42:10 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bhatla N, Kaul N, Lal N, Kriplani A, Agarwal N, Saxena R, et al</AU>
<TI>Comparison of effect of daily versus weekly iron supplementation during pregnancy on lipid peroxidation</TI>
<SO>Journal of Obstetrics and Gynaecology Research</SO>
<YR>2009</YR>
<VL>35</VL>
<NO>3</NO>
<PG>438-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bhutta-2006" MODIFIED="2010-11-15 22:31:13 +0000" MODIFIED_BY="[Empty name]" NAME="Bhutta 2006" YEAR="(acce">
<REFERENCE MODIFIED="2010-11-15 22:31:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Bhutta Z</AU>
<TI>Severe anemia treatment trials, Pakistan</TI>
<SO>ClinicalTrials.gov (http://clinicaltrials.gov/)</SO>
<YR>(accessed 21 March 2006)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Breymann-1998" NAME="Breymann 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Breymann C, Visca E, Huch R, Huch A</AU>
<TI>Recombinant human erythropoietin (rhEPO) for the therapy of severe iron deficiency anaemia during pregnancy</TI>
<SO>21st Conference of the Swiss Society of Gynecology and Obstetrics; 1988; Switzerland</SO>
<YR>1998</YR>
<PG>24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;rhEPO/parenteral iron vs. parenteral iron only in the treatment of severe pregnancy anemia.&lt;br&gt;Christian Berymann, University of Zurich.&lt;br&gt;Tel: +12555134&lt;br&gt;Fax: +12554430&lt;/p&gt;&lt;p&gt;Dept Ob/Gyn, Clinic Obstetrics and Division of Feto-Maternal Medicine, Fraunklinikstr. 108091 Zurich.&lt;/p&gt;&lt;p&gt;mailto: chb@fhk.smtp.usz.ch&lt;/p&gt;" PRIMARY="NO" TYPE="CORRESPONDENCE">
<AU>Breymann C</AU>
<TI>rhEPO/parenteral iron vs parenteral iron only in the treatment of severe pregnancy anemia</TI>
<SO>Personal communication</SO>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Breymann-2002" NAME="Breymann 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Breymann C. Iron deficiency and anaemia in pregnancy: modern aspects of diagnosis and therapy. Blood Cells, Molecules, &amp;amp; Diseases 2002;29(3):506-16&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Breymann C</AU>
<TI>Iron deficiency and anaemia in pregnancy: modern aspects of diagnosis and therapy</TI>
<SO>Blood Cells, Molecules, &amp; Diseases</SO>
<YR>2002</YR>
<VL>29</VL>
<NO>3</NO>
<PG>506-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buglanov-1984" NAME="Buglanov 1984" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buglanov AA, Saiapina EV, Turaev AT</AU>
<TI>A comparative study of the effectiveness of iron preparations in the treatment of iron deficiency anemias in pregnant women</TI>
<SO>Akusherstvo i Ginekologiia</SO>
<YR>1994</YR>
<VL>6</VL>
<PG>16-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chan-2009" MODIFIED="2010-11-15 22:32:23 +0000" MODIFIED_BY="[Empty name]" NAME="Chan 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-11-15 22:32:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chan KK, Chan BC, Lam KF, Tam S, Lao TT</AU>
<TI>Iron supplement in pregnancy and development of gestational diabetes: a randomised placebo-controlled trial</TI>
<SO>BJOG: an international journal of obstetrics and gynaecology</SO>
<YR>2009</YR>
<VL>116</VL>
<NO>6</NO>
<PG>789-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chanarin-1965" NAME="Chanarin 1965" YEAR="1965">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chanarin I, Rothman D</AU>
<TI>Response to folic and folinic acid in megaloblastic anaemia in pregnancy</TI>
<SO>Journal of Obstetrics and Gynaecology of the British Commonwealth</SO>
<YR>1965</YR>
<VL>72</VL>
<PG>374-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Christiansen-1961" NAME="Christiansen 1961" YEAR="1961">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Christiansen TC, Koszewski BJ, Grier ME</AU>
<TI>Evaluation of a new cobalt chelate with iron in pregnancy anemia</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1961</YR>
<VL>82</VL>
<PG>213-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coelho-2000" NAME="Coelho 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coelho K, Ramdas S, Pillai S</AU>
<TI>A comparative study of changes in haemoglobin with high and low dose iron preparations in pregnant women</TI>
<SO>Journal of Obstetrics and Gynecology of India</SO>
<YR>2000</YR>
<VL>50</VL>
<NO>2</NO>
<PG>37-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Souza-2009" MODIFIED="2011-08-11 09:43:18 +0100" MODIFIED_BY="Heather Maxwell" NAME="De Souza 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-08-11 09:43:18 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Souza AI, Batista Filho M, Bresani CC, Ferreira LO, Figueiroa JN</AU>
<TI>Adherence and side effects of three ferrous sulfate treatment regimens on anemic pregnant women in clinical trials</TI>
<SO>Cadernos de Saude Publica</SO>
<YR>2009</YR>
<VL>25</VL>
<NO>6</NO>
<PG>1225-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dede-2005" NAME="Dede 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dede D, Uygur B, Yilmaz T, Mungan M, Ugur M</AU>
<TI>Intravenous iron sucrose complex vs. oral ferrous sulfate for postpartum iron deficiency anemia</TI>
<SO>International Journal of Gynecology &amp; Obstetrics</SO>
<YR>2005</YR>
<VL>90</VL>
<PG>238-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dochi-1988" MODIFIED="2010-11-15 22:33:32 +0000" MODIFIED_BY="[Empty name]" NAME="Dochi 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-03-10 16:52:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dochi T</AU>
<TI>Clinical evaluation of combined therapy with slow-releasing iron preparations and Aldioxa (Isalon) in pregnant women with anemia</TI>
<TO>Nimpu Hinketsu ni Taisuru Johosei Seizai to Arujiokisa Seizai (Isaron) Heiyo Ryoho</TO>
<SO>Kiso to Rinsho (The Clinical Report)</SO>
<YR>1988</YR>
<VL>22</VL>
<NO>9</NO>
<PG>2855-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dommisse-1982" NAME="Dommisse 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dommisse J, Du Toit ED, Nicholson N</AU>
<TI>Folic acid - has it a role in the treatment of severe iron deficiency anaemia in pregnancy?</TI>
<SO>South African Medical Journal</SO>
<YR>1982</YR>
<VL>61</VL>
<PG>831-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ekstrom-2002" MODIFIED="2011-08-11 09:43:57 +0100" MODIFIED_BY="Heather Maxwell" NAME="Ekstrom 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-08-11 09:43:57 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ekstrom EC, Hyder SM, Chowdhury AM, Chowdhury SA, Lonnerdal B, Habicht JP, et al</AU>
<TI>Efficacy and trial effectiveness of weekly and daily iron supplementation among pregnant women in rural Bangladesh: disentangling the issues</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2002</YR>
<VL>76</VL>
<PG>1392-400</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Finzi-1972" NAME="Finzi 1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Finzi C, Bailo U</AU>
<TI>Treatment of anemia in pregnancy: comparison of an iron delayed-action preparation and conventional preparations</TI>
<SO>Minerva Medica</SO>
<YR>1972</YR>
<VL>63</VL>
<NO>43</NO>
<PG>2445-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fochi-1985" NAME="Fochi 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Fochi F, Ciampini M, Ceccarelli G. Efficacy of iron therapy: a comparative evaluation of four iron preparations administered to anaemic pregnant women. J Int Med Res 1985; 13(1): 1-11.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fochi F, Ciampini M, Ceccarelli G</AU>
<TI>Efficacy of iron therapy: a comparative evaluation of four iron preparations administered to anaemic pregnant women</TI>
<SO>Journal of International Medical Research</SO>
<YR>1985</YR>
<VL>13</VL>
<NO>1</NO>
<PG>1-11</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1985154970"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Govan-2005" MODIFIED="2010-11-15 22:39:43 +0000" MODIFIED_BY="[Empty name]" NAME="Govan 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-11-15 22:39:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Govan AD, Scott JM</AU>
<TI>Intravenous iron in the treatment of anemia of pregnancy. 1949</TI>
<SO>European Journal Obstetrics &amp; Gynecology and Reproductive Biology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>Suppl 2</NO>
<PG>S33-S35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Graham-2007" MODIFIED="2010-11-15 22:40:32 +0000" MODIFIED_BY="[Empty name]" NAME="Graham 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-11-15 22:40:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Graham JM, Haskell MJ, Pandey P, Shrestha RK, Brown KH, Allen LH</AU>
<TI>Supplementation with iron and riboflavin enhances dark adaptation response to vitamin A-fortified rice in iron-deficient, pregnant, nightblind Nepali women</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2007</YR>
<VL>85</VL>
<NO>5</NO>
<PG>1375-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Halksworth-2003" NAME="Halksworth 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Halksworth G, Moseley L, Carter K, Worwood M. Iron absorption from spatone (a natural mineral water) for prevention of iron deficiency in pregnancy. Clinical &amp;amp; Laboratory Haematology 2003;25(4):227-31&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Halksworth G, Moseley L, Carter K, Worwood M</AU>
<TI>Iron absorption from spatone (a natural mineral water) for prevention of iron deficiency in pregnancy</TI>
<SO>Clinical &amp; Laboratory Haematology</SO>
<YR>2003</YR>
<VL>25</VL>
<NO>4</NO>
<PG>227-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Hamilton-1973" NAME="Hamilton 1973" YEAR="1973">
<REFERENCE NOTES="&lt;p&gt;Hamilton PJS, Gebbie DAM. Antenatal clinics as trial units in evaluating treatment of anaemia in pregnancy. Proceedings of Annual Scientific Conference 1973.&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hamilton PJS, Gebbie DAM</AU>
<TI>Antenatal clinics as trial units in evaluating treatment of anaemia in pregnancy</TI>
<SO>The use and abuse of drugs and chemicals in Tropical Africa. Proceedings of the 1973 Annual Scientific Conference of the East African Research Council; 1973; Nairobi, Kenya</SO>
<YR>1973</YR>
<PG>463-6</PG>
<ED>Bagshawe AF, Maina G, Mngola, EN</ED>
<PB>East African Literature Bureau</PB>
<CY>Nairobi</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hampel-1974" NAME="Hampel 1974" YEAR="1974">
<REFERENCE NOTES="&lt;p&gt;Hampel K, Roetz R. Influence of a long-time substitution with folate-iron combination in pregnancy on serum folate and serum iron and on hematological parameters. Geburtshilfe Frauenheilkd 1974; 34: 409-417.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hampel K, Roetz R</AU>
<TI>Influence of a long-time substitution with folate-iron combination in pregnancy on serum folate and serum iron and on hematological parameters</TI>
<SO>Geburtshilfe und Frauenheilkunde</SO>
<YR>1974</YR>
<VL>34</VL>
<PG>409-17</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1974293872"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hancock-1968" MODIFIED="2010-11-15 22:41:28 +0000" MODIFIED_BY="[Empty name]" NAME="Hancock 1968" YEAR="1968">
<REFERENCE MODIFIED="2010-11-15 22:23:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hancock KW, Walker PA, Harper TA</AU>
<TI>Mobilisation of iron in pregnancy</TI>
<SO>Lancet</SO>
<YR>1968</YR>
<VL>2</VL>
<PG>1055-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harrison-1971" MODIFIED="2010-11-15 22:41:40 +0000" MODIFIED_BY="[Empty name]" NAME="Harrison 1971" YEAR="1971">
<REFERENCE MODIFIED="2010-11-15 22:23:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harrison KA, Ajabor LN, Lawson JB</AU>
<TI>Ethacrynic acid and packed-blood-cell transfusion in treatment of severe anaemia in pregnancy</TI>
<SO>Lancet</SO>
<YR>1971</YR>
<VL>1</VL>
<NO>7688</NO>
<PG>11-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Hawkins-1970" NAME="Hawkins 1970" YEAR="1970">
<REFERENCE NOTES="&lt;p&gt;Hawkins DF. Relative efficacy of sustained release iron and iron with folic acid treatment in pregnancy. CPCG Database 1987. Registre 3304.&lt;/p&gt;" PRIMARY="NO" TYPE="CORRESPONDENCE">
<AU>Hawkins DF</AU>
<TI>Relative efficacy of sustained release iron and iron with folic acid treatment in pregnancy</TI>
<SO>Personal communication</SO>
<YR>1987</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Holly-1955" NAME="Holly 1955" YEAR="1955">
<REFERENCE NOTES="&lt;p&gt;Holly R. Anemia in pregnancy. Obstet Gynecol 1955; 5: 562-569.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holly R</AU>
<TI>Anemia in pregnancy</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1955</YR>
<VL>5</VL>
<PG>562-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hosokawa-1989" MODIFIED="2010-11-15 22:41:50 +0000" MODIFIED_BY="[Empty name]" NAME="Hosokawa 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-11-15 22:23:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hosokawa K</AU>
<TI>Studies on anemia in pregnant women: therapeutic efficacy of iron monotherapy vs. combination therapy with iron and vitamin C</TI>
<TO>Nimpu Hinketsu ni Kansuru Kenkyu: Tetsuzai Tandoku Narabini Tetsuzai to Bitamin C Heiyo Ryoho no Chiryo Koka ni Tsuite</TO>
<SO>Rinsho to Kenkyu (The Japanese Journal of Clinical and Experimental Medicine)</SO>
<YR>1989</YR>
<VL>66</VL>
<NO>10</NO>
<PG>3329-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Izak-1973" NAME="Izak 1973" YEAR="1973">
<REFERENCE NOTES="&lt;p&gt;Izak G, Levy S, Rachmilewitz M, Grossowicz N. The effect of iron and folic acid therapy on combined ironand folate deficiency anaemia: the results of a clinical trial. Scand J Haematol 1973; 11(3): 236-240.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Izak G, Levy S, Rachmilewitz M, Grossowicz N</AU>
<TI>The effect of iron and folic acid therapy on combined iron and folate deficiency anaemia: the results of a clinical trial</TI>
<SO>Scandinavian Journal of Haematology</SO>
<YR>1973</YR>
<VL>11</VL>
<NO>3</NO>
<PG>236-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1974063093"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jackson-1982" NAME="Jackson 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;Jackson RT, Latham MC. Anemia of pregnancy in Liberia. Am J Clin Nutr 1982; 35: 710-714.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jackson RT, Latham MC</AU>
<TI>Anemia of pregnancy in Liberia, West Africa: a therapeutic trial</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1982</YR>
<VL>35</VL>
<PG>710-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1982179371"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jaud-1979" NAME="Jaud 1979" YEAR="1979">
<REFERENCE NOTES="&lt;p&gt;Jaud W. Folate- and iron- deficiency in pregnancy. Geburtshilfe Frauenheilkd 1979; 39(4): 317-323.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jaud W</AU>
<TI>Folate- and iron- deficiency in pregnancy</TI>
<SO>Geburtshilfe und Frauenheilkunde</SO>
<YR>1979</YR>
<VL>39</VL>
<NO>4</NO>
<PG>317-23</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1979170627"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Juarez_x002d_Vazquez-2002" NAME="Juarez-Vazquez 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Juarez-Vazquez J, Bonizzoni E, Scotti A. Iron plus folate is more effective than iron alone in the treatment of iron deficiency anaemia in pregnancy: a randomised, double blind clinical trial. BJOG: an international journal of obstetrics and gynaecology 2002;109:1009-14&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Juarez-Vazquez J, Bonizzoni E, Scotti A</AU>
<TI>Iron plus folate is more effective than iron alone in the treatment of iron deficiency anaemia in pregnancy: a randomised, double blind clinical trial</TI>
<SO>BJOG: an international journal of obstetrics and gynaecology</SO>
<YR>2002</YR>
<VL>109</VL>
<PG>1009-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kore-2006" MODIFIED="2010-11-15 22:41:59 +0000" MODIFIED_BY="[Empty name]" NAME="Kore 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-11-15 22:23:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kore SJ, Ambiye VR, Gandewar</AU>
<TI>Improving compliance of oral iron. Role of modified drug release system [abstract]</TI>
<SO>49th All India Congress of Obstetrics and Gynaecology; 2006 January 6-9; Cochin, Kerala State, India</SO>
<YR>2006</YR>
<PG>41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Krafft-2009" MODIFIED="2011-08-11 09:47:21 +0100" MODIFIED_BY="Heather Maxwell" NAME="Krafft 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-08-11 09:47:21 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krafft A, Bencaiova G, Breymann C</AU>
<TI>Selective use of recombinant human erythropoietin in pregnant patients with severe anemia or nonresponsive to iron sucrose alone</TI>
<SO>Fetal Diagnosis and Therapy</SO>
<YR>2009</YR>
<VL>25</VL>
<NO>2</NO>
<PG>239-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ma-2008" MODIFIED="2010-11-15 22:42:27 +0000" MODIFIED_BY="[Empty name]" NAME="Ma 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-03-10 16:58:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ma AG, Schouten EG., Zhang FZ, Kok FJ, Yang F, Jiang DC, et al</AU>
<TI>Retinol and riboflavin supplementation decreases the prevalence of anemia in chinese pregnant women taking iron and folic acid supplements</TI>
<SO>Journal of Nutrition</SO>
<YR>2008</YR>
<VL>138</VL>
<NO>10</NO>
<PG>1946-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mahale-1993" NAME="Mahale 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Mahale AR, Shah SH. New schedule of intramuscular iron administration for pregnant women. Asia Oceania J Obstet Gynaecol 1993; 19: 141-144&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mahale AR, Shah SH</AU>
<TI>New schedule of intramuscular iron administration for pregnant women</TI>
<SO>Asia-Oceania Journal of Obstetrics and Gynaecology</SO>
<YR>1993</YR>
<VL>19</VL>
<PG>141-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1993393475"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mahmoudian-2005" MODIFIED="2010-11-15 22:42:38 +0000" MODIFIED_BY="[Empty name]" NAME="Mahmoudian 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-11-15 22:23:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mahmoudian A, Khademloo MD</AU>
<TI>The effect of simultaneous administration of zinc sulfate and ferrous sulfate in the treatment of anemic pregnant women</TI>
<SO>Journal of Research in Medical Sciences</SO>
<YR>2005</YR>
<VL>10</VL>
<NO>4</NO>
<PG>205-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mathan-1979" NAME="Mathan 1979" YEAR="1979">
<REFERENCE NOTES="&lt;p&gt;Mathan BVI, Baker SH, Sood SK, Ramachandran K, Ramalingaswami V. WHO sponsored collaborative studies on nutritional anaemia in India. The effects of ascorbic acid and protein supplementation on the response of pregnant women to iron, pteroyglutamic acid and cyanocobalamin therapy. British Journal of Nutrition 1979;42:391-8&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mathan BVI, Baker SH, Sood SK, Ramachandran K, Ramalingaswami V</AU>
<TI>WHO sponsored collaborative studies on nutritional anaemia in India. The effects of ascorbic acid and protein supplementation on the response of pregnant women to iron, pteroyglutamic acid and cyanocobalamin therapy</TI>
<SO>British Journal of Nutrition</SO>
<YR>1979</YR>
<VL>42</VL>
<PG>391-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Milman-2006" MODIFIED="2010-11-15 22:43:32 +0000" MODIFIED_BY="[Empty name]" NAME="Milman 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-11-15 22:43:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Milman N, Byg KE, Bergholt T, Eriksen L</AU>
<TI>Side effects of oral iron prophylaxis in pregnancy--myth or reality?</TI>
<SO>Acta Haematologica</SO>
<YR>2006</YR>
<VL>115</VL>
<NO>1-2</NO>
<PG>53-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Minganti-1995" NAME="Minganti 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Minganti E, Farina A, Farina F, Calora A, d Aloja P, Dossi L, et al</AU>
<TI>Clinical study on the therapeutic efficacy and tolerability of ferrimannitol-albumin in pregnancy</TI>
<TO>Indagine clinica sull efficacia terapeutica e sulla tollerabilita della ferri-mannitol-albumina in gravidanza</TO>
<SO>Giornale Italiano di Ostetricia e Ginecologia</SO>
<YR>1995</YR>
<VL>10</VL>
<PG>597-600</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mukhopadhyay-2004" NAME="Mukhopadhyay 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mukhopadhyay A, Bhatla N, Kriplani A, Pandey RM, Saxena R</AU>
<TI>Erythrocyte indices in pregnancy: effect of intermittent iron supplementation</TI>
<SO>National Medical Journal of India</SO>
<YR>2004</YR>
<VL>17</VL>
<NO>3</NO>
<PG>135-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mukhopadhyay-2004a" NAME="Mukhopadhyay 2004a" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;Mukhopadhyay A, Bhatla N, Kriplani A, Pandey RM, Saxena R. Daily versus intermittent iron supplementation in pregnant women: Hematological and pregnancy outcome. Journal of Obstetrics and Gynaecology Research 2004;30(6):409-17&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mukhopadhyay A, Bhatla N, Kriplani A, Pandey RM, Saxena R</AU>
<TI>Daily versus intermittent iron supplementation in pregnant women: hematological and pregnancy outcome</TI>
<SO>Journal of Obstetrics and Gynaecology Research</SO>
<YR>2004</YR>
<VL>30</VL>
<NO>6</NO>
<PG>409-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ogunbode-1984" NAME="Ogunbode 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Ogunbode O, Damole IO. Treatment of anaemia in obstetric patients with sustained-release (Ferrograd Folic 500 Plus) and conventional fersolate and folic acid as separate drugs. Current Therapeutic Research, Clinical and Experimental 1984;35(6):1038-42&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ogunbode O, Damole IO</AU>
<TI>Treatment of anaemia in obstetric patients with sustained-release (Ferrograd Folic 500 Plus) and conventional fersolate and folic acid as separate drugs</TI>
<SO>Current Therapeutic Research, Clinical and Experimental</SO>
<YR>1984</YR>
<VL>35</VL>
<NO>6</NO>
<PG>1038-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Preziosi-1997" NAME="Preziosi 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Preziosi P, Prual A, Galan P, Daouda H, Boureima H, Hercberg S. Effect of iron supplementation on the iron status of pregnant women: consequences for newborns. Am J Clin Nutr 1997; 66: 1178-1182.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Preziosi P, Prual A, Galan P, Daouda H, Boureima H, Hercberg S</AU>
<TI>Effect of iron supplementation on the iron status of pregnant women: consequences for newborns</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1997</YR>
<VL>66</VL>
<PG>1178-82</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1998019349"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reddy-2000" NAME="Reddy 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;page numbers 343, 346 = correct - LH 14022007&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reddy PS, Adsul BB, Gandewar K, Desai A</AU>
<TI>Mumfer (iron polymaltose complex) in the management of anaemia in pregnancy--an Indian study</TI>
<SO>Journal of the Indian Medical Association</SO>
<YR>2000</YR>
<VL>98</VL>
<NO>6</NO>
<PG>343, 346</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ridwan-1996" NAME="Ridwan 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ridwan E, Schultink W, Dillon D, Gross R</AU>
<TI>Effects of weekly iron supplementation on pregnant indonesian women are similar to those of daily supplementation</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1996</YR>
<VL>63</VL>
<PG>884-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sagaonkar-2009" MODIFIED="2011-08-11 09:49:55 +0100" MODIFIED_BY="Heather Maxwell" NAME="Sagaonkar 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-08-11 09:49:55 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sagaonkar S, Sukhija S, Tayal R, Sagaonkar PD</AU>
<TI>Pregnancy induced iron deficiency and the evaluation and comparison of the efficacy and safety of ferrous fumarate and carbonyl iron in its treatment - PERFECT trial</TI>
<SO>Journal of Obstetrics and Gynecology of India</SO>
<YR>2009</YR>
<VL>59</VL>
<NO>6</NO>
<PG>552-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schoyerer-1975" MODIFIED="2011-06-09 13:42:46 +0100" MODIFIED_BY="[Empty name]" NAME="Schoyerer 1975" YEAR="1975">
<REFERENCE MODIFIED="2011-06-09 13:42:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schoyerer W</AU>
<TI>The addition of folic acid to the iron substitution during pregnancy</TI>
<SO>Schweizerische Rundschau fur Medizin Praxis//Revue Suisse de Medecine Praxis</SO>
<YR>1975</YR>
<VL>64</VL>
<NO>28</NO>
<PG>903-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scott-2005" MODIFIED="2010-11-15 22:44:24 +0000" MODIFIED_BY="[Empty name]" NAME="Scott 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-11-15 22:44:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scott JM, Govan AD</AU>
<TI>Anemia of pregnancy treated with intravenous iron. 1951</TI>
<SO>European Journal of Obstetrics &amp; Gynecology and Reproductive Biology</SO>
<YR>2005</YR>
<VL>123</VL>
<NO>Suppl 2</NO>
<PG>S29-S32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sharma-2004" MODIFIED="2011-08-11 09:50:41 +0100" MODIFIED_BY="Heather Maxwell" NAME="Sharma 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-08-11 09:50:41 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharma JB, Jain S, Mallika V, Singh T, Kumar A, Arora R, et al</AU>
<TI>A prospective, partially randomized study of pregnancy outcomes and hematologic responses to oral and intramuscular iron treatment in moderately anemic pregnant women</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2004</YR>
<VL>79</VL>
<NO>1</NO>
<PG>116-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Siega_x002d_Riz-2001" MODIFIED="2010-03-12 19:30:46 +0000" MODIFIED_BY="[Empty name]" NAME="Siega-Riz 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-03-12 19:30:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siega-Riz A, Hartzema A, Turnbull C, Thorp JJ, McDonald T</AU>
<TI>A trial of selective versus routine iron supplementation to prevent third trimester anemia during pregnancy</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2001</YR>
<VL>185</VL>
<NO>6 Suppl</NO>
<PG>S119</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Siega_x002d_Riz-2006" MODIFIED="2010-11-15 22:45:14 +0000" MODIFIED_BY="[Empty name]" NAME="Siega-Riz 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-11-15 22:45:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siega-Riz AM, Hartzema AG, Turnbull C, Thorp J, McDonald T, Cogswell ME</AU>
<TI>The effects of prophylactic iron given in prenatal supplements on iron status and birth outcomes: a randomized controlled trial</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2006</YR>
<VL>194</VL>
<NO>2</NO>
<PG>512-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sigridov-2005" MODIFIED="2010-11-15 22:45:40 +0000" MODIFIED_BY="[Empty name]" NAME="Sigridov 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-11-15 22:45:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sigridov I, Ivanov S</AU>
<TI>Ferro-folgamma--a good alternative in the treatment of iron deficiency anemia and depleted iron stores in pregnant women</TI>
<SO>Akusherstvo i Ginekologiia</SO>
<YR>2005</YR>
<VL>44</VL>
<NO>7</NO>
<PG>22-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sood-1975" MODIFIED="2011-08-11 09:51:28 +0100" MODIFIED_BY="Heather Maxwell" NAME="Sood 1975" YEAR="1975">
<REFERENCE MODIFIED="2011-08-11 09:51:28 +0100" MODIFIED_BY="Heather Maxwell" NOTES="&lt;p&gt;Sood SK, Ramachandran K, Mathur M, et al. W.H.O. sponsored collaborative studies on nutritional anaemia in India. 1. The effects of supplemental oral iron administration to pregnant women. Q J Med 1975; 44: 241-258.&lt;/p&gt;" NOTES_MODIFIED="2011-08-11 09:51:28 +0100" NOTES_MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sood SK, Ramachandran K, Mathur M, Gupta K, Ramalingaswami V, Swarnabai C, et al</AU>
<TI>WHO sponsored collaborative studies on nutritional anaemia in India. 1. The effects of supplemental oral iron administration to pregnant women</TI>
<SO>Quarterly Journal of Medicine</SO>
<YR>1975</YR>
<VL>44</VL>
<NO>174</NO>
<PG>241-58</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1976053828"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stein-1991" NAME="Stein 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Stein ML, Gunston KD, May RM. Iron dextran in the treatment of iron-deficiency anaemia of pregnancy. Haematological response and incidence of side-effects. S Afr Med J 1991; 79: 195-196.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stein ML, Gunston KD, May RM</AU>
<TI>Iron dextran in the treatment of iron-deficiency anaemia of pregnancy. Haematological response and incidence of side-effects</TI>
<SO>South African Medical Journal</SO>
<YR>1991</YR>
<VL>79</VL>
<PG>195-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1991142847"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steiner-1977" NAME="Steiner 1977" YEAR="1977">
<REFERENCE NOTES="&lt;p&gt;Steiner H, Hilgarth M. [Treatment of anemia in pregnancy]. Fortschr Med 1977; 95: 753-756.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steiner H, Hilgarth M</AU>
<TI>Treatment of anemia in pregnancy</TI>
<SO>Fortschritte der Medizin</SO>
<YR>1977</YR>
<VL>95</VL>
<PG>753-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1977163809"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Szarfarc-2001" NAME="Szarfarc 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Szarfarc SC, de Cassana LM, Fujimori E, Guerra-Shinohara EM, de Oliveira IM</AU>
<TI>Relative effectiveness of iron bis-glycinate chelate (Ferrochel) and ferrous sulfate in the control of iron deficiency in pregnant women</TI>
<SO>Archivos Latinoamericanos de Nutricion</SO>
<YR>2001</YR>
<VL>51</VL>
<NO>1 Suppl 1</NO>
<PG>42-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tange-1993" MODIFIED="2010-11-15 22:46:43 +0000" MODIFIED_BY="[Empty name]" NAME="Tange 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-11-15 22:23:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Tange E, Weigand E, Mbofung CM</AU>
<TI>Effect of iron supplementation on anemic and non-anemic pregnant teenagers in Cameroon</TI>
<SO>TEMA 8: Proceedings of the Eighth International Symposium on Trace Elements in Man and Animals; 1993 May 16-22; Dresden, Germany</SO>
<YR>1993</YR>
<PG>220-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thirunavukkarasu-2009" MODIFIED="2010-11-15 22:47:06 +0000" MODIFIED_BY="[Empty name]" NAME="Thirunavukkarasu 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-11-15 22:47:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thirunavukkarasu S, Bhandary A.</AU>
<TI>A novel short-course regimen of intramuscular iron therapy for anaemic pregnant women</TI>
<SO>Tropical Doctor</SO>
<YR>2009</YR>
<VL>39</VL>
<NO>4</NO>
<PG>227-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tomar-2006" MODIFIED="2010-11-15 22:47:27 +0000" MODIFIED_BY="[Empty name]" NAME="Tomar 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-11-15 22:23:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tomar R, Dubey K, Pandit U</AU>
<TI>Comparative study - efficacy, safety, compliance of intravenous iron and intra muscular iron in severe iron deficiency [abstract]</TI>
<SO>49th All India Congress of Obstetrics and Gynaecology; 2006 January 6-9; Cochin, Kerala State, India</SO>
<YR>2006</YR>
<PG>3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Valli-Rani-1995" MODIFIED="2011-08-11 09:53:47 +0100" MODIFIED_BY="Heather Maxwell" NAME="Valli Rani 1995" YEAR="1995">
<REFERENCE MODIFIED="2011-08-11 09:53:47 +0100" MODIFIED_BY="Heather Maxwell" NOTES="&lt;p&gt;Valli Rani N, Pandey J, Das B, et al. Pregnancy associated anemia and iron: a pilot study. Indian J Pathol Microbiol 1995; 38(3): 293-297.&lt;/p&gt;" NOTES_MODIFIED="2011-08-11 09:53:47 +0100" NOTES_MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Valli Rani N, Pandey J, Das B, Shruti, Talib VH, Singh K et al</AU>
<TI>Pregnancy associated anemia and iron: a pilot study</TI>
<SO>Indian Journal of Pathology and Microbiology</SO>
<YR>1995</YR>
<VL>38</VL>
<NO>3</NO>
<PG>293-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1996416871"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-den-Broek-2006" MODIFIED="2011-08-11 09:36:40 +0100" MODIFIED_BY="Heather Maxwell" NAME="Van den Broek 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-08-11 09:36:40 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van den Broek NR, White SA, Flowers C, Cook JD, Letsky EA, Tanumihardjo SA, et al</AU>
<TI>Randomised trial of vitamin A supplementation in pregnant women in rural Malawi found to be anaemic on screening by HemoCue</TI>
<SO>BJOG: an international journal of obstetrics and gynaecology</SO>
<YR>2006</YR>
<VL>113</VL>
<NO>5</NO>
<PG>569-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Visca-1996" NAME="Visca 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Visca E, Breymann CC, Huch R, Huch A. Recombinant erythropoietin (rhEPO) and iron vs. parenteral iron only for the treatment of pregnancy anemia; a prospective and randomised study. The abstracts of The 15th European Congress of Perinatal Medicine. Glasgow, Scotland. September 10-13, 1996. Poster P264.&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Visca E, Breymann CC, Huch R, Huch A</AU>
<TI>Recombinant erythropoietin (rhEPO) and iron vs. parenteral iron only for the treatment of pregnancy anemia; a prospective and randomised study</TI>
<SO>15th European Congress of Perinatal Medicine; 1996 September 10-13; Glasgow, Scotland, UK</SO>
<YR>1996</YR>
<PG>184</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Von-Peiker-1986" NAME="Von Peiker 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Von Peiker G, Muller B, Schwarz A, Dawcsynski H, Linke E</AU>
<TI>The diagnosis and treatment of iron deficiency anaemia in pregnancy</TI>
<SO>Zentralblatt fur Gynakologie</SO>
<YR>1986</YR>
<VL>108</VL>
<PG>1487-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-1998" NAME="Wu 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wu Y, Weng L, Wu L</AU>
<TI>Clinical experience with iron supplementation in pregnancy</TI>
<SO>Chinese Journal of Obstetrics &amp; Gynecology</SO>
<YR>1998</YR>
<VL>33</VL>
<NO>4</NO>
<PG>206-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Young-2000" NAME="Young 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Young MW, Lupafya E, Kapenda E, Bobrow EA. The effectiveness of weekly iron supplementation in pregnant women of rural northern malawi. Tropical Doctor 2000;30(2):84-8&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Young MW, Lupafya E, Kapenda E, Bobrow EA</AU>
<TI>The effectiveness of weekly iron supplementation in pregnant women of rural northern malawi</TI>
<SO>Tropical Doctor</SO>
<YR>2000</YR>
<VL>30</VL>
<NO>2</NO>
<PG>84-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhou-2006" MODIFIED="2010-11-15 22:47:38 +0000" MODIFIED_BY="[Empty name]" NAME="Zhou 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-03-10 16:46:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhou SJ, Gibson RA, Crowther CA, Baghurst P, Makrides M</AU>
<TI>Effect of iron supplementation during pregnancy on the intelligence quotient and behavior of children at 4 y of age: long-term follow-up of a randomized controlled trial</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2006</YR>
<VL>83</VL>
<NO>5</NO>
<PG>1112-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2011-08-23 22:09:44 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Paleru-2011" MODIFIED="2011-08-23 22:09:44 +0100" MODIFIED_BY="[Empty name]" NAME="Paleru 2011" YEAR="2011">
<REFERENCE MODIFIED="2011-08-23 22:09:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Paleru N, Anagani M, Sree J</AU>
<TI>Intravenous iron sucrose versus oral iron supplementation for treatment of iron deficiency anaemia in pregnancy</TI>
<SO>54th All India Congress of Obstetrics and Gynaecology; 2011 January 5-9; Hyderabad, Andhra Pradesh, India</SO>
<YR>2011</YR>
<PG>64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pandit-2009" MODIFIED="2010-11-15 22:48:27 +0000" MODIFIED_BY="[Empty name]" NAME="Pandit 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-11-15 22:23:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pandit S, Deshmukh P</AU>
<TI>A random prospective comparative study to evaluate the efficacy of intravenous iron sucrose versus oral ferrous sulphate in the treatment of iron deficiency anaemia of pregnancy</TI>
<SO>International Journal of Gynecology &amp; Obstetrics</SO>
<YR>2009</YR>
<VL>107</VL>
<NO>Suppl 2</NO>
<PG>S424</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sarkate-2007" MODIFIED="2010-11-15 22:48:56 +0000" MODIFIED_BY="[Empty name]" NAME="Sarkate 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-11-15 22:23:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sarkate P, Patil A, Parulekar S, Rege NN, Samant BD, Lokhande J, et al</AU>
<TI>A randomised double-blind study comparing sodium feredetate with ferrous fumarate in anaemia in pregnancy</TI>
<SO>Journal of the Indian Medical Association</SO>
<YR>2007</YR>
<VL>105</VL>
<NO>5</NO>
<PG>278, 280-1, 284</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2010-11-15 22:49:02 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Ruangvutilet-2009" MODIFIED="2010-11-15 22:49:02 +0000" MODIFIED_BY="[Empty name]" NAME="Ruangvutilet 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-11-02 09:01:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Ruangvutilet P</AU>
<TI>Comparison study of intravenous (IV) versus oral iron (Fe) for iron deficiency anemia treatment in late pregnancy (EIVF)</TI>
<SO>ClinicalTrials.gov (http://clinicaltrials.gov/)</SO>
<YR>(accessed 4 January 2009)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2011-08-24 10:04:29 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2011-08-23 22:25:07 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Adam-2005" MODIFIED="2010-04-19 16:06:24 +0100" MODIFIED_BY="[Empty name]" NAME="Adam 2005" TYPE="JOURNAL_ARTICLE">
<AU>Adam I, Khamis AH, Elbashir MI</AU>
<TI>Prevalence and risk factors for anaemia in pregnant women of eastern Sudan</TI>
<SO>Transactions of the Royal Society of Tropical Hygiene and Medicine</SO>
<YR>2005</YR>
<VL>99</VL>
<NO>10</NO>
<PG>739-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Allen-2000" MODIFIED="2010-11-15 22:49:28 +0000" MODIFIED_BY="[Empty name]" NAME="Allen 2000" TYPE="JOURNAL_ARTICLE">
<AU>Allen LH</AU>
<TI>Anemia and iron deficiency: effects on pregnancy outcome</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2000</YR>
<VL>71</VL>
<NO>5 Suppl</NO>
<PG>1280S-1284S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brabin-2001" MODIFIED="2010-04-19 16:06:24 +0100" MODIFIED_BY="[Empty name]" NAME="Brabin 2001" TYPE="JOURNAL_ARTICLE">
<AU>Brabin BJ, Hakimi M, Pelletier D</AU>
<TI>An analysis of anemia and pregnancy-related maternal mortality</TI>
<SO>Journal of Nutrition</SO>
<YR>2001</YR>
<VL>131</VL>
<PG>604S-615S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Edwards-2005" MODIFIED="2010-11-15 22:52:01 +0000" MODIFIED_BY="[Empty name]" NAME="Edwards 2005" TYPE="JOURNAL_ARTICLE">
<AU>Edwards P, Arango M, Balica L, Cottingham R, El-Sayed H, Farrell B, et al</AU>
<TI>Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6 months</TI>
<SO>Lancet</SO>
<YR>2005</YR>
<VL>365</VL>
<NO>9475</NO>
<PG>1957-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2010-04-19 16:06:24 +0100" MODIFIED_BY="[Empty name]" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7109</NO>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goroll-1997" MODIFIED="2011-08-11 09:56:06 +0100" MODIFIED_BY="Heather Maxwell" NAME="Goroll 1997" TYPE="OTHER">
<AU>Goroll H, May LA, Mulley AG</AU>
<TI>Primary care medicine on CD</TI>
<SO>Vol 1, Number 1</SO>
<YR>1997</YR>
<PB>Lippincott Raven Publishers</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gupta-2010" MODIFIED="2010-04-19 16:06:24 +0100" MODIFIED_BY="[Empty name]" NAME="Gupta 2010" TYPE="JOURNAL_ARTICLE">
<AU>Gupta SD, Khanna A, Gupta R, Sharma NK, Sharma ND</AU>
<TI>Maternal mortality ratio and predictors of maternal deaths in selected desert districts in rajasthan a community-based survey and case control study</TI>
<SO>Womens Health Issues</SO>
<YR>2010</YR>
<VL>20</VL>
<NO>1</NO>
<PG>80-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harbord-2006" MODIFIED="2010-04-19 16:06:24 +0100" MODIFIED_BY="[Empty name]" NAME="Harbord 2006" TYPE="JOURNAL_ARTICLE">
<AU>Harbord RM, Egger M, Sterne JA</AU>
<TI>A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints</TI>
<SO>Statistics in Medicine</SO>
<YR>2006</YR>
<VL>25</VL>
<NO>20</NO>
<PG>3443-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2005" NAME="Higgins 2005" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 4.2.4 [updated March 2005]</TI>
<SO>In: The Cochrane Library, Issue 2, 2005. Chichester, UK: John Wiley &amp; Sons, Ltd</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2011-08-23 22:19:54 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated September 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Klajnbard-2010" MODIFIED="2010-11-15 22:55:44 +0000" MODIFIED_BY="[Empty name]" NAME="Klajnbard 2010" TYPE="JOURNAL_ARTICLE">
<AU>Klajnbard A, Szecsi PB, Colov NP, Andersen MR, Jørgensen M, Bjørngaard B, et al</AU>
<TI>Laboratory reference intervals during pregnancy, delivery and the early postpartum period</TI>
<SO>Clinical Chemistry and Laboratory Medicine</SO>
<YR>2010</YR>
<VL>48</VL>
<NO>2</NO>
<PG>237-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Letsky-1991" MODIFIED="2011-08-23 22:20:40 +0100" MODIFIED_BY="[Empty name]" NAME="Letsky 1991" TYPE="BOOK_SECTION">
<AU>Letsky E</AU>
<TI>The haematological system</TI>
<SO>Clinical Physiology in Obstetrics</SO>
<YR>1991</YR>
<PG>39-82</PG>
<EN>2nd</EN>
<ED>Hytten F, Chamberlain G</ED>
<PB>Blackwell Scientific Publications</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Letsky-2001" MODIFIED="2010-04-19 16:06:24 +0100" MODIFIED_BY="[Empty name]" NAME="Letsky 2001" TYPE="JOURNAL_ARTICLE">
<AU>Letsky EA</AU>
<TI>Maternal anaemia in pregnancy, iron and pregnancy - a haematologist's viewpoint</TI>
<SO>Fetal and Maternal Medicine Review</SO>
<YR>2001</YR>
<VL>12</VL>
<NO>3</NO>
<PG>159-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lone-2004" MODIFIED="2010-04-19 16:06:24 +0100" MODIFIED_BY="[Empty name]" NAME="Lone 2004" TYPE="JOURNAL_ARTICLE">
<AU>Lone FW, Qureshi RN, Emmanuel F</AU>
<TI>Maternal anaemia and its impact on perinatal outcome in a tertiary care hospital in Pakistan</TI>
<SO>Eastern Mediterranean Health Journal</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>6</NO>
<PG>801-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16335767"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lops-1995" MODIFIED="2011-08-11 09:57:42 +0100" MODIFIED_BY="Heather Maxwell" NAME="Lops 1995" TYPE="JOURNAL_ARTICLE">
<AU>Lops VR, Hunter LP, Dixon LR</AU>
<TI>Anemia in pregnancy</TI>
<SO>American Family Physician</SO>
<YR>1995</YR>
<VL>51</VL>
<PG>1189-97</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1995225250"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Magpie-2002" MODIFIED="2010-11-10 19:27:29 +0000" MODIFIED_BY="[Empty name]" NAME="Magpie 2002" TYPE="JOURNAL_ARTICLE">
<AU>Magpie Trial Collaborative Group</AU>
<TI>Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>359</VL>
<NO>9321</NO>
<PG>1877-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mahomed-1989" MODIFIED="2011-08-23 22:16:40 +0100" MODIFIED_BY="[Empty name]" NAME="Mahomed 1989" TYPE="BOOK_SECTION">
<AU>Mahomed K, Hytten F</AU>
<TI>Iron and folate supplementation in pregnancy</TI>
<SO>Effective Care in Pregnancy and Childbirth</SO>
<YR>1989</YR>
<VL>1</VL>
<PG>301-17</PG>
<ED>Chalmers I, Enkin M, Keirse MJNC</ED>
<PB>Oxford University Press</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mani-1995" MODIFIED="2010-04-19 16:06:24 +0100" MODIFIED_BY="[Empty name]" NAME="Mani 1995" TYPE="JOURNAL_ARTICLE">
<AU>Mani S, Duffy TP</AU>
<TI>Anemia of pregnancy</TI>
<SO>Perinatal Hematology</SO>
<YR>1995</YR>
<VL>22</VL>
<NO>3</NO>
<PG>593-607</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McLean-2009" MODIFIED="2010-11-15 22:57:18 +0000" MODIFIED_BY="[Empty name]" NAME="McLean 2009" TYPE="JOURNAL_ARTICLE">
<AU>McLean E, Cogswell M, Egli I, Wojdyla D, de Benoist B</AU>
<TI>Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993-2005</TI>
<SO>Public Health Nutrition</SO>
<YR>2009</YR>
<VL>12</VL>
<NO>4</NO>
<PG>444-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Noronha-2010" MODIFIED="2010-11-15 22:58:24 +0000" MODIFIED_BY="[Empty name]" NAME="Noronha 2010" TYPE="JOURNAL_ARTICLE">
<AU>Noronha JA, Bhaduri A, Vinod Bhat H, Kamath A</AU>
<TI>Maternal risk factors and anaemia in pregnancy: a prospective retrospective cohort study</TI>
<SO>Journal of Obstetrics and Gynaecology</SO>
<YR>2010</YR>
<VL>30</VL>
<NO>2</NO>
<PG>132-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pena_x002d_Rosas-2009" MODIFIED="2011-08-23 22:17:12 +0100" MODIFIED_BY="[Empty name]" NAME="Pena-Rosas 2009" TYPE="COCHRANE_REVIEW">
<AU>Pena-Rosas JP, Viteri FE</AU>
<TI>Effects and safety of preventive oral iron or iron+folic acid supplementation for women during pregnancy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2010-11-03 14:47:54 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-11-03 14:47:54 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004736.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2011" MODIFIED="2011-06-08 06:56:29 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 2011" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan) [Computer program] Version 5.1. Copenhagen: The Nordic Cochrane Centre</TI>
<YR>2011</YR>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Scholl-1992" MODIFIED="2010-04-19 16:06:24 +0100" MODIFIED_BY="[Empty name]" NAME="Scholl 1992" TYPE="JOURNAL_ARTICLE">
<AU>Scholl TO, Hediger ML, Fischer RL, Shearer JW</AU>
<TI>Anemia vs iron deficiency: increased risk of preterm delivery in a prospective study</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1992</YR>
<VL>55</VL>
<PG>985-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Scholl-2000" MODIFIED="2011-08-23 22:25:07 +0100" MODIFIED_BY="[Empty name]" NAME="Scholl 2000" TYPE="JOURNAL_ARTICLE">
<AU>Scholl TO, Reilly T</AU>
<TI>Anemia, iron and pregnancy outcome</TI>
<SO>Journal of Nutrition</SO>
<YR>2000</YR>
<VL>130</VL>
<NO>2 Suppl</NO>
<PG>443S-447S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-2010" MODIFIED="2010-11-15 22:59:22 +0000" MODIFIED_BY="[Empty name]" NAME="Schulz 2010" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Altman DG, Moher D; for the CONSORT Group</AU>
<TI>CONSORT 2010 statement: updated guidelines for reporting parallel-group randomized trials</TI>
<SO>BMJ</SO>
<YR>2010</YR>
<VL>340</VL>
<PG>c332</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Steer-1995" MODIFIED="2010-04-19 16:06:24 +0100" MODIFIED_BY="[Empty name]" NAME="Steer 1995" TYPE="JOURNAL_ARTICLE">
<AU>Steer P, Alam MA, Wadsworth J, Welch A</AU>
<TI>Relation between maternal haemoglobin concentration and birth weight in different ethnic groups</TI>
<SO>BMJ</SO>
<YR>1995</YR>
<VL>310</VL>
<NO>6978</NO>
<PG>489-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-den-Broek-2010" MODIFIED="2011-08-11 10:02:07 +0100" MODIFIED_BY="Heather Maxwell" NAME="Van den Broek 2010" TYPE="COCHRANE_REVIEW">
<AU>Van den Broek N, Dou L, Othman M, Neilson JP, Gates S, Gülmezoglu AM</AU>
<TI>Vitamin A supplementation during pregnancy for maternal and newborn outcomes</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>11</NO>
<IDENTIFIERS MODIFIED="2011-08-11 10:02:07 +0100" MODIFIED_BY="Heather Maxwell">
<IDENTIFIER MODIFIED="2011-08-11 10:02:01 +0100" MODIFIED_BY="Heather Maxwell" TYPE="DOI" VALUE="10.1002/14651858.CD001996.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Walter-1994" MODIFIED="2010-04-19 16:06:24 +0100" MODIFIED_BY="[Empty name]" NAME="Walter 1994" TYPE="JOURNAL_ARTICLE">
<AU>Walter T</AU>
<TI>Effect of iron-deficiency anaemia on cognitive skills in infancy and childhood</TI>
<SO>Baillieres Clinical Haematology</SO>
<YR>1994</YR>
<VL>7</VL>
<PG>815-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1989" MODIFIED="2010-04-19 16:06:24 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 1989" TYPE="BOOK">
<AU>World Health Organization</AU>
<SO>Preventing and controlling iron deficiency anaemia through primary health care</SO>
<YR>1989</YR>
<PB>WHO</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1992" MODIFIED="2011-08-11 09:59:28 +0100" MODIFIED_BY="Heather Maxwell" NAME="WHO 1992" TYPE="BOOK">
<AU>World Health Organization</AU>
<SO>The prevalence of anaemia in women: a tabulation of available information (WHO/MCH/MSM/92)</SO>
<YR>1992</YR>
<EN>2nd</EN>
<PB>WHO, Maternal Health and Safe Motherhood Programme, Division of Family Health</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2000" MODIFIED="2010-04-19 16:06:24 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 2000" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>Maternal mortality in 2000. Estimates developed by WHO, UNICEF and UNFPA</TI>
<SO>www.who.int</SO>
<YR>(accessed 2004)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2001" MODIFIED="2011-08-11 10:27:23 +0100" MODIFIED_BY="Heather Maxwell" NAME="WHO 2001" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>Iron deficiency anaemia, assessment, prevention, and control: a guide for programme managers</TI>
<SO>http://www.who.int/reproductive-health/docs/anaemia.pdf</SO>
<YR>(accessed February 14 2007)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Williams-1992" MODIFIED="2011-08-11 09:59:42 +0100" MODIFIED_BY="Heather Maxwell" NAME="Williams 1992" TYPE="JOURNAL_ARTICLE">
<AU>Williams MD, Wheby MS</AU>
<TI>Anemia in pregnancy</TI>
<SO>Medical Clinics of North America</SO>
<YR>1992</YR>
<VL>76</VL>
<PG>631-47</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1992252444"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2011-08-24 10:04:29 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Cuervo-2001" MODIFIED="2011-08-24 10:04:29 +0100" MODIFIED_BY="[Empty name]" NAME="Cuervo 2001" TYPE="COCHRANE_REVIEW">
<AU>Cuervo LG, Mahomed K</AU>
<TI>Treatments for iron deficiency anaemia in pregnancy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2011-08-23 22:36:13 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-08-23 22:36:13 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003094"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Reveiz-2007" MODIFIED="2011-01-13 12:16:04 +0000" MODIFIED_BY="Denise Atherton" NAME="Reveiz 2007" TYPE="COCHRANE_REVIEW">
<AU>Reveiz L, Gyte GML, Cuervo LG</AU>
<TI>Treatments for iron-deficiency anaemia in pregnancy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2011-01-13 12:16:04 +0000" MODIFIED_BY="Denise Atherton">
<IDENTIFIER MODIFIED="2011-01-13 12:16:04 +0000" MODIFIED_BY="Denise Atherton" TYPE="DOI" VALUE="10.1002/14651858.CD003094.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2011-06-09 07:41:18 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Khalafallah-2010" MODIFIED="2011-06-09 07:41:17 +0100" MODIFIED_BY="[Empty name]" NAME="Khalafallah 2010" TYPE="JOURNAL_ARTICLE">
<AU>Khalafallah A, Dennis A, Bates J, Bates G, Robertson IK, Smith L, et al</AU>
<TI>A prospective randomized, controlled trial of intravenous versus oral iron for moderate iron deficiency anaemia of pregnancy</TI>
<SO>Journal of Internal Medicine</SO>
<YR>2010</YR>
<VL>268</VL>
<NO>3</NO>
<PG>286-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Paleru-2011" MODIFIED="2011-06-09 07:41:17 +0100" MODIFIED_BY="[Empty name]" NAME="Paleru 2011" TYPE="CONFERENCE_PROC">
<AU>Paleru N, Anagani M, Sree J</AU>
<TI>Intravenous iron sucrose versus oral iron supplementation for treatment of iron deficiency anaemia in pregnancy</TI>
<SO>54th All India Congress of Obstetrics and Gynaecology; 2011 January 5-9; Hyderabad, Andhra Pradesh, India</SO>
<YR>2011</YR>
<PG>64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sagaonkar-2009" MODIFIED="2011-06-09 07:41:17 +0100" MODIFIED_BY="[Empty name]" NAME="Sagaonkar 2009" TYPE="JOURNAL_ARTICLE">
<AU>Sagaonkar S, Sukhija S, Tayal R, Sagaonkar PD</AU>
<TI>Pregnancy induced iron deficiency and the evaluation and comparison of the efficacy and safety of ferrous fumarate and carbonyl iron in its treatment - PERFECT trial</TI>
<SO>Journal of Obstetrics and Gynecology of India</SO>
<YR>2009</YR>
<VL>59</VL>
<NO>6</NO>
<PG>552-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schoyerer-1975" MODIFIED="2011-06-09 07:41:17 +0100" MODIFIED_BY="[Empty name]" NAME="Schoyerer 1975" TYPE="JOURNAL_ARTICLE">
<AU>Schoyerer W</AU>
<TI>The addition of folic acid to the iron substitution during pregnancy</TI>
<TO>Der Folsäurezusatz zur Eisensubstitution in der Schwangerschaft</TO>
<SO>Schweizerische Rundschau fur Medizin Praxis//Revue Suisse de Medecine Praxis</SO>
<YR>1975</YR>
<VL>64</VL>
<NO>28</NO>
<PG>903-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sun-2010" MODIFIED="2011-06-09 07:41:17 +0100" MODIFIED_BY="[Empty name]" NAME="Sun 2010" TYPE="JOURNAL_ARTICLE">
<AU>Sun YY, Ma AG, Yang F, Zhang FZ, Luo YB, Jiang DC, et al</AU>
<TI>A combination of iron and retinol supplementation benefits iron status, IL-2 level and lymphocyte proliferation in anemic pregnant women</TI>
<SO>Asia Pacific Journal of Clinical Nutrition</SO>
<YR>2010</YR>
<VL>19</VL>
<NO>4</NO>
<PG>513-9</PG>
<IDENTIFIERS/>
</REFERENCE>
</PENDING_REFERENCES>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2011-08-12 13:43:30 +0100" MODIFIED_BY="Heather Maxwell">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2011-08-12 13:42:51 +0100" MODIFIED_BY="Heather Maxwell" NOTES="&lt;p&gt;Judgements marked as &amp;quot;unclear&amp;quot; without text in the description will not be published in the Cochrane Library.&lt;/p&gt;" NOTES_MODIFIED="2011-08-12 13:42:51 +0100" NOTES_MODIFIED_BY="Heather Maxwell" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2011-08-12 13:39:06 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Al-2005">
<CHAR_METHODS MODIFIED="2011-08-11 17:20:26 +0100" MODIFIED_BY="Heather Maxwell">
<P>Group allocation was predetermined by one of the authors who was not involved with women's care. Authors used opaque envelopes that were consecutively-numbered by means of a computer-generated randomisation table. As each woman gave consent for the study, the next envelope was opened to assign the participant to either of the 2 groups.<BR/>A sample-size analysis was performed before initiation of the study. The analysis was based on the ITT principle.<BR/>No participants were lost to follow up, and there were no dropouts.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-12 13:39:06 +0100" MODIFIED_BY="Heather Maxwell">
<P>90 pregnant women, between the 26th and 34th weeks of gestation, with established iron-deficiency anaemia who had Hb levels between 8 and 10.5 g/dL and ferritin levels less than 13 g/ L.<BR/>Women were excluded when serum folate and vitamin B12 levels were found to be less than 4 pg/mL and 100 pg/mL respectively.<BR/>Anaemia from causes other than iron-deficiency, multiple pregnancy, previous blood transfusion, history of haematological disease, risk of preterm labour, intolerance to iron derivatives, recent administration of iron for the treatment of iron-deficiency anaemia, or current usage of iron supplement<BR/>were the reasons for other exclusions.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-12 13:03:50 +0100" MODIFIED_BY="Heather Maxwell">
<P>Experimental group: the dose for total iron sucrose was calculated from the following formula: weight x (target Hb &#8211; actual Hb) x 0.24 + 500 mg. In each infusion, the maximum total dose administered was 200 mg elemental iron in 100 mL 0.9% NaCl, infused in 20&#8211;30 minutes. Total dose was administered over 5 days and maximum daily dose administered was 400 mg elemental iron. Most of the women received iron sucrose at the rate of 200 mg every other day.</P>
<P>Control group: 3 x 100 mg iron polymaltose complex (300 mg elemental iron per day) tablets per day orally administered iron were given throughout pregnancy.</P>
<P>Both groups were supplemented by 0.5 mg folic acid treatment per day.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-08-12 13:02:45 +0100" MODIFIED_BY="Heather Maxwell">
<P>The primary outcome measure was Hb concentration on day 28 and at birth. Secondary outcome measures included ferritin levels, the recorded adverse effects, and fetal birthweight.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-08-12 13:02:45 +0100" MODIFIED_BY="Heather Maxwell"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-12 13:13:03 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Bayoumeu-2002">
<CHAR_METHODS MODIFIED="2011-08-12 13:04:40 +0100" MODIFIED_BY="Heather Maxwell">
<P>Women were assigned to the group treatment by a randomisation table.<BR/>Sample size and power calculation were described. Neither the women nor caregivers were blinded to the interventions. It is unclear if the outcome assessor was blinded to the interventions. The trialists reported that 3 (6%) women were excluded from the study and that 2 others where lost to follow up.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-12 13:04:23 +0100" MODIFIED_BY="Heather Maxwell">
<P>50 pregnant women.<BR/>Inclusion criteria: pregnant women at 6 months of pregnancy &gt; 18 years, with Hb 8-10 g/dL at 6 months; MCV &lt; 100 fl; ferritin &lt; 50 ug/l (corresponds to iron store of &lt; 500 mg).</P>
<P>Exclusion criteria: anaemia not linked to iron deficiency; asthma; cirrhosis; viral hepatitis; multiple pregnancy; risk of premature birth; suspected acute infection; parenteral iron treatment before inclusion; intolerance to iron. Also transport problems, etc.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-12 13:13:03 +0100" MODIFIED_BY="Heather Maxwell">
<P>Experiment group: IV iron sucrose. Total dose calculated from weight before pregnancy in kg x (target Hb - actual Hb) x 0.24 + 500 mg rounded up to nearest 100 mg. Target Hb set at 120 g/L because of physiological haemodilution during pregnancy. Given in 6 slow IV injections (days 1, 4, 8, 12, 15 and 21).</P>
<P>Control group: oral iron. 3 x 80 mg iron sulphate tablets (Tardyferon) per day for 4 weeks (i.e. 240 mg elemental iron a day for 4 weeks). Women asked to note compliance in calendar.<BR/>"Women were also given 15 mg folic acid per day to prevent an eventual folic-acid deficiency and to eliminate the influence of such a deficiency on the results."<BR/>"After 4 weeks, physician or midwife decided duration and dose of any continuing iron treatment."</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>The trial measured haematological response, transferrin level and saturation coefficient, erythrocytic folates, ferritin level, baby's ferritin level and full blood cell count and adverse reactions.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-08-12 13:04:23 +0100" MODIFIED_BY="Heather Maxwell"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-12 13:13:32 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Breymann-2001">
<CHAR_METHODS>
<P>Women randomly assigned to 2 treatment groups by means of a computer-generated list. It is unclear whether participants, clinicians and outcome assessor were blinded to the interventions. Trial had no withdrawals. No description of the sample size or power calculation was recorded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-12 13:13:32 +0100" MODIFIED_BY="Heather Maxwell">
<P>40 pregnant women. Inclusion criteria: pregnant women with Hb &lt; 10 g/dL in 2nd trimester and &lt; 11 g/dL in 3rd trimester; ferritin &lt; 15 ug/l.</P>
<P>Exclusion criteria: women with anaemia not caused by iron deficiency, e.g. B12 or folate deficiency; chronic bleeding; renal failure.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-12 13:13:32 +0100" MODIFIED_BY="Heather Maxwell">
<P>Women were randomised to receive IV administered iron sucrose (200 mg IV administered twice weekly 72 to 96 hours apart) with vs. without adjuvant recombinant human erythropoietin (300 U/kg body weight). All women received orally administered iron sulphate (80 mg twice daily) for = 2 weeks before starting. Random assignment was initiated when the Hb dropped to &lt; 10.0 g/dL despite orally administered iron supplementation. Median durations of therapy were 18 days in group 1 and 25 days in group 2.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Blood index values, maternal outcomes (which cannot be obtained separately for both groups of treatment) and safety were reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-08-12 13:13:32 +0100" MODIFIED_BY="Heather Maxwell"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-12 13:14:29 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Dawson-1965">
<CHAR_METHODS MODIFIED="2010-03-11 15:19:33 +0000" MODIFIED_BY="[Empty name]">
<P>Method of allocation was a random-number table. It is not clearly stated how allocation was concealed.<BR/>Loss to follow up: at 2 weeks: loss: A = 24%; B = 9%; C = 27%.<BR/>At 4 weeks: loss: A = 48%; B = 39%; C = 38%.<BR/>At 8 weeks: loss: A = 88%; B = 70%; C = 85%.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-12 13:14:29 +0100" MODIFIED_BY="Heather Maxwell">
<P>74 pregnant women in the 3rd trimester with Hb less than 10 g/dL, MCHC under 30% and a marrow aspiration indicating iron deficiency. Women with toxemia, infection or antepartum haemorrhage were excluded. All women received prophylactic folate and oral iron was stopped prior to randomisation.<BR/>Women were followed for 8 weeks and outcomes assessed at admission, 2, 4 and 8 weeks. Side effects were assessed during the treatment period.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Iron sorbitol-citric acid complex (Jectofer) IM 25 women.<BR/>Iron dextran (Imferon) IM 23 women.<BR/>Iron dextran (Imferon) IV 26 women.<BR/>Dosages of all preparations were calculated to replace iron stores.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-06 10:35:21 +0000" MODIFIED_BY="Denise Atherton">
<P>Side effects:<BR/>1. pain at injection site;<BR/>2. skin discolouration;<BR/>3. venous thrombosis;<BR/>4. nausea or vomiting;<BR/>5. headaches;<BR/>6. shivering;<BR/>7. itching;<BR/>8. metallic taste in mouth.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-08-12 13:14:29 +0100" MODIFIED_BY="Heather Maxwell">
<P>Other outcomes were not considered due to a high dropout rate. Hb level data are not included due to 81% dropouts at predelivery. The authors made an additional trial of iron dextran IV vs. iron dextran + 50 mg of hydrocortisone in the infusion to assess if this had any effect on the rate of side effects.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-12 13:15:32 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-De-Souza-2004">
<CHAR_METHODS MODIFIED="2011-08-12 13:14:59 +0100" MODIFIED_BY="Heather Maxwell">
<P>Method of allocation generation and concealment are unclear.<BR/>Neither the women nor treating physicians were blinded to the interventions. Trialists reported that the laboratory was blind to the interventions. 41 (21.5%) women were reported to drop the trial or were lost to follow up and the reasons described. ITT analysis was not used.<BR/>Sample size and power calculation were described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-12 13:14:59 +0100" MODIFIED_BY="Heather Maxwell">
<P>150 pregnant women at 16-20 weeks of gestation, with an initial Hb of &lt; 11 g/dL and &gt; 8 g/dL.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-12 13:15:32 +0100" MODIFIED_BY="Heather Maxwell">
<P>Women were randomly distributed into 3 groups, 1 receiving daily (300 mg of ferrous sulphate), the 2nd twice-weekly and the 3rd once-weekly iron supplementation for 16 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-08-12 13:14:59 +0100" MODIFIED_BY="Heather Maxwell">
<P>The trial measured Hb concentration, MCV and ferritin before and after the treatment.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-08-12 13:14:59 +0100" MODIFIED_BY="Heather Maxwell"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-12 13:15:41 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Digumarthi-2008">
<CHAR_METHODS MODIFIED="2011-01-06 09:51:21 +0000" MODIFIED_BY="Denise Atherton">
<P>Open randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-12 13:15:41 +0100" MODIFIED_BY="Heather Maxwell">
<P>30 pregnant women with moderate anaemia. Singleton pregnancy, 20 to 32 weeks with Hb from 7.1 to 9 g/dL.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-12 13:15:41 +0100" MODIFIED_BY="Heather Maxwell">
<P>IV iron sucrose (Weight in kg x (target Hb - actual Hb) x 0.25 + 500) vs. oral ferrous fumerate (300 mg of iron + 1.5 mg folic acid, twice day).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-08-12 13:15:41 +0100" MODIFIED_BY="Heather Maxwell">
<P>Hb rise, serum ferritin, serum iron, transferrin saturation.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-06 09:51:28 +0000" MODIFIED_BY="Denise Atherton">
<P>Abstract publication.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-12 13:16:37 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Kaisi-1988">
<CHAR_METHODS>
<P>A randomisation list was used to generate the randomisation sequence.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-12 13:16:02 +0100" MODIFIED_BY="Heather Maxwell">
<P>630 pregnant women. The study was done in a population of indigenous women. Inclusion criteria were:<BR/>1. diagnosis of iron-deficiency anaemia defined as Hb under 10 g/dL; MCHC under 32%; hypochromia; poikilocytosis and anisocytosis;<BR/>2. age 16 years and above;<BR/>3. gestational age under 36 weeks.</P>
<P>Exclusion criteria were:<BR/>1. history of reaction to parenteral iron;<BR/>2. hypersensitivity to iron dextran;<BR/>3. asthma history;<BR/>4. allergic conditions;<BR/>5. hepatic impairment;<BR/>6. renal impairment;<BR/>7. rheumatoid arthritis;<BR/>8. fever.</P>
<P>314 women received the full dose while 309 women received the 2/3 dose. Age, gravidity, parity, duration of pregnancy and basal Hb levels were similar for the groups. Nearly one fourth of the women had Hb levels under 7.0 g/dL in both groups.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-06 09:59:15 +0000" MODIFIED_BY="Denise Atherton">
<P>The dose of the 2 studied treatments was determined according to the recommendations of providers. In the intervention group, women received 2/3 of the total dose calculated of iron dextran 'Imferon' while in the control group they received the total dose of iron dextran plus 10 additional ml as suggested for pregnant women. The iron dextran was diluted in 500 ml of 5% dextrose and infused at a steady rate of 40 drops per minute. A test dose was given at the start of each infusion. This test dose was administered at a rate of 5 drops per minute over 10 minutes.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-08-12 13:16:02 +0100" MODIFIED_BY="Heather Maxwell">
<P>Women were followed up regularly throughout the remaining part of their pregnancy, during delivery and for 16 weeks postpartum. Infants were examined at the time of birth. Maternal Hb levels were assessed at each visit to the antenatal clinic and 6 and 16 weeks after delivery. Cord Hb was measured as well.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-08-12 13:16:37 +0100" MODIFIED_BY="Heather Maxwell">
<P>Women were analysed by ITT. Loss to follow up for Hb result was 47% so these results were not included in this review. For other clinical outcomes, loss to follow up was 18% and 20% so they were included.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-12 13:41:25 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Khalafallah-2010">
<CHAR_METHODS MODIFIED="2011-08-12 13:41:25 +0100" MODIFIED_BY="Heather Maxwell">
<P>Single site, prospective, non blinded randomised-controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-12 13:17:01 +0100" MODIFIED_BY="Heather Maxwell">
<P>Two hundred women matched for Hb concentration and serum ferritin level were recruited. Women aged 18 years or above were identified with moderate iron deficiency anaemia defined as Hb &lt;115 g &#8260;L and low iron stores based on a serum ferritin level &lt; 30 lg &#8260;L. Most of the women (75%) had ferritin levels below 20 lg &#8260;L and were equally distributed in both groups.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-12 13:17:01 +0100" MODIFIED_BY="Heather Maxwell">
<P>Patients were randomised to daily oral ferrous sulphate 250 mg (elemental iron 80 mg) with or without a single intravenous iron polymaltose infusion. The IV arm required a single intravenous infusion of iron polymaltose (Ferrosig, Sigma Pharmaceuticals, Sydney, Australia) within 1 week after booking followed by oral iron identical to the other arm.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-08-12 13:17:01 +0100" MODIFIED_BY="Heather Maxwell">
<P>Primary outcomes were Hb level and mean serum ferritin level. Secondary outcomes were tolerability, safety and compliance and the effect of iron therapy on birth weight and gestational age at delivery. Cord blood Hb and iron studies data were collected at 37 consecutive deliveries to assess the effects of IV plus oral iron.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-12 13:42:00 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Komolafe-2003">
<CHAR_METHODS>
<P>The women were assigned randomly by offering them a choice from sealed envelopes containing computer-generated random numbers. No description of the sample size or power calculation was described and neither the participants nor treating physicians were blinded to the interventions. This trial had no withdrawals.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-12 13:42:00 +0100" MODIFIED_BY="Heather Maxwell">
<P>60 women at 14-32 weeks of pregnancy were included.<BR/>Inclusion criteria: PCV 22% to 26% due to iron-deficiency anaemia. Iron-deficiency anaemia defined as: Hb genotype AA; MCV &lt; 75 pg; MCHC &lt; 32 g/dL; blood film - picture of iron-deficiency anaemia.</P>
<P>Exclusion criteria: symptomatic anaemia; acute malaria; acute urinary tract infection; history of allergy to parenteral iron; multiple pregnancy atopic individual and haemoglobinopathy.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-12 13:18:04 +0100" MODIFIED_BY="Heather Maxwell">
<P>Experiment group: 30 women.<BR/>IM iron dextran. 50 mg iron dextran into buttock preceded by 25 mg promethazine tablet 30 minutes before. If no untoward reaction after 48 hours, 250 mg (5 ml) iron dextran thrice weekly I = until total dose given.<BR/>Total dose = iron (mg) = weight (kg) x Hb deficit (g/dL) x 4.4 + 500.</P>
<P>Control group: 30 women.<BR/>Oral Fe: 200 mg ferrous sulphate 3 times daily between meals, with vitamin C 100 mg 3 times daily and 5 mg folic acid.<BR/>Both groups were treated for 6 weeks.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-08-12 13:18:04 +0100" MODIFIED_BY="Heather Maxwell">
<P>The trial measured the mean PCV, corrected anaemia at the end of the follow-up period, the cost of the treatment and the side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Results given in % and not specific numbers.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-06 10:31:19 +0000" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-Kumar-2005">
<CHAR_METHODS>
<P>Participants were randomly allocated to 2 groups. Method of allocation generation and allocation concealment were unclear. <BR/>Both the participants and treating physicians were not blinded to the interventions.<BR/>Sample size considerations were not provided. 47 women in parenteral iron group and 23 women in oral iron group were lost to follow up.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-19 15:46:15 +0100" MODIFIED_BY="[Empty name]">
<P>220 pregnant women were including according to the following criteria.</P>
<P>Inclusion criteria: women with gestation period of 16-24 weeks, were selected according to the following inclusion criteria: singleton pregnancy, moderate anaemia (Hb 8-11 g%) by cyanmethaemoglobin method, microcytic hypochromic blood smear and willingness for enrolment to the study.</P>
<P>Exclusion criteria: the women with anaemia due to haemoglobinopathies, chronic bleeding, parasitosis, diseases of liver, cardiovascular system and kidney; medical disorders like tuberculosis, diabetes mellitus; women who had any form of parenteral iron therapy for anaemia during pregnancy; women with antepartum haemorrhage and intolerance to test dose (0.5 ml) of IM administration of iron were excluded from the study.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experiment group: IM iron: parenteral iron group were given 2 IM injections of 250 mg elemental iron as iron sorbitol citric acid in a injection volume of 5 ml at an interval of 4-6 weeks in the antenatal clinic. An initial test dose of 0.5 ml was given. If there was no adverse reaction to the test dose, then a full 250 mg dose was given deeply in the outer quadrant of the buttock using Z-tract technique.</P>
<P>Control group: oral iron: tablets of 100 mg elemental iron (ferrous sulphate) and 500 Ag of folic acid daily.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-06 10:31:19 +0000" MODIFIED_BY="Denise Atherton">
<P>The trial measured values of blood indices at 36 weeks as well as mean birthweight, mode of delivery and side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-12 13:19:12 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Mumtaz-2000">
<CHAR_METHODS MODIFIED="2011-08-12 13:19:12 +0100" MODIFIED_BY="Heather Maxwell">
<P>Randomisation was performed using a random-number generator, and each women was assigned a unique identifier. The women and the investigator were blinded to the allocation of treatment group (daily vs. twice weekly) at initial recruitment and the 3 follow-up visits. The appearance of the capsules and the blister packs of the 2 groups were identical. The randomisation code was opened only after the follow-up for all participants had been completed. Sample size considerations were provided. This trial had 86 participants, (45%) that did not complete the entire duration of follow up (i.e. 4 follow-up visits). However, data on 83.8% of the participants were available for 4 weeks of follow-up.<BR/>Analysis by ITT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-12 13:19:12 +0100" MODIFIED_BY="Heather Maxwell">
<P>191 pregnant women between the age of 17-35 years, with an initial Hb of &lt; 110 g/L were included.<BR/>Uneventful obstetric history.<BR/>All given health education materials on importance of diet in pregnancy.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-12 13:19:12 +0100" MODIFIED_BY="Heather Maxwell">
<P>Experiment group: daily iron - plus daily folate. 200 mg iron sulphate (60 mg elemental iron) each day and 1 mg folate.<BR/>Control group: twice weekly iron - plus daily folate. 200 mg iron sulphate (60 mg elemental) twice weekly and 1 mg folate. Placebo was given for the rest of the days.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-06 10:31:22 +0000" MODIFIED_BY="Denise Atherton">
<P>Venous blood samples were taken for complete blood count at each visit and for serum ferritin at the 1st, 3rd and 4th visits. A peripheral film was made to rule out congenital disorders such as thalassaemia minor.<BR/>No information about maternal and fetal outcomes and side effects was provided.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-08-12 13:19:12 +0100" MODIFIED_BY="Heather Maxwell">
<P>There was no difference between the women who dropped out compared with those who continued in the trial in terms of age, initial Hb, parity and in the 2 treatment groups (41 versus 45).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-12 13:20:19 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Nappi-2009">
<CHAR_METHODS MODIFIED="2010-04-19 15:45:52 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective, randomised, controlled, double blind trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-12 13:19:59 +0100" MODIFIED_BY="Heather Maxwell">
<P>100 pregnant women with iron deficiency anaemia. Inclusion criteria were: physiological course of pregnancy, singleton pregnancy, gestational age 12 weeks and 36 weeks, Hb values11 mg/dl, serum iron 30 µg/dl, serum ferritin12 µg/dl and TIBC 450 µg/dl. Exclusion criteria were: gestational (such as hypertension, gestational diabetes) or pre-existent maternal diseases and fetal abnormalities.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-12 13:20:19 +0100" MODIFIED_BY="Heather Maxwell">
<P>Group A received bovine lactoferrin at the oral dose of one capsule of 100 mg twice a day for 4 weeks.</P>
<P>Group B received ferrous sulphate at the daily oral dose of one tablet of 520 mg (containing 100 mg elementary iron) for 4 weeks.</P>
<P>Both groups received an additional supplementation with calcium mefolinate at the daily oral dose of 1 x 15 mg tablet.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-06 10:06:49 +0000" MODIFIED_BY="Denise Atherton">
<P>The primary outcome measure was the Hb level before and after 1 month of treatment. Secondary outcomes were serum ferritin, serum iron and TIBC levels and the difference in symptom scores between groups.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-12 19:47:28 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-12 13:39:13 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Ogunbode-1980">
<CHAR_METHODS>
<P>There was no information on methods of randomisation. No description of the sample size or power calculation was described and both the participants and treating physicians were blinded to the interventions. No participants were reported to have dropped out or were lost to follow up.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>91 women in the first or second trimester of pregnancy with a PCV of 33% or less were randomly allocated to 3 treatment groups.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-12 13:22:46 +0100" MODIFIED_BY="Heather Maxwell">
<P>In group A, 32 participants received 200 mg of oral ferrous sulphate thrice daily; in group B 28 participants received 400 mg of oral ferrous sulphate 3 times daily; in group C, 31 women received IM iron poly (sorbitol gluconic acid) complex ferastral (500 mg iron) on alternate days until completion of the required dose (between 1250 to 2500 mg of iron). No formal formula to calculate the dose was described. All participants received 5 mg of folic acid and 25 mg of pyrimethamine once weekly.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-08-12 13:39:13 +0100" MODIFIED_BY="Heather Maxwell">
<P>The trial measured the reticulocyte response and haematocrit level.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-12 13:42:51 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Oluboyede-1980">
<CHAR_METHODS MODIFIED="2011-01-06 10:08:17 +0000" MODIFIED_BY="Denise Atherton">
<P>Participants were allocated by restricted random allocation. There was no further information on methods of randomisation. No description of the sample size or power calculation was described and neither the participants nor treating physicians were blinded to the interventions. 1 participant from the imferon group was reported to have dropped out due to a severe reaction.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-12 13:22:54 +0100" MODIFIED_BY="Heather Maxwell">
<P>63 pregnant women with established iron-deficiency anaemia defined as a PCV of 30% or less were included. Hb AA genotype only.<BR/>Exclusion criteria: if previously had iron therapy.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-12 13:42:51 +0100" MODIFIED_BY="Heather Maxwell">
<P>Experiment group: 32 women. IM ferastral (sorbitol gluconic acid). 500 mg ferastral (5 ml in each buttock) IM on alternate days until completion of required dose.<BR/>Control group: 31 women. IV imferon (iron dextran). Calculated dose given in 540 ml normal saline and 50 ml promethazine hydrochloride (phenegran) was given IM before infusion. Drip ran slowly for first 30 minutes then 60 drops a minute until completion. Discharged home though 10 kept in.<BR/>All women received anti-malarial of 25 mg pyrimethamine and 5 mg of folic acid throughout pregnancy.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-19 15:44:59 +0100" MODIFIED_BY="[Empty name]">
<P>Weekly or 2-weekly PCV estimations were done on all participants, after 4 weeks of treatment liver function tests were repeated and after 6 weeks bone marrow aspirations were repeated on 21 women. The trial also measured the reticulocyte response in 10 women randomly selected from each group and babies birth weights and any complication within the first week of life.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-08-12 13:22:55 +0100" MODIFIED_BY="Heather Maxwell"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-12 13:23:34 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Saha-2007">
<CHAR_METHODS MODIFIED="2010-04-19 15:44:23 +0100" MODIFIED_BY="[Empty name]">
<P>A double blinded randomised control trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-12 13:23:34 +0100" MODIFIED_BY="Heather Maxwell">
<P>100 pregnant women between 20 and 40 years; gestation 14-27 weeks; Hb &lt; 9 and &gt; 7 g/dL; and serum ferritin &lt; mcg/L. Patients with a history of anaemia due to any other causes were excluded (i.e. chronic blood loss, haemolytic anaemia, thalassaemia). Women with other chronic or severe diseases were also excluded (hepatic, renal, cardiovascular etc.).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-06 10:09:32 +0000" MODIFIED_BY="Denise Atherton">
<P>Group 1 (48 participants): iron polymaltose, 100 mg elemental iron + folic acid 500 mcg for 8 weeks (1 tablet orally once day) + placebo (1 tablet orally once day).</P>
<P>Gourp 2 (52 participants): 60 mg elemental iron + folic acid 500 mcg for 8 weeks (1 tablet orally twice day).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-08-12 13:23:34 +0100" MODIFIED_BY="Heather Maxwell">
<P>The primary efficacy parameter was the proportion of women achieving normal Hb level (&gt; 11 g/dL). Adverse events and costs were also collected. No clinical outcomes were collected.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-08-12 13:23:34 +0100" MODIFIED_BY="Heather Maxwell"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-11 17:47:33 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Singh-1998">
<CHAR_METHODS>
<P>Women were allocated using sealed envelopes with consecutive numbers.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-06 10:09:54 +0000" MODIFIED_BY="Denise Atherton">
<P>First 100 women with diagnosed iron-deficiency anaemia while attending for antenatal care at the National University Hospital, Singapore. Data provided by 1 of the authors reveals that compared groups had similar age distribution, parity, mean total income, weight, height, history of anaemia in previous pregnancies, history of intrauterine growth retardation in previous pregnancies and similar time-gap between pregnancies.<BR/>Races were distributed as follows: Chinese (10% parenteral and 6% of oral iron therapy), Malayan (46% and 78% in the same order), Indian (16 and 8%). History of preterm delivery was seen in 16% of the parenteral treatment group and 12% of oral iron group.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-11 17:47:33 +0100" MODIFIED_BY="Heather Maxwell">
<P>Total dose iron polymaltose complex - iron dextrin (ferrum Hausmann) infusion vs. oral therapy with 3 x 200 mg/day iron fumarate. The dose was determined according to the body weight and estimated iron deficiency.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-06 10:31:30 +0000" MODIFIED_BY="Denise Atherton">
<P>This paper provided data at 36 weeks, delivery and 6 weeks' postpartum. The paper provided haematological outcomes. In addition, the publication mentioned some side effects and similar clinical outcomes in both groups. The authors were contacted and provided precise data on clinical outcomes and side effects that were included too.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-04-19 15:43:51 +0100" MODIFIED_BY="[Empty name]">
<P>Dr Kuldip Singh at the National University Hospital - University of Singapore was the contacted author. Contact was established through a search on Internet. Further contact is being undertaken to check the units used for serum iron and ferritin estimations, then further comparison tables can be added to this review.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-12 13:26:03 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Sood-1979">
<CHAR_METHODS MODIFIED="2011-08-12 13:24:15 +0100" MODIFIED_BY="Heather Maxwell">
<P>There was no information on methods of randomisation. No description of the sample size or power calculation was described and researchers kept unmasked the 5 groups. 2 women were reported to have dropped in the group receiving IV iron due to severe delayed adverse allergic reaction.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-12 13:26:03 +0100" MODIFIED_BY="Heather Maxwell">
<P>151 pregnant women.<BR/>Inclusion criteria: pregnant women, 26 + 2 weeks' gestation. Divided into 3 strata according to their Hb concentration: 50-79; 80-109; 110 or above.<BR/>Exclusion criteria: women with chronic illness; with Hb &lt; 50 g/L; who had received haematinics during the last months.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-12 13:24:15 +0100" MODIFIED_BY="Heather Maxwell">
<P>Within each stratum they were randomised to 1 of the following groups. 1. Oral ferrous sulphate providing 120 mg of 120 mg elemental iron, given once per day 6 weeks.<BR/>2. Iron dextran complex providing 100 mg iron given IM twice per week. 3. Iron as in group 1 + pteroylmonoglutamic acid (5 mg, 6 day/week) + cyanocobalamin (100 µg IM once per 14 day). 4. Iron IM as in group 2 + pteroylmonoglutamic acid + cyanocobalamin as in group 3.<BR/>5. Iron dextran complex given IV as a single total dose infusion according to the formula (15 - women's Hb (g/dL)) x (body-weight (kg) x 3) + pteroylmonoglutamic acid + cyanocobalamin as in group 3. Treatment was continued for 10-12 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-08-12 13:24:15 +0100" MODIFIED_BY="Heather Maxwell">
<P>Hb, PCV was estimated 48 before the treatment was started and at least 48 hours after the last injection or tablet was given.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-08-12 13:24:13 +0100" MODIFIED_BY="Heather Maxwell"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-12 13:26:32 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Suharno-1993">
<CHAR_METHODS>
<P>Allocation was done using a random-number list from 1 to 305 and allocating women sequentially in the list. The manufacturers of the active treatments provided placebos. An independent researcher randomly labelled the active and placebo preparations. Coding colours were given to the preparations and these codes were opened once the data for all analyses had been entered in the computer and cleaned.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-12 13:26:32 +0100" MODIFIED_BY="Heather Maxwell">
<P>305 pregnant women. The study was conducted from April to September 1992 in 20 rural villages in 3 sub districts of Bogor, West Java. Participants came from middle and low socio-economic groups. They were aged between 17 and 35 years, with parity in the ranges of 0 to 4 and gestational age of 16 to 25 weeks.<BR/>572 women met inclusion criteria. 305 participated in the study.<BR/>Hb levels of participants were in the range of 8.0 to 10.9 g/dL. Women receiving iron or vitamin A treatments or supplements in the 6 months prior to study were excluded. Outcomes were assessed 2 and 7 days after the last dose of treatment was given (24 to 33 weeks). Participants had similar age, height, weight, pregnancies, parity and gestational age at admission.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>4 different groups received 2 active treatments at most (factorial design). All preparations were given daily for 8 weeks.<BR/>1. 60 mg elemental oral iron (as ferrous sulphate) + vitamin A (2.4 mg of retinol as retinyl palmitate).<BR/>2. 60 mg elemental oral iron (as ferrous sulphate ) + placebo of vitamin A.<BR/>3. Placebo of oral iron + vitamin A (2.4 mg of retinol as retinyl palmitate).<BR/>4. Placebo or oral iron + placebo or vitamin A.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-08-12 13:26:32 +0100" MODIFIED_BY="Heather Maxwell">
<P>Hb, ferritin and serum iron mean values and standard deviations were extracted for this review from the published paper. Percentage of women that became non-anaemic (Hb &gt; 10.9 g/dL) was counted as a dichotomised variable. Numbers needed to treat were calculated by the authors of this review.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-08-12 13:26:32 +0100" MODIFIED_BY="Heather Maxwell">
<P>Results for vitamin A + placebo were not considered since this is part of a different review. Vitamin A combined with iron was included in this review. Serum iron levels were given in umol/l and converted to mg/l by the authors (umol/l x 0.056 = mg/l). Loss to follow up accounted for 17% of the women. Analysis was done by ITT.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-12 13:27:14 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Sun-2010">
<CHAR_METHODS MODIFIED="2011-08-12 13:27:14 +0100" MODIFIED_BY="Heather Maxwell">
<P>Double-blind randomised trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-12 13:27:14 +0100" MODIFIED_BY="Heather Maxwell">
<P>Pregnant women, 12 to 24-week gestation, age between 20-30 years, were examined for eligibility. Of these women, 186 anaemic pregnant women with Hb concentration &#8805; 80 and &lt; 110 g/L were included.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-11 17:52:11 +0100" MODIFIED_BY="Heather Maxwell">
<P>Group I (n=47) was supplemented daily with 60 mg iron as ferrous sulfate.</P>
<P>Group II (n=46) with 60 mg iron and 0.4 mg folic acid.</P>
<P>Group III (n=46) with 60 mg iron, 2.0 mg retinol and 0.4 mg folic acid.</P>
<P>Group C (n=47) was the placebo control group.</P>
<P>Only group 1 and 4 were included for analysis in the review.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-08-12 13:27:14 +0100" MODIFIED_BY="Heather Maxwell">
<P>- Hb concentration at 2 months of treatment</P>
<P>- Plasma ferritin</P>
<P>- Plasma iron concentrations</P>
<P>- Peripheral blood lymphocytes</P>
<P>No clinical outcomes or adverse events were reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-08-12 13:27:14 +0100" MODIFIED_BY="Heather Maxwell"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-12 13:29:30 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Symonds-1969">
<CHAR_METHODS>
<P>Women were assigned randomly although the method is not clearly specified. Baseline data for the 4 groups compared are very similar.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-12 13:29:29 +0100" MODIFIED_BY="Heather Maxwell">
<P>103 women attending the Queen Elizabeth Hospital in Woodville, Australia. Inclusion criteria were a gestational age of 32 weeks or less and a Hb level of 10.8 g/dL or less.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-11 16:49:02 +0100" MODIFIED_BY="Heather Maxwell">
<P>4 treatment groups were assembled.<BR/>1. Ferrous gluconate 108 mg of elemental iron daily divided in 3 doses given orally throughout pregnancy.<BR/>2. Ferrogradumet tablets (controlled-release) iron tablets with 105 mg elemental iron given once daily throughout pregnancy.<BR/>3. Placebo for the controlled-release iron tablets provided by the same pharmaceutical laboratory.<BR/>4. IV iron-dextran 2% solution. Initial test dose of 2 ml IV followed by 5 injections of 5 ml (100 mg).</P>
<P>Participants received controlled-release iron or placebo for the first month. After that time side effects were evaluated, and then all participants were given a daily dose of active controlled-release oral iron. The trial was masked only the first 2 months and only for these 2 groups.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-06 10:31:43 +0000" MODIFIED_BY="Denise Atherton">
<P>For this review, side effects were considered. The other data were incomplete, without reported standard deviations of mean values and irrelevant due to important flaws in the design of the study.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-08-12 13:29:30 +0100" MODIFIED_BY="Heather Maxwell">
<P>Hb results were presented as increases in Hb. Since standard deviations for the values cannot be added to baseline data, the data were not included.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-12 13:29:50 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Wali-2002">
<CHAR_METHODS>
<P>There was no information on methods of randomisation described and neither the participants nor treating physicians were blinded to the interventions. No description of the sample size or power calculation was provided.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-12 13:29:50 +0100" MODIFIED_BY="Heather Maxwell">
<P>60 pregnant women with anaemia were included in the study.<BR/>Inclusion criteria: pregnant women; 12-34 weeks; iron-deficiency anaemia; Hb 5-10 g/dL; PCV &lt; 30%; MCV &lt; 80 fl; MCH &lt; 28 pg.<BR/>Women with Hb &lt; 7 g/dL (n = 2) were given IV iron sucrose (Venofer) as an alternative to blood transfusion; those with Hb 7-10 g/dL were randomised for IV iron or IM iron.<BR/>Exclusion criteria: chronic diseases; anaemic failure.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-12 13:29:50 +0100" MODIFIED_BY="Heather Maxwell">
<P>Experiment group A: 15 women.<BR/>IV iron sucrose 500 mg for iron storage.</P>
<P>Experiment group B: 20 women.<BR/>IV iron sucrose 200 mg iron.</P>
<P>Experiment group C: 25 women<BR/>IM iron sorbitol with varying doses depending on Hb level; 5 g/dL - 24 injections; 6 g/dL - 22 injections; 7 g/dL - 20 injections; 8 g/dL - 17 injections; 9 g/dL - 14 injections; 10 g/dL - 12 injections; 11 g/dL - 10 injections.</P>
<P>After parenteral iron, oral iron given till birth of baby.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-08-12 13:29:50 +0100" MODIFIED_BY="Heather Maxwell">
<P>The trial outcomes focused on laboratory values (Hb) and side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-08-12 13:29:50 +0100" MODIFIED_BY="Heather Maxwell"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-06 10:35:37 +0000" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-Zhou-2007">
<CHAR_METHODS MODIFIED="2011-01-06 10:13:26 +0000" MODIFIED_BY="Denise Atherton">
<P>Double blind randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-06 10:13:44 +0000" MODIFIED_BY="Denise Atherton">
<P>Pregnant women (N = 180) diagnosed with anaemia (Hb &lt; 110 g/L) at the routine mid-pregnancy blood test were approached to take part in our study. They were eligible if between 24 and 32 weeks' gestation and had a singleton pregnancy. Women were excluded if they were taking iron or vitamin and mineral supplements containing iron, other causes of anaemia, history of thalassaemia or drug and alcohol abuse and had diabetes requiring insulin or a known fetal abnormality.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-06 10:13:54 +0000" MODIFIED_BY="Denise Atherton">
<P>Ferrous sulphate containing 20, 40 or 80 mg of elemental iron per tablet, which did not contain other micronutrients (1 tablet daily between meals from enrolment for 8 weeks or until birth).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-06 10:35:37 +0000" MODIFIED_BY="Denise Atherton">
<P>The primary outcomes of the study were Hb levels and incidence of anaemia at the end of the intervention, and gastro-intestinal side effects during treatment. Secondary outcomes included incidence of iron deficiency, iron-deficiency anaemia and haemoconcentration at the end of treatment as well as pregnancy outcomes.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-12 20:40:22 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-08-12 13:30:38 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Zutschi-2004">
<CHAR_METHODS>
<P>There was no information on methods of randomisation. No women were reported to have dropped out or were lost to follow up. Neither the women nor treating physicians were blinded to the interventions. No description of the sample size or power calculation was described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-12 13:30:37 +0100" MODIFIED_BY="Heather Maxwell">
<P>200 women with uncomplicated pregnancy enrolled at 24-26 weeks of gestation with a Hb of &gt; 8 gm% but &lt; 11 gm% were included.</P>
<P>Women dropped out of study if Hb fell below 8 g/l or if severe problems arose.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-06 10:19:57 +0000" MODIFIED_BY="Denise Atherton">
<P>Group A (100 women) received injectable iron-sorbitol-citrate in 3 IM doses of 150 mg each at 4-weekly intervals and group B (100 women) were given oral iron having 100 mg elemental iron daily for at least 100 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-08-12 13:30:38 +0100" MODIFIED_BY="Heather Maxwell">
<P>The trial measured Hb levels at the time of inclusion into the study, 4-weekly thereafter and at delivery as well as the proportion of caesarean delivery.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-08-12 13:30:38 +0100" MODIFIED_BY="Heather Maxwell"/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>Hb: haemoglobin<BR/>IM: intramuscular<BR/>ITT: intention-to-treat<BR/>IV: intravenous<BR/>MCH: mean corpuscular haemoglobin<BR/>MCHC: mean corpuscular haemoglobin concentration<BR/>MCV: mean corpuscular volume<BR/>PCV: packed cell volume<BR/>TIBC: total iron binding capacity<BR/>vs: versus<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2011-08-12 13:43:30 +0100" MODIFIED_BY="Heather Maxwell" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Al-Momen-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial. Sequential allocation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Allaire-1961">
<CHAR_REASON_FOR_EXCLUSION>
<P>Loss to follow up of 56%. Used quasi-random allocation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-11 17:11:28 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Amir-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-11 17:11:28 +0100" MODIFIED_BY="Heather Maxwell">
<P>Excluded: inclusion criteria Hb &lt; 12 g/dL. No baseline characteristics that lead to infer levels of Hb at the beginning of the study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-11 17:18:16 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Ayub-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-11 17:18:16 +0100" MODIFIED_BY="Heather Maxwell">
<P>Non-randomised study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bare-1960">
<CHAR_REASON_FOR_EXCLUSION>
<P>They allocated participants using alternate order. This is not considered random.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Barrada-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Insufficient information for critical appraisal was provided. There are no explicit inclusion or exclusion criteria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-11 17:12:06 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Basu-1973">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-11 17:12:06 +0100" MODIFIED_BY="Heather Maxwell">
<P>Randomisation method not provided. No information is provided regarding blinding or number of women that completed the trial or that were accounted for each result.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-06 10:20:32 +0000" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-Bencaiova-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-06 10:20:32 +0000" MODIFIED_BY="Denise Atherton">
<P>Non-anaemic pregnant women.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-06 10:20:35 +0000" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-Bhatla-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-06 10:20:35 +0000" MODIFIED_BY="Denise Atherton">
<P>Non-anaemic women.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-13 17:12:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bhutta-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-13 17:12:18 +0000" MODIFIED_BY="[Empty name]">
<P>Mebendazol and multivitamin trial. Ongoing. </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Breymann-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised open-label trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-06 10:23:11 +0000" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-Breymann-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-06 10:23:11 +0000" MODIFIED_BY="Denise Atherton">
<P>Not a randomised controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Buglanov-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>No mention of randomisation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-06 10:20:47 +0000" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-Chan-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-06 10:20:47 +0000" MODIFIED_BY="Denise Atherton">
<P>Iron supplementation from early pregnancy in anaemic and non-anaemic women. No subgroup data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chanarin-1965">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study addressed megaloblastic anaemia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-12 13:43:30 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Christiansen-1961">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-12 13:43:30 +0100" MODIFIED_BY="Heather Maxwell">
<P>Alternate participants; not Hb &lt; 11.0 g/d/L.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Coelho-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>No mention that women were anaemic.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-06 10:20:56 +0000" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-De-Souza-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-06 10:20:56 +0000" MODIFIED_BY="Denise Atherton">
<P>A convenience sample was used and allocation was consecutively and casually unblinded by the main researcher to each of the three experimental groups.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-19 15:42:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dede-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-19 15:42:21 +0100" MODIFIED_BY="[Empty name]">
<P>Postpartum iron-deficiency anaemia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-11 17:13:14 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Dochi-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-11 17:13:14 +0100" MODIFIED_BY="Heather Maxwell">
<P>Non-iron trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dommisse-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Folic acid trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-12 13:39:49 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Ekstrom-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-12 13:39:49 +0100" MODIFIED_BY="Heather Maxwell">
<P>Centers were randomly assign (not women) and only some women had Hb &lt; 11.5 g/dL.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Finzi-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>No random allocation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fochi-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomisation is not well balanced. The paper does not explain unbalanced groups.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-06 10:21:04 +0000" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-Govan-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-06 10:21:04 +0000" MODIFIED_BY="Denise Atherton">
<P>Case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-11 17:13:32 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Graham-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-11 17:13:32 +0100" MODIFIED_BY="Heather Maxwell">
<P>A vitamin A-fortified rice curry dish with iron + vitamins vs. placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-11 17:13:39 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Halksworth-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-11 17:13:39 +0100" MODIFIED_BY="Heather Maxwell">
<P>No randomisation method. Evaluated the absorption of iron.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hamilton-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation was done using a haphazard strategy, not a random one.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hampel-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Used a haphazard allocation method (day of diagnosis).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-06 10:21:13 +0000" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-Hancock-1968">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-06 10:21:13 +0000" MODIFIED_BY="Denise Atherton">
<P>Non randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-11 17:13:50 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Harrison-1971">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-11 17:13:50 +0100" MODIFIED_BY="Heather Maxwell">
<P>Non-iron RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-12 13:31:34 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Hawkins-1970">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-12 13:31:34 +0100" MODIFIED_BY="Heather Maxwell">
<P>The study evaluates the use of medication in women with Hb levels over 10.5 g/dL and uses non-random strategy for allocation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-12 13:31:41 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Holly-1955">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-12 13:31:41 +0100" MODIFIED_BY="Heather Maxwell">
<P>The study is in women with Hb levels over 10 g/dL. Treatment allocation was not random.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-06 10:21:21 +0000" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-Hosokawa-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-06 10:21:21 +0000" MODIFIED_BY="Denise Atherton">
<P>Vitamin C trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Izak-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>Although the authors state that allocation was random, the groups are very different (184, 76 and 22). The authors used an inappropriate control group of healthy women. They do not explain the randomisation method.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jackson-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>More than 50% of their women were lost to follow up.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jaud-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Used open-randomisation list. We tried to contact to verify data but it was impossible. Open-randomisation lists are considered inadequate since there is no concealment and it is prone to bias.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Juarez_x002d_Vazquez-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>The trial evaluated folic acid + iron versus iron.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-06 10:21:30 +0000" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-Kore-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-06 10:21:30 +0000" MODIFIED_BY="Denise Atherton">
<P>Non randomised study. Only the abstract was available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-19 15:42:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Krafft-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-19 15:42:14 +0100" MODIFIED_BY="[Empty name]">
<P>Non randomised study. No comparison.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-06 10:21:40 +0000" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-Ma-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-06 10:21:40 +0000" MODIFIED_BY="Denise Atherton">
<P>Retinol and Riboflavin supplementation trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mahale-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study has dropouts that surpasses the limit established for this review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-06 10:21:43 +0000" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-Mahmoudian-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-06 10:21:43 +0000" MODIFIED_BY="Denise Atherton">
<P>Zinc trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-11 17:17:42 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Mathan-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-11 17:17:42 +0100" MODIFIED_BY="Heather Maxwell">
<P>The trial evaluated group 1 iron + pteroylmonoglutamic acid and cyanocobalamin versus group 1 + ascorbic acid versus group 1 + calcium caseinate.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-06 10:21:48 +0000" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-Milman-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-06 10:21:48 +0000" MODIFIED_BY="Denise Atherton">
<P>Non-anaemic pregnant women.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Minganti-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Sample size: 15 participants. Data not available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-12 13:31:47 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Mukhopadhyay-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-12 13:31:47 +0100" MODIFIED_BY="Heather Maxwell">
<P>The trial excludes women with Hb level &lt; 10 g/dL. The mean baseline Hb was 11.3 and 11.6 g/dL in both groups of treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mukhopadhyay-2004a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Double publication.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ogunbode-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Folic acid trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Preziosi-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>No fundamental data to assess validity.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Reddy-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>No comparison group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-19 15:42:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ridwan-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-19 15:42:05 +0100" MODIFIED_BY="[Empty name]">
<P>Health centres were randomised, rather than individuals.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-11 17:14:45 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Sagaonkar-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-11 17:14:45 +0100" MODIFIED_BY="Heather Maxwell">
<P>Assessed two different iron drugs and varied types of vitamins at the same time.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-11 17:14:47 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Schoyerer-1975">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-11 17:14:47 +0100" MODIFIED_BY="Heather Maxwell">
<P>Folic acid trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-06 10:21:59 +0000" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-Scott-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-06 10:21:59 +0000" MODIFIED_BY="Denise Atherton">
<P>Series of cases description.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sharma-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomisation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-11 17:15:22 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Siega_x002d_Riz-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-11 17:15:22 +0100" MODIFIED_BY="Heather Maxwell">
<P>Trialists reported that a subgroup of anaemic patients (women with Hb &gt; 9 g/dL and ferritin &lt; 40 g/l) was randomised  to receive prenatal supplements with 30 or 60 mg of iron. A subsequent publication only focus on the non-anaemic group (<LINK REF="STD-Siega_x002d_Riz-2006" TYPE="STUDY">Siega-Riz 2006</LINK>). The principal author was contacted to get data on the subgroup of anaemic patients. The author said "that it will not be possible".<BR/>
<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-06 10:22:15 +0000" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-Siega_x002d_Riz-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-06 10:22:15 +0000" MODIFIED_BY="Denise Atherton">
<P>Non-anaemic pregnant women.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-06 10:22:16 +0000" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-Sigridov-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-06 10:22:16 +0000" MODIFIED_BY="Denise Atherton">
<P>Not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sood-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study has a high proportion of women lost to follow up exceeding the cut-off point established for this review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stein-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>No fundamental data to assess validity.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Steiner-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>No information regarding random allocation or allocation concealment. Insufficient baseline data provided.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Szarfarc-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-anaemic women.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-11 17:15:54 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Tange-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-11 17:15:54 +0100" MODIFIED_BY="Heather Maxwell">
<P>Non-randomised trial. The number of anaemic participant was not provided for each group of treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-11 17:16:12 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Thirunavukkarasu-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-11 17:16:12 +0100" MODIFIED_BY="Heather Maxwell">
<P>Not a controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-11 17:16:11 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Tomar-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-11 17:16:11 +0100" MODIFIED_BY="Heather Maxwell">
<P>Non-randomised study. Only the abstract was available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Valli-Rani-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>They used sequential strategy for allocation and not a random one.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-11 17:16:43 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Van-den-Broek-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-11 17:16:43 +0100" MODIFIED_BY="Heather Maxwell">
<P>Non-iron trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Visca-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>No fundamental data to assess validity.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Von-Peiker-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>The differences between the groups was not iron, but vitamins.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-11 17:16:35 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Wu-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-11 17:16:35 +0100" MODIFIED_BY="Heather Maxwell">
<P>The numbers of participants in the 3 groups are not similar (93 for maternal, 50 for ferrous sulphate and 35 for ferroids) and is higher at follow-up than at the beginning of the trial. It is unclear how they were allocated to the groups and whether therefore they are similar at baseline.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Young-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>A weekly iron/folate supplement was compared with a standard daily iron/folate supplement in pregnant women living in rural Malawi. Acid folic trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-06 10:22:46 +0000" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-Zhou-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-06 10:22:46 +0000" MODIFIED_BY="Denise Atherton">
<P>Non-anaemic women.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>Hb: haemoglobin<BR/>vs: versus</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2011-08-12 13:39:49 +0100" MODIFIED_BY="Heather Maxwell" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2011-08-12 13:32:05 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Paleru-2011">
<CHAR_METHODS MODIFIED="2011-06-09 14:55:33 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised open label controlled trial. No further details on the methods to generate randomisation and allocation concealment were provided.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-12 13:32:05 +0100" MODIFIED_BY="Heather Maxwell">
<P>80 antenatal women with anaemia (Hb levels between 8 and 10.5 g/dL) and serum ferritin &lt; 13 mcg/L.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-12 13:32:05 +0100" MODIFIED_BY="Heather Maxwell">
<P>300 mg oral iron sulphate per day vs. IV iron sucrose</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-08-12 13:32:05 +0100" MODIFIED_BY="Heather Maxwell">
<P>Levels of Hb and ferritin on the day 28<SUP>th </SUP>and at delivery. No data on findings were provided.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-06-09 17:44:34 +0100" MODIFIED_BY="[Empty name]">
<P>Poster presentation. No numerical data were provided for analysis.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2011-08-12 13:32:15 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Pandit-2009">
<CHAR_METHODS MODIFIED="2011-06-09 14:55:37 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial. No further details on the methods to generate randomisation and allocation concealment were provided.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-06 10:23:45 +0000" MODIFIED_BY="Denise Atherton">
<P>100 anaemic pregnant women were recruited. All women were selected between 16 to 24 weeks of gestational age, irrespective of their parity, socio-economic status and dietary habits.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-12 13:32:15 +0100" MODIFIED_BY="Heather Maxwell">
<P>Women were randomly divided into study and control groups and were given study group (N = 50) &#8211; IV iron sucrose injections. Control group (N = 50) &#8211; oral ferrous sulphate tablets.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-06 10:31:59 +0000" MODIFIED_BY="Denise Atherton">
<P>The outcome of pregnancy, birthweight of babies and side effects of both methods were also studied.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-06 10:24:15 +0000" MODIFIED_BY="Denise Atherton">
<P>Poster presentation. No numerical data were provided for analysis. We attempted to find the authors on the Web but this strategy was unsuccessful.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2011-08-12 13:39:49 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Sarkate-2007">
<CHAR_METHODS MODIFIED="2011-01-06 10:24:18 +0000" MODIFIED_BY="Denise Atherton">
<P>Double blind randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-12 13:39:49 +0100" MODIFIED_BY="Heather Maxwell">
<P>Pregnant women with gestation period between 12 and 26 weeks having serum Hb &lt; 10 g/dL, serum ferritin &lt; 12 mcg/L.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-06 10:24:30 +0000" MODIFIED_BY="Denise Atherton">
<P>Group 1: sodium feredetate (33 mg elemental iron) + vitamin B12 (15 mcg) + folic acid (1.5 mcg), twice day.</P>
<P>Group 2: sodium feredetate (66 mg elemental iron) + vitamin B12 (15 mcg) + folic acid (1.5 mcg), twice day.</P>
<P>Group 3: Ferrous fumarate (100 mg elemental iron) + vitamin B12 (15 mcg) + folic acid (1.5 mcg), twice day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-06 10:24:45 +0000" MODIFIED_BY="Denise Atherton">
<P>Haematological levels; adverse events. 77% of patients completed all the visits. 11 patients withdrawn due to treatment failure at day 45. The data for their subsequent follow-up visits were computed using the principle of last observation. More patients were recruited due to drop-outs. Trialists did not report the total number of patients that were finally enrolled. Data of 48 patients were available for analysis.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-04-19 16:08:50 +0100" MODIFIED_BY="[Empty name]">
<P>Trialist did not report the total number of participants that were analysed in each group and no further analysis was possible. We attempted to contact some of the authors by electronic email but no response was obtained.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES>
<P>Hb: haemoglobin<BR/>IV: intravenous<BR/>vs: versus<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2011-08-12 13:32:31 +0100" MODIFIED_BY="Heather Maxwell" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2011-08-11 17:03:36 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Ruangvutilet-2009">
<CHAR_STUDY_NAME/>
<CHAR_METHODS MODIFIED="2010-11-02 09:01:52 +0000" MODIFIED_BY="[Empty name]">
<P>Open randomised controlled trial. Phase IV study. No further details on the methods to generate randomisation and allocation concealment were provided.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-11 17:03:18 +0100" MODIFIED_BY="Heather Maxwell">
<P>Women aged between 18 and 45 years old, singleton pregnancy at 32 weeks' gestation, having anaemia (less than 11 g/dL). No underlying disease.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-02 09:01:52 +0000" MODIFIED_BY="[Empty name]">
<P>Intravenous versus oral iron (Venofer vs Ferli-6). No further detail was provided. </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-08-11 17:03:36 +0100" MODIFIED_BY="Heather Maxwell">
<P>Serum ferritin, Hb level.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES MODIFIED="2010-11-02 09:01:52 +0000" MODIFIED_BY="[Empty name]">
<P>Ongoing study. We attempted to contact some of the authors by electronic email but no response was obtained.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>Hb: haemoglobin</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2011-08-12 13:30:18 +0100" MODIFIED_BY="Heather Maxwell">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2011-08-11 17:37:34 +0100" MODIFIED_BY="Heather Maxwell" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-06 09:46:35 +0000" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Al-2005">
<DESCRIPTION>
<P>Group allocation was predetermined by one of the authors who was not involved with patient care. Opaque envelopes were consecutively numbered by means of a computer-generated randomisation table. As each patient gave consent for the study, the next envelope was opened to assign the patient to either of the 2 groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-06 09:50:06 +0000" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Bayoumeu-2002">
<DESCRIPTION>
<P>Women were assigned to the group treatment by a randomisation table.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-06 09:50:29 +0000" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Breymann-2001">
<DESCRIPTION>
<P>Women randomly assigned to 2 treatment groups by means of a computer-generated list.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-06 09:50:59 +0000" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Dawson-1965">
<DESCRIPTION>
<P>Method of allocation was a random-number table.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-06 09:51:13 +0000" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-De-Souza-2004">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-06 09:51:32 +0000" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Digumarthi-2008">
<DESCRIPTION>
<P>"Randomized". Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-06 09:59:41 +0000" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Kaisi-1988">
<DESCRIPTION>
<P>Randomisation list.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-08-11 17:35:11 +0100" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Khalafallah-2010">
<DESCRIPTION>
<P>"Central randomisation by computer will follow thereafter" (data from the Australian New Zealand clinical trials Registry. The trial was retrospectively registered: ACTRN12609000177257).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-08-11 17:37:34 +0100" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Komolafe-2003">
<DESCRIPTION>
<P>Computer-generated random numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-06 10:05:35 +0000" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Kumar-2005">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-06 10:06:05 +0000" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Mumtaz-2000">
<DESCRIPTION>
<P>Random-number generator.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-06 10:06:54 +0000" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Nappi-2009">
<DESCRIPTION>
<P>Computer-generated randomisation list.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-06 10:08:02 +0000" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Ogunbode-1980">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-06 10:08:38 +0000" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Oluboyede-1980">
<DESCRIPTION>
<P>"Restricted random allocation."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-06 10:09:37 +0000" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Saha-2007">
<DESCRIPTION>
<P>"Randomized."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-06 10:10:50 +0000" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Singh-1998">
<DESCRIPTION>
<P>Randomised.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-06 10:11:41 +0000" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Sood-1979">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-06 10:12:18 +0000" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Suharno-1993">
<DESCRIPTION>
<P>Random-number list.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-09 13:50:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sun-2010">
<DESCRIPTION>
<P>"Randomized". Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-06 10:12:49 +0000" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Symonds-1969">
<DESCRIPTION>
<P>"Randomly".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-06 10:13:18 +0000" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Wali-2002">
<DESCRIPTION>
<P>No description other than "randomised".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-06 10:14:20 +0000" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Zhou-2007">
<DESCRIPTION>
<P>"Computer-generated randomizations schedule was generated by an independent consultant with stratification for Hb (Hb &lt; 100 or &gt; 100 g/L) to ensure that there were equal proportions of women with more severe anaemia in all groups."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-06 10:20:09 +0000" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Zutschi-2004">
<DESCRIPTION>
<P>No description other than "randomized".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2011-08-11 17:37:35 +0100" MODIFIED_BY="Heather Maxwell" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-06 09:46:43 +0000" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Al-2005">
<DESCRIPTION>
<P>Consecutive numbered opaque envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-06 09:50:07 +0000" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Bayoumeu-2002">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-24 22:24:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Breymann-2001">
<DESCRIPTION>
<P>Not described in the article but the author provided additional information upon request.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-06 09:51:00 +0000" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Dawson-1965">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-06 09:51:14 +0000" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-De-Souza-2004">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-06 09:51:33 +0000" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Digumarthi-2008">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-06 09:59:42 +0000" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Kaisi-1988">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-25 19:37:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Khalafallah-2010">
<DESCRIPTION>
<P>"If the patients agree to participate in the trial, randomisation will follow in different department by the Pharmacy clinical trial personnel where a special computer programme will assign the treatment in random fashion without influence of treating team. This is usually conducted in blocks until full recruitment occurs".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-08-11 17:37:35 +0100" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Komolafe-2003">
<DESCRIPTION>
<P>"Sealed envelopes".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-06 10:05:37 +0000" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Kumar-2005">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-11 15:48:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mumtaz-2000">
<DESCRIPTION>
<P>Randomisation was performed using a random-number generator, and each women was assigned a unique identifier. The randomisation code was opened only after the follow up for all participants had been completed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-06 10:06:55 +0000" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Nappi-2009">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-06 10:08:02 +0000" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Ogunbode-1980">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-06 10:08:39 +0000" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Oluboyede-1980">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-06 10:09:37 +0000" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Saha-2007">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-11 15:52:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Singh-1998">
<DESCRIPTION>
<P>Sealed envelopes with consecutive numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-06 10:11:42 +0000" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Sood-1979">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-11 16:01:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Suharno-1993">
<DESCRIPTION>
<P>An independent researcher randomly labelled the active and placebo preparations. Coding colours were given to the preparations and these codes were opened once the data for all analyses had been entered in the computer and cleaned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-09 13:50:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sun-2010">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-06 10:12:52 +0000" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Symonds-1969">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-06 10:13:19 +0000" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Wali-2002">
<DESCRIPTION>
<P>No description.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-06 10:14:23 +0000" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Zhou-2007">
<DESCRIPTION>
<P>"The iron tablets were packed in bottles with childproof lids, which were labelled with a unique study number according to the randomizations schedule by the Pharmacy Department at the CYWHS."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-06 10:20:12 +0000" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Zutschi-2004">
<DESCRIPTION>
<P>No description.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-08-11 17:37:36 +0100" MODIFIED_BY="Heather Maxwell" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-01-06 09:46:44 +0000" MODIFIED_BY="Denise Atherton" RESULT="NO" STUDY_ID="STD-Al-2005">
<DESCRIPTION>
<P>Not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-01-06 09:50:09 +0000" MODIFIED_BY="Denise Atherton" RESULT="NO" STUDY_ID="STD-Bayoumeu-2002">
<DESCRIPTION>
<P>Neither the women nor caregivers were blinded to the interventions. It is unclear if the outcome assessor was blinded to the interventions.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-01-06 09:50:32 +0000" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Breymann-2001">
<DESCRIPTION>
<P>It is unclear whether participants, clinicians and outcome assessor were blinded to the interventions. Probably not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-01-06 09:51:00 +0000" MODIFIED_BY="Denise Atherton" RESULT="NO" STUDY_ID="STD-Dawson-1965">
<DESCRIPTION>
<P>Not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-11 15:32:01 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-De-Souza-2004">
<DESCRIPTION>
<P>Neither the women nor treating physicians were blinded to the interventions. Trialists reported that the laboratory was blind to the interventions.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-01-06 09:51:34 +0000" MODIFIED_BY="Denise Atherton" RESULT="NO" STUDY_ID="STD-Digumarthi-2008">
<DESCRIPTION>
<P>Not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-01-06 09:59:42 +0000" MODIFIED_BY="Denise Atherton" RESULT="NO" STUDY_ID="STD-Kaisi-1988">
<DESCRIPTION>
<P>Not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-08-11 17:35:14 +0100" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Khalafallah-2010">
<DESCRIPTION>
<P>Not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-08-11 17:37:36 +0100" MODIFIED_BY="Heather Maxwell" RESULT="NO" STUDY_ID="STD-Komolafe-2003">
<DESCRIPTION>
<P>Neither the participants nor treating physicians were blinded to the interventions.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-11 15:43:47 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kumar-2005">
<DESCRIPTION>
<P>Both the participants and treating physicians were not blinded to the interventions.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-11 15:48:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mumtaz-2000">
<DESCRIPTION>
<P>The women and the investigator were blinded to the allocation of treatment group. The appearance of the capsules and the blister packs of the 2 groups were identical.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-01-06 10:06:58 +0000" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Nappi-2009">
<DESCRIPTION>
<P>Both researchers and patients were blinded to group assignment. The tablets were similar and neither the researchers nor the patients could differentiate the treatment assigned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-01-06 10:08:03 +0000" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Ogunbode-1980">
<DESCRIPTION>
<P>Both the participants and treating physicians were blinded to the interventions.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-01-06 10:08:40 +0000" MODIFIED_BY="Denise Atherton" RESULT="NO" STUDY_ID="STD-Oluboyede-1980">
<DESCRIPTION>
<P>Neither the participants nor treating physicians were blinded to the interventions.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-12 14:19:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Saha-2007">
<DESCRIPTION>
<P>Participants and outcome assessors were blind. Both of the drugs were dispensed in identical capsules to ensure blinding. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-01-06 10:10:53 +0000" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Singh-1998">
<DESCRIPTION>
<P>No sufficient detail to decide.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-01-06 10:11:42 +0000" MODIFIED_BY="Denise Atherton" RESULT="NO" STUDY_ID="STD-Sood-1979">
<DESCRIPTION>
<P>Not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-11 16:01:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Suharno-1993">
<DESCRIPTION>
<P>An independent researcher randomly labelled the active and placebo preparations. Coding colours were given to the preparations and these codes were opened once the data for all analyses had been entered in the computer and cleaned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-09 13:50:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sun-2010">
<DESCRIPTION>
<P>&#8220;The capsules were coloured red, yellow, green and blue during manufacture by Hurun (a Chinese food-additive company, Beijing). Both trial participants and the research team were unaware of the group assignment. The trial was decoded after analysis of the primary outcomes&#8221;. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-11 16:05:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Symonds-1969">
<DESCRIPTION>
<P>The trial was masked only the first 2 months and only for these 2 groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-01-06 10:13:20 +0000" MODIFIED_BY="Denise Atherton" RESULT="NO" STUDY_ID="STD-Wali-2002">
<DESCRIPTION>
<P>Neither the participants nor treating physicians were blinded to the interventions.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-01-06 10:14:32 +0000" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Zhou-2007">
<DESCRIPTION>
<P>"Trial participants and the research team were unaware of the treatment group assignment". The trial was unblinded after the analysis of the primary outcomes."</P>
<P>"The tablets were identical in size, colour and shape."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-01-06 10:20:13 +0000" MODIFIED_BY="Denise Atherton" RESULT="NO" STUDY_ID="STD-Zutschi-2004">
<DESCRIPTION>
<P>Neither the women nor treating physicians were blinded to the interventions.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2011-08-12 13:30:18 +0100" MODIFIED_BY="Heather Maxwell" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-08-11 17:22:53 +0100" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Al-2005">
<DESCRIPTION>
<P>The analysis was based on the ITT principle. No participants were lost to follow up, and there were no dropouts. Relevant neonatal outcomes were not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-11 14:57:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bayoumeu-2002">
<DESCRIPTION>
<P>The trialists reported that 3 (6%) women were excluded from the study and that 2 others where lost to follow up. No clinical outcomes were measured. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-11 15:11:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Breymann-2001">
<DESCRIPTION>
<P>Trial had no withdrawals.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-11 15:19:40 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dawson-1965">
<DESCRIPTION>
<P>Loss to follow up: at 2 weeks: loss: A = 24%; B = 9%; C = 27%.<BR/>At 4 weeks: loss: A = 48%; B = 39%; C = 38%.<BR/>At 8 weeks: loss: A = 88%; B = 70%; C = 85%.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-01-06 09:51:17 +0000" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-De-Souza-2004">
<DESCRIPTION>
<P>21.5% of women were reported to drop the trial or were lost to follow up. The reasons were described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-12 15:56:37 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Digumarthi-2008">
<DESCRIPTION>
<P>Losses to follow up not reported. No clinical outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-01-06 10:34:15 +0000" MODIFIED_BY="Denise Atherton" RESULT="NO" STUDY_ID="STD-Kaisi-1988">
<DESCRIPTION>
<P>High rate of loss to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-08-11 17:35:15 +0100" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Khalafallah-2010">
<DESCRIPTION>
<P>8.5% of participants did not complete the trial (8 and 9 participants in the oral and IV iron group respectively).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-11 15:41:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Komolafe-2003">
<DESCRIPTION>
<P>This trial had no withdrawals.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-11 15:44:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kumar-2005">
<DESCRIPTION>
<P>47 women in parenteral iron group and 23 women in oral iron group were lost to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-08-11 17:41:05 +0100" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Mumtaz-2000">
<DESCRIPTION>
<P>This trial had 86 participants, (45%) that did not complete the entire duration of follow up (i.e. 4 follow-up visits). However data on 83.8% of the participants were available for 4 weeks of follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-01-06 10:07:44 +0000" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Nappi-2009">
<DESCRIPTION>
<P>2 patients (4%) from the group assigned to ferrous sulphate were lost to follow up. No clinical outcomes were collected. The total number of adverse events were not reported for each group; only the median gastrointestinal side effects score were presented.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-11 15:50:34 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ogunbode-1980">
<DESCRIPTION>
<P>No participants were reported to have dropped out or were lost to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-01-06 10:08:43 +0000" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Oluboyede-1980">
<DESCRIPTION>
<P>1 participant from the imferon group was reported to have dropped out due to a severe reaction.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-01-06 10:09:41 +0000" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Saha-2007">
<DESCRIPTION>
<P>No losses to follow up or discontinuation were reported. No clinical outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-01-06 10:31:37 +0000" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Singh-1998">
<DESCRIPTION>
<P>The paper provided haematological outcomes. In addition, the publication mentioned some side effects and similar clinical outcomes in both groups. The authors were contacted and provided precise data on clinical outcomes and side effects that were included too.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-11 16:00:28 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sood-1979">
<DESCRIPTION>
<P>The paper provided haematological outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-01-06 10:12:27 +0000" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Suharno-1993">
<DESCRIPTION>
<P>Some outcomes not fully reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-08-11 17:52:45 +0100" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Sun-2010">
<DESCRIPTION>
<P>Few participants were lost to follow up. Standard deviations of placebo group were not provided and had to be calculated. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-01-06 10:31:47 +0000" MODIFIED_BY="Denise Atherton" RESULT="NO" STUDY_ID="STD-Symonds-1969">
<DESCRIPTION>
<P>For this review, side effects were considered. The other data were incomplete, without reported standard deviations of mean values.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-08-12 13:30:18 +0100" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Wali-2002">
<DESCRIPTION>
<P>The trial outcomes focused on laboratory values (Hb) and side effects.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-01-06 10:14:37 +0000" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Zhou-2007">
<DESCRIPTION>
<P>Only 1 patient was lost to follow up. Pregnancy outcomes and neonatal complications at birth were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-01-06 10:20:16 +0000" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Zutschi-2004">
<DESCRIPTION>
<P>No dropout or lost to follow up were reported. Few clinical outcomes were provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2011-08-12 13:16:47 +0100" MODIFIED_BY="Heather Maxwell" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-11 14:40:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Al-2005">
<DESCRIPTION>
<P>Protocol of the study is not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-11 14:50:07 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bayoumeu-2002">
<DESCRIPTION>
<P>Protocol of the study is not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-11 15:11:35 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Breymann-2001">
<DESCRIPTION>
<P>Protocol of the study is not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-11 15:19:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dawson-1965">
<DESCRIPTION>
<P>Protocol of the study is not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-11 15:32:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Souza-2004">
<DESCRIPTION>
<P>Protocol of the study is not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 15:56:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Digumarthi-2008">
<DESCRIPTION>
<P>Protocol of the study is not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-08-12 13:16:47 +0100" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Kaisi-1988">
<DESCRIPTION>
<P>Protocol of the study is not available. . Loss to follow up for Hb result was 47% so these results were not included in this review. For other clinical outcomes, loss to follow up was 18% and 20% so they were included.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-25 19:39:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Khalafallah-2010">
<DESCRIPTION>
<P>The protocol was not available. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-11 15:42:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Komolafe-2003">
<DESCRIPTION>
<P>Protocol of the study is not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-11 15:44:15 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kumar-2005">
<DESCRIPTION>
<P>Protocol of the study is not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-11 15:49:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mumtaz-2000">
<DESCRIPTION>
<P>Protocol of the study is not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 20:00:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nappi-2009">
<DESCRIPTION>
<P>Protocol of the study is not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-11 15:49:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ogunbode-1980">
<DESCRIPTION>
<P>Protocol of the study is not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-11 15:52:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Oluboyede-1980">
<DESCRIPTION>
<P>Protocol of the study is not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 14:27:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saha-2007">
<DESCRIPTION>
<P>Protocol of the study is not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-11 16:00:43 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Singh-1998">
<DESCRIPTION>
<P>Protocol of the study is not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-11 16:00:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sood-1979">
<DESCRIPTION>
<P>Protocol of the study is not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-11 16:00:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Suharno-1993">
<DESCRIPTION>
<P>Protocol of the study is not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-08-11 17:52:49 +0100" MODIFIED_BY="Heather Maxwell" RESULT="NO" STUDY_ID="STD-Sun-2010">
<DESCRIPTION>
<P>No clinical outcomes and adverse events were informed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-11 16:03:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Symonds-1969">
<DESCRIPTION>
<P>Protocol of the study is not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-11 16:06:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wali-2002">
<DESCRIPTION>
<P>Protocol of the study is not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 22:40:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhou-2007">
<DESCRIPTION>
<P>Protocol of the study is not available. The Australian Clinical Trials Registry (ACTR) (Reference no. 12606000357550).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-11 16:13:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zutschi-2004">
<DESCRIPTION>
<P>Protocol of the study is not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2011-08-11 17:37:39 +0100" MODIFIED_BY="Heather Maxwell" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-11 14:35:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Al-2005">
<DESCRIPTION>
<P>Maternal and infant baseline characteristics were provided. </P>
<P>Competing interests and funding were not declared. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 13:54:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bayoumeu-2002">
<DESCRIPTION>
<P>Baseline characteristics were provided. Supported by Maternity Hospital Nano. Competing interests not declared. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-11 15:17:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Breymann-2001">
<DESCRIPTION>
<P>Baseline characteristics were provided. Competing interests and funding were not declared.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-11 15:24:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dawson-1965">
<DESCRIPTION>
<P>Competing interests and funding were not declared.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-11 15:34:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-De-Souza-2004">
<DESCRIPTION>
<P>Baseline characteristics were provided. Competing interests and funding were not declared.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 15:57:15 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Digumarthi-2008">
<DESCRIPTION>
<P>No baseline characteristics were reported. Competing interests and funding were not declared.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-15 17:08:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kaisi-1988">
<DESCRIPTION>
<P>Baseline characteristics were reported.Competing interests and funding were not declared.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-25 19:40:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Khalafallah-2010">
<DESCRIPTION>
<P>All authors declare no financial conflicts of interest. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-08-11 17:37:39 +0100" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Komolafe-2003">
<DESCRIPTION>
<P>Baseline characteristics were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-15 17:14:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kumar-2005">
<DESCRIPTION>
<P>Baseline characteristics were reported. Competing interests and funding were not declared.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-11 15:54:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mumtaz-2000">
<DESCRIPTION>
<P>Characteristics of the women at the beginning of the study were provided. Competing interests and funding were not declared.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-19 15:45:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nappi-2009">
<DESCRIPTION>
<P>Baseline characteristics were provided. The authors report no conflicts of interest. Funding was not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-06 10:08:06 +0000" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Ogunbode-1980">
<DESCRIPTION>
<P>Baseline characteristics were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-15 17:14:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Oluboyede-1980">
<DESCRIPTION>
<P>Competing interests and funding were not declared.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 14:30:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Saha-2007">
<DESCRIPTION>
<P>Baseline characteristics were provided. Competing interests were declared. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-06 10:11:04 +0000" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Singh-1998">
<DESCRIPTION>
<P>Data provided by 1 of the authors reveals that compared groups had similar age distribution, parity, mean total income, weight, height, history of anaemia in previous pregnancies, history of intrauterine growth retardation in previous pregnancies and similar time-gap between pregnancies.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-15 17:15:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sood-1979">
<DESCRIPTION>
<P>Competing interests and funding were not declared.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-11 16:03:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Suharno-1993">
<DESCRIPTION>
<P>Baseline characteristics were provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-09 13:51:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sun-2010">
<DESCRIPTION>
<P>Baseline characteristics were provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-11 16:05:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Symonds-1969">
<DESCRIPTION>
<P>Baseline characteristics of participants were provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-15 17:16:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wali-2002">
<DESCRIPTION>
<P>Competing interests and funding were not declared.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-06 10:19:44 +0000" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Zhou-2007">
<DESCRIPTION>
<P>Baseline characteristics were provided. "Funding from the Adelaide Women&#8217;s &amp; Children&#8217;s Hospital Research Foundation. The iron and placebo tablets used in the trial were manufactured and donated by Soul Pattinson Manufacturing, Kingsgrove, NSW, Australia. The funding organizations had no role in the design and conduct of the study, the analysis and interpretation of the data, or the preparation, review and approval of the manuscript. MM and RAG occasionally provide advice to manufacturers of nutritional supplements. SJZ and CAC have no known conflict of interest.".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-11 16:16:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zutschi-2004">
<DESCRIPTION>
<P>Baseline characteristics were partially presented. Competing interests and funding were not declared.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2011-06-01 22:28:22 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2011-06-01 22:28:22 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE>FDA iron adverse effects description</TITLE>
<TABLE COLS="2" ROWS="12">
<TR>
<TH>
<P>Drug substance</P>
</TH>
<TH>
<P>Adverse effect</P>
</TH>
</TR>
<TR>
<TD>
<P>Iron</P>
</TD>
<TD>
<P>Oral preparations: produces gastrointestinal irritation and abdominal pain with nausea and vomiting, when administered orally. The effect is usually dose related to the amount of elemental iron, rather than the preparation. Diarrhoea and constipation. Better to administer with foods, and to increase doses gradually. Oral liquid preparations may stain teeth. Oral preparations should not be given concomitantly with parenteral preparations. Parenteral preparations: anaphylactoid reactions, peripheral vascular flushing with intravenous administration, tachycardia, hypotension and syncope, thrombophlebitis (higher if given with glucose 5% versus sodium chloride 0.9%), nausea, vomiting, taste disturbance. Delayed reactions may include arthralgia, myalgia, regional lymphadenopathy, chills, fever, paraesthesia, dizziness, malaise, headache, nausea, vomiting and haematuria. Intramuscular use in animals has resulted in the development of sarcomas at the injection site. It interacts with enalapril (potentiates adverse systemic reactions) and chloramphenicol.</P>
</TD>
</TR>
<TR>
<TD>
<P>Iron sulphate (oral)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Ferrous gluconate (oral)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Iron fumarate (oral)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Iron sucrose (intravenous)</P>
</TD>
<TD>
<P>In addition to the adverse effects for parenteral preparations: bronchospasm, dyspnoea, myalgia, pruritus, urticaria, rash, reactions in the injection site.</P>
</TD>
</TR>
<TR>
<TD>
<P>Iron sorbitol</P>
</TD>
<TD>
<P>In addition to the adverse effects for parenteral preparations: severe systemic reactions with potentially fatal cardiac complications. Dark urine. Do not administer intravenously.</P>
</TD>
</TR>
<TR>
<TD>
<P>Iron dextran (intramuscular)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Iron polymaltose complex -iron dextrin-</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Adjuvant recombinant human erythropoietin</P>
</TD>
<TD>
<P>Epoetin: recombinant human erythropoietin.<BR/>Darbepoetin: derivative of epoetin.<BR/>Headache, hypertension and seizures, specially in people with poor renal function. Thrombosis at vascular access sites, flu-like symptoms, hyperkalaemia, skin rashes, and rare reports of anaphylactoid reactions.<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Iron polymaltose complex (oral)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>&#8224;Martindale, The Complete Drug reference. Pharmaceutical Press. 32 ed. London 1999. &#8225;British National Formulary. Royal Pharmaceutical Society. 49 ed. London, March 2005<BR/>
<BR/>&#8225;British National Formulary. Royal Pharmaceutical Society. 49 ed. London, March 2005<BR/>&#8224;Martindale, The Complete Drug reference. Pharmaceutical Press. 32 ed. London 1999.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2011-08-12 13:01:48 +0100" MODIFIED_BY="Heather Maxwell">
<COMPARISON ID="CMP-001" MODIFIED="2011-08-12 13:00:17 +0100" MODIFIED_BY="Heather Maxwell" NO="1">
<NAME>Oral iron versus placebo</NAME>
<DICH_OUTCOME CHI2="3.310871628136946E-31" CI_END="0.5524779697915487" CI_START="0.25932275036075414" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.37851037851037855" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="52" I2="100.00000000000001" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.2576850349075002" LOG_CI_START="-0.5861593809447913" LOG_EFFECT_SIZE="-0.42192220792614576" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="1.0" P_Z="4.775729976556795E-7" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="63" TOTAL_2="62" WEIGHT="100.0" Z="5.035110606287554">
<NAME>Anaemic during 2nd trimester</NAME>
<GROUP_LABEL_1>Oral iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.5524779697915486" CI_START="0.2593227503607541" EFFECT_SIZE="0.3785103785103785" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="52" LOG_CI_END="-0.2576850349075003" LOG_CI_START="-0.5861593809447914" LOG_EFFECT_SIZE="-0.4219222079261458" ORDER="16092" O_E="0.0" SE="0.192947456836541" STUDY_ID="STD-Suharno-1993" TOTAL_1="63" TOTAL_2="62" VAR="0.03722872109968885" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="42.39914438772989" CI_END="2.422674660969131" CI_START="0.26681273705438313" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="1.3447436990117572" ESTIMABLE="YES" I2="97.64146183975969" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2011-08-12 13:00:17 +0100" MODIFIED_BY="Heather Maxwell" NO="2" P_CHI2="7.44257988571917E-11" P_Q="1.0" P_Z="0.014481190041824063" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.5907308441305457" TOTALS="YES" TOTAL_1="107" TOTAL_2="108" UNITS="" WEIGHT="100.0" Z="2.4451002072658157">
<NAME>Haemoglobin levels (g/dL)</NAME>
<GROUP_LABEL_1>Oral iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral iron</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.9805639069789724" CI_START="0.619436093021029" EFFECT_SIZE="0.8000000000000007" ESTIMABLE="YES" MEAN_1="11.3" MEAN_2="10.5" ORDER="16093" SD_1="0.52" SD_2="0.51" SE="0.09212613517556283" STUDY_ID="STD-Suharno-1993" TOTAL_1="63" TOTAL_2="62" WEIGHT="50.47784554438577"/>
<CONT_DATA CI_END="2.1775345471353713" CI_START="1.6224654528646294" EFFECT_SIZE="1.9000000000000004" ESTIMABLE="YES" MEAN_1="11.8" MEAN_2="9.9" MODIFIED="2011-06-09 16:03:39 +0100" MODIFIED_BY="[Empty name]" ORDER="222" SD_1="0.77" SD_2="0.55" SE="0.14160186070995587" STUDY_ID="STD-Sun-2010" TOTAL_1="44" TOTAL_2="46" WEIGHT="49.522154455614235"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.8753101181288578" CI_START="0.5246898818711416" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.6999999999999997" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="5.036874757833787E-15" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="63" TOTAL_2="62" UNITS="" WEIGHT="100.0" Z="7.82598747762862">
<NAME>Ferritin levels (ug/l)</NAME>
<GROUP_LABEL_1>Oral iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral iron</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.8753101181288578" CI_START="0.5246898818711416" EFFECT_SIZE="0.6999999999999997" ESTIMABLE="YES" MEAN_1="3.3" MEAN_2="2.6" ORDER="16094" SD_1="0.5" SD_2="0.5" SE="0.08944558140439413" STUDY_ID="STD-Suharno-1993" TOTAL_1="63" TOTAL_2="62" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.051060943189125595" CI_START="0.028939056810874365" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.03999999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2011-05-31 18:21:47 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="1.3618896528758723E-12" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="63" TOTAL_2="62" UNITS="" WEIGHT="100.0" Z="7.0878728912267075">
<NAME>Serum iron (mg/l)</NAME>
<GROUP_LABEL_1>Oral iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral iron</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.051060943189125595" CI_START="0.028939056810874365" EFFECT_SIZE="0.03999999999999998" ESTIMABLE="YES" MEAN_1="0.43" MEAN_2="0.39" ORDER="16095" SD_1="0.04" SD_2="0.02" SE="0.005643442061370986" STUDY_ID="STD-Suharno-1993" TOTAL_1="63" TOTAL_2="62" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.905869747027957" CI_START="0.6562922530505398" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.96875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" I2="0.0" I2_Q="100.00000000000001" ID="CMP-001.05" LOG_CI_END="0.7712838644423333" LOG_CI_START="-0.18290272217498188" LOG_EFFECT_SIZE="0.29419057113367575" METHOD="MH" MODIFIED="2011-01-06 10:32:12 +0000" MODIFIED_BY="Denise Atherton" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.22682627100329966" Q="3.923545028599243E-32" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="24" TOTAL_2="27" WEIGHT="100.0" Z="1.2085747842199022">
<NAME>Side effects</NAME>
<GROUP_LABEL_1>Oral iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.905869747027957" CI_START="0.6562922530505398" EFFECT_SIZE="1.96875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.7712838644423333" LOG_CI_START="-0.18290272217498188" LOG_EFFECT_SIZE="0.29419057113367575" ORDER="16096" O_E="0.0" SE="0.5604939242787911" STUDY_ID="STD-Symonds-1969" TOTAL_1="24" TOTAL_2="27" VAR="0.31415343915343913" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="37.535107731874334" CI_START="0.539494921518607" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="4.5" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="1.5744376667001105" LOG_CI_START="-0.26801263914942325" LOG_EFFECT_SIZE="0.6532125137753437" METHOD="MH" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.16460469219884133" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="24" TOTAL_2="27" WEIGHT="100.0" Z="1.3897503744723556">
<NAME>Nausea and vomiting</NAME>
<GROUP_LABEL_1>Oral iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="37.53510773187432" CI_START="0.5394949215186072" EFFECT_SIZE="4.5" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5744376667001105" LOG_CI_START="-0.268012639149423" LOG_EFFECT_SIZE="0.6532125137753437" ORDER="16097" O_E="0.0" SE="1.0822644299321198" STUDY_ID="STD-Symonds-1969" TOTAL_1="24" TOTAL_2="27" VAR="1.1712962962962963" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.014623419966478" CI_START="0.3152537280845553" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.6036448137988041" LOG_CI_START="-0.5013397689040416" LOG_EFFECT_SIZE="0.05115252244738129" METHOD="MH" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.8560038985476003" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="24" TOTAL_2="27" WEIGHT="100.0" Z="0.18146334941617062">
<NAME>Constipation</NAME>
<GROUP_LABEL_1>Oral iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.014623419966478" CI_START="0.3152537280845553" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6036448137988041" LOG_CI_START="-0.5013397689040416" LOG_EFFECT_SIZE="0.05115252244738129" ORDER="16098" O_E="0.0" SE="0.6490734136415512" STUDY_ID="STD-Symonds-1969" TOTAL_1="24" TOTAL_2="27" VAR="0.4212962962962963" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="111.14669554729056" CI_START="0.2821496387776728" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="5.6" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="2.0458965554118835" LOG_CI_START="-0.5495205013994826" LOG_EFFECT_SIZE="0.7481880270062004" METHOD="MH" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.25847268777525434" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="24" TOTAL_2="27" WEIGHT="100.0" Z="1.1300084375632684">
<NAME>Abdominal cramps</NAME>
<GROUP_LABEL_1>Oral iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="111.14669554729048" CI_START="0.2821496387776729" EFFECT_SIZE="5.6" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.045896555411883" LOG_CI_START="-0.5495205013994824" LOG_EFFECT_SIZE="0.7481880270062004" ORDER="16099" O_E="0.0" SE="1.5245608266926296" STUDY_ID="STD-Symonds-1969" TOTAL_1="24" TOTAL_2="27" VAR="2.3242857142857143" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2011-08-12 13:00:49 +0100" MODIFIED_BY="Heather Maxwell" NO="2">
<NAME>Oral iron + vitamin A versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.14867280748509243" CI_START="0.009636604639650456" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.03785103785103785" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="52" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-0.8277684574303124" LOG_CI_START="-2.016075958421979" LOG_EFFECT_SIZE="-1.4219222079261458" METHOD="MH" MODIFIED="2011-05-31 18:21:50 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="2.724527114760805E-6" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="63" TOTAL_2="62" WEIGHT="100.0" Z="4.690564208384078">
<NAME>Anaemic during 2nd trimester</NAME>
<GROUP_LABEL_1>Oral iron + vit A</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours iron + vit A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.14867280748509243" CI_START="0.009636604639650456" EFFECT_SIZE="0.03785103785103785" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="52" LOG_CI_END="-0.8277684574303124" LOG_CI_START="-2.016075958421979" LOG_EFFECT_SIZE="-1.4219222079261458" ORDER="16100" O_E="0.0" SE="0.6980177082995022" STUDY_ID="STD-Suharno-1993" TOTAL_1="63" TOTAL_2="62" VAR="0.48722872109968884" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.485904919880997" CI_START="1.1140950801190044" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.3000000000000007" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.02" MODIFIED="2011-08-12 13:00:49 +0100" MODIFIED_BY="Heather Maxwell" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="9.388473782596475E-43" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="63" TOTAL_2="62" UNITS="" WEIGHT="100.0" Z="13.705679126367917">
<NAME>Haemoglobin levels (g/dL)</NAME>
<GROUP_LABEL_1>Oral iron + vit A</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours iron + vit A</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.485904919880997" CI_START="1.1140950801190044" EFFECT_SIZE="1.3000000000000007" ESTIMABLE="YES" MEAN_1="11.8" MEAN_2="10.5" ORDER="16101" SD_1="0.55" SD_2="0.51" SE="0.09485119183178398" STUDY_ID="STD-Suharno-1993" TOTAL_1="63" TOTAL_2="62" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.8753101181288578" CI_START="0.5246898818711416" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.6999999999999997" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="5.036874757833787E-15" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="63" TOTAL_2="62" UNITS="" WEIGHT="100.0" Z="7.82598747762862">
<NAME>Ferritin levels (ug/l)</NAME>
<GROUP_LABEL_1>Oral iron + vit A</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours iron + vit A</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.8753101181288578" CI_START="0.5246898818711416" EFFECT_SIZE="0.6999999999999997" ESTIMABLE="YES" MEAN_1="3.3" MEAN_2="2.6" ORDER="16102" SD_1="0.5" SD_2="0.5" SE="0.08944558140439413" STUDY_ID="STD-Suharno-1993" TOTAL_1="63" TOTAL_2="62" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.09106094318912558" CI_START="0.06893905681087434" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.07999999999999996" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="1.2946045085651283E-45" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="63" TOTAL_2="62" UNITS="" WEIGHT="100.0" Z="14.175745782453415">
<NAME>Serum iron (mg/l)</NAME>
<GROUP_LABEL_1>Oral iron + vit A</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours iron + vit A</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.09106094318912558" CI_START="0.06893905681087434" EFFECT_SIZE="0.07999999999999996" ESTIMABLE="YES" MEAN_1="0.47" MEAN_2="0.39" ORDER="16103" SD_1="0.04" SD_2="0.02" SE="0.005643442061370986" STUDY_ID="STD-Suharno-1993" TOTAL_1="63" TOTAL_2="62" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2011-08-11 16:49:20 +0100" MODIFIED_BY="Heather Maxwell" NO="3">
<NAME>Controlled-release oral iron versus regular oral iron</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.3268738978949353" CI_START="0.3960678749431795" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.96" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.3667728478624357" LOG_CI_START="-0.40223038178329895" LOG_EFFECT_SIZE="-0.017728766960431602" METHOD="MH" MODIFIED="2011-01-06 10:32:20 +0000" MODIFIED_BY="Denise Atherton" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.9279925058085803" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="24" WEIGHT="100.0" Z="0.09037086813993545">
<NAME>Side effects</NAME>
<GROUP_LABEL_1>Ctrl release iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Regular oral iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ctrl rel Fe</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours reg oral Fe</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.3268738978949353" CI_START="0.3960678749431796" EFFECT_SIZE="0.96" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.3667728478624357" LOG_CI_START="-0.4022303817832989" LOG_EFFECT_SIZE="-0.017728766960431602" ORDER="16108" O_E="0.0" SE="0.4517163037212837" STUDY_ID="STD-Symonds-1969" TOTAL_1="25" TOTAL_2="24" VAR="0.20404761904761903" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.4104938154659434" CI_START="0.27022479730668864" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.96" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.5328172663253258" LOG_CI_START="-0.568274800246189" LOG_EFFECT_SIZE="-0.017728766960431602" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.949674883784265" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="24" WEIGHT="100.0" Z="0.06311505783697835">
<NAME>Nausea and vomiting</NAME>
<GROUP_LABEL_1>Ctrl release iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Regular oral iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ctrl rel Fe</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours reg oral Fe</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.4104938154659434" CI_START="0.27022479730668864" EFFECT_SIZE="0.96" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5328172663253258" LOG_CI_START="-0.568274800246189" LOG_EFFECT_SIZE="-0.017728766960431602" ORDER="16109" O_E="0.0" SE="0.6467869303977418" STUDY_ID="STD-Symonds-1969" TOTAL_1="25" TOTAL_2="24" VAR="0.41833333333333333" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9965053157931023" CI_START="0.028850411538783545" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.24" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" I2_Q="100.0" ID="CMP-003.03" LOG_CI_END="0.30027047086220604" LOG_CI_START="-1.5398479874389939" LOG_EFFECT_SIZE="-0.619788758288394" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.18673144990150983" Q="4.220011975148067E-32" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="24" WEIGHT="100.0" Z="1.320310264578863">
<NAME>Constipation</NAME>
<GROUP_LABEL_1>Ctrl release iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Regular oral iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ctrl rel Fe</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours reg oral Fe</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9965053157931023" CI_START="0.028850411538783545" EFFECT_SIZE="0.24" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.30027047086220604" LOG_CI_START="-1.5398479874389939" LOG_EFFECT_SIZE="-0.619788758288394" ORDER="16110" O_E="0.0" SE="1.0808946911393973" STUDY_ID="STD-Symonds-1969" TOTAL_1="25" TOTAL_2="24" VAR="1.1683333333333332" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.954154035990667" CI_START="0.0465064263900966" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.48" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.6949695056694307" LOG_CI_START="-1.3324870309182564" LOG_EFFECT_SIZE="-0.3187587626244128" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.5376998212319031" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="24" WEIGHT="100.0" Z="0.6162950309671221">
<NAME>Abdominal cramps</NAME>
<GROUP_LABEL_1>Ctrl release iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Regular oral iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ctrl rel Fe</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours reg oral Fe</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.9541540359906655" CI_START="0.04650642639009664" EFFECT_SIZE="0.48" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6949695056694305" LOG_CI_START="-1.332487030918256" LOG_EFFECT_SIZE="-0.3187587626244128" ORDER="16111" O_E="0.0" SE="1.190938005663323" STUDY_ID="STD-Symonds-1969" TOTAL_1="25" TOTAL_2="24" VAR="1.4183333333333332" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2011-06-01 22:05:24 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Intramuscular iron sorbito-citric acid versus intramuscular dextran</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7155692973431163" CI_START="0.5790173827328493" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9966666666666667" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.2344082652927412" LOG_CI_START="-0.23730839808320675" LOG_EFFECT_SIZE="-0.0014500663952327743" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.9903857744071619" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="0.012049936457652703">
<NAME>Pain at injection site</NAME>
<GROUP_LABEL_1>IM iron sorb-cit</GROUP_LABEL_1>
<GROUP_LABEL_2>IM iron dextran</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM sorb-cit</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IM dextran</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7155692973431163" CI_START="0.5790173827328493" EFFECT_SIZE="0.9966666666666667" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.2344082652927412" LOG_CI_START="-0.23730839808320675" LOG_EFFECT_SIZE="-0.0014500663952327743" ORDER="16112" O_E="0.0" SE="0.27708870310217454" STUDY_ID="STD-Dawson-1965" TOTAL_1="25" TOTAL_2="23" VAR="0.07677814938684502" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.6509549632630888" CI_START="0.06924373997713958" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2123076923076923" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="13" I2="0.0" I2_Q="100.0" ID="CMP-004.02" LOG_CI_END="-0.18644905733490483" LOG_CI_START="-1.1596194831483333" LOG_EFFECT_SIZE="-0.6730342702416191" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.006708461032649797" Q="1.508785292677162E-31" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="2.7109803073437564">
<NAME>Skin discolouration at injection site</NAME>
<GROUP_LABEL_1>IM iron sorb-cit</GROUP_LABEL_1>
<GROUP_LABEL_2>IM iron dextran</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM sorb-cit</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IM dextran</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6509549632630888" CI_START="0.06924373997713958" EFFECT_SIZE="0.2123076923076923" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="13" LOG_CI_END="-0.18644905733490483" LOG_CI_START="-1.1596194831483333" LOG_EFFECT_SIZE="-0.6730342702416191" ORDER="16113" O_E="0.0" SE="0.5716451253941076" STUDY_ID="STD-Dawson-1965" TOTAL_1="25" TOTAL_2="23" VAR="0.326778149386845" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="23" WEIGHT="0.0" Z="0.0">
<NAME>Venous thrombosis</NAME>
<GROUP_LABEL_1>IM iron sorb-cit</GROUP_LABEL_1>
<GROUP_LABEL_2>IM iron dextran</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM sorb-cit</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IM dextran</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="16114" O_E="0.0" SE="0.0" STUDY_ID="STD-Dawson-1965" TOTAL_1="25" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="13.873257535648168" CI_START="0.061009463554260755" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.92" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="1.1421784483587567" LOG_CI_START="-1.214602793667646" LOG_EFFECT_SIZE="-0.036212172654444715" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.9519723936651197" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="0.060230073915246075">
<NAME>Nausea or vomiting</NAME>
<GROUP_LABEL_1>IM iron sorb-cit</GROUP_LABEL_1>
<GROUP_LABEL_2>IM iron dextran</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM sorb-cit</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IM dextran</GRAPH_LABEL_2>
<DICH_DATA CI_END="13.873257535648168" CI_START="0.061009463554260755" EFFECT_SIZE="0.92" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1421784483587567" LOG_CI_START="-1.214602793667646" LOG_EFFECT_SIZE="-0.036212172654444715" ORDER="16115" O_E="0.0" SE="1.384384967821608" STUDY_ID="STD-Dawson-1965" TOTAL_1="25" TOTAL_2="23" VAR="1.9165217391304348" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9880948104984353" CI_START="0.01748159104189776" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.13142857142857142" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="-0.005201381626165083" LOG_CI_START="-1.7574190437112378" LOG_EFFECT_SIZE="-0.8813102126687016" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.048655273546637574" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="1.9716001195679376">
<NAME>Headaches</NAME>
<GROUP_LABEL_1>IM iron sorb-cit</GROUP_LABEL_1>
<GROUP_LABEL_2>IM iron dextran</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM sorb-cit</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IM dextran</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9880948104984353" CI_START="0.01748159104189776" EFFECT_SIZE="0.13142857142857142" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="-0.005201381626165083" LOG_CI_START="-1.7574190437112378" LOG_EFFECT_SIZE="-0.8813102126687016" ORDER="16116" O_E="0.0" SE="1.0292613283260854" STUDY_ID="STD-Dawson-1965" TOTAL_1="25" TOTAL_2="23" VAR="1.0593788819875776" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.195817676132171" CI_START="0.01315688646851685" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3076923076923077" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-004.06" LOG_CI_END="0.857080150886292" LOG_CI_START="-1.8808468728440408" LOG_EFFECT_SIZE="-0.5118833609788743" METHOD="MH" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.4636374323790845" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="0.7328704842081468">
<NAME>Shivering</NAME>
<GROUP_LABEL_1>IM iron sorb-cit</GROUP_LABEL_1>
<GROUP_LABEL_2>IM iron dextran</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM sorb-cit</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IM dextran</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.195817676132171" CI_START="0.01315688646851685" EFFECT_SIZE="0.3076923076923077" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.857080150886292" LOG_CI_START="-1.8808468728440408" LOG_EFFECT_SIZE="-0.5118833609788743" ORDER="16117" O_E="0.0" SE="1.6082718866965442" STUDY_ID="STD-Dawson-1965" TOTAL_1="25" TOTAL_2="23" VAR="2.5865384615384617" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.259421277861904" CI_START="0.2596780004317872" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.92" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-004.07" LOG_CI_END="0.513140496343213" LOG_CI_START="-0.5855648416521025" LOG_EFFECT_SIZE="-0.036212172654444715" METHOD="MH" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.8972020041534372" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="0.12919670406654646">
<NAME>Itching</NAME>
<GROUP_LABEL_1>IM iron sorb-cit</GROUP_LABEL_1>
<GROUP_LABEL_2>IM iron dextran</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours iron sorb-ci</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IM dextran</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.259421277861904" CI_START="0.2596780004317872" EFFECT_SIZE="0.92" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.513140496343213" LOG_CI_START="-0.5855648416521025" LOG_EFFECT_SIZE="-0.036212172654444715" ORDER="16118" O_E="0.0" SE="0.6453849542175853" STUDY_ID="STD-Dawson-1965" TOTAL_1="25" TOTAL_2="23" VAR="0.4165217391304348" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="30.562822446029404" CI_START="0.44310043759585366" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.68" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-004.08" LOG_CI_END="1.4851934584159185" LOG_CI_START="-0.353497821068883" LOG_EFFECT_SIZE="0.5658478186735176" METHOD="MH" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.22768731197074277" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="1.2063377443562984">
<NAME>Metallic taste in mouth</NAME>
<GROUP_LABEL_1>IM iron sorb-cit</GROUP_LABEL_1>
<GROUP_LABEL_2>IM iron dextran</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours iron sorb-ci</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IM dextran</GRAPH_LABEL_2>
<DICH_DATA CI_END="30.562822446029404" CI_START="0.44310043759585344" EFFECT_SIZE="3.68" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.4851934584159185" LOG_CI_START="-0.3534978210688832" LOG_EFFECT_SIZE="0.5658478186735176" ORDER="16119" O_E="0.0" SE="1.080056359237996" STUDY_ID="STD-Dawson-1965" TOTAL_1="25" TOTAL_2="23" VAR="1.1665217391304348" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2011-06-01 22:05:24 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Intramuscular iron dextran versus intravenous iron dextran</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="14.053132224841256" CI_START="1.4549158462739828" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="4.521739130434782" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="1.1477731325227798" LOG_CI_START="0.16283787403959507" LOG_EFFECT_SIZE="0.6553055032811874" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.009106236145649729" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="23" TOTAL_2="26" WEIGHT="100.0" Z="2.608039816302199">
<NAME>Pain at injection site</NAME>
<GROUP_LABEL_1>IM iron dextran</GROUP_LABEL_1>
<GROUP_LABEL_2>IV iron dextran</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM dextran</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IV dextran</GRAPH_LABEL_2>
<DICH_DATA CI_END="14.053132224841264" CI_START="1.4549158462739826" EFFECT_SIZE="4.521739130434782" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" LOG_CI_END="1.14777313252278" LOG_CI_START="0.16283787403959502" LOG_EFFECT_SIZE="0.6553055032811874" ORDER="16120" O_E="0.0" SE="0.5785558463411834" STUDY_ID="STD-Dawson-1965" TOTAL_1="23" TOTAL_2="26" VAR="0.334726867335563" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="103.81320568449642" CI_START="2.080295964204939" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="14.695652173913043" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="2.016252601981778" LOG_CI_START="0.3181251265383459" LOG_EFFECT_SIZE="1.1671888642600619" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.0070532729149497255" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="23" TOTAL_2="26" WEIGHT="100.0" Z="2.6943185010401627">
<NAME>Skin discolouration at injection site</NAME>
<GROUP_LABEL_1>IM iron dextran</GROUP_LABEL_1>
<GROUP_LABEL_2>IV iron dextran</GROUP_LABEL_2>
<GRAPH_LABEL_1>Fvaours IM dextran</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IV dextran</GRAPH_LABEL_2>
<DICH_DATA CI_END="103.81320568449642" CI_START="2.080295964204939" EFFECT_SIZE="14.695652173913043" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="1" LOG_CI_END="2.016252601981778" LOG_CI_START="0.3181251265383459" LOG_EFFECT_SIZE="1.1671888642600619" ORDER="16121" O_E="0.0" SE="0.9974884849420435" STUDY_ID="STD-Dawson-1965" TOTAL_1="23" TOTAL_2="26" VAR="0.9949832775919732" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.2036050509226994" CI_START="0.007090653560381638" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.125" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="0.34313375915660366" LOG_CI_START="-2.149313733140491" LOG_EFFECT_SIZE="-0.9030899869919435" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.15551749776195226" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="23" TOTAL_2="26" WEIGHT="100.0" Z="1.4203098398447405">
<NAME>Venous thrombosis</NAME>
<GROUP_LABEL_1>IM iron dextran</GROUP_LABEL_1>
<GROUP_LABEL_2>IV iron dextran</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM dextran</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IV dextran</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.2036050509227003" CI_START="0.007090653560381638" EFFECT_SIZE="0.125" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.3431337591566038" LOG_CI_START="-2.149313733140491" LOG_EFFECT_SIZE="-0.9030899869919435" ORDER="16122" O_E="0.0" SE="1.464075994789382" STUDY_ID="STD-Dawson-1965" TOTAL_1="23" TOTAL_2="26" VAR="2.1435185185185186" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.832384828080971" CI_START="0.054775312132139896" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5652173913043478" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="0.7658461715510438" LOG_CI_START="-1.261415138972556" LOG_EFFECT_SIZE="-0.24778448371075615" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.6318547066057979" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="23" TOTAL_2="26" WEIGHT="100.0" Z="0.47911797209359336">
<NAME>Nausea or vomiting</NAME>
<GROUP_LABEL_1>IM iron dextran</GROUP_LABEL_1>
<GROUP_LABEL_2>IV iron dextran</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM dextran</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IV dextran</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.832384828080974" CI_START="0.05477531213213987" EFFECT_SIZE="0.5652173913043478" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7658461715510441" LOG_CI_START="-1.2614151389725563" LOG_EFFECT_SIZE="-0.24778448371075615" ORDER="16123" O_E="0.0" SE="1.190823328906894" STUDY_ID="STD-Dawson-1965" TOTAL_1="23" TOTAL_2="26" VAR="1.4180602006688963" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="17.17180605207287" CI_START="0.9116143185371036" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.9565217391304346" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-005.05" LOG_CI_END="1.2348159746717036" LOG_CI_START="-0.04018886206470205" LOG_EFFECT_SIZE="0.5973135563035007" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.06629768113978096" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="23" TOTAL_2="26" WEIGHT="100.0" Z="1.8364056732977436">
<NAME>Headaches</NAME>
<GROUP_LABEL_1>IM iron dextran</GROUP_LABEL_1>
<GROUP_LABEL_2>IV iron dextran</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM dextran</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IV dextran</GRAPH_LABEL_2>
<DICH_DATA CI_END="17.17180605207287" CI_START="0.9116143185371036" EFFECT_SIZE="3.9565217391304346" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.2348159746717036" LOG_CI_START="-0.04018886206470205" LOG_EFFECT_SIZE="0.5973135563035007" ORDER="16124" O_E="0.0" SE="0.748944152474695" STUDY_ID="STD-Dawson-1965" TOTAL_1="23" TOTAL_2="26" VAR="0.5609173435260392" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.832384828080971" CI_START="0.054775312132139896" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5652173913043478" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-005.06" LOG_CI_END="0.7658461715510438" LOG_CI_START="-1.261415138972556" LOG_EFFECT_SIZE="-0.24778448371075615" METHOD="MH" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.6318547066057979" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="23" TOTAL_2="26" WEIGHT="100.0" Z="0.47911797209359336">
<NAME>Shivering</NAME>
<GROUP_LABEL_1>IM iron dextran</GROUP_LABEL_1>
<GROUP_LABEL_2>IV iron dextran</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM dextran</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IV dextran</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.832384828080974" CI_START="0.05477531213213987" EFFECT_SIZE="0.5652173913043478" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7658461715510441" LOG_CI_START="-1.2614151389725563" LOG_EFFECT_SIZE="-0.24778448371075615" ORDER="16125" O_E="0.0" SE="1.190823328906894" STUDY_ID="STD-Dawson-1965" TOTAL_1="23" TOTAL_2="26" VAR="1.4180602006688963" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.03827381692046" CI_START="0.3762319678259141" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5072463768115942" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-005.07" LOG_CI_END="0.7809128030364173" LOG_CI_START="-0.4245443059133672" LOG_EFFECT_SIZE="0.17818424856152504" METHOD="MH" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.5623038780645356" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="23" TOTAL_2="26" WEIGHT="100.0" Z="0.5794228715398784">
<NAME>Itching</NAME>
<GROUP_LABEL_1>IM iron dextran</GROUP_LABEL_1>
<GROUP_LABEL_2>IV iron dextran</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM dextran</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IV dextran</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.03827381692046" CI_START="0.3762319678259141" EFFECT_SIZE="1.5072463768115942" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7809128030364173" LOG_CI_START="-0.4245443059133672" LOG_EFFECT_SIZE="0.17818424856152504" ORDER="16126" O_E="0.0" SE="0.708091472906029" STUDY_ID="STD-Dawson-1965" TOTAL_1="23" TOTAL_2="26" VAR="0.5013935340022296" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="17.065106640316344" CI_START="0.07488279005022852" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1304347826086956" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-005.08" LOG_CI_END="1.2321090065411875" LOG_CI_START="-1.125617982634737" LOG_EFFECT_SIZE="0.05324551195322505" METHOD="MH" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.9294591489764942" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="23" TOTAL_2="26" WEIGHT="100.0" Z="0.08852533499070972">
<NAME>Metallic taste in mouth</NAME>
<GROUP_LABEL_1>IM iron dextran</GROUP_LABEL_1>
<GROUP_LABEL_2>IV iron dextran</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM dextran</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IV dextran</GRAPH_LABEL_2>
<DICH_DATA CI_END="17.065106640316344" CI_START="0.07488279005022852" EFFECT_SIZE="1.1304347826086956" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2321090065411875" LOG_CI_START="-1.125617982634737" LOG_EFFECT_SIZE="0.05324551195322505" ORDER="16127" O_E="0.0" SE="1.3849405043787608" STUDY_ID="STD-Dawson-1965" TOTAL_1="23" TOTAL_2="26" VAR="1.9180602006688963" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.261450738231801" CI_START="0.010636702461941568" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2129032258064516" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-005.09" LOG_CI_END="0.6295574724248089" LOG_CI_START="-1.9731929890096171" LOG_EFFECT_SIZE="-0.671817758292404" METHOD="MH" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.3116310756057137" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="32" WEIGHT="100.0" Z="1.0118054957153806">
<NAME>Severe delayed allergic reaction</NAME>
<GROUP_LABEL_1>IM iron dextran</GROUP_LABEL_1>
<GROUP_LABEL_2>IV iron dextran</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM dextran</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IV dextran</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.261450738231801" CI_START="0.010636702461941568" EFFECT_SIZE="0.2129032258064516" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6295574724248089" LOG_CI_START="-1.9731929890096171" LOG_EFFECT_SIZE="-0.671817758292404" ORDER="16128" O_E="0.0" SE="1.5288685048691535" STUDY_ID="STD-Sood-1979" TOTAL_1="30" TOTAL_2="32" VAR="2.3374389051808406" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2011-06-01 22:05:25 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Intramuscular iron sorbitol citric acid versus intravenous iron dextran</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="13.93674871982704" CI_START="1.4573014734455583" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="4.506666666666667" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="1.1441614697642517" LOG_CI_START="0.1635494040076576" LOG_EFFECT_SIZE="0.6538554368859547" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.008955682984250595" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="26" WEIGHT="100.0" Z="2.613741258432106">
<NAME>Pain at injection site</NAME>
<GROUP_LABEL_1>IM iron sorb-cit</GROUP_LABEL_1>
<GROUP_LABEL_2>IV iron dextran</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM sorb-cit</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IV dextran</GRAPH_LABEL_2>
<DICH_DATA CI_END="13.936748719827046" CI_START="1.457301473445558" EFFECT_SIZE="4.506666666666667" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="3" LOG_CI_END="1.144161469764252" LOG_CI_START="0.16354940400765755" LOG_EFFECT_SIZE="0.6538554368859547" ORDER="16129" O_E="0.0" SE="0.576016381533435" STUDY_ID="STD-Dawson-1965" TOTAL_1="25" TOTAL_2="26" VAR="0.33179487179487177" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="28.033646195879708" CI_START="0.3472398821039103" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.12" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="1.4476795879410067" LOG_CI_START="-0.4593703999041209" LOG_EFFECT_SIZE="0.4941545940184428" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.3097573599833391" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="26" WEIGHT="100.0" Z="1.015731326650274">
<NAME>Skin discolouration at injection site</NAME>
<GROUP_LABEL_1>IM iron sorb-cit</GROUP_LABEL_1>
<GROUP_LABEL_2>IV iron dextran</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM sorb-cit</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IV dextran</GRAPH_LABEL_2>
<DICH_DATA CI_END="28.033646195879708" CI_START="0.3472398821039103" EFFECT_SIZE="3.12" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4476795879410067" LOG_CI_START="-0.4593703999041209" LOG_EFFECT_SIZE="0.4941545940184428" ORDER="16130" O_E="0.0" SE="1.1202106029099148" STUDY_ID="STD-Dawson-1965" TOTAL_1="25" TOTAL_2="26" VAR="1.2548717948717947" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.0384638881810737" CI_START="0.006531197115949592" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.1153846153846154" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="0.30930302223771905" LOG_CI_START="-2.1850072087400303" LOG_EFFECT_SIZE="-0.9378520932511555" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.14051404520833122" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="26" WEIGHT="100.0" Z="1.4738794739876626">
<NAME>Venous thrombosis</NAME>
<GROUP_LABEL_1>IM iron sorb-cit</GROUP_LABEL_1>
<GROUP_LABEL_2>IV iron dextran</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM sorb-cit</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IV dextran</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0384638881810737" CI_START="0.006531197115949592" EFFECT_SIZE="0.11538461538461539" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.30930302223771905" LOG_CI_START="-2.1850072087400303" LOG_EFFECT_SIZE="-0.9378520932511555" ORDER="16131" O_E="0.0" SE="1.4651701767111036" STUDY_ID="STD-Dawson-1965" TOTAL_1="25" TOTAL_2="26" VAR="2.146723646723647" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.381165751618114" CI_START="0.05024933489898373" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.52" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-006.04" LOG_CI_END="0.7308763694678755" LOG_CI_START="-1.298869682198277" LOG_EFFECT_SIZE="-0.28399665636520083" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.5833720597865655" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="26" WEIGHT="100.0" Z="0.5484658711356306">
<NAME>Nausea or vomiting</NAME>
<GROUP_LABEL_1>IM iron sorb-cit</GROUP_LABEL_1>
<GROUP_LABEL_2>IV iron dextran</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM sorb-cit</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IV dextran</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.381165751618111" CI_START="0.050249334898983755" EFFECT_SIZE="0.52" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7308763694678753" LOG_CI_START="-1.2988696821982768" LOG_EFFECT_SIZE="-0.28399665636520083" ORDER="16132" O_E="0.0" SE="1.192282878153696" STUDY_ID="STD-Dawson-1965" TOTAL_1="25" TOTAL_2="26" VAR="1.4215384615384614" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.381165751618114" CI_START="0.05024933489898373" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.52" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-006.05" LOG_CI_END="0.7308763694678755" LOG_CI_START="-1.298869682198277" LOG_EFFECT_SIZE="-0.28399665636520083" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.5833720597865655" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="26" WEIGHT="100.0" Z="0.5484658711356306">
<NAME>Headaches</NAME>
<GROUP_LABEL_1>IM iron sorb-cit</GROUP_LABEL_1>
<GROUP_LABEL_2>IV iron dextran</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM sorb-cit</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IV dextran</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.381165751618111" CI_START="0.050249334898983755" EFFECT_SIZE="0.52" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7308763694678753" LOG_CI_START="-1.2988696821982768" LOG_EFFECT_SIZE="-0.28399665636520083" ORDER="16133" O_E="0.0" SE="1.192282878153696" STUDY_ID="STD-Dawson-1965" TOTAL_1="25" TOTAL_2="26" VAR="1.4215384615384614" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.122770474379209" CI_START="0.010462890171214661" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2076923076923077" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-006.06" LOG_CI_END="0.6151891571430304" LOG_CI_START="-1.980348333438729" LOG_EFFECT_SIZE="-0.6825795881478495" METHOD="MH" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.3026016049616902" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="26" WEIGHT="100.0" Z="1.030870418328736">
<NAME>Shivering</NAME>
<GROUP_LABEL_1>IM iron sorb-cit</GROUP_LABEL_1>
<GROUP_LABEL_2>IV iron dextran</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM sorb-cit</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IV dextran</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.122770474379207" CI_START="0.010462890171214661" EFFECT_SIZE="0.2076923076923077" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6151891571430301" LOG_CI_START="-1.980348333438729" LOG_EFFECT_SIZE="-0.6825795881478495" ORDER="16134" O_E="0.0" SE="1.5246315700855155" STUDY_ID="STD-Dawson-1965" TOTAL_1="25" TOTAL_2="26" VAR="2.3245014245014244" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.58197179332073" CI_START="0.34447405247466123" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3866666666666667" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-006.07" LOG_CI_END="0.7467876375922199" LOG_CI_START="-0.46284348577805934" LOG_EFFECT_SIZE="0.14197207590708033" METHOD="MH" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.6454628212659277" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="26" WEIGHT="100.0" Z="0.46007439823964613">
<NAME>Itching</NAME>
<GROUP_LABEL_1>IM iron sorb-cit</GROUP_LABEL_1>
<GROUP_LABEL_2>IV iron dextran</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM sorb-cit</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IV dextran</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.58197179332073" CI_START="0.3444740524746614" EFFECT_SIZE="1.3866666666666667" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7467876375922199" LOG_CI_START="-0.4628434857780591" LOG_EFFECT_SIZE="0.14197207590708033" ORDER="16135" O_E="0.0" SE="0.7105433096383321" STUDY_ID="STD-Dawson-1965" TOTAL_1="25" TOTAL_2="26" VAR="0.5048717948717948" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="34.70673103489391" CI_START="0.4986237390839566" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="4.16" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" I2_Q="100.0" ID="CMP-006.08" LOG_CI_END="1.540413710174892" LOG_CI_START="-0.3022270489214065" LOG_EFFECT_SIZE="0.6190933306267428" METHOD="MH" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="0.18783073292568234" Q="4.208466746500802E-32" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="26" WEIGHT="100.0" Z="1.3170235436368638">
<NAME>Metallic taste in mouth</NAME>
<GROUP_LABEL_1>IM iron sorb-cit</GROUP_LABEL_1>
<GROUP_LABEL_2>IV iron dextran</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM sorb-cit</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IV dextran</GRAPH_LABEL_2>
<DICH_DATA CI_END="34.70673103489391" CI_START="0.4986237390839566" EFFECT_SIZE="4.16" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.540413710174892" LOG_CI_START="-0.3022270489214065" LOG_EFFECT_SIZE="0.6190933306267428" ORDER="16136" O_E="0.0" SE="1.0823763031120284" STUDY_ID="STD-Dawson-1965" TOTAL_1="25" TOTAL_2="26" VAR="1.1715384615384614" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2011-06-01 22:05:25 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Intravenous iron versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.037380083063955" CI_START="0.18519249636765206" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="0.48249914083133905" LOG_CI_START="-0.7323766140479389" LOG_EFFECT_SIZE="-0.12493873660829995" METHOD="MH" MODIFIED="2011-01-06 10:32:30 +0000" MODIFIED_BY="Denise Atherton" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.6868538131186186" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0" Z="0.40312834138423836">
<NAME>Side effects</NAME>
<GROUP_LABEL_1>IV iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IV iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.037380083063955" CI_START="0.18519249636765195" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.48249914083133905" LOG_CI_START="-0.7323766140479391" LOG_EFFECT_SIZE="-0.12493873660829995" ORDER="16137" O_E="0.0" SE="0.7136240321480628" STUDY_ID="STD-Symonds-1969" TOTAL_1="27" TOTAL_2="27" VAR="0.5092592592592593" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.836867951075732" CI_START="0.014177999655571498" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="0.8941425290950501" LOG_CI_START="-1.8483850385343752" LOG_EFFECT_SIZE="-0.47712125471966244" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.49526728049818114" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0" Z="0.6819552055167947">
<NAME>Nausea or vomiting</NAME>
<GROUP_LABEL_1>IV iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IV iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.836867951075732" CI_START="0.014177999655571498" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8941425290950501" LOG_CI_START="-1.8483850385343752" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="16138" O_E="0.0" SE="1.6109742689559308" STUDY_ID="STD-Symonds-1969" TOTAL_1="27" TOTAL_2="27" VAR="2.5952380952380953" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.09403515879801" CI_START="0.02984668129253159" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-007.03" LOG_CI_END="0.3209839691975418" LOG_CI_START="-1.5251039518534668" LOG_EFFECT_SIZE="-0.6020599913279624" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.20110978592140805" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0" Z="1.2783962086307363">
<NAME>Constipation</NAME>
<GROUP_LABEL_1>IV iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IV iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.094035158798011" CI_START="0.02984668129253159" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.320983969197542" LOG_CI_START="-1.5251039518534668" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="16139" O_E="0.0" SE="1.084401183107952" STUDY_ID="STD-Symonds-1969" TOTAL_1="27" TOTAL_2="27" VAR="1.175925925925926" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-007.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>Abdominal cramps</NAME>
<GROUP_LABEL_1>IV iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IV iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="16140" O_E="0.0" SE="0.0" STUDY_ID="STD-Symonds-1969" TOTAL_1="27" TOTAL_2="27" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2011-08-12 13:01:17 +0100" MODIFIED_BY="Heather Maxwell" NO="8">
<NAME>Intravenous iron versus regular oral iron</NAME>
<DICH_OUTCOME CHI2="1.2403886113708091E-31" CI_END="1.3107622229036386" CI_START="0.11071780527196118" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.380952380952381" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" I2="100.0" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="0.11752391621589846" LOG_CI_START="-0.9557825316998496" LOG_EFFECT_SIZE="-0.41912930774197565" METHOD="MH" MODIFIED="2011-01-06 10:32:39 +0000" MODIFIED_BY="Denise Atherton" NO="1" P_CHI2="0.0" P_Q="1.0" P_Z="0.1258328380619775" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="24" WEIGHT="100.0" Z="1.530743339210725">
<NAME>Side effects</NAME>
<GROUP_LABEL_1>IV iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral regular iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IV iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral iron</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3107622229036382" CI_START="0.11071780527196118" EFFECT_SIZE="0.38095238095238093" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.11752391621589832" LOG_CI_START="-0.9557825316998496" LOG_EFFECT_SIZE="-0.4191293077419757" ORDER="16141" O_E="0.0" SE="0.6304655204583137" STUDY_ID="STD-Symonds-1969" TOTAL_1="27" TOTAL_2="24" VAR="0.39748677248677244" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4125057291275112" CI_END="0.7395839244885918" CI_START="0.15023462170022467" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-008.02" LOG_CI_END="-0.13101253718535294" LOG_CI_START="-0.8232299722539719" LOG_EFFECT_SIZE="-0.47712125471966244" METHOD="MH" NO="2" P_CHI2="0.4934899747003305" P_Q="1.0" P_Z="0.006895088641187057" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="122" TOTAL_2="122" WEIGHT="100.0" Z="2.7018691761683233">
<NAME>Nausea or vomiting or epigastric discomfort</NAME>
<GROUP_LABEL_1>IV iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral regular iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IV iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral iron</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1067831399564798" CI_START="0.19246566358759865" EFFECT_SIZE="0.46153846153846156" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="13" LOG_CI_END="0.04406253474824553" LOG_CI_START="-0.7156467385946318" LOG_EFFECT_SIZE="-0.3357921019231931" ORDER="16142" O_E="0.0" SE="0.4462569877831597" STUDY_ID="STD-Al-2005" TOTAL_1="45" TOTAL_2="45" VAR="0.19914529914529913" WEIGHT="61.904761904761905"/>
<DICH_DATA CI_END="2.695941239682091" CI_START="0.007569958486080607" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4307104221511428" LOG_CI_START="-2.1209065021796567" LOG_EFFECT_SIZE="-0.8450980400142568" ORDER="16143" O_E="0.0" SE="1.4988324120593923" STUDY_ID="STD-Singh-1998" TOTAL_1="50" TOTAL_2="50" VAR="2.246498599439776" WEIGHT="16.666666666666668"/>
<DICH_DATA CI_END="1.9683136117825746" CI_START="0.006272211368372842" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.29409429583093266" LOG_CI_START="-2.2025793147095825" LOG_EFFECT_SIZE="-0.9542425094393249" ORDER="16144" O_E="0.0" SE="1.4665584375651899" STUDY_ID="STD-Symonds-1969" TOTAL_1="27" TOTAL_2="27" VAR="2.150793650793651" WEIGHT="21.428571428571427"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.1674697691729656" CI_END="0.7057877968319721" CI_START="0.01763094645085036" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.11155136418533015" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="17" I2="14.344677146681155" I2_Q="0.0" ID="CMP-008.03" LOG_CI_END="-0.15132585492242653" LOG_CI_START="-1.7537243736139518" LOG_EFFECT_SIZE="-0.9525251142681891" METHOD="MH" MODIFIED="2011-06-03 10:26:25 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.27992179666712447" P_Q="1.0" P_Z="0.01979819394820325" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.26846699243917815" TOTALS="YES" TOTAL_1="77" TOTAL_2="74" WEIGHT="100.0" Z="2.3301505793452955">
<NAME>Constipation</NAME>
<GROUP_LABEL_1>Favours IV iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral regular iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IV iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral iron</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6065437761835669" CI_START="0.002261571491367019" EFFECT_SIZE="0.037037037037037035" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="13" LOG_CI_END="-0.21713784925927773" LOG_CI_START="-2.645589679058697" LOG_EFFECT_SIZE="-1.4313637641589874" ORDER="16145" O_E="0.0" SE="1.4264846258546091" STUDY_ID="STD-Singh-1998" TOTAL_1="50" TOTAL_2="50" VAR="2.0348583877995643" WEIGHT="38.46457874934706"/>
<DICH_DATA CI_END="1.8535855670061387" CI_START="0.02664172451943739" EFFECT_SIZE="0.2222222222222222" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.268012639149423" LOG_CI_START="-1.5744376667001105" LOG_EFFECT_SIZE="-0.6532125137753437" ORDER="16146" O_E="0.0" SE="1.0822644299321198" STUDY_ID="STD-Symonds-1969" TOTAL_1="27" TOTAL_2="24" VAR="1.1712962962962963" WEIGHT="61.53542125065293"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.5442186080130917" CI_START="0.008997118583471707" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.17857142857142858" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-008.04" LOG_CI_END="0.5495205013994826" LOG_CI_START="-2.0458965554118835" LOG_EFFECT_SIZE="-0.7481880270062004" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.25847268777525434" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="24" WEIGHT="100.0" Z="1.1300084375632684">
<NAME>Abdominal cramps</NAME>
<GROUP_LABEL_1>IV iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral regular iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IV iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral iron</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.54421860801309" CI_START="0.008997118583471716" EFFECT_SIZE="0.17857142857142858" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5495205013994824" LOG_CI_START="-2.045896555411883" LOG_EFFECT_SIZE="-0.7481880270062004" ORDER="16147" O_E="0.0" SE="1.5245608266926296" STUDY_ID="STD-Symonds-1969" TOTAL_1="27" TOTAL_2="24" VAR="2.3242857142857143" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2556514878846094" CI_END="0.8617783276734802" CI_START="0.02835413423119197" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.1563169164882227" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" I2="0.0" I2_Q="100.0" ID="CMP-008.05" LOG_CI_END="-0.06460443191180398" LOG_CI_START="-1.5473836089795083" LOG_EFFECT_SIZE="-0.8059940204456563" METHOD="MH" NO="5" P_CHI2="0.880006717715681" P_Q="0.0" P_Z="0.03310936705149294" Q="6.499086089802474E-32" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="119" TOTAL_2="118" WEIGHT="100.0" Z="2.1307545671798915">
<NAME>Diarrhoea</NAME>
<GROUP_LABEL_1>IV iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral regular iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IV iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral iron</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0053002069486316" CI_START="0.006156524080317877" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.3021793986327516" LOG_CI_START="-2.2106644175114014" LOG_EFFECT_SIZE="-0.9542425094393249" ORDER="16148" O_E="0.0" SE="1.4760568963805756" STUDY_ID="STD-Al-2005" TOTAL_1="45" TOTAL_2="45" VAR="2.178743961352657" WEIGHT="47.21627408993576"/>
<DICH_DATA CI_END="7.476637125846737" CI_START="0.013695997047389556" EFFECT_SIZE="0.32" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8737063029327973" LOG_CI_START="-1.8634063462929853" LOG_EFFECT_SIZE="-0.494850021680094" ORDER="16149" O_E="0.0" SE="1.6077935190813526" STUDY_ID="STD-Bayoumeu-2002" TOTAL_1="24" TOTAL_2="23" VAR="2.585" WEIGHT="16.059957173447536"/>
<DICH_DATA CI_END="2.695941239682091" CI_START="0.007569958486080607" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4307104221511428" LOG_CI_START="-2.1209065021796567" LOG_EFFECT_SIZE="-0.8450980400142568" ORDER="16150" O_E="0.0" SE="1.4988324120593923" STUDY_ID="STD-Singh-1998" TOTAL_1="50" TOTAL_2="50" VAR="2.246498599439776" WEIGHT="36.7237687366167"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.06775420208940687" CI_END="1.5875713304086516" CI_START="0.04570607111368565" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2693726937269373" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-008.06" LOG_CI_END="0.20073324748018398" LOG_CI_START="-1.3400261089880834" LOG_EFFECT_SIZE="-0.5696464307539498" METHOD="MH" MODIFIED="2010-11-10 19:54:45 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.9666903029270555" P_Q="1.0" P_Z="0.14726280005221523" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="84" TOTAL_2="83" WEIGHT="100.0" Z="1.4492678347366907">
<NAME>Blood transfusion required</NAME>
<GROUP_LABEL_1>IV iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral regular iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IV iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral iron</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.970891595095491" CI_START="0.013939608861256886" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.901506902722716" LOG_CI_START="-1.8557494121620408" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="16151" O_E="0.0" SE="1.6196260080021871" STUDY_ID="STD-Al-2005" TOTAL_1="45" TOTAL_2="45" VAR="2.623188405797101" WEIGHT="27.121771217712176"/>
<DICH_DATA CI_END="7.476637125846737" CI_START="0.013695997047389556" EFFECT_SIZE="0.32" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8737063029327973" LOG_CI_START="-1.8634063462929853" LOG_EFFECT_SIZE="-0.494850021680094" ORDER="16152" O_E="0.0" SE="1.6077935190813526" STUDY_ID="STD-Bayoumeu-2002" TOTAL_1="24" TOTAL_2="23" VAR="2.585" WEIGHT="27.675276752767527"/>
<DICH_DATA CI_END="3.845086034384406" CI_START="0.010402888164868843" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5849060616512035" LOG_CI_START="-1.982846070323241" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2010-03-12 16:01:54 +0000" MODIFIED_BY="[Empty name]" ORDER="175" O_E="0.0" SE="1.5083103128998356" STUDY_ID="STD-Digumarthi-2008" TOTAL_1="15" TOTAL_2="15" VAR="2.275" WEIGHT="45.20295202952029"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.0716170819277262" CI_START="-1.371617081927727" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.15000000000000036" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.07" MODIFIED="2010-11-10 19:54:45 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.8098184970335931" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="24" TOTAL_2="23" UNITS="" WEIGHT="100.0" Z="0.24066018888429572">
<NAME>Neonates mean hemoglobin</NAME>
<GROUP_LABEL_1>IV iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral regular Iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IV iron</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.0716170819277262" CI_START="-1.371617081927727" EFFECT_SIZE="-0.15000000000000036" ESTIMABLE="YES" MEAN_1="15.15" MEAN_2="15.3" ORDER="16153" SD_1="2.1" SD_2="2.17" SE="0.6232854744085535" STUDY_ID="STD-Bayoumeu-2002" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.1615820664429561" CI_START="0.33841793355704397" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.75" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.08" MODIFIED="2010-11-10 19:54:45 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="3.549173940993011E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="45" TOTAL_2="45" UNITS="" WEIGHT="100.0" Z="3.5715185579126154">
<NAME>Maternal haemoglobin at birth</NAME>
<GROUP_LABEL_1>IV iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral regular iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IV iron</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.1615820664429561" CI_START="0.33841793355704397" EFFECT_SIZE="0.75" ESTIMABLE="YES" MEAN_1="12.01" MEAN_2="11.26" ORDER="16154" SD_1="0.88" SD_2="1.1" SE="0.2099947089280532" STUDY_ID="STD-Al-2005" TOTAL_1="45" TOTAL_2="45" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-008.09" MODIFIED="2010-11-10 19:54:45 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Maternal haemoglobin at 6 weeks</NAME>
<GROUP_LABEL_1>IV iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral regular iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IV iron</GRAPH_LABEL_2>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="58.36082201910054" CI_START="-62.36082201910054" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.10" MODIFIED="2010-11-10 19:54:45 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.948220503617301" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="24" TOTAL_2="23" UNITS="" WEIGHT="100.0" Z="0.06494159353627904">
<NAME>Neonates ferritin level</NAME>
<GROUP_LABEL_1>IV iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral regular Iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IV iron</GRAPH_LABEL_2>
<CONT_DATA CI_END="58.36082201910054" CI_START="-62.36082201910054" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="132.0" MEAN_2="134.0" ORDER="16155" SD_1="104.0" SD_2="107.0" SE="30.79690366517905" STUDY_ID="STD-Bayoumeu-2002" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.4309367897982757" CI_END="0.8236913273703457" CI_START="0.04973497160738488" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.43671314948886525" ESTIMABLE="YES" I2="41.70688291469248" I2_Q="0.0" ID="CMP-008.11" MODIFIED="2011-08-12 13:01:17 +0100" MODIFIED_BY="Heather Maxwell" NO="11" P_CHI2="0.17987972691242105" P_Q="1.0" P_Z="0.026976251942133066" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.05152971431319641" TOTALS="YES" TOTAL_1="84" TOTAL_2="83" UNITS="" WEIGHT="100.0" Z="2.2118612715040014">
<NAME>Mean maternal haemoglobin at 4 weeks ( g/dL)</NAME>
<GROUP_LABEL_1>IV iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral regular iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IV iron</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.9693557138554855" CI_START="0.39064428614451396" EFFECT_SIZE="0.6799999999999997" ESTIMABLE="YES" MEAN_1="11.08" MEAN_2="10.4" ORDER="16156" SD_1="0.72" SD_2="0.68" SE="0.14763317904710835" STUDY_ID="STD-Al-2005" TOTAL_1="45" TOTAL_2="45" WEIGHT="53.16466708155579"/>
<CONT_DATA CI_END="0.8390208468724716" CI_START="-0.6190208468724727" EFFECT_SIZE="0.10999999999999943" ESTIMABLE="YES" MEAN_1="11.11" MEAN_2="11.0" ORDER="16157" SD_1="1.3" SD_2="1.25" SE="0.3719562464529428" STUDY_ID="STD-Bayoumeu-2002" TOTAL_1="24" TOTAL_2="23" WEIGHT="20.53028055844674"/>
<CONT_DATA CI_END="0.8093775671402458" CI_START="-0.4093775671402472" EFFECT_SIZE="0.1999999999999993" ESTIMABLE="YES" MEAN_1="10.6" MEAN_2="10.4" MODIFIED="2010-03-12 15:59:52 +0000" MODIFIED_BY="[Empty name]" ORDER="174" SD_1="0.8" SD_2="0.9" SE="0.3109126351029605" STUDY_ID="STD-Digumarthi-2008" TOTAL_1="15" TOTAL_2="15" WEIGHT="26.305052359997468"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-008.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-11-10 19:54:45 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="50" WEIGHT="0.0" Z="0.0">
<NAME>Maternal mortality</NAME>
<GROUP_LABEL_1>IV iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral regular iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IV iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral iron</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="16158" O_E="0.0" SE="0.0" STUDY_ID="STD-Singh-1998" TOTAL_1="50" TOTAL_2="50" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-008.13" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-11-10 19:54:45 +0000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="50" WEIGHT="0.0" Z="0.0">
<NAME>Preterm labour</NAME>
<GROUP_LABEL_1>IV iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral regular iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IV iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral iron</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="16159" O_E="0.0" SE="0.0" STUDY_ID="STD-Singh-1998" TOTAL_1="50" TOTAL_2="50" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.4687016179260016" CI_END="1.670865179169432" CI_START="0.45822069281531347" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-008.14" LOG_CI_END="0.22294140841825463" LOG_CI_START="-0.3389253023736281" LOG_EFFECT_SIZE="-0.057991946977686754" METHOD="MH" MODIFIED="2010-11-10 19:54:45 +0000" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.49358512714557456" P_Q="1.0" P_Z="0.6857807400342409" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="95" TOTAL_2="95" WEIGHT="100.0" Z="0.4045875126128386">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>IV iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral regular iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IV iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral iron</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6022497168424192" CI_START="0.3510688715292946" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.20473020350541898" LOG_CI_START="-0.4546076767220189" LOG_EFFECT_SIZE="-0.12493873660829995" ORDER="16160" O_E="0.0" SE="0.38729833462074165" STUDY_ID="STD-Al-2005" TOTAL_1="45" TOTAL_2="45" VAR="0.14999999999999997" WEIGHT="75.0"/>
<DICH_DATA CI_END="4.384751004320472" CI_START="0.35634862697115655" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6419449362379852" LOG_CI_START="-0.44812491022187245" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="16161" O_E="0.0" SE="0.6403124237432849" STUDY_ID="STD-Singh-1998" TOTAL_1="50" TOTAL_2="50" VAR="0.41" WEIGHT="25.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.59508521794332" CI_START="0.2617775092331654" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-008.15" LOG_CI_END="0.9342501869566456" LOG_CI_START="-0.5820676688452829" LOG_EFFECT_SIZE="0.17609125905568124" METHOD="MH" MODIFIED="2010-11-10 19:54:45 +0000" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="1.0" P_Q="1.0" P_Z="0.6489477312144929" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="0.4552245090577255">
<NAME>Operative vaginal birth</NAME>
<GROUP_LABEL_1>IV iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral regular iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IV iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral iron</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.59508521794332" CI_START="0.2617775092331654" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9342501869566456" LOG_CI_START="-0.5820676688452829" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="16162" O_E="0.0" SE="0.8906926143924925" STUDY_ID="STD-Singh-1998" TOTAL_1="50" TOTAL_2="50" VAR="0.7933333333333332" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.005706334947157405" CI_END="2.2563495958328836" CI_START="0.3354737918041152" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8700265251989391" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-008.16" LOG_CI_END="0.3534063895393768" LOG_CI_START="-0.4743414025276042" LOG_EFFECT_SIZE="-0.06046750649411373" METHOD="MH" MODIFIED="2010-11-10 19:54:45 +0000" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.9397848448710305" P_Q="1.0" P_Z="0.7746075780101502" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="74" TOTAL_2="73" WEIGHT="100.0" Z="0.2863532493815813">
<NAME>Postpartum haemorrhage</NAME>
<GROUP_LABEL_1>IV iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral regular iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IV iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral iron</GRAPH_LABEL_2>
<DICH_DATA CI_END="14.434266565279833" CI_START="0.06362656347132332" EFFECT_SIZE="0.9583333333333334" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1593947213830598" LOG_CI_START="-1.1963615327710861" LOG_EFFECT_SIZE="-0.018483405694013126" ORDER="16163" O_E="0.0" SE="1.3837828848716724" STUDY_ID="STD-Bayoumeu-2002" TOTAL_1="24" TOTAL_2="23" VAR="1.914855072463768" WEIGHT="12.732095490716182"/>
<DICH_DATA CI_END="2.3711569500113296" CI_START="0.30984616077291294" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.374960301455169" LOG_CI_START="-0.5088538807163955" LOG_EFFECT_SIZE="-0.06694678963061322" ORDER="16164" O_E="0.0" SE="0.519156825558337" STUDY_ID="STD-Singh-1998" TOTAL_1="50" TOTAL_2="50" VAR="0.2695238095238095" WEIGHT="87.26790450928382"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-008.17" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-11-10 19:54:45 +0000" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="50" WEIGHT="0.0" Z="0.0">
<NAME>Low birthweight (under 2500 g)</NAME>
<GROUP_LABEL_1>IV iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral regular iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IV iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral iron</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="16165" O_E="0.0" SE="0.0" STUDY_ID="STD-Singh-1998" TOTAL_1="50" TOTAL_2="50" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="5.326082491971963" CI_END="278.6796706512335" CI_START="-170.10652912732814" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="54.28657076195269" ESTIMABLE="YES" I2="62.44894811496795" I2_Q="0.0" ID="CMP-008.18" MODIFIED="2011-06-03 10:35:08 +0100" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.06973596851161856" P_Q="1.0" P_Z="0.63538107781885" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="23673.591442684592" TOTALS="YES" TOTAL_1="119" TOTAL_2="118" UNITS="" WEIGHT="100.0" Z="0.4741666459000377">
<NAME>Neonatal birthweight</NAME>
<GROUP_LABEL_1>IV iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral regular iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IV iron</GRAPH_LABEL_2>
<CONT_DATA CI_END="245.55841911917733" CI_START="-127.55841911917733" EFFECT_SIZE="59.0" ESTIMABLE="YES" MEAN_1="3498.0" MEAN_2="3439.0" ORDER="16166" SD_1="452.0" SD_2="451.0" SE="95.18461593719391" STUDY_ID="STD-Al-2005" TOTAL_1="45" TOTAL_2="45" WEIGHT="40.04309916161537"/>
<CONT_DATA CI_END="766.0220429617099" CI_START="-16.02204296170987" EFFECT_SIZE="375.0" ESTIMABLE="YES" MEAN_1="3595.0" MEAN_2="3220.0" ORDER="16167" SD_1="785.0" SD_2="570.0" SE="199.5047082732345" STUDY_ID="STD-Bayoumeu-2002" TOTAL_1="24" TOTAL_2="23" WEIGHT="20.649768067667473"/>
<CONT_DATA CI_END="73.76522293342822" CI_START="-311.7652229334282" EFFECT_SIZE="-119.0" ESTIMABLE="YES" MEAN_1="2967.0" MEAN_2="3086.0" MODIFIED="2011-06-03 10:35:08 +0100" MODIFIED_BY="[Empty name]" ORDER="16168" SD_1="541.0" SD_2="437.0" SE="98.35141076771599" STUDY_ID="STD-Singh-1998" TOTAL_1="50" TOTAL_2="50" WEIGHT="39.30713277071715"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.555512649633486" CI_START="0.5619565122283143" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-008.19" LOG_CI_END="0.6585372569136663" LOG_CI_START="-0.25029729160181663" LOG_EFFECT_SIZE="0.2041199826559248" METHOD="MH" MODIFIED="2010-11-10 19:54:46 +0000" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="1.0" P_Q="1.0" P_Z="0.37864404086862413" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="0.8803974610869179">
<NAME>Small-for-gestational age</NAME>
<GROUP_LABEL_1>IV iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral regular iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IV iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral iron</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.555512649633486" CI_START="0.5619565122283143" EFFECT_SIZE="1.6" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.6585372569136663" LOG_CI_START="-0.25029729160181663" LOG_EFFECT_SIZE="0.2041199826559248" ORDER="16169" O_E="0.0" SE="0.5338539126015656" STUDY_ID="STD-Singh-1998" TOTAL_1="50" TOTAL_2="50" VAR="0.285" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="15.548273108710726" CI_START="0.06431582420814068" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-008.20" LOG_CI_END="1.1916821605007981" LOG_CI_START="-1.1916821605007981" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2010-11-10 19:54:46 +0000" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="0.0">
<NAME>Five minute Apgar score under seven</NAME>
<GROUP_LABEL_1>IV iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral regular iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IV iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral iron</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.548273108710726" CI_START="0.06431582420814068" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1916821605007981" LOG_CI_START="-1.1916821605007981" LOG_EFFECT_SIZE="0.0" ORDER="16170" O_E="0.0" SE="1.4" STUDY_ID="STD-Singh-1998" TOTAL_1="50" TOTAL_2="50" VAR="1.96" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-008.21" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-11-10 19:54:46 +0000" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="74" TOTAL_2="73" WEIGHT="0.0" Z="0.0">
<NAME>Neonatal mortality</NAME>
<GROUP_LABEL_1>IV iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral regular iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IV iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral iron</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="16171" O_E="0.0" SE="0.0" STUDY_ID="STD-Bayoumeu-2002" TOTAL_1="24" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="16172" O_E="0.0" SE="0.0" STUDY_ID="STD-Singh-1998" TOTAL_1="50" TOTAL_2="50" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.8666645145002185" CI_START="0.18020998267739943" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.71875" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-008.22" LOG_CI_END="0.45737687047470876" LOG_CI_START="-0.744221155079335" LOG_EFFECT_SIZE="-0.1434221423023131" METHOD="MH" MODIFIED="2010-11-10 19:54:46 +0000" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="1.0" P_Q="1.0" P_Z="0.6398699422844616" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0" Z="0.467880651465783">
<NAME>Haemoglobin level &gt; 12 g/dL at 30 days</NAME>
<GROUP_LABEL_1>IV iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral regular iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IV iron</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.8666645145002176" CI_START="0.18020998267739946" EFFECT_SIZE="0.71875" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4573768704747086" LOG_CI_START="-0.7442211550793348" LOG_EFFECT_SIZE="-0.1434221423023131" ORDER="16173" O_E="0.0" SE="0.7058246282165999" STUDY_ID="STD-Bayoumeu-2002" TOTAL_1="24" TOTAL_2="23" VAR="0.49818840579710144" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="101.30867743480944" CI_START="0.2467705692445457" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-008.23" LOG_CI_END="2.005646645761614" LOG_CI_START="-0.6077066370895766" LOG_EFFECT_SIZE="0.6989700043360189" METHOD="MH" MODIFIED="2010-11-10 19:54:46 +0000" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="1.0" P_Q="1.0" P_Z="0.2944415948517184" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="45" TOTAL_2="45" WEIGHT="100.0" Z="1.0484277374682145">
<NAME>Gestational hypertension</NAME>
<GROUP_LABEL_1>IV iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral regular iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IV iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral iron</GRAPH_LABEL_2>
<DICH_DATA CI_END="101.30867743480944" CI_START="0.24677056924454582" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.005646645761614" LOG_CI_START="-0.6077066370895764" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="16174" O_E="0.0" SE="1.5350966546541733" STUDY_ID="STD-Al-2005" TOTAL_1="45" TOTAL_2="45" VAR="2.3565217391304345" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.05234709739238" CI_START="0.009870822769781833" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-008.24" LOG_CI_END="0.6077066370895766" LOG_CI_START="-2.005646645761614" LOG_EFFECT_SIZE="-0.6989700043360187" METHOD="MH" MODIFIED="2010-11-10 19:54:46 +0000" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="1.0" P_Q="1.0" P_Z="0.2944415948517184" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="45" TOTAL_2="45" WEIGHT="100.0" Z="1.0484277374682145">
<NAME>Gestational diabetes</NAME>
<GROUP_LABEL_1>IV iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral regular iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IV iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.052347097392378" CI_START="0.009870822769781833" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6077066370895764" LOG_CI_START="-2.005646645761614" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="16175" O_E="0.0" SE="1.5350966546541733" STUDY_ID="STD-Al-2005" TOTAL_1="45" TOTAL_2="45" VAR="2.3565217391304345" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9449090601105814" CI_START="1.2126111270276292" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5357142857142858" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-008.25" LOG_CI_END="0.288899299432683" LOG_CI_START="0.08372154904205167" LOG_EFFECT_SIZE="0.18631042423736732" METHOD="MH" MODIFIED="2010-11-10 19:54:46 +0000" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="1.0" P_Q="1.0" P_Z="3.716081448563703E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="45" TOTAL_2="45" WEIGHT="100.0" Z="3.5594670548283007">
<NAME>Haemoglobin level &gt; 11 g/dL at birth</NAME>
<GROUP_LABEL_1>IV iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral regular iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IV iron</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9449090601105814" CI_START="1.2126111270276292" EFFECT_SIZE="1.5357142857142858" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="28" LOG_CI_END="0.288899299432683" LOG_CI_START="0.08372154904205167" LOG_EFFECT_SIZE="0.18631042423736732" ORDER="16176" O_E="0.0" SE="0.12052242622570139" STUDY_ID="STD-Al-2005" TOTAL_1="45" TOTAL_2="45" VAR="0.014525655223329634" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="109.49149975922646" CI_START="0.2717294601053757" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="5.454545454545454" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-008.26" LOG_CI_END="2.0393804045555357" LOG_CI_START="-0.5658632741046986" LOG_EFFECT_SIZE="0.7367585652254186" METHOD="MH" MODIFIED="2010-11-10 19:54:46 +0000" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="1.0" P_Q="1.0" P_Z="0.2676247689804818" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="35" WEIGHT="100.0" Z="1.108549088878951">
<NAME>Severe delayed allergic reaction</NAME>
<GROUP_LABEL_1>IV iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral regular iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IV iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral iron</GRAPH_LABEL_2>
<DICH_DATA CI_END="109.49149975922646" CI_START="0.2717294601053756" EFFECT_SIZE="5.454545454545454" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0393804045555357" LOG_CI_START="-0.5658632741046988" LOG_EFFECT_SIZE="0.7367585652254186" ORDER="16177" O_E="0.0" SE="1.530333033009218" STUDY_ID="STD-Sood-1979" TOTAL_1="32" TOTAL_2="35" VAR="2.341919191919192" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="15.499949390237665" CI_START="0.06451633968752375" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-008.27" LOG_CI_END="1.1903302801331046" LOG_CI_START="-1.1903302801331048" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2010-11-10 19:54:46 +0000" MODIFIED_BY="[Empty name]" NO="27" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="45" TOTAL_2="45" WEIGHT="100.0" Z="0.0">
<NAME>Arthralgia</NAME>
<GROUP_LABEL_1>IV iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral regular iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IV iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral iron</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.499949390237672" CI_START="0.06451633968752372" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1903302801331048" LOG_CI_START="-1.1903302801331048" LOG_EFFECT_SIZE="0.0" ORDER="16178" O_E="0.0" SE="1.3984117975602022" STUDY_ID="STD-Al-2005" TOTAL_1="45" TOTAL_2="45" VAR="1.9555555555555557" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2011-08-11 16:49:45 +0100" MODIFIED_BY="Heather Maxwell" NO="9">
<NAME>Intravenous iron versus controlled-release oral iron</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.368915379914709" CI_START="0.11503296542365163" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3968253968253968" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="0.13637660286595768" LOG_CI_START="-0.9391776844290459" LOG_EFFECT_SIZE="-0.40140054078154414" METHOD="MH" MODIFIED="2011-01-06 10:32:48 +0000" MODIFIED_BY="Denise Atherton" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.14348638826060522" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="25" WEIGHT="100.0" Z="1.462930532842445">
<NAME>Side effects</NAME>
<GROUP_LABEL_1>IV iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Control release iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IV iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ctrl rel Fe</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.368915379914709" CI_START="0.11503296542365163" EFFECT_SIZE="0.3968253968253968" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.13637660286595768" LOG_CI_START="-0.9391776844290459" LOG_EFFECT_SIZE="-0.40140054078154414" ORDER="16179" O_E="0.0" SE="0.6317859124366728" STUDY_ID="STD-Symonds-1969" TOTAL_1="27" TOTAL_2="25" VAR="0.39915343915343915" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.824366524108519" CI_START="0.005834901375116242" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.10317460317460317" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-009.02" LOG_CI_END="0.2611120946320825" LOG_CI_START="-2.233966480253535" LOG_EFFECT_SIZE="-0.9864271928107261" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.12120388784025189" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="25" WEIGHT="100.0" Z="1.5497401891390157">
<NAME>Nausea or vomiting</NAME>
<GROUP_LABEL_1>IV iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Control release iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IV iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ctrl rel Fe</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8243665241085198" CI_START="0.005834901375116237" EFFECT_SIZE="0.10317460317460317" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.26111209463208274" LOG_CI_START="-2.2339664802535353" LOG_EFFECT_SIZE="-0.9864271928107261" ORDER="16180" O_E="0.0" SE="1.4656215057259492" STUDY_ID="STD-Symonds-1969" TOTAL_1="27" TOTAL_2="25" VAR="2.1480463980463984" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="14.026374384632664" CI_START="0.06112333784852388" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9259259259259259" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-009.03" LOG_CI_END="1.1469454266781303" LOG_CI_START="-1.2137929376520293" LOG_EFFECT_SIZE="-0.0334237554869497" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.9557408943848755" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="25" WEIGHT="100.0" Z="0.055499040446256476">
<NAME>Constipation</NAME>
<GROUP_LABEL_1>IV iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Control release iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IV iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ctrl rel Fe</GRAPH_LABEL_2>
<DICH_DATA CI_END="14.02637438463267" CI_START="0.06112333784852386" EFFECT_SIZE="0.9259259259259259" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1469454266781303" LOG_CI_START="-1.2137929376520296" LOG_EFFECT_SIZE="-0.0334237554869497" ORDER="16181" O_E="0.0" SE="1.3867094010509062" STUDY_ID="STD-Symonds-1969" TOTAL_1="27" TOTAL_2="25" VAR="1.922962962962963" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.26493714386709" CI_START="0.013187311433658873" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.30952380952380953" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-009.04" LOG_CI_END="0.8612318611406106" LOG_CI_START="-1.879843737322738" LOG_EFFECT_SIZE="-0.5093059380910637" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.4664037930680467" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="25" WEIGHT="99.99999999999999" Z="0.7283427690432732">
<NAME>Abdominal cramps</NAME>
<GROUP_LABEL_1>IV iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Control release iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IV iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ctrl rel Fe</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.264937143867087" CI_START="0.013187311433658885" EFFECT_SIZE="0.30952380952380953" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8612318611406103" LOG_CI_START="-1.8798437373227375" LOG_EFFECT_SIZE="-0.5093059380910637" ORDER="16182" O_E="0.0" SE="1.6101213750804138" STUDY_ID="STD-Symonds-1969" TOTAL_1="27" TOTAL_2="25" VAR="2.5924908424908426" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2011-06-01 22:05:26 +0100" MODIFIED_BY="[Empty name]" NO="10">
<NAME>2/3 dose intravenous iron versus full dose intravenous iron</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.245874540658246" CI_START="0.3525290188116599" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6627268889826932" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-010.01" LOG_CI_END="0.0954743111489011" LOG_CI_START="-0.4528051277759637" LOG_EFFECT_SIZE="-0.1786654083135313" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.20147178974327973" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="309" TOTAL_2="314" WEIGHT="99.99999999999999" Z="1.2773696794624911">
<NAME>Allergic reaction during infusion</NAME>
<GROUP_LABEL_1>2/3 dose IV iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Full dose IV iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 2/3 dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours full dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.245874540658246" CI_START="0.3525290188116599" EFFECT_SIZE="0.6627268889826932" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="23" LOG_CI_END="0.0954743111489011" LOG_CI_START="-0.4528051277759637" LOG_EFFECT_SIZE="-0.1786654083135313" ORDER="16185" O_E="0.0" SE="0.3220620564514596" STUDY_ID="STD-Kaisi-1988" TOTAL_1="309" TOTAL_2="314" VAR="0.10372396820574314" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.8602224749842187" CI_START="0.44724533327227073" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6202664649266592" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="77" I2="0.0" I2_Q="0.0" ID="CMP-010.02" LOG_CI_END="-0.06538921484619517" LOG_CI_START="-0.349454182330573" LOG_EFFECT_SIZE="-0.20742169858838408" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.004205834579817804" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="309" TOTAL_2="314" WEIGHT="100.00000000000001" Z="2.862296343301911">
<NAME>Allergic reaction after infusion</NAME>
<GROUP_LABEL_1>2/3 dose IV iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Full dose IV iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 2/3 dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours full dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8602224749842187" CI_START="0.44724533327227073" EFFECT_SIZE="0.6202664649266592" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="77" LOG_CI_END="-0.06538921484619517" LOG_CI_START="-0.349454182330573" LOG_EFFECT_SIZE="-0.20742169858838408" ORDER="16186" O_E="0.0" SE="0.1668611680445906" STUDY_ID="STD-Kaisi-1988" TOTAL_1="309" TOTAL_2="314" VAR="0.027842649401205104" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="12.995819748459322" CI_START="0.49661367642195414" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.540453074433657" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-010.03" LOG_CI_END="1.1138036790662698" LOG_CI_START="-0.30398132442543396" LOG_EFFECT_SIZE="0.40491117732041787" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.26292319874668757" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="309" TOTAL_2="314" WEIGHT="100.0" Z="1.1195087019981653">
<NAME>Life-threatening allergic reaction during infusion</NAME>
<GROUP_LABEL_1>2/3 dose IV iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Full dose IV iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 2/3 dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours full dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="12.995819748459322" CI_START="0.49661367642195414" EFFECT_SIZE="2.540453074433657" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.1138036790662698" LOG_CI_START="-0.30398132442543396" LOG_EFFECT_SIZE="0.40491117732041787" ORDER="16187" O_E="0.0" SE="0.8328139291999812" STUDY_ID="STD-Kaisi-1988" TOTAL_1="309" TOTAL_2="314" VAR="0.6935790406695113" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.8924601941756143" CI_START="0.2709022506012156" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4917005950516755" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="31" I2="0.0" I2_Q="0.0" ID="CMP-010.04" LOG_CI_END="-0.0494111453394701" LOG_CI_START="-0.5671873869209523" LOG_EFFECT_SIZE="-0.3082992661302112" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.019593581290530942" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="309" TOTAL_2="314" WEIGHT="100.0" Z="2.334040883103177">
<NAME>Discomfort needing analgesics after infusion</NAME>
<GROUP_LABEL_1>2/3 dose IV iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Full dose IV iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 2/3 dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours full dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8924601941756143" CI_START="0.2709022506012156" EFFECT_SIZE="0.4917005950516755" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="31" LOG_CI_END="-0.0494111453394701" LOG_CI_START="-0.5671873869209523" LOG_EFFECT_SIZE="-0.3082992661302112" ORDER="16188" O_E="0.0" SE="0.3041443273386945" STUDY_ID="STD-Kaisi-1988" TOTAL_1="309" TOTAL_2="314" VAR="0.09250377185230696" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.095726371419415" CI_START="0.2980703792173723" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7903631787126932" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-010.05" LOG_CI_END="0.32133457834023194" LOG_CI_START="-0.5256811798936074" LOG_EFFECT_SIZE="-0.10217330077668778" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.6363197136853536" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="309" TOTAL_2="314" WEIGHT="100.0" Z="0.472850682545627">
<NAME>Immobilised by painful joints</NAME>
<GROUP_LABEL_1>2/3 dose IV iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Full dose IV iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 2/3 dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours full dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.095726371419415" CI_START="0.2980703792173723" EFFECT_SIZE="0.7903631787126932" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.32133457834023194" LOG_CI_START="-0.5256811798936074" LOG_EFFECT_SIZE="-0.10217330077668778" ORDER="16189" O_E="0.0" SE="0.49754124918218107" STUDY_ID="STD-Kaisi-1988" TOTAL_1="309" TOTAL_2="314" VAR="0.2475472946377652" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.349428697565902E-32" CI_END="2.026450202245996" CI_START="0.3602963638237755" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8544721407624633" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" I2="100.0" I2_Q="0.0" ID="CMP-010.06" LOG_CI_END="0.30673593590623327" LOG_CI_START="-0.44334012083396257" LOG_EFFECT_SIZE="-0.06830209246386465" METHOD="MH" NO="6" P_CHI2="0.0" P_Q="1.0" P_Z="0.721129603215435" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="248" TOTAL_2="259" WEIGHT="100.0" Z="0.35694951223931104">
<NAME>Non-live births</NAME>
<GROUP_LABEL_1>2/3 dose IV iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Full dose IV iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 2/3 dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours full dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0264502022459965" CI_START="0.3602963638237755" EFFECT_SIZE="0.8544721407624634" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.3067359359062334" LOG_CI_START="-0.44334012083396257" LOG_EFFECT_SIZE="-0.0683020924638646" ORDER="16190" O_E="0.0" SE="0.4405983886655534" STUDY_ID="STD-Kaisi-1988" TOTAL_1="248" TOTAL_2="259" VAR="0.19412694009468204" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.0650886181876604" CI_START="0.13203755755691302" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5221774193548387" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-010.07" LOG_CI_END="0.3149386930694712" LOG_CI_START="-0.8793025178873624" LOG_EFFECT_SIZE="-0.2821819124089456" METHOD="MH" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.35433050727664783" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="248" TOTAL_2="259" WEIGHT="99.99999999999999" Z="0.9262222410949114">
<NAME>Neonatal death</NAME>
<GROUP_LABEL_1>2/3 dose IV iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Full dose IV iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 2/3 dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours full dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0650886181876604" CI_START="0.13203755755691302" EFFECT_SIZE="0.5221774193548387" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.3149386930694712" LOG_CI_START="-0.8793025178873624" LOG_EFFECT_SIZE="-0.2821819124089456" ORDER="16191" O_E="0.0" SE="0.7015031989053792" STUDY_ID="STD-Kaisi-1988" TOTAL_1="248" TOTAL_2="259" VAR="0.49210673807448" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9273452626341274" CI_START="0.25150934587625456" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.696236559139785" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-010.08" LOG_CI_END="0.2849595206883809" LOG_CI_START="-0.599445872289672" LOG_EFFECT_SIZE="-0.15724317580064565" METHOD="MH" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.48583721496599086" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="248" TOTAL_2="259" WEIGHT="100.0" Z="0.6969450069638226">
<NAME>Stillbirth</NAME>
<GROUP_LABEL_1>2/3 dose IV iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Full dose IV iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 2/3 dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours full dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9273452626341279" CI_START="0.25150934587625445" EFFECT_SIZE="0.696236559139785" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.28495952068838093" LOG_CI_START="-0.5994458722896723" LOG_EFFECT_SIZE="-0.15724317580064565" ORDER="16192" O_E="0.0" SE="0.5195041057126092" STUDY_ID="STD-Kaisi-1988" TOTAL_1="248" TOTAL_2="259" VAR="0.2698845158522578" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="29.918415733923844" CI_START="0.32809535603506546" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.1330645161290325" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-010.09" LOG_CI_END="1.4759385926606319" LOG_CI_START="-0.48399991671123577" LOG_EFFECT_SIZE="0.49596933797469805" METHOD="MH" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.32122116430236825" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="248" TOTAL_2="259" WEIGHT="100.0" Z="0.9919515691113395">
<NAME>Spontaneous abortion</NAME>
<GROUP_LABEL_1>2/3 dose IV iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Full dose IV iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 2/3 dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours full dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="29.918415733923844" CI_START="0.32809535603506546" EFFECT_SIZE="3.1330645161290325" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4759385926606319" LOG_CI_START="-0.48399991671123577" LOG_EFFECT_SIZE="0.49596933797469805" ORDER="16193" O_E="0.0" SE="1.151277582257126" STUDY_ID="STD-Kaisi-1988" TOTAL_1="248" TOTAL_2="259" VAR="1.3254400714078132" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" MODIFIED="2011-08-12 13:01:48 +0100" MODIFIED_BY="Heather Maxwell" NO="11">
<NAME>Intravenous iron sucrose with adjuvant recombinant human erythropoietin versus intravenous iron sucrose</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5623477480712826" CI_START="0.025602494738690536" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-011.01" LOG_CI_END="0.19377770576380984" LOG_CI_START="-1.5917177144358472" LOG_EFFECT_SIZE="-0.6989700043360187" METHOD="MH" MODIFIED="2011-08-12 13:01:48 +0100" MODIFIED_BY="Heather Maxwell" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.12489714589710044" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="1.534538839219438">
<NAME>Hb &lt; 11 g/dL at 4 weeks</NAME>
<GROUP_LABEL_1>rhEPO +IV Fe sucrose</GROUP_LABEL_1>
<GROUP_LABEL_2>IV Fe sucrose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rhEPO+IV Fe</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IV Fe</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5623477480712817" CI_START="0.025602494738690536" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.1937777057638096" LOG_CI_START="-1.5917177144358472" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="16194" O_E="0.0" SE="1.0488088481701514" STUDY_ID="STD-Breymann-2001" TOTAL_1="20" TOTAL_2="20" VAR="1.0999999999999999" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="9.642873570657315" CI_START="2.9571264293426784" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="6.299999999999997" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-011.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="2.2096225134762945E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" UNITS="" WEIGHT="100.0" Z="3.6937601263138284">
<NAME>Mean corpuscular volume</NAME>
<GROUP_LABEL_1>rhEPO +IV Fe sucrose</GROUP_LABEL_1>
<GROUP_LABEL_2>IV Fe sucrose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IV Fe</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours rhEPO+IV Fe</GRAPH_LABEL_2>
<CONT_DATA CI_END="9.642873570657315" CI_START="2.9571264293426784" EFFECT_SIZE="6.299999999999997" ESTIMABLE="YES" MEAN_1="91.1" MEAN_2="84.8" ORDER="16195" SD_1="4.3" SD_2="6.3" SE="1.7055790805471318" STUDY_ID="STD-Breymann-2001" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.577326316861588" CI_START="0.38799898695703405" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-011.03" LOG_CI_END="0.4111694083221442" LOG_CI_START="-0.41116940832214427" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.0">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>rhEPO +IV Fe sucrose</GROUP_LABEL_1>
<GROUP_LABEL_2>IV Fe sucrose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rhEPO+IV Fe</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IV Fe</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.577326316861588" CI_START="0.38799898695703405" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.4111694083221442" LOG_CI_START="-0.41116940832214427" LOG_EFFECT_SIZE="0.0" ORDER="16196" O_E="0.0" SE="0.48304589153964794" STUDY_ID="STD-Breymann-2001" TOTAL_1="20" TOTAL_2="20" VAR="0.23333333333333334" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.083060192649951" CI_START="0.04918297059741634" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-011.04" LOG_CI_END="0.7061252525673394" LOG_CI_START="-1.3081852438953019" LOG_EFFECT_SIZE="-0.3010299956639812" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.5579989793003175" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.585816288803313">
<NAME>Metallic taste</NAME>
<GROUP_LABEL_1>rhEPO +IV Fe sucrose</GROUP_LABEL_1>
<GROUP_LABEL_2>IV Fe sucrose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rhEPO+IV Fe</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IV Fe</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.083060192649951" CI_START="0.04918297059741634" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7061252525673394" LOG_CI_START="-1.3081852438953019" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="16197" O_E="0.0" SE="1.1832159566199232" STUDY_ID="STD-Breymann-2001" TOTAL_1="20" TOTAL_2="20" VAR="1.4" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="14.903914722906746" CI_START="0.06709646549862758" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-011.05" LOG_CI_END="1.1733003569528007" LOG_CI_START="-1.1733003569528007" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.0">
<NAME>Warm feeling</NAME>
<GROUP_LABEL_1>rhEPO +IV Fe sucrose</GROUP_LABEL_1>
<GROUP_LABEL_2>IV Fe sucrose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rhEPO+IV Fe</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IV Fe</GRAPH_LABEL_2>
<DICH_DATA CI_END="14.903914722906746" CI_START="0.06709646549862758" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1733003569528007" LOG_CI_START="-1.1733003569528007" LOG_EFFECT_SIZE="0.0" ORDER="16198" O_E="0.0" SE="1.378404875209022" STUDY_ID="STD-Breymann-2001" TOTAL_1="20" TOTAL_2="20" VAR="1.9" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="120.43592724464625" CI_START="-380.4359272446462" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-130.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-011.06" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.3089597676255288" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" UNITS="" WEIGHT="100.0" Z="1.0174072098740936">
<NAME>Birthweight</NAME>
<GROUP_LABEL_1>Iron + EPO</GROUP_LABEL_1>
<GROUP_LABEL_2>Iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="120.43592724464625" CI_START="-380.4359272446462" EFFECT_SIZE="-130.0" ESTIMABLE="YES" MEAN_1="3332.0" MEAN_2="3462.0" ORDER="16199" SD_1="282.0" SD_2="497.0" SE="127.77578017762208" STUDY_ID="STD-Breymann-2001" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.723921203524791" CI_START="0.014385324265142151" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-011.07" LOG_CI_END="0.8878378346245852" LOG_CI_START="-1.84208034406391" LOG_EFFECT_SIZE="-0.47712125471966244" METHOD="MH" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.49327758741034344" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.6851051308492764">
<NAME>Birth &lt; 37 weeks</NAME>
<GROUP_LABEL_1>Iron + EPO</GROUP_LABEL_1>
<GROUP_LABEL_2>Iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.723921203524791" CI_START="0.014385324265142151" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8878378346245852" LOG_CI_START="-1.84208034406391" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="16200" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Breymann-2001" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.615492308281684" CI_START="-5.01549230828169" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.20000000000000284" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-011.08" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.9351219131393074" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" UNITS="" WEIGHT="100.0" Z="0.08140243443725721">
<NAME>Maternal mean blood pressure</NAME>
<GROUP_LABEL_1>Iron + EPO</GROUP_LABEL_1>
<GROUP_LABEL_2>Iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.615492308281684" CI_START="-5.01549230828169" EFFECT_SIZE="-0.20000000000000284" ESTIMABLE="YES" MEAN_1="75.8" MEAN_2="76.0" ORDER="16201" SD_1="8.3" SD_2="7.2" SE="2.4569289774024807" STUDY_ID="STD-Breymann-2001" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-011.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Need transfusion</NAME>
<GROUP_LABEL_1>Iron + EPO</GROUP_LABEL_1>
<GROUP_LABEL_2>Iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="16202" O_E="0.0" SE="0.0" STUDY_ID="STD-Breymann-2001" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" MODIFIED="2011-06-01 22:05:26 +0100" MODIFIED_BY="[Empty name]" NO="12">
<NAME>Intramuscular iron sorbitol citric acid versus oral iron</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4806455026675966" CI_START="1.0148286366376444" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2258064516129032" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="62" I2="0.0" I2_Q="0.0" ID="CMP-012.01" LOG_CI_END="0.1704510918338323" LOG_CI_START="0.0063927137312426476" LOG_EFFECT_SIZE="0.08842190278253749" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.034625746268007414" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="100" TOTAL_2="100" WEIGHT="100.0" Z="2.112708255471165">
<NAME>Not anaemic at term</NAME>
<GROUP_LABEL_1>IM iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IM iron</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4806455026675966" CI_START="1.0148286366376444" EFFECT_SIZE="1.2258064516129032" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="62" LOG_CI_END="0.1704510918338323" LOG_CI_START="0.0063927137312426476" LOG_EFFECT_SIZE="0.08842190278253749" ORDER="16203" O_E="0.0" SE="0.09636870339953017" STUDY_ID="STD-Zutschi-2004" TOTAL_1="100" TOTAL_2="100" VAR="0.009286926994906618" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.7798614782693034" CI_START="0.3001385217306949" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5399999999999991" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="1.0219997755743504E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="100" TOTAL_2="100" UNITS="" WEIGHT="100.0" Z="4.412465725168807">
<NAME>Mean maternal haemoglobin at birth</NAME>
<GROUP_LABEL_1>IM iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IM iron</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.7798614782693034" CI_START="0.3001385217306949" EFFECT_SIZE="0.5399999999999991" ESTIMABLE="YES" MEAN_1="10.5" MEAN_2="9.96" ORDER="16204" SD_1="0.84" SD_2="0.89" SE="0.12238055401083948" STUDY_ID="STD-Zutschi-2004" TOTAL_1="100" TOTAL_2="100" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.1346597609148894" CI_START="0.6653402390851076" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.3999999999999986" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="1.8771988682606347E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="100" TOTAL_2="100" UNITS="" WEIGHT="100.0" Z="3.7349936995854534">
<NAME>Mean maternal hematocrit level at birth</NAME>
<GROUP_LABEL_1>IM iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IM iron</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.1346597609148894" CI_START="0.6653402390851076" EFFECT_SIZE="1.3999999999999986" ESTIMABLE="YES" MEAN_1="31.2" MEAN_2="29.8" ORDER="16205" SD_1="2.6" SD_2="2.7" SE="0.37483329627982626" STUDY_ID="STD-Zutschi-2004" TOTAL_1="100" TOTAL_2="100" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8126578205567303" CI_START="0.6565401539837139" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-012.04" LOG_CI_END="0.25831582909851286" LOG_CI_START="-0.18273870731971337" LOG_EFFECT_SIZE="0.037788560889399754" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.7369835210482667" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="100" TOTAL_2="100" WEIGHT="100.00000000000001" Z="0.3358506137236128">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>IM iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral iron</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8126578205567303" CI_START="0.6565401539837139" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="22" LOG_CI_END="0.25831582909851286" LOG_CI_START="-0.18273870731971337" LOG_EFFECT_SIZE="0.037788560889399754" ORDER="16206" O_E="0.0" SE="0.25907761794723244" STUDY_ID="STD-Zutschi-2004" TOTAL_1="100" TOTAL_2="100" VAR="0.06712121212121214" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.5304699223922418" CI_START="-0.030469922392241777" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.25" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.05" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.05570647252749903" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="28" TOTAL_2="28" UNITS="" WEIGHT="100.0" Z="1.913324895674185">
<NAME>Haematocrit (%) at 4 weeks of treatment</NAME>
<GROUP_LABEL_1>IM iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral iron (600 mg)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IM iron</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.5304699223922418" CI_START="-0.030469922392242" EFFECT_SIZE="1.25" ESTIMABLE="YES" MEAN_1="32.5" MEAN_2="31.25" ORDER="16207" SD_1="2.65" SD_2="2.22" SE="0.6533129855917891" STUDY_ID="STD-Ogunbode-1980" TOTAL_1="28" TOTAL_2="28" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="3.9756685073879794" CI_START="1.2643314926120153" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.6199999999999974" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.06" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="1.5193999499919284E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="31" TOTAL_2="28" UNITS="" WEIGHT="100.0" Z="3.787877059554138">
<NAME>Haematocrit (%) at 8 weeks of treatment</NAME>
<GROUP_LABEL_1>IM iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral iron (600 mg)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IM iron</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.9756685073879794" CI_START="1.2643314926120153" EFFECT_SIZE="2.6199999999999974" ESTIMABLE="YES" MEAN_1="35.29" MEAN_2="32.67" ORDER="16208" SD_1="3.6" SD_2="1.3" SE="0.6916803155983081" STUDY_ID="STD-Ogunbode-1980" TOTAL_1="31" TOTAL_2="28" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.5304699223922418" CI_START="-0.030469922392241777" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.25" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.07" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.05570647252749903" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="28" TOTAL_2="28" UNITS="" WEIGHT="100.0" Z="1.913324895674185">
<NAME>Haematocrit (%) at 4 weeks of treatment</NAME>
<GROUP_LABEL_1>IM iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral iron (1200 mg)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IM iron</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.5304699223922418" CI_START="-0.030469922392242" EFFECT_SIZE="1.25" ESTIMABLE="YES" MEAN_1="32.5" MEAN_2="31.25" ORDER="16209" SD_1="2.65" SD_2="2.22" SE="0.6533129855917891" STUDY_ID="STD-Ogunbode-1980" TOTAL_1="28" TOTAL_2="28" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.176118278876799" CI_START="1.023881721123204" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.6000000000000014" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.08" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.0012241162916379678" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="31" TOTAL_2="28" UNITS="" WEIGHT="99.99999999999999" Z="3.233200469850323">
<NAME>Haematocrit (%) at 8 weeks of treatment</NAME>
<GROUP_LABEL_1>IM iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral iron (1200 mg)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IM iron</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.176118278876799" CI_START="1.023881721123204" EFFECT_SIZE="2.6000000000000014" ESTIMABLE="YES" MEAN_1="35.29" MEAN_2="32.69" ORDER="16210" SD_1="3.6" SD_2="2.53" SE="0.8041567555878665" STUDY_ID="STD-Ogunbode-1980" TOTAL_1="31" TOTAL_2="28" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-013" MODIFIED="2011-06-01 22:05:26 +0100" MODIFIED_BY="[Empty name]" NO="13">
<NAME>Intramuscular iron dextran versus oral iron + vitamin C + folic acid</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="5.2695756291092115" CI_START="3.6704243708907933" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="4.470000000000002" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-013.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="6.142906780954427E-28" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="99.99999999999999" Z="10.957111112371622">
<NAME>Haematocrit</NAME>
<GROUP_LABEL_1>IM iron dextran</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral Fe+vitC+folic a</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fe+vitC+FA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IM iron</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.2695756291092115" CI_START="3.6704243708907933" EFFECT_SIZE="4.470000000000002" ESTIMABLE="YES" MEAN_1="32.67" MEAN_2="28.2" ORDER="16211" SD_1="1.58" SD_2="1.58" SE="0.4079542458005146" STUDY_ID="STD-Komolafe-2003" TOTAL_1="30" TOTAL_2="30" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="79.95581208416971" CI_START="1.5133358894863447" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="11.0" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-013.02" LOG_CI_END="1.9028500386180767" LOG_CI_START="0.1799353316983733" LOG_EFFECT_SIZE="1.0413926851582251" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.017819483615207524" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="2.3693478829520562">
<NAME>Not anaemic at 6 weeks (packed cell volume &gt; 33%)</NAME>
<GROUP_LABEL_1>IM iron dextran</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral Fe+vitC+folic a</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fe+vitC+FA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IM iron</GRAPH_LABEL_2>
<DICH_DATA CI_END="79.95581208416971" CI_START="1.5133358894863456" EFFECT_SIZE="11.0" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="1" LOG_CI_END="1.9028500386180767" LOG_CI_START="0.17993533169837356" LOG_EFFECT_SIZE="1.0413926851582251" ORDER="16212" O_E="0.0" SE="1.0120486274099798" STUDY_ID="STD-Komolafe-2003" TOTAL_1="30" TOTAL_2="30" VAR="1.024242424242424" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-014" MODIFIED="2011-06-01 22:05:27 +0100" MODIFIED_BY="[Empty name]" NO="14">
<NAME>Intramuscular iron sorbitol citric acid versus oral iron + folic acid</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.03527265713894048" CI_START="-0.4847273428610591" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.2599999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-014.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.02335389268901644" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="75" TOTAL_2="75" UNITS="" WEIGHT="100.0" Z="2.2675951644009555">
<NAME>Mean haemoglobin at 36 weeks</NAME>
<GROUP_LABEL_1>IM iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral iron+folic ac</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral Fe+FA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IM iron</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.03527265713894048" CI_START="-0.4847273428610591" EFFECT_SIZE="-0.2599999999999998" ESTIMABLE="YES" MEAN_1="10.94" MEAN_2="11.2" ORDER="16213" SD_1="0.56" SD_2="0.82" SE="0.11465891446663301" STUDY_ID="STD-Kumar-2005" TOTAL_1="75" TOTAL_2="75" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0613177933991067" CI_START="0.6390175461672358" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8235294117647058" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="51" I2="0.0" I2_Q="0.0" ID="CMP-014.02" LOG_CI_END="0.02584544540398471" LOG_CI_START="-0.19448721680405648" LOG_EFFECT_SIZE="-0.08432088570003593" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.13357583957160038" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="75" TOTAL_2="75" WEIGHT="100.0" Z="1.500148888143897">
<NAME>Haemoglobin &gt; 11 g/dL at 36 weeks</NAME>
<GROUP_LABEL_1>IM iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral iron+folic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IM iron</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0613177933991065" CI_START="0.6390175461672358" EFFECT_SIZE="0.8235294117647058" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="51" LOG_CI_END="0.025845445403984615" LOG_CI_START="-0.19448721680405648" LOG_EFFECT_SIZE="-0.08432088570003593" ORDER="16214" O_E="0.0" SE="0.1294244964452713" STUDY_ID="STD-Kumar-2005" TOTAL_1="75" TOTAL_2="75" VAR="0.016750700280112038" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.725714819527823" CI_START="0.4130085577985882" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-014.03" LOG_CI_END="0.8277384486266783" LOG_CI_START="-0.3840409493939655" LOG_EFFECT_SIZE="0.2218487496163564" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.4729743296436527" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="75" TOTAL_2="75" WEIGHT="100.0" Z="0.7176480471173932">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>IM iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral iron+folic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral Fe+FA</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.725714819527823" CI_START="0.4130085577985882" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8277384486266783" LOG_CI_START="-0.3840409493939655" LOG_EFFECT_SIZE="0.2218487496163564" ORDER="16215" O_E="0.0" SE="0.7118052168020874" STUDY_ID="STD-Kumar-2005" TOTAL_1="75" TOTAL_2="75" VAR="0.5066666666666667" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="124.34705623408098" CI_START="-164.34705623408098" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-20.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-014.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.7859582653913808" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="75" TOTAL_2="75" UNITS="" WEIGHT="100.0" Z="0.2715627232967842">
<NAME>Mean birthweight (kg)</NAME>
<GROUP_LABEL_1>IM Iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral iron+folic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral Fe+FA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IM iron</GRAPH_LABEL_2>
<CONT_DATA CI_END="124.34705623408098" CI_START="-164.34705623408098" EFFECT_SIZE="-20.0" ESTIMABLE="YES" MEAN_1="2610.0" MEAN_2="2630.0" ORDER="16216" SD_1="420.0" SD_2="480.0" SE="73.64781055808787" STUDY_ID="STD-Kumar-2005" TOTAL_1="75" TOTAL_2="75" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6155108067149149" CI_START="0.005115696394951917" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.09090909090909091" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-014.05" LOG_CI_END="0.20830986751055386" LOG_CI_START="-2.291095237827004" LOG_EFFECT_SIZE="-1.041392685158225" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.10241382679689016" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="75" TOTAL_2="75" WEIGHT="100.00000000000001" Z="1.633262372966083">
<NAME>Diarrhoea</NAME>
<GROUP_LABEL_1>IM iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral iron+folic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral Fe+FA</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6155108067149149" CI_START="0.005115696394951917" EFFECT_SIZE="0.09090909090909091" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.20830986751055386" LOG_CI_START="-2.291095237827004" LOG_EFFECT_SIZE="-1.041392685158225" ORDER="16217" O_E="0.0" SE="1.46816293113009" STUDY_ID="STD-Kumar-2005" TOTAL_1="75" TOTAL_2="75" VAR="2.1555023923444976" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0011766913949642" CI_START="0.0034561408013160533" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.058823529411764705" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-014.06" LOG_CI_END="5.107301527432808E-4" LOG_CI_START="-2.461408572909291" LOG_EFFECT_SIZE="-1.2304489213782739" METHOD="MH" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.05009513049429402" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="75" TOTAL_2="75" WEIGHT="100.0" Z="1.9591507875323777">
<NAME>Constipation</NAME>
<GROUP_LABEL_1>IM iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral iron+folic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral Fe+FA</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0011766913949642" CI_START="0.0034561408013160533" EFFECT_SIZE="0.058823529411764705" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="5.107301527432808E-4" LOG_CI_START="-2.461408572909291" LOG_EFFECT_SIZE="-1.2304489213782739" ORDER="16218" O_E="0.0" SE="1.4461435853157338" STUDY_ID="STD-Kumar-2005" TOTAL_1="75" TOTAL_2="75" VAR="2.0913312693498454" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.8882926138964357" CI_START="0.003118435365957047" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.05263157894736842" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-014.07" LOG_CI_END="-0.05144394901043142" LOG_CI_START="-2.5060632528952267" LOG_EFFECT_SIZE="-1.278753600952829" METHOD="MH" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.041139838208658186" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="75" TOTAL_2="75" WEIGHT="100.0" Z="2.0421178950249796">
<NAME>Dyspepsia</NAME>
<GROUP_LABEL_1>IM iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral iron+folic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral Fe+FA</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8882926138964357" CI_START="0.003118435365957047" EFFECT_SIZE="0.05263157894736842" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="9" LOG_CI_END="-0.05144394901043142" LOG_CI_START="-2.5060632528952267" LOG_EFFECT_SIZE="-1.278753600952829" ORDER="16219" O_E="0.0" SE="1.4418555296634448" STUDY_ID="STD-Kumar-2005" TOTAL_1="75" TOTAL_2="75" VAR="2.0789473684210527" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1984.1855338294065" CI_START="7.874767623088314" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="125.0" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-014.08" LOG_CI_END="3.2975822789829805" LOG_CI_START="0.8962377470331329" LOG_EFFECT_SIZE="2.0969100130080562" METHOD="MH" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="6.194035165929941E-4" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="75" TOTAL_2="75" WEIGHT="100.0" Z="3.422972463663988">
<NAME>Local site mainly pain</NAME>
<GROUP_LABEL_1>IM iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral iron+folic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral Fe+FA</GRAPH_LABEL_2>
<DICH_DATA CI_END="1984.1855338294065" CI_START="7.874767623088314" EFFECT_SIZE="125.0" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="0" LOG_CI_END="3.2975822789829805" LOG_CI_START="0.8962377470331329" LOG_EFFECT_SIZE="2.0969100130080562" ORDER="16220" O_E="0.0" SE="1.410561664914482" STUDY_ID="STD-Kumar-2005" TOTAL_1="75" TOTAL_2="75" VAR="1.989684210526316" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1795.8219038731509" CI_START="7.1103932814609205" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="113.0" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-014.09" LOG_CI_END="3.254263264402378" LOG_CI_START="0.8518936225644618" LOG_EFFECT_SIZE="2.0530784434834195" METHOD="MH" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="8.081382975229762E-4" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="75" TOTAL_2="75" WEIGHT="100.0" Z="3.349992221500563">
<NAME>Staining</NAME>
<GROUP_LABEL_1>IM iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral iron+folic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral Fe+FA</GRAPH_LABEL_2>
<DICH_DATA CI_END="1795.8219038731509" CI_START="7.1103932814609205" EFFECT_SIZE="113.0" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="0" LOG_CI_END="3.254263264402378" LOG_CI_START="0.8518936225644618" LOG_EFFECT_SIZE="2.0530784434834195" ORDER="16221" O_E="0.0" SE="1.4111638195371095" STUDY_ID="STD-Kumar-2005" TOTAL_1="75" TOTAL_2="75" VAR="1.9913833255705637" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="226.73089888924466" CI_START="0.7453770122551951" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="13.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-014.10" LOG_CI_END="2.3555107098162784" LOG_CI_START="-0.12762400520260508" LOG_EFFECT_SIZE="1.1139433523068367" METHOD="MH" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.07866347753998075" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="75" TOTAL_2="75" WEIGHT="100.0" Z="1.7584940826076847">
<NAME>Arthralgia</NAME>
<GROUP_LABEL_1>IM iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral iron+folic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral Fe+FA</GRAPH_LABEL_2>
<DICH_DATA CI_END="226.73089888924466" CI_START="0.7453770122551951" EFFECT_SIZE="13.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.3555107098162784" LOG_CI_START="-0.12762400520260508" LOG_EFFECT_SIZE="1.1139433523068367" ORDER="16222" O_E="0.0" SE="1.4586056233171698" STUDY_ID="STD-Kumar-2005" TOTAL_1="75" TOTAL_2="75" VAR="2.1275303643724697" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="477.47021791995166" CI_START="1.7613664024192484" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="29.0" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-014.11" LOG_CI_END="2.678946287759766" LOG_CI_START="0.2458497080381462" LOG_EFFECT_SIZE="1.462397997898956" METHOD="MH" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.018470480068605286" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="75" TOTAL_2="75" WEIGHT="100.0" Z="2.3560490206873537">
<NAME>Itching and rash</NAME>
<GROUP_LABEL_1>IM iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral iron+folic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral Fe+FA</GRAPH_LABEL_2>
<DICH_DATA CI_END="477.47021791995166" CI_START="1.7613664024192484" EFFECT_SIZE="29.0" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="0" LOG_CI_END="2.678946287759766" LOG_CI_START="0.2458497080381462" LOG_EFFECT_SIZE="1.462397997898956" ORDER="16223" O_E="0.0" SE="1.4292129749507927" STUDY_ID="STD-Kumar-2005" TOTAL_1="75" TOTAL_2="75" VAR="2.0426497277676954" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="289.3400638131447" CI_START="0.9988246915803396" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="17.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-014.12" LOG_CI_END="2.461408572909291" LOG_CI_START="-5.107301527432858E-4" LOG_EFFECT_SIZE="1.2304489213782739" METHOD="MH" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.05009513049429402" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="75" TOTAL_2="75" WEIGHT="100.0" Z="1.9591507875323777">
<NAME>Fever</NAME>
<GROUP_LABEL_1>IM iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral iron+folic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral Fe+FA</GRAPH_LABEL_2>
<DICH_DATA CI_END="289.3400638131447" CI_START="0.9988246915803396" EFFECT_SIZE="17.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" LOG_CI_END="2.461408572909291" LOG_CI_START="-5.107301527432858E-4" LOG_EFFECT_SIZE="1.2304489213782739" ORDER="16224" O_E="0.0" SE="1.4461435853157338" STUDY_ID="STD-Kumar-2005" TOTAL_1="75" TOTAL_2="75" VAR="2.0913312693498454" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="258.02320450623444" CI_START="0.8720145943097283" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="15.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-014.13" LOG_CI_END="2.41165876462932" LOG_CI_START="-0.059476246517957326" LOG_EFFECT_SIZE="1.1760912590556813" METHOD="MH" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.062094882519997965" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="75" TOTAL_2="75" WEIGHT="100.0" Z="1.865617620958162">
<NAME>Malaise</NAME>
<GROUP_LABEL_1>IM iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral iron+folic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral Fe+FA</GRAPH_LABEL_2>
<DICH_DATA CI_END="258.02320450623444" CI_START="0.8720145943097283" EFFECT_SIZE="15.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.41165876462932" LOG_CI_START="-0.059476246517957326" LOG_EFFECT_SIZE="1.1760912590556813" ORDER="16225" O_E="0.0" SE="1.451556937863496" STUDY_ID="STD-Kumar-2005" TOTAL_1="75" TOTAL_2="75" VAR="2.1070175438596492" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="164.28702824446148" CI_START="0.4930395349258546" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-014.14" LOG_CI_END="2.215603273816972" LOG_CI_START="-0.3071182549383219" LOG_EFFECT_SIZE="0.9542425094393249" METHOD="MH" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.1381412077900339" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="75" TOTAL_2="75" WEIGHT="100.0" Z="1.4827486345201113">
<NAME>Vaso-vagal due to apprehension</NAME>
<GROUP_LABEL_1>IM iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral iron+folic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral Fe+FA</GRAPH_LABEL_2>
<DICH_DATA CI_END="164.28702824446148" CI_START="0.4930395349258546" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.215603273816972" LOG_CI_START="-0.3071182549383219" LOG_EFFECT_SIZE="0.9542425094393249" ORDER="16226" O_E="0.0" SE="1.4818591136638255" STUDY_ID="STD-Kumar-2005" TOTAL_1="75" TOTAL_2="75" VAR="2.1959064327485383" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="383.3733012589396" CI_START="1.3798561304682517" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="23.0" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-014.15" LOG_CI_END="2.583621864620139" LOG_CI_START="0.13983380741504656" LOG_EFFECT_SIZE="1.3617278360175928" METHOD="MH" NO="15" P_CHI2="1.0" P_Q="1.0" P_Z="0.028942952048852826" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="75" TOTAL_2="75" WEIGHT="100.0" Z="2.184262671610363">
<NAME>Systemic ache</NAME>
<GROUP_LABEL_1>IM iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral iron+folic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral Fe+FA</GRAPH_LABEL_2>
<DICH_DATA CI_END="383.3733012589396" CI_START="1.3798561304682517" EFFECT_SIZE="23.0" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="0" LOG_CI_END="2.583621864620139" LOG_CI_START="0.13983380741504656" LOG_EFFECT_SIZE="1.3617278360175928" ORDER="16227" O_E="0.0" SE="1.4354932017482516" STUDY_ID="STD-Kumar-2005" TOTAL_1="75" TOTAL_2="75" VAR="2.0606407322654463" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0089361626161917" CI_START="0.27194626122042903" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5238095238095238" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-014.16" LOG_CI_END="0.003863688436522229" LOG_CI_START="-0.5655169075879106" LOG_EFFECT_SIZE="-0.2808266095756942" METHOD="MH" NO="16" P_CHI2="1.0" P_Q="1.0" P_Z="0.0531913436752517" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="75" TOTAL_2="75" WEIGHT="100.0" Z="1.9333642365474395">
<NAME>Haemoglobin &gt; 12 g/dL at 36 weeks</NAME>
<GROUP_LABEL_1>IMiron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral iron+folic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IM iron</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0089361626161917" CI_START="0.27194626122042903" EFFECT_SIZE="0.5238095238095238" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="21" LOG_CI_END="0.003863688436522229" LOG_CI_START="-0.5655169075879106" LOG_EFFECT_SIZE="-0.2808266095756942" ORDER="16228" O_E="0.0" SE="0.334456980584158" STUDY_ID="STD-Kumar-2005" TOTAL_1="75" TOTAL_2="75" VAR="0.11186147186147186" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-015" MODIFIED="2011-06-01 22:05:27 +0100" MODIFIED_BY="[Empty name]" NO="15">
<NAME>Oral iron daily versus oral iron twice weekly</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.9417273153341756" CI_START="0.13827268466582615" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5400000000000009" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-015.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.008424280774656337" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="84" TOTAL_2="76" UNITS="" WEIGHT="100.0" Z="2.634574526681669">
<NAME>Haemoglobin level at 4 weeks</NAME>
<GROUP_LABEL_1>Oral iron daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral iron twice week</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours twice a week</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours daily</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.9417273153341756" CI_START="0.13827268466582615" EFFECT_SIZE="0.5400000000000009" ESTIMABLE="YES" MEAN_1="10.16" MEAN_2="9.62" ORDER="16229" SD_1="1.52" SD_2="1.05" SE="0.20496668229770984" STUDY_ID="STD-Mumtaz-2000" TOTAL_1="84" TOTAL_2="76" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.6689669536332052" CI_START="0.6710330463667946" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.17" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-015.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="4.310691079838989E-6" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="68" TOTAL_2="61" UNITS="" WEIGHT="100.0" Z="4.595811095733571">
<NAME>Haemoglobin level at 8 weeks</NAME>
<GROUP_LABEL_1>Oral iron daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral iron twice week</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours twice a week</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours daily</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.6689669536332052" CI_START="0.6710330463667946" EFFECT_SIZE="1.17" ESTIMABLE="YES" MEAN_1="10.87" MEAN_2="9.7" ORDER="16230" SD_1="1.72" SD_2="1.14" SE="0.2545796543043612" STUDY_ID="STD-Mumtaz-2000" TOTAL_1="68" TOTAL_2="61" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.861724426023919" CI_START="0.6782755739760803" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.2699999999999996" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-015.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="2.5922921084959515E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="55" TOTAL_2="50" UNITS="" WEIGHT="100.0" Z="4.206610629700876">
<NAME>Haemoglobin level at 12 weeks</NAME>
<GROUP_LABEL_1>Oral iron daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral iron twice week</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours twice a week</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours daily</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.861724426023919" CI_START="0.6782755739760803" EFFECT_SIZE="1.2699999999999996" ESTIMABLE="YES" MEAN_1="11.36" MEAN_2="10.09" ORDER="16231" SD_1="1.83" SD_2="1.23" SE="0.3019057649484205" STUDY_ID="STD-Mumtaz-2000" TOTAL_1="55" TOTAL_2="50" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.6116467164017056" CI_START="-0.011646716401704227" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.3000000000000007" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-015.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.059198383689557085" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="49" TOTAL_2="53" UNITS="" WEIGHT="100.0" Z="1.88671712043362">
<NAME>Haemoglobin level at 16 weeks</NAME>
<GROUP_LABEL_1>Oral iron daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral iron twice week</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours twice a week</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours daily</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.6116467164017056" CI_START="-0.011646716401704227" EFFECT_SIZE="0.3000000000000007" ESTIMABLE="YES" MEAN_1="11.0" MEAN_2="10.7" ORDER="16232" SD_1="0.7" SD_2="0.9" SE="0.1590063485145311" STUDY_ID="STD-De-Souza-2004" TOTAL_1="49" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.2315914622780064" CI_START="0.8559640989464313" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3820861678004535" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-015.05" LOG_CI_END="0.3486146911983411" LOG_CI_START="-0.06754445022521682" LOG_EFFECT_SIZE="0.14053512048656217" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.1855885727294594" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="49" TOTAL_2="53" WEIGHT="100.0" Z="1.3237425172228436">
<NAME>Haemoglobin level &gt; 11 g/dL at 16 weeks of treatment</NAME>
<GROUP_LABEL_1>Oral iron daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral iron twice week</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours twice a week</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours daily</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.2315914622780064" CI_START="0.8559640989464313" EFFECT_SIZE="1.3820861678004535" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="18" LOG_CI_END="0.3486146911983411" LOG_CI_START="-0.06754445022521682" LOG_EFFECT_SIZE="0.14053512048656217" ORDER="16233" O_E="0.0" SE="0.24445393969317158" STUDY_ID="STD-De-Souza-2004" TOTAL_1="49" TOTAL_2="53" VAR="0.05975772863151277" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2111040348833142" CI_START="0.01971433118588417" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.15451895043731778" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-015.06" LOG_CI_END="0.08318145101680653" LOG_CI_START="-1.7052179519007693" LOG_EFFECT_SIZE="-0.8110182504419815" METHOD="MH" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.07546274170205634" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="49" TOTAL_2="53" WEIGHT="100.0" Z="1.7776415705325863">
<NAME>Treatment failure (haemoglobin &lt; 10 g/dL) at 16 weeks</NAME>
<GROUP_LABEL_1>Oral iron daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral iron twice week</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours daily</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours twice a week</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2111040348833142" CI_START="0.01971433118588417" EFFECT_SIZE="0.15451895043731778" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.08318145101680653" LOG_CI_START="-1.7052179519007693" LOG_EFFECT_SIZE="-0.8110182504419815" ORDER="16234" O_E="0.0" SE="1.0505146619936034" STUDY_ID="STD-De-Souza-2004" TOTAL_1="49" TOTAL_2="53" VAR="1.1035810550635348" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-016" MODIFIED="2011-06-01 22:05:27 +0100" MODIFIED_BY="[Empty name]" NO="16">
<NAME>Oral iron daily versus oral iron once week</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.0441583651529265" CI_START="0.35584163484707215" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.6999999999999993" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-016.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="6.706541605391503E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="49" TOTAL_2="48" UNITS="" WEIGHT="100.0" Z="3.986463582160492">
<NAME>Haemoglobin level at 16 weeks</NAME>
<GROUP_LABEL_1>Oral iron daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral iron once week</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours weekly</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours daily</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.0441583651529265" CI_START="0.35584163484707215" EFFECT_SIZE="0.6999999999999993" ESTIMABLE="YES" MEAN_1="11.0" MEAN_2="10.3" ORDER="16235" SD_1="0.7" SD_2="1.0" SE="0.1755942292142123" STUDY_ID="STD-De-Souza-2004" TOTAL_1="49" TOTAL_2="48" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.008279948276731" CI_START="0.9984838234203873" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7331240188383046" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-016.02" LOG_CI_END="0.47831824891912444" LOG_CI_START="-6.589668034652003E-4" LOG_EFFECT_SIZE="0.23882964105782967" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.050633723487770586" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="49" TOTAL_2="48" WEIGHT="100.0" Z="1.9545710298883354">
<NAME>Haemoglobin level &gt; 11 g/dL at 16 weeks of treatment</NAME>
<GROUP_LABEL_1>Oral iron daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral iron once week</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours weekly</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours daily</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.0082799482767317" CI_START="0.9984838234203872" EFFECT_SIZE="1.7331240188383046" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="13" LOG_CI_END="0.47831824891912456" LOG_CI_START="-6.589668034652485E-4" LOG_EFFECT_SIZE="0.23882964105782967" ORDER="16236" O_E="0.0" SE="0.28135358749090567" STUDY_ID="STD-De-Souza-2004" TOTAL_1="49" TOTAL_2="48" VAR="0.0791598411940027" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.35070035390709153" CI_START="0.006840598789725422" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.04897959183673469" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="20" I2="0.0" I2_Q="100.0" ID="CMP-016.03" LOG_CI_END="-0.4550637958526879" LOG_CI_START="-2.1649058807811272" LOG_EFFECT_SIZE="-1.3099848383169077" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.002671319205790079" Q="1.9550291337349532E-31" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="49" TOTAL_2="48" WEIGHT="100.0" Z="3.0032283402383575">
<NAME>Treatment failure (haemoglobin &lt; 10 g/dL) at 16 weeks</NAME>
<GROUP_LABEL_1>Oral iron daily</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral iron once week</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours daily</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours weekly</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.35070035390709153" CI_START="0.006840598789725422" EFFECT_SIZE="0.04897959183673469" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="20" LOG_CI_END="-0.4550637958526879" LOG_CI_START="-2.1649058807811272" LOG_EFFECT_SIZE="-1.3099848383169077" ORDER="16237" O_E="0.0" SE="1.004369704541789" STUDY_ID="STD-De-Souza-2004" TOTAL_1="49" TOTAL_2="48" VAR="1.0087585034013606" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-017" MODIFIED="2011-06-01 22:05:27 +0100" MODIFIED_BY="[Empty name]" NO="17">
<NAME>Oral iron twice week versus oral iron once week</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.7724774888967341" CI_START="0.027522511103263092" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.3999999999999986" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-017.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.03530989598474004" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="53" TOTAL_2="48" UNITS="" WEIGHT="100.0" Z="2.10478650975165">
<NAME>Haemoglobin level at 16 weeks</NAME>
<GROUP_LABEL_1>Oral iron twice week</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral iron once week</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours once week</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours twice week</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.7724774888967341" CI_START="0.027522511103263092" EFFECT_SIZE="0.3999999999999986" ESTIMABLE="YES" MEAN_1="10.7" MEAN_2="10.3" ORDER="16238" SD_1="0.9" SD_2="1.0" SE="0.1900430272366178" STUDY_ID="STD-De-Souza-2004" TOTAL_1="53" TOTAL_2="48" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.989240783506209E-31" CI_END="2.2780603306985734" CI_START="0.6902776623327148" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2539912917271405" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="13" I2="100.0" I2_Q="100.0" ID="CMP-017.02" LOG_CI_END="0.3575652214737785" LOG_CI_START="-0.1609761803312437" LOG_EFFECT_SIZE="0.09829452057126738" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.45744528378705407" Q="8.30344662085058E-33" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="53" TOTAL_2="48" WEIGHT="100.0" Z="0.7430601279924632">
<NAME>Haemoglobin level &gt; 11 g/dL at 16 weeks of treatment</NAME>
<GROUP_LABEL_1>Oral iron twice week</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral iron once week</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours once week</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours twice week</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.278060330698574" CI_START="0.6902776623327149" EFFECT_SIZE="1.2539912917271407" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="13" LOG_CI_END="0.35756522147377856" LOG_CI_START="-0.16097618033124364" LOG_EFFECT_SIZE="0.09829452057126746" ORDER="16239" O_E="0.0" SE="0.30459378624160616" STUDY_ID="STD-De-Souza-2004" TOTAL_1="53" TOTAL_2="48" VAR="0.09277737461699727" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.6825780078788276" CI_START="0.14720227861440927" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3169811320754717" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-017.03" LOG_CI_END="-0.16584770845517163" LOG_CI_START="-0.8320854672946808" LOG_EFFECT_SIZE="-0.4989665878749262" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.0033273338064664735" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="53" TOTAL_2="48" WEIGHT="100.0" Z="2.935758379792691">
<NAME>Treatment Failure (haemoglobin &lt; 10 g/dL) at 16 weeks</NAME>
<GROUP_LABEL_1>Oral iron twice week</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral iron once week</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours twice week</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours once week</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6825780078788275" CI_START="0.14720227861440927" EFFECT_SIZE="0.3169811320754717" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="20" LOG_CI_END="-0.1658477084551717" LOG_CI_START="-0.8320854672946808" LOG_EFFECT_SIZE="-0.4989665878749262" ORDER="16240" O_E="0.0" SE="0.3913513574724222" STUDY_ID="STD-De-Souza-2004" TOTAL_1="53" TOTAL_2="48" VAR="0.1531558849955076" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-018" MODIFIED="2011-06-01 22:05:27 +0100" MODIFIED_BY="[Empty name]" NO="18">
<NAME>Intravenous iron sucrose 500 mg versus intravenous iron sucrose 200 mg</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.182243915649507" CI_START="-0.18224391564950704" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-018.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.15088570538029913" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="20" UNITS="" WEIGHT="100.0" Z="1.4364100137662184">
<NAME>Haemoglobin level at delivery</NAME>
<GROUP_LABEL_1>IV iron sucrose 500</GROUP_LABEL_1>
<GROUP_LABEL_2>IV iron sucrose 200</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 200 mg dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 500 mg dose</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.182243915649507" CI_START="-0.18224391564950704" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="11.8" MEAN_2="11.3" ORDER="16241" SD_1="1.1" SD_2="0.9" SE="0.34809002666934696" STUDY_ID="STD-Wali-2002" TOTAL_1="15" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6754423026831444" CI_START="0.7795687424675241" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-018.02" LOG_CI_END="0.2241294766011431" LOG_CI_START="-0.10814558264576965" LOG_EFFECT_SIZE="0.05799194697768673" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.4938837375399282" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="20" WEIGHT="100.0" Z="0.6841448029667516">
<NAME>Haemoglobin level &gt; 11g/dL at delivery</NAME>
<GROUP_LABEL_1>IV iron sucrose 500</GROUP_LABEL_1>
<GROUP_LABEL_2>IV iron sucrose 200</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 200 mg dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 500 mg dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6754423026831444" CI_START="0.7795687424675241" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.2241294766011431" LOG_CI_START="-0.10814558264576965" LOG_EFFECT_SIZE="0.05799194697768673" ORDER="16242" O_E="0.0" SE="0.19518001458970666" STUDY_ID="STD-Wali-2002" TOTAL_1="15" TOTAL_2="20" VAR="0.0380952380952381" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="19.63729681115055" CI_START="0.09053067715350266" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-018.03" LOG_CI_END="1.2930817043878067" LOG_CI_START="-1.0432042311712066" LOG_EFFECT_SIZE="0.12493873660829993" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.8339580578869564" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="20" WEIGHT="100.0" Z="0.20962795717692104">
<NAME>Moderate abdominal pain</NAME>
<GROUP_LABEL_1>IV iron sucrose 500</GROUP_LABEL_1>
<GROUP_LABEL_2>IV iron sucrose 200</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 500 mg dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 200 mg dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="19.63729681115055" CI_START="0.09053067715350266" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2930817043878067" LOG_CI_START="-1.0432042311712066" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="16243" O_E="0.0" SE="1.37234592334926" STUDY_ID="STD-Wali-2002" TOTAL_1="15" TOTAL_2="20" VAR="1.8833333333333333" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-019" MODIFIED="2011-06-01 22:05:27 +0100" MODIFIED_BY="[Empty name]" NO="19">
<NAME>Intravenous iron sucrose 500 mg versus intramuscular iron sorbitol</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.328797438438585" CI_START="0.8712025615614177" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.6000000000000014" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-019.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="1.6857707688415262E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="25" UNITS="" WEIGHT="100.0" Z="4.3028998317868785">
<NAME>Maternal haemoglobin level at birth</NAME>
<GROUP_LABEL_1>IV iron sucrose 500</GROUP_LABEL_1>
<GROUP_LABEL_2>IM iron sorbitol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IV iron</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.328797438438585" CI_START="0.8712025615614177" EFFECT_SIZE="1.6000000000000014" ESTIMABLE="YES" MEAN_1="11.8" MEAN_2="10.2" ORDER="16244" SD_1="1.1" SD_2="1.2" SE="0.37184226046358243" STUDY_ID="STD-Wali-2002" TOTAL_1="15" TOTAL_2="25" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.626148471593664" CI_START="1.450950920925505" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.857142857142857" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-019.02" LOG_CI_END="0.7502111888215454" LOG_CI_START="0.16165272247790335" LOG_EFFECT_SIZE="0.4559319556497244" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.0023925762453259696" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="25" WEIGHT="100.0" Z="3.0366064327502866">
<NAME>Haemoglobin level &gt; 11g/dL at delivery</NAME>
<GROUP_LABEL_1>IV iron sucrose 500</GROUP_LABEL_1>
<GROUP_LABEL_2>IM iron sorbitol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IV</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.6261484715936625" CI_START="1.4509509209255051" EFFECT_SIZE="2.857142857142857" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.7502111888215452" LOG_CI_START="0.16165272247790344" LOG_EFFECT_SIZE="0.4559319556497244" ORDER="16245" O_E="0.0" SE="0.3457221565416505" STUDY_ID="STD-Wali-2002" TOTAL_1="15" TOTAL_2="25" VAR="0.1195238095238095" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-020" MODIFIED="2011-06-01 22:05:27 +0100" MODIFIED_BY="[Empty name]" NO="20">
<NAME>Intravenous iron sucrose 200 mg versus intramuscular iron sorbitol</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.713878742350715" CI_START="0.4861212576492878" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.1000000000000014" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-020.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="4.44698279057076E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="25" UNITS="" WEIGHT="100.0" Z="3.5120297124775597">
<NAME>Haemoglobin level at delivery</NAME>
<GROUP_LABEL_1>IV iron sucrose 200</GROUP_LABEL_1>
<GROUP_LABEL_2>IM iron sorbitol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IV iron</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.713878742350715" CI_START="0.4861212576492878" EFFECT_SIZE="1.1000000000000014" ESTIMABLE="YES" MEAN_1="11.3" MEAN_2="10.2" ORDER="16246" SD_1="0.9" SD_2="1.2" SE="0.3132091952673165" STUDY_ID="STD-Wali-2002" TOTAL_1="20" TOTAL_2="25" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.989122012868504" CI_START="1.252725426213129" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-020.02" LOG_CI_END="0.6980241250792011" LOG_CI_START="0.09785589226487414" LOG_EFFECT_SIZE="0.3979400086720376" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.009346903192894603" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="25" WEIGHT="99.99999999999999" Z="2.599098194009351">
<NAME>Haemoglobin level &gt; 11 g/dL at delivery</NAME>
<GROUP_LABEL_1>IV iron sucrose 200</GROUP_LABEL_1>
<GROUP_LABEL_2>IM iron sorbitol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IV iron</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.989122012868504" CI_START="1.252725426213129" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="7" LOG_CI_END="0.6980241250792011" LOG_CI_START="0.09785589226487414" LOG_EFFECT_SIZE="0.3979400086720376" ORDER="16247" O_E="0.0" SE="0.35254179083580184" STUDY_ID="STD-Wali-2002" TOTAL_1="20" TOTAL_2="25" VAR="0.12428571428571425" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-021" MODIFIED="2011-06-01 22:05:27 +0100" MODIFIED_BY="[Empty name]" NO="21">
<NAME>Oral ferrous sulphate iron 1200 mg/day versus 600 mg/day</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.5121250630037948" CI_START="-0.7721250630037928" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.370000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-021.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.5254642468695767" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="28" TOTAL_2="28" UNITS="" WEIGHT="100.0" Z="0.6349450666747283">
<NAME>Haematocrit (%) at 4 weeks of treatment</NAME>
<GROUP_LABEL_1>Oral iron 1200 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral iron 600 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 600 mg dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 1200 mg dose</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.5121250630037948" CI_START="-0.7721250630037928" EFFECT_SIZE="0.370000000000001" ESTIMABLE="YES" MEAN_1="31.62" MEAN_2="31.25" ORDER="16248" SD_1="2.14" SD_2="2.22" SE="0.5827275766354537" STUDY_ID="STD-Ogunbode-1980" TOTAL_1="28" TOTAL_2="28" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.073579937511589" CI_START="-1.033579937511597" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.01999999999999602" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-021.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.9703209176757946" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="28" TOTAL_2="28" UNITS="" WEIGHT="100.0" Z="0.03720579549319859">
<NAME>Haematocrit (%) at 8 weeks of treatment</NAME>
<GROUP_LABEL_1>Oral iron 1200 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral iron 600 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 600 mg dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 1200 mg dose</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.073579937511589" CI_START="-1.033579937511597" EFFECT_SIZE="0.01999999999999602" ESTIMABLE="YES" MEAN_1="32.69" MEAN_2="32.67" ORDER="16249" SD_1="2.53" SD_2="1.3" SE="0.5375506620642507" STUDY_ID="STD-Ogunbode-1980" TOTAL_1="28" TOTAL_2="28" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-022" MODIFIED="2011-06-06 15:55:45 +0100" MODIFIED_BY="[Empty name]" NO="22">
<NAME>Oral ferrous sulphate (300 mg) versus ferroids (525 mg)</NAME>
</COMPARISON>
<COMPARISON ID="CMP-023" MODIFIED="2011-06-01 22:05:27 +0100" MODIFIED_BY="[Empty name]" NO="23">
<NAME>Intramuscular iron sorbitol-glu acid versus intravenous iron dextran</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="3.585084180830263" CI_START="0.7749158191697363" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.1799999999999997" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-023.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.002358715973302824" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="31" TOTAL_2="28" UNITS="" WEIGHT="100.0" Z="3.0409007122780136">
<NAME>Haematocrit (%) at 4 weeks of treatment</NAME>
<GROUP_LABEL_1>IM iron sorb-gluc</GROUP_LABEL_1>
<GROUP_LABEL_2>IV iron dextran</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IV iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IM iron</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.585084180830263" CI_START="0.7749158191697363" EFFECT_SIZE="2.1799999999999997" ESTIMABLE="YES" MEAN_1="32.39" MEAN_2="30.21" ORDER="16250" SD_1="2.16" SD_2="3.19" SE="0.7168928571715543" STUDY_ID="STD-Oluboyede-1980" TOTAL_1="31" TOTAL_2="28" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.809778478186418" CI_START="0.15022152181357562" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.4799999999999969" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-023.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.029155626202607816" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="21" TOTAL_2="22" UNITS="" WEIGHT="100.0" Z="2.1813758792933475">
<NAME>Haematocrit (%) at 8 weeks of treatment</NAME>
<GROUP_LABEL_1>IM iron sorb-gluc</GROUP_LABEL_1>
<GROUP_LABEL_2>IV iron dextran</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IV iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IM iron</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.809778478186418" CI_START="0.15022152181357562" EFFECT_SIZE="1.4799999999999969" ESTIMABLE="YES" MEAN_1="34.43" MEAN_2="32.95" ORDER="16251" SD_1="2.31" SD_2="2.13" SE="0.6784708742994995" STUDY_ID="STD-Oluboyede-1980" TOTAL_1="21" TOTAL_2="22" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="14.327041149477905" CI_START="0.06134597093915854" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-023.03" LOG_CI_END="1.1561565082523955" LOG_CI_START="-1.2122139554528824" LOG_EFFECT_SIZE="-0.028028723600243537" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.9629987768704894" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="30" WEIGHT="100.0" Z="0.046390790318470536">
<NAME>Neonatal jaundice</NAME>
<GROUP_LABEL_1>IM iron sorb-gluc</GROUP_LABEL_1>
<GROUP_LABEL_2>IV iron dextran</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IV iron</GRAPH_LABEL_2>
<DICH_DATA CI_END="14.327041149477898" CI_START="0.06134597093915857" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1561565082523952" LOG_CI_START="-1.2122139554528824" LOG_EFFECT_SIZE="-0.028028723600243537" ORDER="16252" O_E="0.0" SE="1.3911925340033515" STUDY_ID="STD-Oluboyede-1980" TOTAL_1="32" TOTAL_2="30" VAR="1.9354166666666666" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="66.61522199816511" CI_START="0.11922423317225214" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.8181818181818183" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-023.04" LOG_CI_END="1.8235734795372827" LOG_CI_START="-0.9236354621851873" LOG_EFFECT_SIZE="0.44996900867604767" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.5208405806790171" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="30" WEIGHT="100.0" Z="0.6420502188750803">
<NAME>Viral hepatitis</NAME>
<GROUP_LABEL_1>IM iron sorb-gluc</GROUP_LABEL_1>
<GROUP_LABEL_2>IV iron dextran</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IV iron</GRAPH_LABEL_2>
<DICH_DATA CI_END="66.61522199816511" CI_START="0.11922423317225214" EFFECT_SIZE="2.8181818181818183" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8235734795372827" LOG_CI_START="-0.9236354621851873" LOG_EFFECT_SIZE="0.44996900867604767" ORDER="16253" O_E="0.0" SE="1.6137241312713606" STUDY_ID="STD-Oluboyede-1980" TOTAL_1="32" TOTAL_2="30" VAR="2.6041055718475072" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.401691333129458" CI_START="0.01324713701913913" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.31313131313131315" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-023.05" LOG_CI_END="0.8693309700979578" LOG_CI_START="-1.8778779716245122" LOG_EFFECT_SIZE="-0.5042735007632773" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.4718107196462381" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="30" WEIGHT="100.0" Z="0.719536024248862">
<NAME>Severe allergic reaction</NAME>
<GROUP_LABEL_1>IM iron sorb-gluc</GROUP_LABEL_1>
<GROUP_LABEL_2>IV iron dextran</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM iron</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IV iron</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.401691333129458" CI_START="0.01324713701913913" EFFECT_SIZE="0.31313131313131315" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8693309700979578" LOG_CI_START="-1.8778779716245122" LOG_EFFECT_SIZE="-0.5042735007632773" ORDER="16254" O_E="0.0" SE="1.6137241312713606" STUDY_ID="STD-Oluboyede-1980" TOTAL_1="32" TOTAL_2="30" VAR="2.6041055718475072" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-024" MODIFIED="2011-06-01 22:05:27 +0100" MODIFIED_BY="[Empty name]" NO="24">
<NAME>Oral iron polymaltose complex (100mg) versus ferrous sulphate (120mg)</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.2018218335313473" CI_START="-0.3018218335313487" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.05000000000000071" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-024.01" MODIFIED="2010-03-12 14:46:06 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.6971600993598799" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="48" TOTAL_2="52" UNITS="" WEIGHT="100.0" Z="0.38915688069122417">
<NAME>Haemoglobin level at 8 weeks</NAME>
<GROUP_LABEL_1>Iron polymaltose complex</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.2018218335313473" CI_START="-0.3018218335313487" EFFECT_SIZE="-0.05000000000000071" ESTIMABLE="YES" MEAN_1="11.19" MEAN_2="11.24" MODIFIED="2010-03-12 14:46:06 +0000" MODIFIED_BY="[Empty name]" ORDER="164" SD_1="0.67" SD_2="0.61" SE="0.1284828882151338" STUDY_ID="STD-Saha-2007" TOTAL_1="48" TOTAL_2="52" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.6361681036481684" CI_START="0.1446333297495809" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.30333333333333334" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-024.02" LOG_CI_END="-0.1964281094456552" LOG_CI_START="-0.8397316153514826" LOG_EFFECT_SIZE="-0.5180798623985688" METHOD="MH" MODIFIED="2010-03-12 14:48:56 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.0015946375110843147" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="48" TOTAL_2="52" WEIGHT="100.0" Z="3.156885862099773">
<NAME>Constipation at 8 weeks</NAME>
<GROUP_LABEL_1>Iron polymaltose complex</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6361681036481684" CI_START="0.1446333297495809" EFFECT_SIZE="0.30333333333333334" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="25" LOG_CI_END="-0.1964281094456552" LOG_CI_START="-0.8397316153514826" LOG_EFFECT_SIZE="-0.5180798623985688" MODIFIED="2010-03-12 14:48:56 +0000" MODIFIED_BY="[Empty name]" ORDER="165" O_E="0.0" SE="0.3778796637727946" STUDY_ID="STD-Saha-2007" TOTAL_1="48" TOTAL_2="52" VAR="0.1427930402930403" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.434697289011412" CI_START="0.8180200242239224" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="33" I2="0.0" I2_Q="0.0" ID="CMP-024.03" LOG_CI_END="0.15676027766921116" LOG_CI_START="-0.08723606515078729" LOG_EFFECT_SIZE="0.03476210625921191" METHOD="MH" MODIFIED="2010-03-12 14:49:50 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.5765226058031417" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="48" TOTAL_2="52" WEIGHT="100.0" Z="0.5584712910641665">
<NAME>Haemoglobin &gt; 11 g/dL at 8 weeks of treatment</NAME>
<GROUP_LABEL_1>Iron polymaltose complex</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.434697289011412" CI_START="0.8180200242239224" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="33" LOG_CI_END="0.15676027766921116" LOG_CI_START="-0.08723606515078729" LOG_EFFECT_SIZE="0.03476210625921191" MODIFIED="2010-03-12 14:47:38 +0000" MODIFIED_BY="[Empty name]" ORDER="166" O_E="0.0" SE="0.14332465957384322" STUDY_ID="STD-Saha-2007" TOTAL_1="48" TOTAL_2="52" VAR="0.020541958041958047" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.6860444225208557" CI_START="0.2500926020583562" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.41421568627450983" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="34" I2="0.0" I2_Q="0.0" ID="CMP-024.04" LOG_CI_END="-0.16364776209054124" LOG_CI_START="-0.6018991548618715" LOG_EFFECT_SIZE="-0.38277345847620636" METHOD="MH" MODIFIED="2010-03-12 14:50:15 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="6.177317232000362E-4" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="48" TOTAL_2="52" WEIGHT="100.0" Z="3.423707055930118">
<NAME>Gastrointestinal intolerance</NAME>
<GROUP_LABEL_1>Iron polymaltose complex</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6860444225208558" CI_START="0.25009260205835615" EFFECT_SIZE="0.41421568627450983" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="34" LOG_CI_END="-0.16364776209054116" LOG_CI_START="-0.6018991548618716" LOG_EFFECT_SIZE="-0.38277345847620636" MODIFIED="2010-03-12 14:50:15 +0000" MODIFIED_BY="[Empty name]" ORDER="167" O_E="0.0" SE="0.25743103749326096" STUDY_ID="STD-Saha-2007" TOTAL_1="48" TOTAL_2="52" VAR="0.06627073906485673" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0430036483730492" CI_START="0.017581600639379847" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.13541666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-024.05" LOG_CI_END="0.018285827568920106" LOG_CI_START="-1.7549415890343834" LOG_EFFECT_SIZE="-0.8683278807327317" METHOD="MH" MODIFIED="2010-03-12 14:50:53 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.05491590143659075" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="48" TOTAL_2="52" WEIGHT="100.0" Z="1.919541009881513">
<NAME>Metallic taste</NAME>
<GROUP_LABEL_1>Iron polymaltose complex</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0430036483730492" CI_START="0.017581600639379847" EFFECT_SIZE="0.13541666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="0.018285827568920106" LOG_CI_START="-1.7549415890343834" LOG_EFFECT_SIZE="-0.8683278807327317" MODIFIED="2010-03-12 14:50:53 +0000" MODIFIED_BY="[Empty name]" ORDER="168" O_E="0.0" SE="1.0416025621300562" STUDY_ID="STD-Saha-2007" TOTAL_1="48" TOTAL_2="52" VAR="1.0849358974358976" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.3949197274509375" CI_START="0.010648014241177737" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2163265306122449" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-024.06" LOG_CI_END="0.6429509471587149" LOG_CI_START="-1.9727313766862014" LOG_EFFECT_SIZE="-0.6648902147637434" METHOD="MH" MODIFIED="2010-03-12 14:51:30 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.3190454701903699" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="48" TOTAL_2="52" WEIGHT="99.99999999999999" Z="0.9964213641161594">
<NAME>Diarrhea</NAME>
<GROUP_LABEL_1>Iron polymaltose complex</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.3949197274509375" CI_START="0.010648014241177737" EFFECT_SIZE="0.2163265306122449" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6429509471587149" LOG_CI_START="-1.9727313766862014" LOG_EFFECT_SIZE="-0.6648902147637434" MODIFIED="2010-03-12 14:51:30 +0000" MODIFIED_BY="[Empty name]" ORDER="169" O_E="0.0" SE="1.536464744862827" STUDY_ID="STD-Saha-2007" TOTAL_1="48" TOTAL_2="52" VAR="2.360723912206392" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.643516903568107" CI_START="0.015039264035444078" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.36054421768707484" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-024.07" LOG_CI_END="0.9366904856547894" LOG_CI_START="-1.8227734159495634" LOG_EFFECT_SIZE="-0.443041465147387" METHOD="MH" MODIFIED="2010-03-12 14:52:51 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.529114723746735" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="48" TOTAL_2="52" WEIGHT="100.0" Z="0.6293579813396945">
<NAME>Rashes</NAME>
<GROUP_LABEL_1>Iron polymaltose complex</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.643516903568107" CI_START="0.015039264035444078" EFFECT_SIZE="0.36054421768707484" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9366904856547894" LOG_CI_START="-1.8227734159495634" LOG_EFFECT_SIZE="-0.443041465147387" MODIFIED="2010-03-12 14:52:51 +0000" MODIFIED_BY="[Empty name]" ORDER="170" O_E="0.0" SE="1.6209227553690084" STUDY_ID="STD-Saha-2007" TOTAL_1="48" TOTAL_2="52" VAR="2.6273905788730585" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2147796171175638" CI_START="0.9236491644376078" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0592592592592593" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="45" I2="0.0" I2_Q="0.0" ID="CMP-024.08" LOG_CI_END="0.08449749624620079" LOG_CI_START="-0.03449295830608928" LOG_EFFECT_SIZE="0.025002268970055728" METHOD="MH" MODIFIED="2010-03-12 14:55:07 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.4101355725919946" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="48" TOTAL_2="52" WEIGHT="100.00000000000001" Z="0.8236550889308198">
<NAME>Compliance</NAME>
<GROUP_LABEL_1>Iron polymaltose complex</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2147796171175638" CI_START="0.9236491644376078" EFFECT_SIZE="1.0592592592592593" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="45" LOG_CI_END="0.08449749624620079" LOG_CI_START="-0.03449295830608928" LOG_EFFECT_SIZE="0.025002268970055728" MODIFIED="2010-03-12 14:55:07 +0000" MODIFIED_BY="[Empty name]" ORDER="171" O_E="0.0" SE="0.06989558201626468" STUDY_ID="STD-Saha-2007" TOTAL_1="48" TOTAL_2="52" VAR="0.0048853923853923835" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="102.06473813387231" CI_START="-116.16473813387233" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-7.050000000000011" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-024.09" MODIFIED="2010-03-12 14:58:30 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.8992292850614125" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="48" TOTAL_2="52" UNITS="" WEIGHT="100.00000000000001" Z="0.12663501124893395">
<NAME>Cost due to hospital visits</NAME>
<GROUP_LABEL_1>Iron polymaltose complex</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="102.0647381338723" CI_START="-116.16473813387232" EFFECT_SIZE="-7.050000000000011" ESTIMABLE="YES" MEAN_1="310.25" MEAN_2="317.3" MODIFIED="2010-03-12 14:58:30 +0000" MODIFIED_BY="[Empty name]" ORDER="172" SD_1="245.54" SD_2="309.6" SE="55.67180774471135" STUDY_ID="STD-Saha-2007" TOTAL_1="48" TOTAL_2="52" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="23.3268363529467" CI_START="-2.7668363529466973" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="10.280000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-024.10" MODIFIED="2010-03-12 14:59:46 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.12251195363044612" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="48" TOTAL_2="52" UNITS="" WEIGHT="100.00000000000001" Z="1.5443153586057763">
<NAME>Cost due to loss of work</NAME>
<GROUP_LABEL_1>Iron polymaltose complex</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="23.3268363529467" CI_START="-2.7668363529466973" EFFECT_SIZE="10.280000000000001" ESTIMABLE="YES" MEAN_1="213.54" MEAN_2="203.26" MODIFIED="2010-03-12 14:59:46 +0000" MODIFIED_BY="[Empty name]" ORDER="173" SD_1="30.83" SD_2="35.7" SE="6.656671477567179" STUDY_ID="STD-Saha-2007" TOTAL_1="48" TOTAL_2="52" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-025" MODIFIED="2011-06-01 22:05:28 +0100" MODIFIED_BY="[Empty name]" NO="25">
<NAME>Oral bovine lactoferrin versus ferrous sulphate</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.07997677201571504" CI_START="-0.5200232279842864" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.3000000000000007" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-025.01" MODIFIED="2011-01-06 10:27:26 +0000" MODIFIED_BY="Denise Atherton" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.007531171410707203" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="49" TOTAL_2="48" UNITS="" WEIGHT="100.0" Z="2.6723960044982733">
<NAME>Mean haemoglobin levels at 1 month</NAME>
<GROUP_LABEL_1>Oral Bovine lactoferrin</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral ferrous sulphate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.07997677201571504" CI_START="-0.5200232279842864" EFFECT_SIZE="-0.3000000000000007" ESTIMABLE="YES" MEAN_1="11.2" MEAN_2="11.5" MODIFIED="2010-03-12 20:09:16 +0000" MODIFIED_BY="[Empty name]" ORDER="176" SD_1="0.5" SD_2="0.6" SE="0.11225881175358364" STUDY_ID="STD-Nappi-2009" TOTAL_1="49" TOTAL_2="48" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-026" MODIFIED="2011-06-01 22:05:28 +0100" MODIFIED_BY="[Empty name]" NO="26">
<NAME>Ferrous sulphate (elementary iron) 20 mg vs 40 mg</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.14279850751300893" CI_START="-0.7427985075130104" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.3000000000000007" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-026.01" MODIFIED="2010-03-13 15:16:57 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.18421334054376953" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="56" TOTAL_2="58" UNITS="" WEIGHT="99.99999999999999" Z="1.3278933541679616">
<NAME>Haemoglobin level at 8 weeks (or until birth)</NAME>
<GROUP_LABEL_1>Ferrous sulphate 20mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 40mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.14279850751300893" CI_START="-0.7427985075130104" EFFECT_SIZE="-0.3000000000000007" ESTIMABLE="YES" MEAN_1="11.1" MEAN_2="11.4" MODIFIED="2010-03-13 15:16:57 +0000" MODIFIED_BY="[Empty name]" ORDER="177" SD_1="1.3" SD_2="1.1" SE="0.22592175723928998" STUDY_ID="STD-Zhou-2007" TOTAL_1="56" TOTAL_2="58" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.517085570374041" CI_START="0.8352914278109214" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.45" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-026.02" LOG_CI_END="0.40089797999395843" LOG_CI_START="-0.07816197552400862" LOG_EFFECT_SIZE="0.16136800223497488" METHOD="MH" MODIFIED="2011-01-06 10:27:44 +0000" MODIFIED_BY="Denise Atherton" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.18670137822442215" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="56" TOTAL_2="58" WEIGHT="100.0" Z="1.320400375755756">
<NAME>Rate of anaemia at 8 weeks</NAME>
<GROUP_LABEL_1>Ferrous sulphate 20mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 40mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.517085570374041" CI_START="0.8352914278109214" EFFECT_SIZE="1.45" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="15" LOG_CI_END="0.40089797999395843" LOG_CI_START="-0.07816197552400862" LOG_EFFECT_SIZE="0.16136800223497488" MODIFIED="2010-03-12 22:51:20 +0000" MODIFIED_BY="[Empty name]" ORDER="178" O_E="0.0" SE="0.28140218925627886" STUDY_ID="STD-Zhou-2007" TOTAL_1="56" TOTAL_2="58" VAR="0.07918719211822658" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.760670655590932" CI_START="0.5768352082399453" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6571428571428573" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-026.03" LOG_CI_END="0.6776681379107844" LOG_CI_START="-0.238948239485461" LOG_EFFECT_SIZE="0.21935994921266166" METHOD="MH" MODIFIED="2011-01-06 10:27:49 +0000" MODIFIED_BY="Denise Atherton" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.34819450378657646" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="56" TOTAL_2="58" WEIGHT="100.0" Z="0.9380971379294785">
<NAME>Rate of moderate anaemia at 8 weeks</NAME>
<GROUP_LABEL_1>Ferrous sulphate 20mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 40mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.760670655590934" CI_START="0.5768352082399452" EFFECT_SIZE="1.6571428571428573" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.6776681379107845" LOG_CI_START="-0.2389482394854611" LOG_EFFECT_SIZE="0.21935994921266166" MODIFIED="2010-03-12 22:52:21 +0000" MODIFIED_BY="[Empty name]" ORDER="179" O_E="0.0" SE="0.5384249974067998" STUDY_ID="STD-Zhou-2007" TOTAL_1="56" TOTAL_2="58" VAR="0.28990147783251236" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.9673585646426644E-31" CI_END="1.1233835565897388" CI_START="0.6669536819932044" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8655892786756012" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="43" I2="100.00000000000001" I2_Q="0.0" ID="CMP-026.04" LOG_CI_END="0.05052806264622568" LOG_CI_START="-0.17590432553357846" LOG_EFFECT_SIZE="-0.06268813144367637" METHOD="MH" MODIFIED="2010-03-12 22:54:24 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="1.0" P_Z="0.27781641601045504" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="59" TOTAL_2="61" WEIGHT="100.0" Z="1.0852376806638944">
<NAME>Nausea at 8 weeks</NAME>
<GROUP_LABEL_1>Ferrous sulphate 20mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 40mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1233835565897385" CI_START="0.6669536819932043" EFFECT_SIZE="0.8655892786756011" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="43" LOG_CI_END="0.0505280626462256" LOG_CI_START="-0.17590432553357851" LOG_EFFECT_SIZE="-0.06268813144367642" MODIFIED="2010-03-12 22:54:24 +0000" MODIFIED_BY="[Empty name]" ORDER="180" O_E="0.0" SE="0.13300750567521538" STUDY_ID="STD-Zhou-2007" TOTAL_1="59" TOTAL_2="61" VAR="0.01769099656594245" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.1644826244813598E-30" CI_END="1.1279788226351821" CI_START="0.7165706567309185" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8990420044215179" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="46" I2="100.0" I2_Q="0.0" ID="CMP-026.05" LOG_CI_END="0.05230094601344214" LOG_CI_START="-0.14474097998341995" LOG_EFFECT_SIZE="-0.0462200169849889" METHOD="MH" MODIFIED="2010-03-12 22:55:13 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="1.0" P_Z="0.3578365404505607" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="59" TOTAL_2="61" WEIGHT="100.0" Z="0.9194953632035697">
<NAME>Heartburn at 8 weeks</NAME>
<GROUP_LABEL_1>Ferrous sulphate 20mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 40mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1279788226351823" CI_START="0.7165706567309185" EFFECT_SIZE="0.899042004421518" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="46" LOG_CI_END="0.05230094601344222" LOG_CI_START="-0.14474097998341995" LOG_EFFECT_SIZE="-0.04622001698498884" MODIFIED="2010-03-12 22:55:13 +0000" MODIFIED_BY="[Empty name]" ORDER="181" O_E="0.0" SE="0.11574340270382112" STUDY_ID="STD-Zhou-2007" TOTAL_1="59" TOTAL_2="61" VAR="0.013396535269458908" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.8836918787844911" CI_START="0.3598917683916131" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5639445300462249" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="33" I2="0.0" I2_Q="0.0" ID="CMP-026.06" LOG_CI_END="-0.053699136197300865" LOG_CI_START="-0.4438280866146163" LOG_EFFECT_SIZE="-0.2487636114059586" METHOD="MH" MODIFIED="2010-03-12 22:56:01 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.012436138779674075" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="59" TOTAL_2="61" WEIGHT="100.0" Z="2.499520830219095">
<NAME>Stomach pain at 8 weeks</NAME>
<GROUP_LABEL_1>Ferrous sulphate 20mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 40mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8836918787844911" CI_START="0.3598917683916131" EFFECT_SIZE="0.5639445300462249" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="33" LOG_CI_END="-0.053699136197300865" LOG_CI_START="-0.4438280866146163" LOG_EFFECT_SIZE="-0.2487636114059586" MODIFIED="2010-03-12 22:56:01 +0000" MODIFIED_BY="[Empty name]" ORDER="182" O_E="0.0" SE="0.22916367664458118" STUDY_ID="STD-Zhou-2007" TOTAL_1="59" TOTAL_2="61" VAR="0.052515990693262155" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2992533852855643" CI_START="0.38516010139853635" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7074041034790366" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-026.07" LOG_CI_END="0.11369385707767556" LOG_CI_START="-0.41435870763241417" LOG_EFFECT_SIZE="-0.15033242527736934" METHOD="MH" MODIFIED="2010-03-12 22:56:44 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.2644338124747906" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="59" TOTAL_2="61" WEIGHT="100.0" Z="1.1159727608328869">
<NAME>Vomiting at 8 weeks</NAME>
<GROUP_LABEL_1>Ferrous sulphate 20mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 40mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2992533852855643" CI_START="0.38516010139853635" EFFECT_SIZE="0.7074041034790366" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="19" LOG_CI_END="0.11369385707767556" LOG_CI_START="-0.41435870763241417" LOG_EFFECT_SIZE="-0.15033242527736934" MODIFIED="2010-03-12 22:56:44 +0000" MODIFIED_BY="[Empty name]" ORDER="183" O_E="0.0" SE="0.3101806904130585" STUDY_ID="STD-Zhou-2007" TOTAL_1="59" TOTAL_2="61" VAR="0.09621206070512164" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.574436064375251" CI_START="0.4152154796341837" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0338983050847457" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-026.08" LOG_CI_END="0.4106821106772114" LOG_CI_START="-0.3817264639399657" LOG_EFFECT_SIZE="0.014477823368622805" METHOD="MH" MODIFIED="2011-01-06 10:27:34 +0000" MODIFIED_BY="Denise Atherton" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.9429046018103979" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="59" TOTAL_2="61" WEIGHT="100.0" Z="0.07161964997852752">
<NAME>Bowel habit: &lt; 3 per week</NAME>
<GROUP_LABEL_1>Ferrous sulphate 20mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 40mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.574436064375251" CI_START="0.4152154796341837" EFFECT_SIZE="1.0338983050847457" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.4106821106772114" LOG_CI_START="-0.3817264639399657" LOG_EFFECT_SIZE="0.014477823368622805" MODIFIED="2010-03-12 22:57:28 +0000" MODIFIED_BY="[Empty name]" ORDER="184" O_E="0.0" SE="0.4654647192158352" STUDY_ID="STD-Zhou-2007" TOTAL_1="59" TOTAL_2="61" VAR="0.2166574048346763" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8656421262668044" CI_START="0.638395032282324" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.091337099811676" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-026.09" LOG_CI_END="0.2708283395747721" LOG_CI_START="-0.19491050113848069" LOG_EFFECT_SIZE="0.03795891921814572" METHOD="MH" MODIFIED="2010-03-12 22:58:06 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.7493593253124426" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="59" TOTAL_2="61" WEIGHT="100.0" Z="0.31948426051687845">
<NAME>Hard stool at 8 weeks</NAME>
<GROUP_LABEL_1>Ferrous sulphate 20mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 40mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8656421262668044" CI_START="0.638395032282324" EFFECT_SIZE="1.091337099811676" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" LOG_CI_END="0.2708283395747721" LOG_CI_START="-0.19491050113848069" LOG_EFFECT_SIZE="0.03795891921814572" MODIFIED="2010-03-12 22:58:06 +0000" MODIFIED_BY="[Empty name]" ORDER="185" O_E="0.0" SE="0.273577300479408" STUDY_ID="STD-Zhou-2007" TOTAL_1="59" TOTAL_2="61" VAR="0.07484453933760027" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9726807442851918" CI_START="0.5007176196498963" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6978813559322034" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="40" I2="0.0" I2_Q="0.0" ID="CMP-026.10" LOG_CI_END="-0.012029681568191779" LOG_CI_START="-0.3004071260325128" LOG_EFFECT_SIZE="-0.15621840380035226" METHOD="MH" MODIFIED="2010-03-12 22:58:46 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.03371331454399456" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="59" TOTAL_2="61" WEIGHT="100.0" Z="2.1234840036798195">
<NAME>Feeling unwell at 8 weeks</NAME>
<GROUP_LABEL_1>Ferrous sulphate 20mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 40mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9726807442851918" CI_START="0.5007176196498963" EFFECT_SIZE="0.6978813559322034" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="40" LOG_CI_END="-0.012029681568191779" LOG_CI_START="-0.3004071260325128" LOG_EFFECT_SIZE="-0.15621840380035226" MODIFIED="2010-03-12 22:58:46 +0000" MODIFIED_BY="[Empty name]" ORDER="186" O_E="0.0" SE="0.16939433836971451" STUDY_ID="STD-Zhou-2007" TOTAL_1="59" TOTAL_2="61" VAR="0.02869444187171333" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="16.15035685839103" CI_START="0.06618712605732495" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0338983050847457" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-026.11" LOG_CI_END="1.2081821229468614" LOG_CI_START="-1.1792264762096158" LOG_EFFECT_SIZE="0.014477823368622805" METHOD="MH" MODIFIED="2010-03-13 16:39:42 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.9810349597816341" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="59" TOTAL_2="61" WEIGHT="100.0" Z="0.023771391614371265">
<NAME>Need transfusion</NAME>
<GROUP_LABEL_1>Ferrous sulphate 20mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 40mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="16.15035685839103" CI_START="0.06618712605732495" EFFECT_SIZE="1.0338983050847457" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2081821229468614" LOG_CI_START="-1.1792264762096158" LOG_EFFECT_SIZE="0.014477823368622805" MODIFIED="2010-03-13 16:39:42 +0000" MODIFIED_BY="[Empty name]" ORDER="207" O_E="0.0" SE="1.4023756290076765" STUDY_ID="STD-Zhou-2007" TOTAL_1="59" TOTAL_2="61" VAR="1.9666574048346763" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.0100818430804983" CI_START="0.5502878731602374" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0517241379310345" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-026.12" LOG_CI_END="0.30321374064169415" LOG_CI_START="-0.2594100577460347" LOG_EFFECT_SIZE="0.021901841447829747" METHOD="MH" MODIFIED="2010-03-13 16:44:32 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.8787175808903533" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="58" TOTAL_2="61" WEIGHT="100.0" Z="0.15259511082135258">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Ferrous sulphate 20mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 40mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0100818430804983" CI_START="0.5502878731602374" EFFECT_SIZE="1.0517241379310345" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.30321374064169415" LOG_CI_START="-0.2594100577460347" LOG_EFFECT_SIZE="0.021901841447829747" MODIFIED="2010-03-13 16:44:32 +0000" MODIFIED_BY="[Empty name]" ORDER="210" O_E="0.0" SE="0.33048800420567037" STUDY_ID="STD-Zhou-2007" TOTAL_1="58" TOTAL_2="61" VAR="0.10922232092384719" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="142.017635212394" CI_START="-206.017635212394" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-32.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-026.13" MODIFIED="2010-03-13 16:46:07 +0000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.7185356020883981" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="58" TOTAL_2="61" UNITS="" WEIGHT="100.0" Z="0.36041661771079353">
<NAME>Birthweight</NAME>
<GROUP_LABEL_1>Ferrous sulphate 20mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 40mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="142.017635212394" CI_START="-206.017635212394" EFFECT_SIZE="-32.0" ESTIMABLE="YES" MEAN_1="3464.0" MEAN_2="3496.0" MODIFIED="2010-03-13 16:46:07 +0000" MODIFIED_BY="[Empty name]" ORDER="211" SD_1="444.0" SD_2="523.0" SE="88.78613922756892" STUDY_ID="STD-Zhou-2007" TOTAL_1="58" TOTAL_2="61" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.045804703713592" CI_START="0.12151118320900345" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7011494252873564" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-026.14" LOG_CI_END="0.6070049149778945" LOG_CI_START="-0.9153837501935974" LOG_EFFECT_SIZE="-0.15418941760785146" METHOD="MH" MODIFIED="2010-03-13 16:47:17 +0000" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.691356267202841" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="58" TOTAL_2="61" WEIGHT="99.99999999999999" Z="0.39701518044940576">
<NAME>Preterm birth</NAME>
<GROUP_LABEL_1>Ferrous sulphate 20mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 40mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.045804703713591" CI_START="0.12151118320900345" EFFECT_SIZE="0.7011494252873564" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6070049149778944" LOG_CI_START="-0.9153837501935974" LOG_EFFECT_SIZE="-0.15418941760785146" MODIFIED="2010-03-13 16:47:17 +0000" MODIFIED_BY="[Empty name]" ORDER="212" O_E="0.0" SE="0.8942586378671651" STUDY_ID="STD-Zhou-2007" TOTAL_1="58" TOTAL_2="61" VAR="0.7996985114000376" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6673416935527792" CI_START="0.07371172305019018" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3505747126436782" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-026.15" LOG_CI_END="0.2220246102766227" LOG_CI_START="-1.1324634368202882" LOG_EFFECT_SIZE="-0.4552194132718327" METHOD="MH" MODIFIED="2011-01-06 10:27:57 +0000" MODIFIED_BY="Denise Atherton" NO="15" P_CHI2="1.0" P_Q="1.0" P_Z="0.187698457615687" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="58" TOTAL_2="61" WEIGHT="99.99999999999999" Z="1.317418277685858">
<NAME>Small-for-gestational age</NAME>
<GROUP_LABEL_1>Ferrous sulphate 20mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 40mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6673416935527785" CI_START="0.0737117230501902" EFFECT_SIZE="0.3505747126436782" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.2220246102766225" LOG_CI_START="-1.132463436820288" LOG_EFFECT_SIZE="-0.4552194132718327" MODIFIED="2010-03-13 16:48:01 +0000" MODIFIED_BY="[Empty name]" ORDER="213" O_E="0.0" SE="0.7956329836886923" STUDY_ID="STD-Zhou-2007" TOTAL_1="58" TOTAL_2="61" VAR="0.6330318447333709" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.968754621696974E-32" CI_END="2.2341274013666452" CI_START="0.2526036818465037" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.751231527093596" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="100.0" I2_Q="0.0" ID="CMP-026.16" LOG_CI_END="0.3491079351774862" LOG_CI_START="-0.5975603236383028" LOG_EFFECT_SIZE="-0.12422619423040833" METHOD="MH" MODIFIED="2010-03-13 16:49:06 +0000" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.0" P_Q="1.0" P_Z="0.6069785778190151" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="58" TOTAL_2="61" WEIGHT="100.0" Z="0.5143911066219788">
<NAME>Fetal distress</NAME>
<GROUP_LABEL_1>Ferrous sulphate 20mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 40mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.2341274013666457" CI_START="0.2526036818465038" EFFECT_SIZE="0.7512315270935961" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.3491079351774863" LOG_CI_START="-0.5975603236383028" LOG_EFFECT_SIZE="-0.12422619423040826" MODIFIED="2010-03-13 16:49:06 +0000" MODIFIED_BY="[Empty name]" ORDER="214" O_E="0.0" SE="0.5560776213118518" STUDY_ID="STD-Zhou-2007" TOTAL_1="58" TOTAL_2="61" VAR="0.3092223209238472" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-027" MODIFIED="2011-06-01 22:05:28 +0100" MODIFIED_BY="[Empty name]" NO="27">
<NAME>Ferrous sulphate (elementary iron) 20 mg vs 80 mg</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.33270069409915715" CI_START="-1.2672993059008442" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.8000000000000007" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-027.01" MODIFIED="2010-03-13 15:17:24 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="7.925330930913387E-4" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="56" TOTAL_2="54" UNITS="" WEIGHT="100.0" Z="3.355389506965699">
<NAME>Haemoglobin level at 8 weeks (or until birth)</NAME>
<GROUP_LABEL_1>Ferrous sulphate 20 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 80 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.33270069409915715" CI_START="-1.2672993059008442" EFFECT_SIZE="-0.8000000000000007" ESTIMABLE="YES" MEAN_1="11.1" MEAN_2="11.9" MODIFIED="2010-03-13 15:17:24 +0000" MODIFIED_BY="[Empty name]" ORDER="187" SD_1="1.3" SD_2="1.2" SE="0.23842239428216072" STUDY_ID="STD-Zhou-2007" TOTAL_1="56" TOTAL_2="54" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.787581482990743" CI_START="0.8704338654310988" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5576923076923077" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="13" I2="0.0" I2_Q="99.99999999999999" ID="CMP-027.02" LOG_CI_END="0.44522757097856364" LOG_CI_START="-0.060264220490862434" LOG_EFFECT_SIZE="0.1924816752438506" METHOD="MH" MODIFIED="2011-01-06 10:28:14 +0000" MODIFIED_BY="Denise Atherton" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.13553298327197605" Q="3.49507942175423E-32" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="56" TOTAL_2="54" WEIGHT="100.0" Z="1.4926341338411226">
<NAME>Rate of patients with anaemia at 8 weeks</NAME>
<GROUP_LABEL_1>Ferrous sulphate 20 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 80 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.787581482990743" CI_START="0.8704338654310988" EFFECT_SIZE="1.5576923076923077" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="13" LOG_CI_END="0.44522757097856364" LOG_CI_START="-0.060264220490862434" LOG_EFFECT_SIZE="0.1924816752438506" MODIFIED="2010-03-13 14:47:36 +0000" MODIFIED_BY="[Empty name]" ORDER="188" O_E="0.0" SE="0.29692838053386406" STUDY_ID="STD-Zhou-2007" TOTAL_1="56" TOTAL_2="54" VAR="0.08816646316646318" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.007698291481348" CI_START="0.4416561633442115" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7592592592592593" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-027.03" LOG_CI_END="0.8455753955051392" LOG_CI_START="-0.3549157045733806" LOG_EFFECT_SIZE="0.24532984546587927" METHOD="MH" MODIFIED="2011-01-06 10:28:10 +0000" MODIFIED_BY="Denise Atherton" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.42309213413357083" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="54" TOTAL_2="57" WEIGHT="100.0" Z="0.8010682651698969">
<NAME>Rate of moderate anaemia at 8 weeks</NAME>
<GROUP_LABEL_1>Ferrous sulphate 20 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 80 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.007698291481348" CI_START="0.4416561633442115" EFFECT_SIZE="1.7592592592592593" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8455753955051392" LOG_CI_START="-0.3549157045733806" LOG_EFFECT_SIZE="0.24532984546587927" MODIFIED="2010-03-13 15:00:45 +0000" MODIFIED_BY="[Empty name]" ORDER="189" O_E="0.0" SE="0.7051744147129078" STUDY_ID="STD-Zhou-2007" TOTAL_1="54" TOTAL_2="57" VAR="0.49727095516569203" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9465671742306477" CI_START="0.5897390411785434" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7471463161535801" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="49" I2="0.0" I2_Q="0.0" ID="CMP-027.04" LOG_CI_END="-0.023848560398007982" LOG_CI_START="-0.22934012064144596" LOG_EFFECT_SIZE="-0.12659434051972696" METHOD="MH" MODIFIED="2010-03-13 15:01:48 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.015739713770941726" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="59" TOTAL_2="60" WEIGHT="100.0" Z="2.4148957531036888">
<NAME>Nausea at 8 weeks</NAME>
<GROUP_LABEL_1>Ferrous sulphate 20 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 80 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9465671742306476" CI_START="0.5897390411785435" EFFECT_SIZE="0.7471463161535801" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="49" LOG_CI_END="-0.023848560398008034" LOG_CI_START="-0.22934012064144588" LOG_EFFECT_SIZE="-0.12659434051972696" MODIFIED="2010-03-13 15:01:48 +0000" MODIFIED_BY="[Empty name]" ORDER="190" O_E="0.0" SE="0.12070675968662378" STUDY_ID="STD-Zhou-2007" TOTAL_1="59" TOTAL_2="60" VAR="0.014570121834044346" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1991751640223531" CI_START="0.7462750524897597" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9459992116673236" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="43" I2="0.0" I2_Q="0.0" ID="CMP-027.05" LOG_CI_END="0.0788826253107542" LOG_CI_START="-0.12710107633100357" LOG_EFFECT_SIZE="-0.0241092255101247" METHOD="MH" MODIFIED="2010-03-13 15:02:46 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.646373943294827" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="59" TOTAL_2="60" WEIGHT="100.0" Z="0.4588053648747458">
<NAME>Heartburn at 8 weeks</NAME>
<GROUP_LABEL_1>Ferrous sulphate 20 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 80 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1991751640223531" CI_START="0.7462750524897597" EFFECT_SIZE="0.9459992116673236" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="43" LOG_CI_END="0.0788826253107542" LOG_CI_START="-0.12710107633100357" LOG_EFFECT_SIZE="-0.0241092255101247" MODIFIED="2010-03-13 15:02:46 +0000" MODIFIED_BY="[Empty name]" ORDER="191" O_E="0.0" SE="0.12099584598013612" STUDY_ID="STD-Zhou-2007" TOTAL_1="59" TOTAL_2="60" VAR="0.014639994744448822" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.8394261579620788" CI_START="0.3453052291443708" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5383848454636092" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="34" I2="0.0" I2_Q="0.0" ID="CMP-027.06" LOG_CI_END="-0.07601750155104267" LOG_CI_START="-0.46179684484385647" LOG_EFFECT_SIZE="-0.26890717319744956" METHOD="MH" MODIFIED="2010-03-13 15:07:53 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.006287808378814525" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="59" TOTAL_2="60" WEIGHT="100.0" Z="2.7323825591741753">
<NAME>Stomach pain at 8 weeks</NAME>
<GROUP_LABEL_1>Ferrous sulphate 20 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 80 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8394261579620788" CI_START="0.3453052291443708" EFFECT_SIZE="0.5383848454636092" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="34" LOG_CI_END="-0.07601750155104267" LOG_CI_START="-0.46179684484385647" LOG_EFFECT_SIZE="-0.26890717319744956" MODIFIED="2010-03-13 15:07:53 +0000" MODIFIED_BY="[Empty name]" ORDER="192" O_E="0.0" SE="0.22660869588874644" STUDY_ID="STD-Zhou-2007" TOTAL_1="59" TOTAL_2="60" VAR="0.05135150105239837" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9310754069135403" CI_START="0.30034493280178115" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5288135593220339" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-027.07" LOG_CI_END="-0.031015144496353696" LOG_CI_START="-0.5223796907510491" LOG_EFFECT_SIZE="-0.2766974176237014" METHOD="MH" MODIFIED="2010-03-13 15:08:35 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.027286716362819253" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="59" TOTAL_2="60" WEIGHT="100.0" Z="2.20739154784923">
<NAME>Vomiting at 8 weeks</NAME>
<GROUP_LABEL_1>Ferrous sulphate 20 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 80 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9310754069135403" CI_START="0.30034493280178115" EFFECT_SIZE="0.5288135593220339" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="25" LOG_CI_END="-0.031015144496353696" LOG_CI_START="-0.5223796907510491" LOG_EFFECT_SIZE="-0.2766974176237014" MODIFIED="2010-03-13 15:08:35 +0000" MODIFIED_BY="[Empty name]" ORDER="193" O_E="0.0" SE="0.28862996676373953" STUDY_ID="STD-Zhou-2007" TOTAL_1="59" TOTAL_2="60" VAR="0.0833072577140374" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.183649637537747" CI_START="0.3742057656511696" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.903954802259887" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-027.08" LOG_CI_END="0.33918295789245195" LOG_CI_START="-0.4268895253042156" LOG_EFFECT_SIZE="-0.043853283705881846" METHOD="MH" MODIFIED="2011-01-06 10:28:18 +0000" MODIFIED_BY="Denise Atherton" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.8224511001543942" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="59" TOTAL_2="60" WEIGHT="100.0" Z="0.22439353599724624">
<NAME>Bowel habit: &lt; 3 per week</NAME>
<GROUP_LABEL_1>Ferrous sulphate 20 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 80 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.183649637537747" CI_START="0.3742057656511696" EFFECT_SIZE="0.903954802259887" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.33918295789245195" LOG_CI_START="-0.4268895253042156" LOG_EFFECT_SIZE="-0.043853283705881846" MODIFIED="2010-03-13 15:09:15 +0000" MODIFIED_BY="[Empty name]" ORDER="194" O_E="0.0" SE="0.44999476874967287" STUDY_ID="STD-Zhou-2007" TOTAL_1="59" TOTAL_2="60" VAR="0.20249529190207155" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3712454827457405" CI_START="0.5146770433937119" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8400884303610906" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-027.09" LOG_CI_END="0.1371152099013968" LOG_CI_START="-0.28846520254792585" LOG_EFFECT_SIZE="-0.07567499632326449" METHOD="MH" MODIFIED="2010-03-13 15:10:17 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.4857866421441439" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="59" TOTAL_2="60" WEIGHT="100.0" Z="0.6970258169081556">
<NAME>Hard stool at 8 weeks</NAME>
<GROUP_LABEL_1>Ferrous sulphate 20 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 80 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3712454827457405" CI_START="0.5146770433937119" EFFECT_SIZE="0.8400884303610906" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="23" LOG_CI_END="0.1371152099013968" LOG_CI_START="-0.28846520254792585" LOG_EFFECT_SIZE="-0.07567499632326449" MODIFIED="2010-03-13 15:10:17 +0000" MODIFIED_BY="[Empty name]" ORDER="195" O_E="0.0" SE="0.24998804092974947" STUDY_ID="STD-Zhou-2007" TOTAL_1="59" TOTAL_2="60" VAR="0.062494020607894094" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0446987078665588" CI_START="0.5271467096970573" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7420980302336234" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="37" I2="0.0" I2_Q="0.0" ID="CMP-027.10" LOG_CI_END="0.018991057549709686" LOG_CI_START="-0.27806849988272625" LOG_EFFECT_SIZE="-0.12953872116650827" METHOD="MH" MODIFIED="2010-03-13 15:11:16 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.08738382991765513" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="59" TOTAL_2="60" WEIGHT="100.0" Z="1.709362461078051">
<NAME>Feeling unwell at 8 weeks</NAME>
<GROUP_LABEL_1>Ferrous sulphate 20 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 80 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0446987078665588" CI_START="0.5271467096970573" EFFECT_SIZE="0.7420980302336234" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="37" LOG_CI_END="0.018991057549709686" LOG_CI_START="-0.27806849988272625" LOG_EFFECT_SIZE="-0.12953872116650827" MODIFIED="2010-03-13 15:11:16 +0000" MODIFIED_BY="[Empty name]" ORDER="196" O_E="0.0" SE="0.17449425450433753" STUDY_ID="STD-Zhou-2007" TOTAL_1="59" TOTAL_2="60" VAR="0.03044824485502452" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.457908194227223" CI_START="0.04737096805468889" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5084745762711864" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-027.11" LOG_CI_END="0.7370262262631836" LOG_CI_START="-1.3244877401081472" LOG_EFFECT_SIZE="-0.2937307569224818" METHOD="MH" MODIFIED="2010-03-13 16:40:50 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.5764871587584754" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="59" TOTAL_2="60" WEIGHT="100.0" Z="0.5585232155696733">
<NAME>Need transfusion</NAME>
<GROUP_LABEL_1>Ferrous sulphate 20 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 80 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.457908194227223" CI_START="0.04737096805468889" EFFECT_SIZE="0.5084745762711864" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7370262262631836" LOG_CI_START="-1.3244877401081472" LOG_EFFECT_SIZE="-0.2937307569224818" MODIFIED="2010-03-13 16:40:50 +0000" MODIFIED_BY="[Empty name]" ORDER="208" O_E="0.0" SE="1.2109435085052318" STUDY_ID="STD-Zhou-2007" TOTAL_1="59" TOTAL_2="60" VAR="1.4663841807909606" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5653436700040952" CI_START="0.46365509965621504" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8519269776876268" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-027.12" LOG_CI_END="0.19460970137184483" LOG_CI_START="-0.3338049591305039" LOG_EFFECT_SIZE="-0.06959762887932953" METHOD="MH" MODIFIED="2010-03-13 16:52:09 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.6056485948962614" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="58" TOTAL_2="60" WEIGHT="100.0" Z="0.5162947064458456">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Ferrous sulphate 20mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 80mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5653436700040952" CI_START="0.46365509965621504" EFFECT_SIZE="0.8519269776876268" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="17" LOG_CI_END="0.19460970137184483" LOG_CI_START="-0.3338049591305039" LOG_EFFECT_SIZE="-0.06959762887932953" MODIFIED="2010-03-13 16:50:39 +0000" MODIFIED_BY="[Empty name]" ORDER="219" O_E="0.0" SE="0.31039338727383453" STUDY_ID="STD-Zhou-2007" TOTAL_1="58" TOTAL_2="60" VAR="0.09634405486332462" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="134.82844636906785" CI_START="-212.82844636906785" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-39.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-027.13" MODIFIED="2010-03-13 16:52:48 +0000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.6601284531678261" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="58" TOTAL_2="61" UNITS="" WEIGHT="100.0" Z="0.4397358257161763">
<NAME>Birthweight</NAME>
<GROUP_LABEL_1>Ferrous sulphate 20mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 80mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="134.82844636906785" CI_START="-212.82844636906785" EFFECT_SIZE="-39.0" ESTIMABLE="YES" MEAN_1="3464.0" MEAN_2="3503.0" MODIFIED="2010-03-13 16:52:48 +0000" MODIFIED_BY="[Empty name]" ORDER="215" SD_1="444.0" SD_2="522.0" SE="88.68961253380391" STUDY_ID="STD-Zhou-2007" TOTAL_1="58" TOTAL_2="61" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="7.401951979532792E-32" CI_END="2.048739604584346" CI_START="0.08357564430258282" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4137931034482758" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="100.00000000000001" I2_Q="99.99999999999999" ID="CMP-027.14" LOG_CI_END="0.3114867629504362" LOG_CI_START="-1.0779202666530987" LOG_EFFECT_SIZE="-0.3832167518513313" METHOD="MH" MODIFIED="2010-03-13 16:53:07 +0000" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.2796225200021687" Q="1.8504879948831968E-32" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="58" TOTAL_2="60" WEIGHT="100.0" Z="1.0811677440776375">
<NAME>Preterm birth</NAME>
<GROUP_LABEL_1>Ferrous sulphate 20mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 80mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0487396045843456" CI_START="0.08357564430258285" EFFECT_SIZE="0.41379310344827586" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.3114867629504361" LOG_CI_START="-1.0779202666530987" LOG_EFFECT_SIZE="-0.38321675185133125" MODIFIED="2010-03-13 16:53:07 +0000" MODIFIED_BY="[Empty name]" ORDER="216" O_E="0.0" SE="0.8161445668648345" STUDY_ID="STD-Zhou-2007" TOTAL_1="58" TOTAL_2="60" VAR="0.6660919540229884" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.101810115908762" CI_START="0.1506875797039714" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0344827586206897" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-027.15" LOG_CI_END="0.8513690562061662" LOG_CI_START="-0.8219225425647536" LOG_EFFECT_SIZE="0.014723256820706378" METHOD="MH" MODIFIED="2011-01-06 10:28:26 +0000" MODIFIED_BY="Denise Atherton" NO="15" P_CHI2="1.0" P_Q="1.0" P_Z="0.9724853304020636" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="58" TOTAL_2="60" WEIGHT="100.0" Z="0.034491361965738106">
<NAME>Small-for-gestational age</NAME>
<GROUP_LABEL_1>Ferrous sulphate 20mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 80mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.101810115908761" CI_START="0.15068757970397142" EFFECT_SIZE="1.0344827586206897" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8513690562061662" LOG_CI_START="-0.8219225425647535" LOG_EFFECT_SIZE="0.014723256820706378" MODIFIED="2010-03-13 16:53:22 +0000" MODIFIED_BY="[Empty name]" ORDER="217" O_E="0.0" SE="0.9828997680450374" STUDY_ID="STD-Zhou-2007" TOTAL_1="58" TOTAL_2="60" VAR="0.9660919540229884" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.612905872438562" CI_START="0.2047823301084311" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5747126436781609" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-027.16" LOG_CI_END="0.2076090231401486" LOG_CI_START="-0.688707519705348" LOG_EFFECT_SIZE="-0.24054924828259974" METHOD="MH" MODIFIED="2010-03-13 16:53:36 +0000" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="1.0" P_Q="1.0" P_Z="0.292794076132727" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="58" TOTAL_2="60" WEIGHT="100.0" Z="1.0520119636425114">
<NAME>Fetal distress</NAME>
<GROUP_LABEL_1>Ferrous sulphate 20mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 80mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6129058724385623" CI_START="0.20478233010843105" EFFECT_SIZE="0.5747126436781609" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.20760902314014865" LOG_CI_START="-0.6887075197053483" LOG_EFFECT_SIZE="-0.24054924828259974" MODIFIED="2010-03-13 16:53:36 +0000" MODIFIED_BY="[Empty name]" ORDER="218" O_E="0.0" SE="0.5265007741058884" STUDY_ID="STD-Zhou-2007" TOTAL_1="58" TOTAL_2="60" VAR="0.27720306513409965" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-028" MODIFIED="2011-06-01 22:05:29 +0100" MODIFIED_BY="[Empty name]" NO="28">
<NAME>Ferrous sulphate (elementary iron) 40 mg vs 80 mg</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.07270656367000905" CI_START="-0.927293436329991" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-028.01" MODIFIED="2010-03-13 15:16:19 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.021821322007179428" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="58" TOTAL_2="54" UNITS="" WEIGHT="99.99999999999999" Z="2.293463715911622">
<NAME>Haemoglobin level at 8 weeks (or until birth)</NAME>
<GROUP_LABEL_1>Ferrous sulphate 40 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 80 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.07270656367000905" CI_START="-0.927293436329991" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="11.4" MEAN_2="11.9" MODIFIED="2010-03-13 15:16:19 +0000" MODIFIED_BY="[Empty name]" ORDER="197" SD_1="1.1" SD_2="1.2" SE="0.2180108612711392" STUDY_ID="STD-Zhou-2007" TOTAL_1="58" TOTAL_2="54" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.787581482990743" CI_START="0.8704338654310988" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5576923076923077" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="13" I2="0.0" I2_Q="99.99999999999999" ID="CMP-028.02" LOG_CI_END="0.44522757097856364" LOG_CI_START="-0.060264220490862434" LOG_EFFECT_SIZE="0.1924816752438506" METHOD="MH" MODIFIED="2011-01-06 10:28:37 +0000" MODIFIED_BY="Denise Atherton" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.13553298327197605" Q="3.49507942175423E-32" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="56" TOTAL_2="54" WEIGHT="100.0" Z="1.4926341338411226">
<NAME>Rate of anaemia at 8 weeks</NAME>
<GROUP_LABEL_1>Ferrous sulphate 40 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 80 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.787581482990743" CI_START="0.8704338654310988" EFFECT_SIZE="1.5576923076923077" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="13" LOG_CI_END="0.44522757097856364" LOG_CI_START="-0.060264220490862434" LOG_EFFECT_SIZE="0.1924816752438506" MODIFIED="2010-03-13 15:18:29 +0000" MODIFIED_BY="[Empty name]" ORDER="198" O_E="0.0" SE="0.29692838053386406" STUDY_ID="STD-Zhou-2007" TOTAL_1="56" TOTAL_2="54" VAR="0.08816646316646318" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.503943367489314" CI_START="0.4114195906757616" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6358024691358024" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-028.03" LOG_CI_END="0.8131767510217487" LOG_CI_START="-0.3857150322333948" LOG_EFFECT_SIZE="0.21373085939417688" METHOD="MH" MODIFIED="2011-01-06 10:28:43 +0000" MODIFIED_BY="Denise Atherton" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.4846645237118963" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="54" TOTAL_2="53" WEIGHT="99.99999999999999" Z="0.698820014697242">
<NAME>Rate of moderate anaemia at 8 weeks</NAME>
<GROUP_LABEL_1>Ferrous sulphate 40 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 80 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.503943367489314" CI_START="0.4114195906757616" EFFECT_SIZE="1.6358024691358024" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8131767510217487" LOG_CI_START="-0.3857150322333948" LOG_EFFECT_SIZE="0.21373085939417688" MODIFIED="2010-03-13 15:19:10 +0000" MODIFIED_BY="[Empty name]" ORDER="199" O_E="0.0" SE="0.7042349680941106" STUDY_ID="STD-Zhou-2007" TOTAL_1="54" TOTAL_2="53" VAR="0.49594689028651295" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2605157387874093" CI_START="0.22815859750759795" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.536281179138322" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="49" I2="0.0" I2_Q="0.0" ID="CMP-028.04" LOG_CI_END="0.1005482726430486" LOG_CI_START="-0.6417631614310649" LOG_EFFECT_SIZE="-0.2706074443940082" METHOD="MH" MODIFIED="2010-03-13 16:32:34 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.15300475590793725" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="61" TOTAL_2="60" WEIGHT="100.0" Z="1.428998182204283">
<NAME>Nausea at 8 weeks</NAME>
<GROUP_LABEL_1>Ferrous sulphate 40 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 80 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2605157387874093" CI_START="0.22815859750759795" EFFECT_SIZE="0.536281179138322" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="49" LOG_CI_END="0.1005482726430486" LOG_CI_START="-0.6417631614310649" LOG_EFFECT_SIZE="-0.2706074443940082" MODIFIED="2010-03-13 16:32:34 +0000" MODIFIED_BY="[Empty name]" ORDER="200" O_E="0.0" SE="0.4360374108759946" STUDY_ID="STD-Zhou-2007" TOTAL_1="61" TOTAL_2="60" VAR="0.19012862368344097" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3034720595308664" CI_START="0.8494148642809404" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0522302706824247" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="43" I2="0.0" I2_Q="0.0" ID="CMP-028.05" LOG_CI_END="0.11510172632013715" LOG_CI_START="-0.07088014337040888" LOG_EFFECT_SIZE="0.022110791474864142" METHOD="MH" MODIFIED="2010-03-13 16:33:20 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.6411956480984999" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="61" TOTAL_2="60" WEIGHT="99.99999999999999" Z="0.4660277373543567">
<NAME>Heartburn at 8 weeks</NAME>
<GROUP_LABEL_1>Ferrous sulphate 40 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 80 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3034720595308664" CI_START="0.8494148642809404" EFFECT_SIZE="1.0522302706824247" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="43" LOG_CI_END="0.11510172632013715" LOG_CI_START="-0.07088014337040888" LOG_EFFECT_SIZE="0.022110791474864142" MODIFIED="2010-03-13 16:33:20 +0000" MODIFIED_BY="[Empty name]" ORDER="201" O_E="0.0" SE="0.10924667088132935" STUDY_ID="STD-Zhou-2007" TOTAL_1="61" TOTAL_2="60" VAR="0.011934835098653493" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.220411898582208E-31" CI_END="1.3146975062623985" CI_START="0.6932454650346744" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9546769527483123" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="34" I2="100.00000000000001" I2_Q="0.0" ID="CMP-028.06" LOG_CI_END="0.11882583915789874" LOG_CI_START="-0.159112962740881" LOG_EFFECT_SIZE="-0.0201435617914911" METHOD="MH" MODIFIED="2010-03-13 16:34:07 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="1.0" P_Z="0.7763367867046236" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="61" TOTAL_2="60" WEIGHT="100.0" Z="0.28409603381724174">
<NAME>Stomach pain at 8 weeks</NAME>
<GROUP_LABEL_1>Ferrous sulphate 40 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 80 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.314697506262399" CI_START="0.6932454650346745" EFFECT_SIZE="0.9546769527483124" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="34" LOG_CI_END="0.11882583915789888" LOG_CI_START="-0.15911296274088094" LOG_EFFECT_SIZE="-0.02014356179149105" MODIFIED="2010-03-13 16:34:07 +0000" MODIFIED_BY="[Empty name]" ORDER="202" O_E="0.0" SE="0.16326262805460157" STUDY_ID="STD-Zhou-2007" TOTAL_1="61" TOTAL_2="60" VAR="0.026654685719295173" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2061186793038619" CI_START="0.4633188522492606" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7475409836065574" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-028.07" LOG_CI_END="0.08139004348481617" LOG_CI_START="-0.33412002817748027" LOG_EFFECT_SIZE="-0.12636499234633203" METHOD="MH" MODIFIED="2010-03-13 16:35:00 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.23321063083924543" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="61" TOTAL_2="60" WEIGHT="100.0" Z="1.1921291482281253">
<NAME>Vomiting at 8 weeks</NAME>
<GROUP_LABEL_1>Ferrous sulphate 40 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 80 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2061186793038619" CI_START="0.4633188522492606" EFFECT_SIZE="0.7475409836065574" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="25" LOG_CI_END="0.08139004348481617" LOG_CI_START="-0.33412002817748027" LOG_EFFECT_SIZE="-0.12636499234633203" MODIFIED="2010-03-13 16:35:00 +0000" MODIFIED_BY="[Empty name]" ORDER="203" O_E="0.0" SE="0.2440726729024594" STUDY_ID="STD-Zhou-2007" TOTAL_1="61" TOTAL_2="60" VAR="0.05957146965775094" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.114610379421446" CI_START="0.361499271364119" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8743169398907104" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-028.08" LOG_CI_END="0.32523035958105323" LOG_CI_START="-0.44189257373006263" LOG_EFFECT_SIZE="-0.0583311070745047" METHOD="MH" MODIFIED="2011-01-06 10:28:48 +0000" MODIFIED_BY="Denise Atherton" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.7656523197810597" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="61" TOTAL_2="60" WEIGHT="100.0" Z="0.29806661769558174">
<NAME>Bowel habit: &lt; 3 per week</NAME>
<GROUP_LABEL_1>Ferrous sulphate 40 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 80 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.114610379421446" CI_START="0.361499271364119" EFFECT_SIZE="0.8743169398907104" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.32523035958105323" LOG_CI_START="-0.44189257373006263" LOG_EFFECT_SIZE="-0.0583311070745047" MODIFIED="2010-03-13 16:35:52 +0000" MODIFIED_BY="[Empty name]" ORDER="204" O_E="0.0" SE="0.4506118083467117" STUDY_ID="STD-Zhou-2007" TOTAL_1="61" TOTAL_2="60" VAR="0.20305100182149363" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.203703627297256E-31" CI_END="1.2735035442006293" CI_START="0.46529888406782416" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7697790449037775" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="23" I2="100.0" I2_Q="0.0" ID="CMP-028.09" LOG_CI_END="0.10500015795659048" LOG_CI_START="-0.3322679890394111" LOG_EFFECT_SIZE="-0.1136339155414103" METHOD="MH" MODIFIED="2010-03-13 16:36:32 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Q="1.0" P_Z="0.3083544383140189" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="61" TOTAL_2="60" WEIGHT="100.0" Z="1.018681024051208">
<NAME>Hard stool at 8 weeks</NAME>
<GROUP_LABEL_1>Ferrous sulphate 40 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 80 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2735035442006295" CI_START="0.4652988840678242" EFFECT_SIZE="0.7697790449037776" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="23" LOG_CI_END="0.10500015795659057" LOG_CI_START="-0.33226798903941107" LOG_EFFECT_SIZE="-0.11363391554141024" MODIFIED="2010-03-13 16:36:32 +0000" MODIFIED_BY="[Empty name]" ORDER="205" O_E="0.0" SE="0.25685347405768777" STUDY_ID="STD-Zhou-2007" TOTAL_1="61" TOTAL_2="60" VAR="0.06597370713550328" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3928601969637695" CI_START="0.8118052158076995" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0633584404076208" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="37" I2="0.0" I2_Q="0.0" ID="CMP-028.10" LOG_CI_END="0.14390752795724476" LOG_CI_START="-0.09054816268955669" LOG_EFFECT_SIZE="0.026679682633844036" METHOD="MH" MODIFIED="2010-03-13 16:37:15 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.6555504293486212" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="61" TOTAL_2="60" WEIGHT="99.99999999999999" Z="0.44606481452452995">
<NAME>Feeling unwell at 8 weeks</NAME>
<GROUP_LABEL_1>Ferrous sulphate 40 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 80 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3928601969637697" CI_START="0.8118052158076994" EFFECT_SIZE="1.0633584404076208" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="37" LOG_CI_END="0.14390752795724482" LOG_CI_START="-0.09054816268955675" LOG_EFFECT_SIZE="0.026679682633844036" MODIFIED="2010-03-13 16:37:15 +0000" MODIFIED_BY="[Empty name]" ORDER="206" O_E="0.0" SE="0.13772043326031744" STUDY_ID="STD-Zhou-2007" TOTAL_1="61" TOTAL_2="60" VAR="0.018966917737409546" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.281334748443555" CI_START="0.045797222946351475" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4918032786885246" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-028.11" LOG_CI_END="0.7227436953798887" LOG_CI_START="-1.3391608559620978" LOG_EFFECT_SIZE="-0.3082085802911046" METHOD="MH" MODIFIED="2010-03-13 16:41:42 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.5579148345092189" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="61" TOTAL_2="60" WEIGHT="100.0" Z="0.5859414944339919">
<NAME>Need transfusion</NAME>
<GROUP_LABEL_1>Ferrous sulphate 40 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 80 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.281334748443555" CI_START="0.045797222946351475" EFFECT_SIZE="0.4918032786885246" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7227436953798887" LOG_CI_START="-1.3391608559620978" LOG_EFFECT_SIZE="-0.3082085802911046" MODIFIED="2010-03-13 16:41:42 +0000" MODIFIED_BY="[Empty name]" ORDER="209" O_E="0.0" SE="1.2111729400504219" STUDY_ID="STD-Zhou-2007" TOTAL_1="61" TOTAL_2="60" VAR="1.4669398907103826" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.492340669649344" CI_START="0.43967632869684886" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8100289296046287" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="17" I2="0.0" I2_Q="100.0" ID="CMP-028.12" LOG_CI_END="0.17386797465176307" LOG_CI_START="-0.3568669153060817" LOG_EFFECT_SIZE="-0.09149947032715933" METHOD="MH" MODIFIED="2010-03-13 17:06:26 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Q="0.0" P_Z="0.49916680853258" Q="7.926290689834086E-33" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="61" TOTAL_2="60" WEIGHT="100.0" Z="0.6758013081068326">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Ferrous sulphate 40mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 80mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.492340669649344" CI_START="0.43967632869684886" EFFECT_SIZE="0.8100289296046287" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="17" LOG_CI_END="0.17386797465176307" LOG_CI_START="-0.3568669153060817" LOG_EFFECT_SIZE="-0.09149947032715933" MODIFIED="2010-03-13 17:06:26 +0000" MODIFIED_BY="[Empty name]" ORDER="220" O_E="0.0" SE="0.3117563015413139" STUDY_ID="STD-Zhou-2007" TOTAL_1="61" TOTAL_2="60" VAR="0.09719199155071863" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="180.81904498287304" CI_START="-194.81904498287304" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-7.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-028.13" MODIFIED="2010-03-13 17:06:48 +0000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.9417681655224961" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="58" TOTAL_2="61" UNITS="" WEIGHT="100.0" Z="0.07304769275677801">
<NAME>Birthweight</NAME>
<GROUP_LABEL_1>Ferrous sulphate 40mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 80mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="180.81904498287304" CI_START="-194.81904498287304" EFFECT_SIZE="-7.0" ESTIMABLE="YES" MEAN_1="3496.0" MEAN_2="3503.0" MODIFIED="2010-03-13 17:06:48 +0000" MODIFIED_BY="[Empty name]" ORDER="221" SD_1="523.0" SD_2="522.0" SE="95.82780421699873" STUDY_ID="STD-Zhou-2007" TOTAL_1="58" TOTAL_2="61" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.3606275841287285" CI_START="0.14754274322605476" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5901639344262295" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-028.14" LOG_CI_END="0.37302747758477817" LOG_CI_START="-0.8310821460717376" LOG_EFFECT_SIZE="-0.22902733424347976" METHOD="MH" MODIFIED="2010-03-13 17:07:07 +0000" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.455915854645388" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="61" TOTAL_2="60" WEIGHT="100.0" Z="0.745588803167786">
<NAME>Preterm birth</NAME>
<GROUP_LABEL_1>Ferrous sulphate 40mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 80mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.3606275841287285" CI_START="0.14754274322605476" EFFECT_SIZE="0.5901639344262295" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.37302747758477817" LOG_CI_START="-0.8310821460717376" LOG_EFFECT_SIZE="-0.22902733424347976" MODIFIED="2010-03-13 17:07:07 +0000" MODIFIED_BY="[Empty name]" ORDER="222" O_E="0.0" SE="0.7072999533746032" STUDY_ID="STD-Zhou-2007" TOTAL_1="61" TOTAL_2="60" VAR="0.5002732240437158" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="14.04410441661656" CI_START="0.6199994303042861" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.9508196721311477" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-028.15" LOG_CI_END="1.1474940497445962" LOG_CI_START="-0.20760870955951807" LOG_EFFECT_SIZE="0.46994267009253904" METHOD="MH" MODIFIED="2011-01-06 10:28:54 +0000" MODIFIED_BY="Denise Atherton" NO="15" P_CHI2="1.0" P_Q="1.0" P_Z="0.17401642961315697" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="61" TOTAL_2="60" WEIGHT="100.0" Z="1.3594108666016775">
<NAME>Small-for-gestational age</NAME>
<GROUP_LABEL_1>Ferrous sulphate 20mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 40mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="14.04410441661656" CI_START="0.6199994303042863" EFFECT_SIZE="2.9508196721311477" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.1474940497445962" LOG_CI_START="-0.2076087095595179" LOG_EFFECT_SIZE="0.46994267009253904" MODIFIED="2010-03-13 17:07:20 +0000" MODIFIED_BY="[Empty name]" ORDER="223" O_E="0.0" SE="0.7959940686820782" STUDY_ID="STD-Zhou-2007" TOTAL_1="61" TOTAL_2="60" VAR="0.6336065573770491" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.921980807016189" CI_START="0.3045123041232703" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7650273224043715" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-028.16" LOG_CI_END="0.28374904647062277" LOG_CI_START="-0.5163951545750057" LOG_EFFECT_SIZE="-0.11632305405219147" METHOD="MH" MODIFIED="2010-03-13 17:07:32 +0000" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="1.0" P_Q="1.0" P_Z="0.5687660313883734" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="61" TOTAL_2="60" WEIGHT="100.0" Z="0.5698697715138479">
<NAME>Fetal distress</NAME>
<GROUP_LABEL_1>Ferrous sulphate 40mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Ferrous sulphate 80mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.921980807016189" CI_START="0.3045123041232703" EFFECT_SIZE="0.7650273224043715" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.28374904647062277" LOG_CI_START="-0.5163951545750057" LOG_EFFECT_SIZE="-0.11632305405219147" MODIFIED="2010-03-13 17:07:32 +0000" MODIFIED_BY="[Empty name]" ORDER="224" O_E="0.0" SE="0.47000866447187595" STUDY_ID="STD-Zhou-2007" TOTAL_1="61" TOTAL_2="60" VAR="0.22090814467863648" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-029" MODIFIED="2011-06-01 22:05:29 +0100" MODIFIED_BY="[Empty name]" NO="29">
<NAME>Intravenous iron + oral iron versus oral iron</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.7469061966008026" CI_START="0.2130938033991982" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.4800000000000004" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-029.01" MODIFIED="2011-05-25 20:23:48 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="4.2385207779271976E-4" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="92" TOTAL_2="91" UNITS="" WEIGHT="100.0" Z="3.5247690932642786">
<NAME>Mean predelivery maternal haemoglobin</NAME>
<GROUP_LABEL_1>IV + Oral iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.7469061966008026" CI_START="0.2130938033991982" EFFECT_SIZE="0.4800000000000004" ESTIMABLE="YES" MEAN_1="12.66" MEAN_2="12.18" MODIFIED="2011-05-25 20:23:48 +0100" MODIFIED_BY="[Empty name]" ORDER="225" SD_1="0.97" SD_2="0.87" SE="0.1361791332423066" STUDY_ID="STD-Khalafallah-2010" TOTAL_1="92" TOTAL_2="91" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.7558182476336078" CI_START="0.024181752366393305" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.39000000000000057" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-029.02" MODIFIED="2011-05-25 20:22:35 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.03666059313948727" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="92" TOTAL_2="91" UNITS="" WEIGHT="100.0" Z="2.0895238521185218">
<NAME>Mean maternal haemoglobin after delivery</NAME>
<GROUP_LABEL_1>IV + Oral iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.7558182476336078" CI_START="0.024181752366393305" EFFECT_SIZE="0.39000000000000057" ESTIMABLE="YES" MEAN_1="11.55" MEAN_2="11.16" MODIFIED="2011-05-25 20:22:35 +0100" MODIFIED_BY="[Empty name]" ORDER="226" SD_1="1.08" SD_2="1.42" SE="0.18664539273126185" STUDY_ID="STD-Khalafallah-2010" TOTAL_1="92" TOTAL_2="91" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3242250761122292" CI_START="0.0603127642716941" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2826086956521739" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-029.03" LOG_CI_END="0.12196180761572246" LOG_CI_START="-1.219590766365197" LOG_EFFECT_SIZE="-0.5488144793747374" METHOD="MH" MODIFIED="2011-05-25 20:36:29 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.10880232968117413" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="92" TOTAL_2="91" WEIGHT="100.0" Z="1.6035996421320784">
<NAME>Tolerate oral iron</NAME>
<GROUP_LABEL_1>IV + Oral iron</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral iron</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3242250761122287" CI_START="0.06031276427169413" EFFECT_SIZE="0.2826086956521739" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.12196180761572233" LOG_CI_START="-1.2195907663651968" LOG_EFFECT_SIZE="-0.5488144793747374" MODIFIED="2011-05-25 20:36:29 +0100" MODIFIED_BY="[Empty name]" ORDER="227" O_E="0.0" SE="0.7880346227487346" STUDY_ID="STD-Khalafallah-2010" TOTAL_1="92" TOTAL_2="91" VAR="0.6209985666507405" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2011-08-12 13:30:19 +0100" MODIFIED_BY="Heather Maxwell">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2011-08-12 13:30:19 +0100" MODIFIED_BY="Heather Maxwell" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2011-08-12 13:30:19 +0100" MODIFIED_BY="Heather Maxwell" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2011-08-24 10:13:53 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2011-08-23 21:41:38 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-02-09 21:38:43 +0000" MODIFIED_BY="[Empty name]">Search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-08-23 21:41:38 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>PubMed (Jan 2005 to June 2011)</B>
</P>
<P>(randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] OR placebo [tiab] OR drug therapy [sh]  OR randomly [tiab]  OR trial [tiab]  OR groups [tiab]) NOT (animals [mh] NOT (humans [mh] AND animals [mh])) AND (Pregnant Women [mh] OR Pregnancy [mh] OR Pregnan* OR Prenatal Care [mh]) AND (Iron OR ferrous OR ferric OR iron [mh]) AND (Anemia* OR anaemia* OR anemic OR anaemic OR anemia [mh])</P>
<P>
<B>CENTRAL (2011, Issue 2 of 4)</B>
</P>
<P>#1 mesh descriptor Pregnant Women explode all trees<BR/>#2 mesh descriptor Pregnancy explode all trees<BR/>#3 mesh descriptor Prenatal care explode all trees<BR/>#4 Iron OR ferrous OR ferric OR mesh descriptor Iron explode all trees<BR/>#5 Anemia* OR anaemia* OR anemic OR anaemic OR mesh descriptor Anemia explode all trees<BR/>#6 #1 OR #2 OR #3<BR/>#7 #6 AND #5 AND #4</P>
<P>
<B>Health Technology Assessment Program (HTA)</B> (<A HREF="http://www.hta.ac.uk/">www.hta.ac.uk/</A>)<B> [United Kingdom]; and LATINREC </B>[<A HREF="http://www.latinrec.org">www.latinrec.org</A>,<B> Colombia] </B>(searched 2 May 2011):</P>
<P>(anemia OR anaemia OR anemic OR anaemic) AND (pregnant OR pregnancy) AND (iron OR ferrous) AND (random OR randomized OR randomised OR aleatory).</P>
<P>
<B>Search Portal of the International Clinical Trials Registry Platform (ICTRP</B>; <A HREF="http://www.who.int/ictrp/">www.who.int/ictrp/</A>) (searched 2 May 2011)</P>
<P>anemia AND pregnant AND ferrous<BR/>anaemia AND pregnant AND ferrous<BR/>anemic AND pregnant AND ferrous<BR/>anemia AND pregnancy AND ferrous<BR/>anaemia AND pregnancy AND ferrous<BR/>anemic AND pregnancy AND ferrous<BR/>anemia AND pregnant AND iron<BR/>anaemia AND pregnant AND iron<BR/>anemic AND pregnant AND iron<BR/>anemia AND pregnancy AND iron<BR/>anaemia AND pregnancy AND iron<BR/>anemic AND pregnancy AND iron</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2011-08-24 10:13:53 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2010-11-18 14:11:03 +0000" MODIFIED_BY="Lynn Hampson">Search strategy used in the previous version of the review</TITLE>
<APPENDIX_BODY MODIFIED="2010-11-18 14:11:15 +0000" MODIFIED_BY="Lynn Hampson">
<P>Authors searched the Cochrane Central Register of Controlled Trials (<I>The Cochrane Library</I> 2005, Issue 4), MEDLINE (1966 to December 2005), EMBASE (1976 to December 2005), LILACS (1982 to 40 edition), and BIOSIS Previews (from 1980 to June 2002) using the following strategy (adapted for each database):</P>
<P>(Randomized-controlled-trial:PT OR Randomized-clinical-trials:PT)<BR/>AND<BR/>(Pregnancy in Mesh OR Prenatal care in Mesh)<BR/>(Anemia, Hypochromic/drug therapy in MESH OR<BR/>Anemia, Hypochromic/prevention and control in MESH OR<BR/>Anemia, Hypochromic/therapy in MESH OR<BR/>Anemia, Iron deficiency/drug therapy in MESH OR<BR/>Anemia, Iron deficiency/prevention and control in MESH OR<BR/>Anemia, Iron deficiency/therapy in MESH)<BR/>Pregnancy complications/prevention and control</P>
<P>Iron/therapeutic use</P>
<P>Haematinics/adverse effects.</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2011-08-24 10:13:53 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2010-02-16 16:01:02 +0000" MODIFIED_BY="Jill V Hampson">Methods used to assess trials included in previous versions of this review</TITLE>
<APPENDIX_BODY MODIFIED="2010-02-16 16:01:04 +0000" MODIFIED_BY="Jill V Hampson">
<SUBSECTION>
<HEADING LEVEL="3">(1) Study selection</HEADING>
<P>Two review authors (L Reveiz (LR) and LG Cuervo (LGC)) checked the titles and abstracts identified from the searches. If it was clear that the study did not refer to a randomised controlled trial on iron-deficiency anaemia in pregnancy, it was excluded. If it was unclear, then we obtained the full text of the study for independent assessment by LR and G Gyte (GG). LR and GG assessed each trial for inclusion and resolved any disagreements through discussion, with referral to a third author (LGC) when necessary. Excluded studies and reasons for exclusion are described in the 'Characteristics of excluded studies' table.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">(2) Assessment of methodological quality</HEADING>
<P>We assessed trials under consideration for methodological quality and for appropriateness for inclusion without consideration of their results. We processed data from included trials as described in the Cochrane Handbook for Systematic Reviews of Interventions (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>). We undertook quality assessment by evaluating the following components for each included study, since there was some evidence that these are associated with biased estimates of treatment effect:<BR/>(a) the method of generation of the randomisation sequence; if it delivered a known chance allocation to each given group but individual allocation could not be anticipated;<BR/>(b) the method of allocation concealment, which was considered 'adequate' when the assignment could not be foreseen;<BR/>(c) who was blinded or not blinded (participants, clinicians, outcome assessors);<BR/>(d) participants lost to follow up in each arm of the study (split into postrandomisation exclusions and later losses if possible), and whether participants were analysed in the groups to which they were originally randomised (intention to treat).</P>
<P>The information was recorded in a table of quality criteria and a description of the quality of each study was given based on a summary of these components.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">(3) Data extraction</HEADING>
<P>Data extraction was carried out independently by one author (LR) using a data extraction form. Data were extracted for all outcomes for all relevant drugs, paying particular attention to the dosage and periodicity of treatment. GG checked the data extraction. We resolved disagreements by discussion until we reached consensus. We obtained missing data from the trial authors, when possible.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">(4) Analysis</HEADING>
<P>To estimate differences between treatments, we pooled the results of randomised controlled trials (RCTs) that evaluated similar interventions (and controls), and calculated a weighted treatment effect across RCTs using a fixed-effect model. The results were expressed as relative risk, and 95% confidence intervals (CI)) for dichotomous outcomes, and weighted mean difference (and 95% CI) for continuous outcomes. Results were expressed as number needed to treat where appropriate. We summarised the information we found available. Quasi-randomised and non-randomised controlled studies were identified and listed, but were not further discussed. A qualitative description was provided for adverse effects when this was available.</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>